A DANCING BEAR SYMBOLIZES RENEWAL AND STRENGTH TO MANY NATIVE AMERICAN CULTURES

American Psychiatric Association
Annual Meeting • May 30 - June 4, 1998
Toronto, Ontario, Canada
May 30, 1998

Dear Colleagues and Guests:

Welcome to the 151st Annual Meeting of the American Psychiatric Association. The theme for this meeting, which reflects our determination, vision and concern for every sector of American psychiatry, is:

**New Challenges for Proven Values:**
*Defending Access, Fairness, Ethics, Decency*

As we work hard to build a better future for our patients, including children, minorities, the elderly and their families, there are some fundamentals we must keep in mind. Indeed, much of the scientific program addresses these issues. There are sessions on confidentiality, psychiatric education, ethics, the doctor/patient relationship, private practice, economics and managed care, as well as many excellent sessions on the latest developments in research and clinical practice.

Two special “Days of Creation” have been planned for Monday and Tuesday, during which several sessions will highlight creativity. On Wednesday, selected sessions will examine “A Time of Violence.”

I am delighted that our international registration has grown so considerably over the past several years. That so many colleagues from around the world attend our Annual Meeting is a tribute to its high quality and diversity. At this meeting we will have a number of outstanding international guests, including leaders from the World Psychiatric Association, some of whom will make presentations and many of whom will represent their organizations at the Opening Session. I expect you to join me at the Opening Session, which will take place on Sunday from 5:00 p.m. to 6:30 p.m.

Those inducted as Fellows into the APA and those receiving awards from the Association will be honored at the Convocation of Fellows on June 1, from 7:30 p.m. to 9:00 p.m. Please join me and your colleagues at the Convocation to congratulate these members and friends of the APA. Our Convocation speaker will be Justice Richard Goldstone.

Helping to plan this meeting has been stimulating and invigorating. It would not be possible without the extensive, dedicated effort of many APA members. Congratulations to the Scientific Program and Local Arrangements Committees for this remarkable ending to what has been an extremely productive and successful year for the APA. For the coming year we are off to a superb beginning which will ensure further advances for our patients in need and our profession.

We hail the Olympian efforts of our Annual Meeting staff in organizing and making coherent, a complex flow of daily challenges. Orchestrating the requirements set by your President and the Scientific Program Committee, and working in concert with the staff in the Meetings and Exhibit Management Office, their dedication has made possible this extraordinary meeting.

Welcome to Toronto!

Herbert S. Sacks, M.D.
President
American Psychiatric Association
Dear APA Members and Guests:

Welcome to Toronto, Canada and the 151st Annual Meeting of the American Psychiatric Association. This exciting city, with its vibrancy, cultural diversity and excitement, provides a fitting setting for the presentations we have planned. As you read through the Program Book, you will notice a number of sessions related to the theme “New Challenges for Proven Values: Defending Access, Fairness, Ethics, Decency,” chosen by our President, Dr. Herbert S. Sacks, M.D. I draw your attention to the Presidential Symposium scheduled on Tuesday at 2:00 p.m., “Paparazzi and Snoopers: New Threats to Confidentiality.”

The Local Arrangements Committee, under the excellent guidance of its Chairperson, Dr. D. Raymond Freebury has developed a wide array of programs that will help you take advantage of Toronto. You will notice that a number of activities are designed especially for families and children.

The Business Meeting will be held on Sunday, from 12:30 p.m. to 1:30 p.m.; all voting all voting members are encouraged to attend. The Opening Session will be held on Sunday from 2:00 p.m. to 3:30 p.m. Exhibits will be open 11:00 a.m.-5:00 p.m. on Sunday, 10:00 a.m.-6:00 p.m. on Monday and Tuesday, and 10:00 a.m.-3:00 p.m. on Wednesday.

The Advances in Research session will be held on Monday at 10:30 a.m. This session highlights the latest research findings in psychiatry and summarizes their relevance to clinical practice. This has become an excellent way to start off the Annual Meeting’s research programs, in conjunction with the Young Investigators’ Poster and Oral/Slide Sessions also on Monday. You will find an expanded number of small group sessions, including Discussion Groups, Research Consultations with selected experts in the field, and the newly created Master Educator Clinical Consultations, a series of clinically-based seminars with outstanding clinician educators, which will be offered to APA members only.

A special aspect of our 1998 scientific program will be a series of collaborative sessions supported in part by the National Institute on Drug Abuse. Special offerings in each of the various program formats will present exciting research discoveries elucidating various biological and psychological aspects of addiction and recovery. Royd E. Bloom, M.D., distinguished psychiatrist and editor of Science, will present the Decade of the Brain as part of this series. For registrants desiring to attend these sessions for an update on various aspects of substance abuse ranging from basic neuroscience to novel treatments and outcome studies, each session in this special track is identified throughout this book as a “Collaborative Session with the National Institute on Drug Abuse.”

You will also note in the Program Book that we are continuing with our expanded series of noon Forums. This format allows us to schedule sessions that may not fit in the usual formats or that focus on late-breaking topics of importance to the field.

I strongly encourage you to fill out and return the evaluation forms for this meeting. The members of the Scientific Program Committee are interested in the opinions of the members regarding the quality and content of the Annual Meeting. The information we obtain is used to plan next year’s program.

Once again, welcome to Toronto. I look forward to sharing a week of exciting and professionally rewarding activities with you.

Sincerely,

Daniel K. Winstead, M.D.
Chairperson
Scientific Program Committee
II

KEY LOCATIONS - CONVENTION CENTRE
Administrative Office Rooms 201C/D, Street Level
American Journal of Psychiatry APA Resource Center
APA Resource Center Exhibit Halls A/B/C, Upper Level
A/V Preview Room Room 202D, Street Level
CME Course Enrollment Exhibit Halls A/B/C, Upper Level
Daily Bulletin Press Conference Room
Exhibit Office Lobby, Street Level
Information/Locator Center Lobby, Street Level
Lost & Found Rooms 202A/B, Street Level
Meetings Management Rooms 202A/B, Street Level
Message Center Street Level Lobby
On-Site Job Bank and Lobby, Upper Level
Placement Center APA Resource Center
Press Office Press Conference Room
Psychiatric Services APA Resource Center
Radio Interviews Press Conference Room
Registration Exhibit Halls A/B/C, Upper Level
Scientific Program Office Room 203D, Street Level

FIRST AID
Located on the Lower Level, North, and the 800 Level, South, Convention Centre. Hours of operation: Friday, May 29, through Thursday, June 4, 7:00 a.m. - 6:00 p.m. Information on emergency services may be found on page 3 of the Leisure Time Activities Brochure.

COURTESY SHUTTLE BUS SERVICE
Your registration badge is needed to ride the shuttle buses. Bus service will be available beginning at 10:30 a.m. on Saturday, May 30, operate daily throughout the meeting until 11:00 p.m., and conclude on Thursday, June 4, at 6:00 p.m. Route maps and schedules are included in the registration packet and published in the APA Exhibits Guide.

LOCAL ARRANGEMENTS COMMITTEE
HOSPITALITY CENTER
Located in the Street Level Lobby, Convention Centre. Hours of operation: Saturday, May 30, 12 noon-5:30 p.m.; Sunday, May 31, to Wednesday, June 3, 9:00 a.m.-5:30 p.m.; and Thursday, June 4, 9:00 a.m.-12 noon. Tickets for leisure time activities will be available at the Tour Desk located in the Street Level Lobby, Convention Centre.

EXHIBITS
Commercial and educational exhibits are located in Exhibit Halls A/B/C, Upper Level, Convention Centre, along with the Publishers’ Bookfair and the APA Resource Center. As a convenience to registrants, the Publishers’ Bookfair will open on Saturday, May 30, at 11:00 a.m. Hours for commercial and educational exhibits: Sunday, May 31, 11:00 a.m.-5:00 p.m., Monday and Tuesday, June 1-2, 10:00 a.m.-6:00 p.m. Please note the relatively new hours for Wednesday, June 3, will be 10:00 a.m.-3:00 p.m. for commercial and educational exhibits, the Publishers’ Bookfair and the APA Resource Center. All exhibits will close on Wednesday, June 3. Please refer to the APA Exhibits Guide for additional information on participating companies.

INFORMATION/LOCATOR CENTER
Located in the Street Level Lobby, Convention Centre and staff during registration hours. Up-to-date general information about the program, component meetings, the local area, and the locations of various activities and events can be obtained there. Meeting participants also can find out where colleagues who are registered for the meeting are staying.

MESSAGE CENTER
Located in the Upper Level Lobby, Convention Centre and staff during registration hours. Messages can be left and picked up at the Message Center. Message monitors will be strategically located in the Exhibit Hall and elsewhere at the Convention Centre. Registrants whose names appear on these monitors should pick up their messages at the Center.

APA RESOURCE CENTER
Located in Exhibit Halls A/B/C, Upper Level, Convention Centre. Hours of operation: Saturday, May 30, 11:00 a.m. to 5:00 p.m.; Sunday, May 31, 8:00 a.m.-5:00 p.m.; Monday and Tuesday, June 1-2, 10:00 a.m.-6:00 p.m.; Wednesday, June 3, 10:00 a.m.-3:00 p.m. See the back cover of this book for a listing of APA programs exhibiting, and free materials and demonstrations that will be offered in the Center.

APA JOB BANK
Located in the APA Resource Center and open during the Center’s hours of operation. The computerized Job Bank gives you the opportunity to walk away with information on hundreds of job openings available to psychiatrists throughout the country. Employers can list available positions on-site. Psychiatrists and employers should stop by the booth to find out how they can access information in the Job Bank database throughout the year.

APA’S COMMUNICATIONS CENTER
Located in the Press Conference Room, Lower Level, Convention Centre. Hours of operation: Saturday, May 30, 8:00 a.m.-6:00 p.m.; and Thursday, June 4, 8:00 a.m.-1:00 p.m. APA’s Division of Public Affairs operates the Communications Center. The Center will house the on-site press office, a media briefing room, and the Daily Bulletin newspaper. Presenters are strongly encouraged to stop by to drop off copies of their papers for members of the media.

The Center is for the use of registered press only. All Annual Meeting sessions are open to the press except CME Courses, the Business Meeting, Clinical and Continuous Clinical Case Conferences and Master Educator Clinical Consultations.

The Daily Bulletin accepts written requests from APA members for publicity of component, committee and allied group events as space allows. Four issues are published. Since the issue for Saturday/Sunday is preprinted, information cannot be added on site. Copy for the Monday, Tuesday, and Wednesday/Thursday issues can be dropped off at the Press Conference Room. The deadlines are noon prior to the date of publication.
On-site fees can be paid by cash, check, money order, VISA or MasterCard. Registration fees are waived only for CME Course Faculty, APA Honorary or Distinguished Fellows (does not include APA Life Fellows or Fellows), all medical students (with proper identification), District Branch Executive Staff (who are not APA members), active members of the Association of Mental Health Clergy (with proper identification), and nonmember program participants (only for the day(s) they present).

**NONMEMBER PSYCHIATRIC RESIDENTS AND REGULAR FULL-TIME STUDENTS** must present documentation of their qualifications to register in their respective category and qualify for the reduced fee. (Examples include: a valid full-time [12 + hrs. per semester] student ID; a letter from your instructor or director of training verifying your status as a psychiatric resident; or similar documentation.)

**Note:** There are no exemptions or reduced fees available for CME courses. The registration fee covers admission to all sessions (except courses), shuttle buses, and includes a badge and copy of the Program Book, APA Exhibits Guide, New Research Program and Abstracts Book, and Syllabus.

**NAME BADGES**

Badges are required for all sessions including the Opening Session and exhibit area. Only an APA member badge will admit you to the Business Meeting.

**Badge Color Codes:** Blue-Members, Tan-Nonmember Psychiatrists, Yellow-Nonmembers, Gray-Press, Red-Exhibitors, Green-APA Staff, White-Temporary Convention Personnel.

**CME COURSE ENROLLMENT**

**TICKET PURCHASE REQUIRED FOR CME COURSES**

Located in Exhibit Halls A/B/C, Upper Level, Convention Centre. Hours of operation: Saturday, May 30, 11:00 a.m.-5:00 p.m.; Sunday, May 31, 7:30 a.m.-5:00 p.m.; Monday through Wednesday, June 1-3, 7:30 a.m.-6:00 p.m.; and Thursday, June 4, 7:30 a.m.-2:00 p.m. Tickets for CME Courses #5-100, not sold by April 20, will be on sale to all registrants beginning at 11:00 a.m. on Saturday, May 30. You must show your registration badge before you can enroll in courses.

**APA ARTS ASSOCIATION**

Located in the APA Resource Center and staffed during the Resource Center's hours. The exhibit includes paintings, photography, ceramics and crafts done by APA members and/or their significant others. Entries in the poster and essay exhibit for children of APA members will also be displayed. Please stop by the exhibit for information on joining the APA Arts Association.

**APA AUXILIARY BOOTH**

Located in the Street Level Lobby, Convention Centre. Hours of operation: Saturday, May 30, through Wednesday, June 3, 9:00 a.m.-5:00 p.m. Stop by the booth to obtain information on the Auxiliary's program schedule and information on membership.

**APA PERIODICALS**

The American Journal of Psychiatry and Psychiatric Services will be located in the APA Periodicals Exhibit in the APA Resource Center and staffed during Resource Center hours. Staff of both journals will be available to answer authors' questions and to receive papers submitted for press.
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

The APA designates this education activity for up to 66 credit hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Please note: The entire scientific program at the Annual Meeting, as outlined below, has been approved for CME credit. The scientific sessions of the official Annual Meeting program, with some exceptions, meet the criteria for Category 1 credit. Sessions in the following program formats are designated as Category 1: Advances in Research, Clinical Case and Continuous Clinical Case Conferences, CME Courses, Debate, Forums, Industry-Supported Symposia, most Lectures, Medical Updates, Research Advances in Medicine, Round Table Discussion, Practice Guidelines Update, Media Sessions, New Research Oral/Slide Sessions, Scientific and Clinical Reports, Presidential Symposium, Review of Psychiatry, Symposia, and Workshops. Other program activities are designated Category 2; these include Research Consultations With, Discussion Groups, Master Educator Clinical Consultations, New Research Poster Sessions, a Video Production Clinic, and some Media Sessions, Lectures and Workshops. Discussion Groups, Master Educator and Research Consultations With sessions are open to 25 participants and are open on a first-come, first-served basis. If there is space available in the room, you may attend. Continuing medical education sessions are open to all Annual Meeting registrants, except for the Clinical Case and Continuous Clinical Case Conferences and the Master Educator Clinical Consultations, which are open to APA members only.

Please note: APA members are required to maintain their own record of CME hours. Reporting of CME credit is on an honor basis.

To document CME credit earned at the Annual Meeting, participants should record the sessions attended on the back page of the Certificate of Attendance found in the front of the 1998 Annual Meeting CME Syllabus & Proceedings Summary Book. Credit is earned on an hour-for-hour basis.

The Certificate of Attendance (or copy) may be forwarded to other organizations requiring verification of participation in the APA Annual Meeting.

The APA requires participation in a total of 150 hours of CME activities within a three-year reporting period. At least 60 hours must be in Category 1 activities.

CME report forms may be obtained from the Office of Education at the APA. Staff will be available at the Office of Education booth in the APA Resource Center to answer any of your questions about CME.

The Annual Meeting Scientific Program Committee needs your recommendations and evaluations to plan next year's Annual Meeting. A participant evaluation form is enclosed with your registration packet and includes instructions for completing the form. BEFORE YOU LEAVE THE MEETING, PLEASE COMPLETE YOUR FORM AND DROP IT IN ONE OF THE EVALUATION BOXES LOCATED THROUGHOUT THE MEETING SITES. You can receive a Certificate of Attendance at the Annual Meeting by returning a completed form to the APA Administrative or Scientific Program Office, the Information/Locator Center or the APA Resource Center; all located in the Convention Centre.

SESSION CAPACITY

We expect "sell out" attendance for many of the scientific sessions. So that all in attendance may benefit, we ask your assistance when overcrowding occurs:

- Please find seating as far forward as possible.
- Move to the center of the row and fill all seats so that chairs are available on aisles for additional attendees.
- Store materials under chairs to maximize seating capacity.
- Overcrowding of meeting rooms may subject the session to shutdown by the Fire Marshal; therefore, we urge all attendees to locate seating rather than stand in aisles or against walls.
- If space does not permit you to attend a session, an audiotape of that session may be available. Please check the order form included in your registration packet.

Thank you for your cooperation.

AUDIOTAPES

Audiotapes of most sessions are available shortly after each session concludes and may be purchased at the Mobitaape Booth located in the Convention Centre.

TAPE RECORDING AND VISUAL REPRODUCTION POLICIES

Audiotape recording is only permitted for personal use. Registrants are welcome to use their own small, portable audiotape recorders to record any session except the Master Educator Clinical Consultations, Clinical Case Conferences and the Continuous Clinical Case Conference, or unless prohibited by the presenters. Larger professional audiotape recorders, however, are not permitted other than those utilized by personnel representing the professional taping firm authorized by APA to audiotape sessions. The badges of personnel representing this firm will clearly identify them. Registrants are not permitted to videotape any session because the intrusive nature of the recording may disrupt the session.

SMOKING POLICY

There will be NO SMOKING in scientific sessions or in the exhibit hall. Smoking will only be permitted in designated areas.
CHILD CARE SERVICES

For the convenience of meeting registrants and their families, the APA, with assistance from the Local Arrangements Committee, has made arrangements for child care during the meeting. The child care service will be located in the Royal York Hotel. Hours of operation will be Sunday, May 31, to Thursday, June 4, 7:30 a.m.-5:00 p.m. Staffing will be available for children ages six months to 12 years.

GUIDE TO THE PROGRAM BOOK

Below, you will find the table of contents for ease in locating information about this meeting. A topic index is included to assist you with finding sessions of interest. The individual program for each day's sessions is listed by start time with the formats listed alphabetically under those times. NOTE: To make it easier for you to plan your day, we have prepared a separate "Days-at-a-Glance," which is included in your registration packet.

If you have any questions about this book or the scientific sessions, please feel free to stop by the Scientific Program Office in the Convention Centre, and we will be glad to help you. Also, all central office APA staff members will be wearing green ribbons on their badges. Please feel free to direct your questions to them.

FUTURE APA MEETINGS

APA ANNUAL MEETINGS

1999 May 15-20 Washington, DC
2000 May 13-18 Chicago, IL
2001 May 5-10 New Orleans, LA
2002 May 18-23 Philadelphia, PA
2003 May 17-22 San Francisco, CA

APA CLINICAL MEETINGS

THE INSTITUTES ON PSYCHIATRIC SERVICES

1998 October 2-6 Los Angeles, CA
1999 October 29-Nov. 2 New Orleans, LA
2000 October 25-29 Philadelphia, PA
2001 October 10-14 Orlando, FL
2002 October 9-13 Chicago, IL
2003 October 29-Nov. 2 Boston, MA
2004 October 6-10 Atlanta, GA
2005 October 5-9 San Diego, CA

Tentative program schedules and hotel information for the 1998 Institute are available at the Annual Meetings Booth in the APA Resource Center and the Information/Locator Center, both located in the Convention Centre.
CONVENTION CENTRE
700 Level

800 Level
CROWNE PLAZA
DOWNTOWN TORONTO

APA ACCOMMODATIONS

A  BEST WESTERN PRIMROSE HOTEL
B  BOND PLACE HOTEL
C  CLARION ESSEX PARK HOTEL
D  CROWNE PLAZA TORONTO CENTRE
E  DELTA CHELSEA INN
F  FOUR SEASONS TORONTO
G  HOLIDAY INN ON KING
H  HOWARD JOHNSON PLAZA HOTEL
I  MARRIOTT EATON CENTRE
J  METROPOLITAN HOTEL
K  NOVOTEL TORONTO CENTRE
L  PARK PLAZA HOTEL
M  RADISSON PLAZA HOTEL ADMIRAL
N  RADISSON PLAZA HOTEL TORONTO
O  ROYAL YORK HOTEL
P  SHERATON CENTRE HOTEL & TOWERS
Q  SKYDOME HOTEL
R  STRATHcona HOTEL
S  SUTTON PLACE HOTEL
T  TORONTO COLONY HOTEL DOWNTOWN
U  TORONTO HILTON
V  WESTIN HARBOUR CASTLE

LANDMARKS

1  CITY HALL
2  CN TOWER
3  EATON CENTRE
4  MAPLE LEAF GARDENS
5  METRO TORONTO CONVENTION CENTRE
6  SKYDOME
7  VARSITY STADIUM/ARENA

TRANSPORTATION

- - - - - - - - - - - - - - - - - - - - - - -
TORONTO SUBWAY LINE
- - - - - - - - - - - - - - - - - - - - - - -
HARBOURFRONT LIGHT
RAPID TRANSIT LINE
SPECIAL ACKNOWLEDGMENTS

The American Psychiatric Association expresses its deep appreciation for the following:

Abbott Laboratories: support of the Industry-Supported Symposium, "Pharmacotherapy of Bipolar Disorder: Newest Advances," Saturday, May 30, 7:00 p.m.; "Practical Approaches to the Treatment of Psychoses in the Elderly," Sunday, May 31, 7:00 p.m.; and "Recent Advances in Psychopharmacology," Tuesday, June 2, 7:00 p.m.

American Academy of Psychiatry and the Law: co-sponsorship of the Manfred S. Guttmacher Award Lecture, Sunday, May 31, 2:30 p.m.

American Association of Chairs of Departments of Psychiatry: support of Office of Research Annual Meeting activities.

American Association of Psychiatric Administrators: co-sponsorship of the Administrative Psychiatry Award Lecture, Monday, June 1, 2:00 p.m.

American Psychiatric Foundation: co-sponsorship of Research in Psychiatry.

Association of Mental Health Clergy: co-support of the Oskar Pfister Award Lecture, Wednesday, June 3, 9:00 a.m.

Bayer: support of the Industry-Supported Symposium, "Hot Topics in Alzheimer's Disease," Tuesday, June 2, 7:00 p.m.

Bristol-Myers Squibb: support of the Industry-Supported Symposium, "Chronic Depression: Optimizing Long-Term Treatment," Sunday, May 31, 9:00 a.m.; "The Anxiety Labyrinth: Finding a Pathway to the Solutions," Sunday, May 31, 1:30 p.m.; the Industry-Supported Breakfast Symposium, "Practical Clinical Strategies for Managing Refractory Depression, Agitation and Antidepressant Side Effects," Monday - Wednesday, 7:00 a.m.; the Solomon Carter Fuller Award Lecture and Reception, Tuesday, June 2, 11:00 a.m.; the APA Auxiliary reception and tea; and the Women Members’ Activity Center; and the American Psychiatric Foundation reception and evening at the symphony.

Center for Mental Health Services: sponsorship of the APA/CMHS Minority Fellowship Program, the AIDS Education Program, Tuesday-Wednesday, June 2-3, 9:00 a.m.; and Practice Research Network (PRN) Annual Meeting activities.

Center for Substance Abuse Treatment: support of the Industry-Supported Symposium, "Practical Alzheimer's Disease Management: A Comparative Review of New Compounds, Diagnosis, Treatment, and Outcomes Assessment," Wednesday, June 3, 7:00 p.m.

Eisai Inc Pfizer Inc: support of the Industry-Supported Symposium, "Maintenance Treatment of Depression: The Final Episode," Saturday, May 30, 7:00 p.m.; "Women and Psychosis: From Lab Bench to Clinical Practice," Sunday, May 31, 9:00 a.m.; "The Depressed Woman: Contemporary Treatments," Sunday, May 31, 1:30 p.m.; "Expanding the Spectrum of Psychoses: The Interface of Affect," Sunday, May 31, 7:00 p.m.; the Adolf Meyer Award Lecture, Tuesday, June 2, 9:00 a.m.; the Simon Bolivar Award Lecture, Wednesday, June 3, 9:00 a.m.; the special sessions on "A Time of Violence," Wednesday, June 3, the APA/Lilly Resident Research Awards; the Daniel X. Freedman Congressional Fellowship; and the President's Reception; Newsline, a closed circuit television news service; the IMG Hospitality Suite; and partial support of the New Research Abstracts and Program Book.

Forest Laboratories, Inc.: support of the Industry-Supported Symposium, "Treating the Difficult-to-Treat Depressed Patient," Tuesday, June 2, 7:00 a.m.; and "Therapeutic Challenges in Geriatric Psychiatry," Wednesday, June 3, 7:00 p.m.

Glaxo Wellcome Inc.: support of the Industry-Supported Symposium, "Management of iatrogenic Sexual Dysfunction," Saturday, May 30, 7:00 p.m.; "Intervention for Refractory Bipolar Disorder," Sunday, May 31, 9:00 a.m.; "Nicotine: An Enemy or an Ally?", Sunday, May 31, 1:30 p.m.; "Sexual Dysfunction and the Patient with Depression," Sunday, May 31, 7:00 p.m.; the APA/Glaxo Wellcome Fellowship Program and reception, Tuesday June 2, 7:00 p.m.; and the American Psychiatric Association reception and evening at the symphony.

Gralnick Foundation: support of the Alexander Gralnick Award for Research in Schizophrenia.

Harding Foundation: co-support of the Oskar Pfister Award Lecture, Wednesday, June 3, 9:00 a.m.

International Academy for Biomedical and Drug Research: support of the Industry-Supported Symposium, "Mood Disorders in Schizophrenia: United States and European Perspectives," Saturday, May 30, 7:00 p.m.

Ittelson Foundation, Inc.: support of the Blanche F. Ittelson Award for Research in Child Psychiatry.

Janssen Pharmaceutica and Research Foundation: support of the Industry-Supported Symposium, "Novel Antipsychotics: Use in Nonpsychotic Disorders Across the Life Cycle," Saturday, May 30, 7:00 p.m.; "Age-Related Memory Loss: Detection and Treatment," Sunday, May 31, 7:00 p.m.; "Pharmacotherapy: Combination Strategies in Clinical Practice," Tuesday, June 2, 7:00 p.m.; "Neurocognition in Schizophrenia," Wednesday, June 3, 7:00 p.m.; the Decade of the Brain Lecture, Monday, June 1, 9:00 a.m.; the Early Career Psychiatrists' Dinner/Forum, Tuesday, June 2, 6:00 p.m.; the reception for the Kun-Po Soo awardees, Wednesday, June 3, 6:30 p.m. and partial support of the shuttle bus system.

SPECIAL ACKNOWLEDGMENTS

Estate of Kun-Po Soo, M.D., Ph.D.: support of the Kun-Po Soo Award.

Lilly Research Laboratories, a division of Eli Lilly & Company: sponsorship of the Lilly Psychiatric Research Fellowship.

Merck & Company, Inc.: support of the William C. Menninger Memorial Convocation Lecture, Monday, June 1, 7:30 p.m.; and an unrestricted educational grant in support of various scientific sessions.

Merck U.S. Human Health: support of the Industry-Supported Symposium, "Update on Diagnosis: Pathophysiology, and Treatment of Primary Headache Disorders for the Practicing Psychiatrist," Tuesday, June 2, 7:00 p.m.

National Institute of Mental Health: support of the Seymour D. Vestermark Award for Psychiatric Education Lecture, Tuesday, June 2, 11:00 a.m.; APA Office of Research Annual Meeting activities for research trainees; and the program for minority research training in psychiatry.

National Institute on Alcohol Abuse and Alcoholism: support of the APA Office of Research Annual Meeting activities for research trainees and Practice Research Network (PRN) activities.

National Institute on Drug Abuse: support of the Annual Meeting program, "Drug Addiction — A Treatable Disease: A Special Research-Based Program Track" and the APA Office of Research/Research Training activities.


Organon Inc.: support of the Industry-Sponsored Symposia, "Issues in the Long-Term Management of Depression, Sunday, May 31, 9:00 a.m.; and "Depressive Disorders: Advances in Clinical Management," Sunday, May 31, 1:30 p.m.

PictureTel: support of the Symposium, "International Health Care and Telepsychiatry," Monday, June 1, 2:00 p.m. by providing equipment, line time and personnel.

Professional Risk Management Services, Inc.: support of the Manfred S. Guttmacher Award Lecture, Sunday, May 31, 2:30 p.m.

Pfizer Inc.: support of the Industry-Supported Symposia, "Cognition in Schizophrenia: The New Therapeutic Goal," Saturday, May 30, 7:00 p.m.; "Treatment Strategies for Successful Outcomes in Patients with Panic Disorder," Sunday, May 31, 7:00 p.m.; "Exploring the Course of Schizophrenia," Tuesday, June 2, 7:00 p.m.; "Management of Mental Disorders in Baby Boomers and Beyond," Wednesday, June 3, 7:00 p.m.; co-support of the symposium, "International Health Care and Telepsychiatry," Monday, June 1, 2:00 p.m.; support of the Residents' Session, "Meet the Experts: Sunny-Side Up," Monday, June 1, 7:00 a.m.; the Abstracts-On Disk Program; the APA Daily Bulletin newspaper; and the pre-meeting publication, "Perspective.

Pfizer International Pharmaceuticals: support of the Office of International Affairs and a daily visitor center for international delegates.

Pharmacia & Upjohn Inc.: support of the Industry-Supported Symposium, "Predicting Outcomes of Antidepressant Treatment," Wednesday, June 3, 7:30 p.m.; co-support of the Industry-Supported Symposium, "OCD Subtypes: From Clinical to Molecular Genetics," Saturday, May 30, 7:00 p.m.; "Clinical Challenges in the Treatment of Depression Subtypes," Tuesday, June 2, 7:00 p.m.; and beverage service in the exhibit hall.

Roche Laboratories, a member of the Roche Group: support of the Benjamin Rush Award Lecture, Wednesday, June 3, 2:00 p.m.

Scios Pharmaceuticals: support of the Assembly/Board of Trustees Reception, Friday, May 29.


Solvay Pharmaceuticals, Inc.: co-support of the Industry-Supported Symposium, "OCD Subtypes: From Clinical to Molecular Genetics," Saturday, May 30, 7:00 p.m.; "Clinical Challenges in the Treatment of Depression Subtypes," Tuesday, June 2, 7:00 p.m.; and the beverage service in the exhibit hall.

van Ameringen Foundation, Inc.: support of the APA Office of Research Annual Meeting activities for research trainees and health services researchers.

VTEL: co-support of the Symposium, "International Health Care and Telepsychiatry," Monday, June 1, 2:00 p.m.

Wyeth-Ayerst Laboratories: support of the Industry-Supported Symposium, "Estrogen Enhancement of Mood and Memory in Postmenopausal Women," Saturday, May 30, 7:00 p.m.; "Juvenile Mood Disorders: From Research to Clinical Practice," Sunday, May 31, 9:00 a.m.; "Treatment of Depression in Difficult Situations," Sunday, May 31, 1:30 p.m.; "Contemporary Issues in Treatment-Resistant Depression," Sunday, May 31, 7:00 p.m.; the Residents, Medical Student, Training Directors luncheon, Tuesday, June 2; and the Alexandra Symonds Award.

Zeneca Pharmaceuticals Group: support of the Industry-Supported Symposium, "Individualizing the Treatment of Psychoses," Sunday, May 31, 9:00 a.m.; "New Atypicals: Data Versus Clinical Experience," Sunday, May 31, 1:30 p.m.; the George Tarjan Award and reception; and the APA/CNHS and APA/Zeneca Fellow's reception, Tuesday, June 2, 7:00 p.m.
FORMAT DESCRIPTIONS

ADVANCES IN RESEARCH
This two-hour session is traditionally chaired by the Chairperson of the Council on Research, and co-chaired by the Chairperson of the Scientific Program Committee. After a brief overview of major advances in research in psychiatry, and a preview of selected research presentations scheduled at the Annual Meeting, leading clinical researchers present the latest developments in four different, clinically-relevant areas of research.

AIDS EDUCATION PROGRAM
APA's AIDS Program Office presents a two-day clinical update on the neuropsychiatric and psychosocial aspects of HIV disease and AIDS.

CLINICAL CASE CONFERENCES
During these 90-minute sessions, clinical material is presented by videotape or the treating therapist. One or more experts then discuss the case. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCES
The presenters will review the progress of psychotherapy in two successive, three-hour sessions on consecutive days, Monday-Tuesday, beginning at 9:00 a.m. Audience participation will be encouraged throughout. Participants are requested to attend both sessions in their entirety. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES
Courses are designed to emphasize learning experiences that actively involve participants and include the opportunity for informal exchange with the faculty. Offered in four-hour (half-day) and six-hour (full-day) sessions, courses either review basic concepts in a special subject area or present advanced material on a circumscribed topic. Enrollment is limited, and participants must purchase tickets to attend.

DEBATE
A controversial topic in psychiatry will be debated by experts in the field, including psychiatrists and non-psychiatrists. The debate format allows for members to hear both pro and con views about important, interesting, and timely concerns for our members. The debate is moderated by someone who has expertise in the topic area. A portion of the time is allocated for questions from the audience to the presenters with active participation by participants.

DISCUSSION GROUPS
This 90-minute format allows small groups to meet informally with selected experts in psychiatry to discuss topics chosen by the experts. Some of these are reserved for residents only. These sessions are limited to 25 participants on a first-come, first-served basis.

FORUMS
These are flexible presentations that afford an opportunity to highlight and select topics that are of timely interest to psychiatrists. Speakers and panel members are chosen for their expertise and leadership in the field.

LECTURES
Lectures feature a small number of distinguished speakers discussing scientific and cultural topics, many of which will extend our understanding beyond the usual limits of clinical psychiatry. Lecturers are invited by the Program Committee.

MASTER EDUCATOR CLINICAL CONSULTATIONS
These are a series of 90-minute, clinically-based seminars with outstanding educators selected from psychiatry training directors throughout the country. Formats and subject matter will vary, but all will utilize clinical material offered by participants. They are presented in conjunction with the American Association of Directors of Psychiatric Residency Training. These sessions are limited to 25 participants on a first-come, first-served basis. THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA PROGRAMS
A media program may involve the showing of a videotape, 16mm film, or computer software demonstration, followed by discussion. Specialized sessions focus on production or consumer/family issues.

MEDICAL UPDATES
These 90-minute sessions are presented to provide psychiatrists with the latest clinical developments in other areas of medicine. Topics may range from subspecialty areas of adult or pediatric medicine (infectious disease, cardiology, gastroenterology, etc.) to new techniques or procedures in surgery or radiology. The interface between psychiatry and these areas is not necessarily emphasized. The intent is to give participants an update from a physician in a particular specialty.

NEW RESEARCH
This format allows for presentation of the very recent findings obtained from ongoing research. The three types of presentations include: Oral/Slide, twelve-minute presentations with three minutes for discussion; Posters, visual, self-explanatory presentations; and Young Investigators' Sessions, with presentations from young investigators, residents, medical students, and research or clinical fellows.

NIDA/NIH WORKSHOP
This three-hour workshop clarifies the grant making process for psychiatrists contemplating applying for an NIDA grant. General information about applying for NIH grants will also be included.

PRACTICE GUIDELINES UPDATE
This two-hour format will provide an update concerning the development of APA practice guidelines. The APA practice guidelines project has moved forward according to a previously approved process designed to result in
documents which are both scientifically sound and clinically useful to practicing psychiatrists. On the basis of nationally-recognized standards for the development of practice guidelines, the APA practice guidelines reflect the following: comprehensive literature reviews, classifications of supporting evidence and the nature of recommendations; and a series of revisions based on input from the Board of Trustees and several related APA components, psychiatric consultants, non-psychiatrist experts, and representatives from related organizations.

RESEARCH ADVANCES IN MEDICINE
This two-hour format presents an overview of cutting-edge research in various aspects of medicine. In contrast to the Medical Update series, which is more clinically focused, this session will help participants keep pace with the rapidly expanding knowledge base and technology in various branches of medicine. Several speakers, authorities in their fields, will present on their topics.

RESEARCH CONSULTATIONS WITH
This 90-minute format provides an opportunity, in a small group setting, for participants to obtain consultations around problems in research from outstanding senior researchers. Participants should come prepared to present a specific problem in research, whether it's one of research design, methodology, subject selection or data analysis, etc., which could be presented briefly to the consultant. These sessions are limited to 25 participants on a first-come, first-served basis.

REVIEW OF PSYCHIATRY
There will be six, three-and-one-half hour sessions presented, based on the annual American Psychiatric Press Review of Psychiatry Series. Each session includes an abridged presentation by the senior author from each of the chapters in each volume. The topics were selected by the overall editors of the series, to represent current areas of new research, new developments in clinical care, and special issues of importance to APA members.

ROUND TABLE
This 90-minute format is designed to establish a dialogue between psychiatrists and other citizens about controversial issues of special interest to our profession. The moderator presents a panel of experts with hypothetical scenarios that highlight controversial and problematic situations with which psychiatrists interface.

SCIENTIFIC AND CLINICAL REPORT SESSIONS
Scientific and Clinical Reports (formerly Paper Sessions) are oral presentations of papers prepared for submission before publication. In this 90-minute format, reports are grouped by topic, with floor discussion from the audience following the presentation of each paper. There is no formal discussant.

SOCIAL SECURITY WORKSHOP
Social Security Administration (SSA) officials present the history/background of SSA disability programs (including new legislative initiatives), describe how psychiatrists can best serve applicants for benefits, and review the clinical information required to expedite the disability determination process. During this three-hour session, time is allocated for group discussion of evaluation of impairments, what constitutes adequate evidence to support disability decisions, etc.

SYMPOSIA
Symposia are three-hour sessions consisting of four to six presentations that are thematically linked and focus on a specific topic relevant to clinical psychiatry. They are designed to provide comprehensive treatment of a topic or discussion of the topic from several points of view by the participants and stimulate discussion with the audience. Some symposia are supported by industry and are designated as "Industry-Supported Symposium" in this Program Book.

WORKSHOPS
Workshops are 90-minute sessions, which typically involve brief presentations from individual panel members, followed by the opportunity for lively and informative discussion. This format provides for substantial audience participation and should be highly interactive.
Continuing Medical Education Policy on Full Disclosure

The American Psychiatric Association requires disclosure of the existence of any significant financial interest or other affiliation a presenter has with any commercial product(s) and/or providers of any commercial services discussed in an educational presentation. The existence of such relationships does not necessarily constitute a conflict of interest, but the prospective audience must be informed of the presenter’s affiliation with a commercial sponsor by way of an acknowledgment printed in this Program Book. This policy is intended to openly identify any potential conflict so that members of the audience in an educational activity are able to form their own judgments about the presentation.

The following presenters have indicated a significant financial interest or other affiliation with a commercial supporter of the session and/or with the manufacturer(s) of a commercial product(s) and/or provider of commercial service(s). The presenter’s name, the manufacturer's name, and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gene G. Abel, M.D.</td>
<td>Abel Screening Inc.</td>
<td>61, 74</td>
</tr>
<tr>
<td>Donald E. Addington, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Zeneca Pharmaceuticals; Janssen</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmacutica and Research Foundation; Abbott Laboratories</td>
<td>69</td>
</tr>
<tr>
<td>Hagop S. Akiskal, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Glaxo Wellcome Inc.; Pfizer Inc.;</td>
<td>4, 117, 118</td>
</tr>
<tr>
<td></td>
<td>SmithKline Beecham Pharmaceuticals; International Academy for Biomedical and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug Research</td>
<td></td>
</tr>
<tr>
<td>Ian E. Alger, M.D.</td>
<td>IEA Video Productions Inc.</td>
<td>13, 17, 32</td>
</tr>
<tr>
<td>Clifford W. Allwood, M.D.</td>
<td>Lundbeck</td>
<td>6</td>
</tr>
<tr>
<td>Jay D. Amsterdam, M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ayest Laboratories; Somerset Laboratories; National Institute of Mental Health;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solvay Pharmaceuticals, Inc.; Organon Inc.; Hoechst Marion Rousell; Lundbeck</td>
<td></td>
</tr>
<tr>
<td>Robert M. Anthenelli, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Lipha Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Mihaly Arato, M.D.</td>
<td>Pfizer Inc.; EGIS (Hungary)</td>
<td>69</td>
</tr>
<tr>
<td>Kimberly A. Arlinghaus, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Wyeth-Ayest Laboratories</td>
<td>121</td>
</tr>
<tr>
<td>Adam K. Ashton, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; Pfizer Inc.; SmithKline Beecham</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals; Wyeth-Ayest Laboratories; Pharmacia &amp; Upjohn Company, Inc.;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Janssen Pharmacutica and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Research Foundation; Abbott Laboratories; Organon Inc.</td>
<td></td>
</tr>
<tr>
<td>Auby H. Axler, M.D.</td>
<td>Tactile Systems; Apple Newton</td>
<td>3</td>
</tr>
<tr>
<td>Robert A. Bailey, M.D.</td>
<td>Therapy Enhancement Associates</td>
<td>102</td>
</tr>
<tr>
<td>David Bakish, M.D.</td>
<td>Pfizer Canada Inc.; Boehringer Ingelheim Canada Inc.; Organon Inc.;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bristol-Myers Squibb; Wyeth-Ayest Laboratories; Eli Lilly and Company; SmithKline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Beecham Pharmaceuticals; Hoffmann-LaRoche</td>
<td>13</td>
</tr>
<tr>
<td>Ross J. Baldessarini, M.D.</td>
<td>Eli Lilly and Company; Merck &amp; Co.; Copley; Hoechst Marion Rousell</td>
<td>111</td>
</tr>
<tr>
<td>Richard Balon, M.D.</td>
<td>Bristol-Myers Squibb; Glaxo Wellcome Inc.; Pfizer Inc.; Wyeth-Ayest Laboratories</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Organon Inc.</td>
<td></td>
</tr>
<tr>
<td>James G. Barbee IV, M.D.</td>
<td>Bristol-Myers Squibb; Janssen Pharmacutica and Research Foundation; Pharmacia &amp;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sano Corporation; Roche Laboratories, a member of the Roche Group; TAP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pharmaceuticals; Ciba Geigy Corporation, Pharmaceuticals Division</td>
<td>3, 30, 47, 56, 74, 83</td>
</tr>
<tr>
<td>Barbara D. Bartlik, M.D.</td>
<td>Pfizer Inc.; Pharmine; Rodale Press</td>
<td>10</td>
</tr>
<tr>
<td>Steven M. Baskin, Ph.D.</td>
<td>Merck U.S. Health</td>
<td>26, 97</td>
</tr>
<tr>
<td>Charles M. Beasley, Jr., M.D.</td>
<td>Eli Lilly and Company</td>
<td>53</td>
</tr>
<tr>
<td>Helmut Beckmann, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Barbara Bell, M.D.</td>
<td>MRC-PMAC; Pfizer Canada Inc.</td>
<td>37</td>
</tr>
<tr>
<td>Laura J. Bemay, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>113</td>
</tr>
<tr>
<td>Joseph Biederman, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Eli Lilly and Company; Wyeth-Ayest Laboratories</td>
<td>7, 118</td>
</tr>
<tr>
<td>Renee L. Binder, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>8, 12, 113</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Robert J. Bischoff, Ph.D.</td>
<td>Therapy Enhancement Associates</td>
<td>102</td>
</tr>
<tr>
<td>Donald W. Black, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>50</td>
</tr>
<tr>
<td>Pierre Blier, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories</td>
<td>98</td>
</tr>
<tr>
<td>Howard E. Book, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Abbott Laboratories (employer)</td>
<td>41</td>
</tr>
<tr>
<td>Soo Borson, M.D.</td>
<td>American Psychiatric Press, Inc.</td>
<td>41</td>
</tr>
<tr>
<td>Linda Bosma, M.D.</td>
<td>Eli Lilly Nederland</td>
<td>111</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Merck U.S. Health; Pfizer Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; National Institute of Mental Health</td>
<td>3, 63</td>
</tr>
<tr>
<td>Theron C. Bowers, M.D.</td>
<td>Caduceus Medical Software</td>
<td>88</td>
</tr>
<tr>
<td>John M.W. Bradford, M.B.</td>
<td>Pfizer International, Inc.</td>
<td>64, 74, 109</td>
</tr>
<tr>
<td>Kathleen T. Brady, M.D.</td>
<td>Abbott Laboratories; Pfizer Inc.; Bristol-Myers Squibb</td>
<td>3, 16, 55, 61, 118</td>
</tr>
<tr>
<td>David L. Bratt, M.D.</td>
<td>Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>John C.S. Breitner, M.D.</td>
<td>Bayer</td>
<td>68</td>
</tr>
<tr>
<td>Thomas E. Brown, Ph.D.</td>
<td>The Psychological Corporation</td>
<td>1, 5, 30</td>
</tr>
<tr>
<td>Gina Browne, M.D.</td>
<td>Pfizer Canada, Inc.</td>
<td>57</td>
</tr>
<tr>
<td>Peter F. Buckley, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>10</td>
</tr>
<tr>
<td>Tal Burt, M.D.</td>
<td>Redtop Company, L.L.C.</td>
<td>19, 54, 56, 91</td>
</tr>
<tr>
<td>Marian I. Butterfield, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Pfizer Inc.</td>
<td>17, 111</td>
</tr>
<tr>
<td>Joseph R. Calabrese, M.D.</td>
<td>Abbott Laboratories; E-Merck; Glaxo Wellcome Inc.; Lily Research Laboratories, a division of Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>6, 16, 69, 96</td>
</tr>
<tr>
<td>Joshua W. Calhoun, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>101</td>
</tr>
<tr>
<td>Marc Cantillon, M.D.</td>
<td>Zeneca Pharmaceuticals</td>
<td>86</td>
</tr>
<tr>
<td>William T. Carpenter, Jr., M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Daniel E. Casey, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation</td>
<td>69</td>
</tr>
<tr>
<td>Jacqueelyn B. Chang, M.D.</td>
<td>Zeneca Pharmaceuticals</td>
<td>114</td>
</tr>
<tr>
<td>Dennis S. Charney, M.D.</td>
<td>Organon Inc.; Wyeth-Ayerst Laboratories</td>
<td>7, 11, 46, 62</td>
</tr>
<tr>
<td>James C.Y. Chou, M.D.</td>
<td><em>Pass the Boards!</em></td>
<td>8</td>
</tr>
<tr>
<td>Anita L.H. Clayton, M.D.</td>
<td>Pfizer Inc.; Wyeth-Ayerst Laboratories; Eli Lilly and Company; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals; Organon Inc.; Glaxo Wellcome Inc.</td>
<td>3, 53</td>
</tr>
<tr>
<td>Paula J. Clayton, M.D.</td>
<td>Merck &amp; Co.; Eli Lilly and Company; Organon Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Kathleen F. Clougherty, M.S.W.</td>
<td>National Institute of Mental Health; Pfizer Inc.; Bristol-Myers Squibb; American Psychiatric Press, Inc.; Eli Lilly and Company</td>
<td>1</td>
</tr>
<tr>
<td>Emil F. Coccoro, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Abbott Laboratories; SmithKline Beecham Pharmaceuticals</td>
<td>46, 94</td>
</tr>
<tr>
<td>Bruce M. Cohen, M.D.</td>
<td>Eli Lilly and Company</td>
<td>65</td>
</tr>
<tr>
<td>Lee S. Cohen, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Roche Laboratories, a member of the Roche Group; Pfizer Inc.</td>
<td>6, 9, 27, 36</td>
</tr>
<tr>
<td>Lewis M. Cohen, M.D.</td>
<td>National Kidney Foundation of Massachusetts and Rhode Island; the Open Society; the Greenwall Foundation; Eli Lilly and Company (employer)</td>
<td>107</td>
</tr>
<tr>
<td>Jerome A. Collins, M.D.</td>
<td>Bristol-Myers Squibb; Merck &amp; Co.</td>
<td>21</td>
</tr>
<tr>
<td>Robert R. Conley, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Merck &amp; Co.</td>
<td>120</td>
</tr>
<tr>
<td>Ian A. Cook, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Peter E. Cook, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Ortho-McNeil Pharmaceutical</td>
<td>48</td>
</tr>
<tr>
<td>Theresa L. Crenshaw, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>12</td>
</tr>
</tbody>
</table>
DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey L. Cummings, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Eisai Inc.; Bayer; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Zeneca Pharmaceuticals</td>
<td>13, 17, 100, 105</td>
</tr>
<tr>
<td>Anthony M. D'Agostino, M.D.</td>
<td>Bristol-Myers Squibb; Glaxo Wellcome Inc.; Roche Laboratories, a member of the Roche Group; SmithKline Beecham Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Organon Inc.; Pfizer Inc.</td>
<td>22, 119</td>
</tr>
<tr>
<td>Jonathan R.T. Davidson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>41</td>
</tr>
<tr>
<td>Jonathan S. Davine, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>6, 10</td>
</tr>
<tr>
<td>John M. Davis, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pfizer Inc.</td>
<td>88</td>
</tr>
<tr>
<td>Jesus J. De La Gandara, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Jeffrey D. Delisie, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.</td>
<td>114</td>
</tr>
<tr>
<td>Pedro L. Delgado, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories</td>
<td>99</td>
</tr>
<tr>
<td>Davangere P. Devanand, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories</td>
<td>13, 62, 95</td>
</tr>
<tr>
<td>Ruth A. Dickson, M.D.</td>
<td>Zeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation</td>
<td>6</td>
</tr>
<tr>
<td>Park E. Dietz, M.D.</td>
<td>Threat Assessment Group, Inc.; Novartis Pharmaceuticals Corporation</td>
<td>12</td>
</tr>
<tr>
<td>Lisa B. Dixon, M.D.</td>
<td>Zeneca Pharmaceuticals</td>
<td>10</td>
</tr>
<tr>
<td>John P. Docherty, M.D.</td>
<td>Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>38</td>
</tr>
<tr>
<td>Roberto A. Dominguez, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Ciba Geigy Corporation, Pharmaceuticals Division; Bristol-Myers Squibb; Pfizer Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Rachelle Doody, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.</td>
<td>100</td>
</tr>
<tr>
<td>P. Murali Doraiswamy, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bayer; Eli Lilly and Company; Forest Laboratories, Inc.</td>
<td>66</td>
</tr>
<tr>
<td>Sharon G. Dott, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Zeneca Pharmaceuticals; Abbott Laboratories</td>
<td>7</td>
</tr>
<tr>
<td>Wayne C. Drevets, M.D.</td>
<td>Pfizer Inc.</td>
<td>100</td>
</tr>
<tr>
<td>David L. Dunner, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals, Pfizer Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Organon Inc.; Glaxo Wellcome Inc.; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>7, 69</td>
</tr>
<tr>
<td>Jane L. Eisen, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>10, 34</td>
</tr>
<tr>
<td>James M. Ellison, M.D.</td>
<td>Eli Lilly and Company</td>
<td>93, 114</td>
</tr>
<tr>
<td>Graham J. Emrich, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb</td>
<td>42</td>
</tr>
<tr>
<td>Dwight L. Evans, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; National Institute of Mental Health; Solvay Pharmaceuticals, Inc.</td>
<td>10, 11</td>
</tr>
<tr>
<td>Stephen V. Faraone, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>8</td>
</tr>
<tr>
<td>Martin R. Farlow, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Novartis Pharmaceuticals Corporation; Bayer; Eli Lilly and Company; Somerset Pharmaceuticals; Sigma Tau Pharmaceutical Company; Wyeth-Ayerst Laboratories; Quintiles, Pfizer Inc.; TEVA Marion Partners; National Institute on Aging; Eisai Inc.; Takeda Pharmaceuticals; Janssen Pharmaceutica and Research Foundation</td>
<td>68</td>
</tr>
<tr>
<td>Maurizio Fava, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Roche Laboratories, a member of the Roche Group; Synthelabo Pharmaceuticals; Organon Inc.; Bristol-Myers Squibb; Lorex Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; National Institute of Mental Health; Abbott Laboratories; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Theodore and Vada Stanley Foundation; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; EM Industries, Inc.; Pharmacia &amp; Upjohn Company, Inc.; American Suicide Foundation; Chicago Consortium for Psychiatric Research; American Association of Suicidology; American Society of Clinical Psychopharmacology; Janssen Pharmaceutica and Research Foundation</td>
<td>69, 83, 98</td>
</tr>
<tr>
<td>Jan A. Fawcett, M.D.</td>
<td>National Institute of Mental Health; Abbott Laboratories; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Theodore and Vada Stanley Foundation; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; EM Industries, Inc.; Pharmacia &amp; Upjohn Company, Inc.; American Suicide Foundation; Chicago Consortium for Psychiatric Research; American Association of Suicidology; American Society of Clinical Psychopharmacology; Janssen Pharmaceutica and Research Foundation</td>
<td>13, 68</td>
</tr>
</tbody>
</table>

XX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frank G. Feeley, J.D.</td>
<td>Psychiatrists’ Purchasing Group</td>
<td>85</td>
</tr>
<tr>
<td>Sidney Fein, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>68</td>
</tr>
<tr>
<td>Joel S. Feiner, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>103, 114</td>
</tr>
<tr>
<td>Wayne S. Fenton, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>120</td>
</tr>
<tr>
<td>Francisco Fernandez, M.D.</td>
<td>Bristol-Myers Squibb; Organon Inc.; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories</td>
<td>21</td>
</tr>
<tr>
<td>Steven H. Ferris, Ph.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation</td>
<td>7, 13</td>
</tr>
<tr>
<td>Ivy Fettes, M.D.</td>
<td>Merck U.S. Health</td>
<td>69</td>
</tr>
<tr>
<td>Susan J. Feister, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.</td>
<td>48</td>
</tr>
<tr>
<td>Robert L. Findling, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Zeneica Pharmaceuticals; Abbott Laboratories</td>
<td>6, 16</td>
</tr>
<tr>
<td>Sanford L. Finkel, M.D.</td>
<td>Pfizer Inc. (employer)</td>
<td>99</td>
</tr>
<tr>
<td>W. W. Fleischhacker, M.D.</td>
<td>Eli Lilly and Company; Knoll; Lundbeck; Janssen Pharmaceutica and Research Foundation; International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Alastair J. Flint, M.B.</td>
<td>Forest Laboratories, Inc.</td>
<td>53, 100</td>
</tr>
<tr>
<td>Charles V. Ford, M.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.; Pfizer Inc.; Eli Lilly and Company</td>
<td>1</td>
</tr>
<tr>
<td>Allen J. Frances, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb; Solvay Pharmaceuticals, Inc.; Abbott Laboratories; Zeneica Pharmaceuticals; McNeil Pharmaceuticals; Novartis Pharmaceuticals Corporation; Eli Lilly and Company</td>
<td>47</td>
</tr>
<tr>
<td>Richard J. Frances, M.D.</td>
<td>Pfizer Inc.; Abbott Laboratories; Warner-Lambert; Janssen Pharmaceutica and Research Foundation</td>
<td>16, 47, 65</td>
</tr>
<tr>
<td>Ellen Frank, Ph.D.</td>
<td>Hartford Foundation; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Jewish Healthcare Foundation</td>
<td>2, 9</td>
</tr>
<tr>
<td>Robert Freedman, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>9, 46</td>
</tr>
<tr>
<td>Ellen W. Freeman, Ph.D.</td>
<td>Pfizer Inc.</td>
<td>122</td>
</tr>
<tr>
<td>Mark A. Frye, M.D.</td>
<td>Abbott Laboratories</td>
<td>16, 76</td>
</tr>
<tr>
<td>Abby J. Fyer, M.D.</td>
<td>Merck &amp; Co.; Marion-Merrell Dow; Pfizer Inc.</td>
<td>64</td>
</tr>
<tr>
<td>Glen O. Gabbard, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>16, 42, 56, 64, 70, 97</td>
</tr>
<tr>
<td>Alan J. Gelenberg, M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Zeneica Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Warner-Lambert; Merck-Medco; Eli Lilly and Company</td>
<td>24</td>
</tr>
<tr>
<td>Mark S. George, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Du Pont Pharma; Medi-Physics, Inc., Amersham Healthcare; Picker International; Dantec (Medtronic); Glaxo Wellcome Inc.; Solvay Pharmaceuticals, Inc.; Duphar; Parke-Davis, Division of Warner-Lambert Company</td>
<td>17, 66</td>
</tr>
<tr>
<td>Robert A. George, M.D.</td>
<td>MedChek</td>
<td>47</td>
</tr>
<tr>
<td>Leslie H. Gise, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Merck-Medco</td>
<td>97, 122</td>
</tr>
<tr>
<td>Stuart Gitlow, M.D.</td>
<td>JZSZ Online Productions Inc.; America Online Inc.</td>
<td>39</td>
</tr>
<tr>
<td>Alexander H. Glassman, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Du Pont Pharma; Merck &amp; Co.; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Abbott Laboratories; Forest Laboratories, Inc.</td>
<td>9, 70, 117</td>
</tr>
<tr>
<td>William M. Glazer, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>12</td>
</tr>
<tr>
<td>Ira D. Glick, M.D.</td>
<td>Abbott Laboratories; Zeneica Pharmaceuticals; Otsuka; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation</td>
<td>10</td>
</tr>
<tr>
<td>Donald C. Goff, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Cortex Pharmaceuticals</td>
<td>67</td>
</tr>
<tr>
<td>Robert M. Goisman, M.D.</td>
<td>Eli Lilly and Company</td>
<td>16</td>
</tr>
<tr>
<td>Joseph F. Goldberg, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.</td>
<td>84</td>
</tr>
<tr>
<td>Jill M. Goldstein, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>6, 66</td>
</tr>
<tr>
<td>Michael G. Goldstein, M.D.</td>
<td>Glaxo Wellcome Inc.; McNeil Pharmaceuticals; Eli Lilly and Company; Du Pont Pharma; Merck &amp; Co.; Sano Corporation; Bristol-Myers Squibb; Glaxo Wellcome Inc.</td>
<td>15, 117</td>
</tr>
<tr>
<td>Kimberley P. Good, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>99</td>
</tr>
</tbody>
</table>

XXI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wayne K. Goodman, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>Paul J. Goodnick, M.D.</td>
<td>Bristol-Myers Squibb; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Organon Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Jack M. Gorman, M.D.</td>
<td>Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company; Intereuron; Forest Laboratories, Inc.; Bristol-Myers Squibb</td>
<td>2, 12, 66, 81, 92</td>
</tr>
<tr>
<td>Carl G. Gottfries, Ph.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>70, 100</td>
</tr>
<tr>
<td>John F. Greden, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Alan I. Green, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Hoechst Marion Roussel; Zeneca Pharmaceuticals; Pfizer Inc.; Otsuka</td>
<td>10, 34</td>
</tr>
<tr>
<td>Michael F. Green, Ph.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>99</td>
</tr>
<tr>
<td>David M. Greenberg, M.B.</td>
<td>Pfizer International</td>
<td>74</td>
</tr>
<tr>
<td>John H. Greist, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Bristol-Myers Squibb; Oiba Geigy Corporation, Pharmaceuticals Division; Hoffman-La Roche</td>
<td>10</td>
</tr>
<tr>
<td>Carlos M. Grilo, Ph.D.</td>
<td>National Institutes of Health; Eli Lilly and Company</td>
<td>84, 96</td>
</tr>
<tr>
<td>George T. Grosberg, M.D.</td>
<td>Pfizer Inc.; Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Eli Lilly and Company; Zeneca Pharmaceuticals; Somerset</td>
<td>7, 73, 95</td>
</tr>
<tr>
<td>Alan M. Gruenberg, M.D.</td>
<td>American Home Products; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Zeneca Pharmaceuticals</td>
<td>83, 103</td>
</tr>
<tr>
<td>Lynn R. Grush, M.D.</td>
<td>Eli Lilly and Company</td>
<td>27</td>
</tr>
<tr>
<td>Raquel E. Gur, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>11</td>
</tr>
<tr>
<td>Uriel Halbreich, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>4</td>
</tr>
<tr>
<td>Robert E. Hales, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>15, 41, 44, 73</td>
</tr>
<tr>
<td>Mark H. Halman, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Bristol-Myers Squibb</td>
<td>41, 93</td>
</tr>
<tr>
<td>Katherine A. Halmi, M.D.</td>
<td>Eli Lilly and Company</td>
<td>16, 118</td>
</tr>
<tr>
<td>Susan H. Hamilton</td>
<td>Eli Lilly and Company (employee)</td>
<td>27</td>
</tr>
<tr>
<td>Cary L. Hamlin, M.D.</td>
<td>Fear Free Technology, Inc.</td>
<td>44</td>
</tr>
<tr>
<td>Robert D. Hare, Ph.D.</td>
<td>Psychopathy Checklist (Revised)</td>
<td>64</td>
</tr>
<tr>
<td>Joel T. Haigrove, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>4, 56</td>
</tr>
<tr>
<td>Patricia A. Harris, M.D.</td>
<td>Zeneca Pharmaceuticals</td>
<td>54</td>
</tr>
<tr>
<td>Phillip D. Harvey, Ph.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>3, 67, 99</td>
</tr>
<tr>
<td>Donald P. Hay, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Searle; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Richard G. Heimberg, Ph.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>64</td>
</tr>
<tr>
<td>David J. Hellerstein, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb</td>
<td>111</td>
</tr>
<tr>
<td>Marvin I. Herz, M.D.</td>
<td>Zeneca Pharmaceuticals; Abbott Laboratories; Pfizer Inc.</td>
<td>81</td>
</tr>
<tr>
<td>R. Randolph Hillard, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.</td>
<td>114</td>
</tr>
<tr>
<td>Robert M.A. Hirschfeld, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Organon Inc.; Pfizer Inc.; Hoffman-La Roche; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals</td>
<td>7, 12, 94, 117</td>
</tr>
<tr>
<td>Barbara Hochstrasser, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Lundbeck; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Eric Hollander, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Abbott Laboratories; Glaxo Wellcome Inc.; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company; Pfizer Inc.</td>
<td>3, 9, 67, 92</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>------------------</td>
<td>---------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Leonard Holmes, Ph.D.</td>
<td>The Mining Company; Abbott Laboratories; Adis International Consumers Union; Adcare Association; Advanstar; ALZA Corporation; American Association of Physicians in Alcoholism and Addictions; American Cyanamid; American Medical Association; American Medical Video; American Pharmaceutical Association; American Psychiatric Association; Boehringer Ingelheim; Brookside Hospital; Bruno &amp; Bruno; Caduceus Foundation; Cahners Health Communications; Cheshire Communication; Ciba Geigy Corporation, Pharmaceuticals Division; Consumers Report, Cooley Hospital, David Croasbee, Inc.; Dupont Pharma; Merck &amp; Co.; DynaGen Corporation; Edelman Communications; Elsevier Publishing; Eli Lilly and Company; Fine &amp; Associates; Glaxo Wellcome Inc.; Healthcare Communications Network; Health Values; Henry Ford Hospital; Hoechst Marion Roussel; Marion-Merrell Dow; Humphrey; Farrington and McLan; International Food Information Council; International Life Sciences Institute; Intramedical Health Services; J. Wiley and Sons; Lederle Laboratories; Lifesign Stop Smoking Program; Mae Milban Publishing; Manchester Mental Health Association; Manises Communications; McNeil Pharmaceutical/McNeil Consumer; Medco Management, Inc.; Medical Age Publishing; Medical Economics; Medical Marketing Group; Memorial Sloan Kettering Cancer Center; Miller Fenwick; Miriam Hospital; Montefiore Hospital; National Coffee Manufacturers; National Institutes of Health; Ness Motley and Associates; Neuromedical Technologies, Inc.; Neuroscience Ventures; New England Journal of Medicine; New York State; Nissen &amp; Lumsden; Orbis, Inc.; Palo Alto Center for Disease Prevention; Parke-Davis, Division of Warner-Lambert; Patient Care; Pharmacia &amp; Upjohn Company, Inc.; AB Leo Pharmaceuticals; Kabi Pharmacia; Pharmacia Consumer; Pinney Associates/Corporate Health Policies; Plenum Press; Porter Novelli; Princeton Scientifics; Proctor &amp; Gamble; SmithKline Beecham Pharmaceuticals; Southern Medical Association; Springer-Verlag; St. Peters Medical Center; Symedco; Washington University; Weil, Gotshal &amp; Manges; Wilkerson Group; Wilmer, Cutler &amp; Pickering</td>
<td>33</td>
</tr>
<tr>
<td>John R. Hughes, M.D.</td>
<td>Abbott Laboratories; Adis International Consumers Union; Adcare Association; Advanstar; ALZA Corporation; American Association of Physicians in Alcoholism and Addictions; American Cyanamid; American Medical Association; American Medical Video; American Pharmaceutical Association; American Psychiatric Association; Boehringer Ingelheim; Brookside Hospital; Bruno &amp; Bruno; Caduceus Foundation; Cahners Health Communications; Cheshire Communication; Ciba Geigy Corporation, Pharmaceuticals Division; Consumers Report, Cooley Hospital, David Croasbee, Inc.; Dupont Pharma; Merck &amp; Co.; DynaGen Corporation; Edelman Communications; Elsevier Publishing; Eli Lilly and Company; Fine &amp; Associates; Glaxo Wellcome Inc.; Healthcare Communications Network; Health Values; Henry Ford Hospital; Hoechst Marion Roussel; Marion-Merrell Dow; Humphrey; Farrington and McLan; International Food Information Council; International Life Sciences Institute; Intramedical Health Services; J. Wiley and Sons; Lederle Laboratories; Lifesign Stop Smoking Program; Mae Milban Publishing; Manchester Mental Health Association; Manises Communications; McNeil Pharmaceutical/McNeil Consumer; Medco Management, Inc.; Medical Age Publishing; Medical Economics; Medical Marketing Group; Memorial Sloan Kettering Cancer Center; Miller Fenwick; Miriam Hospital; Montefiore Hospital; National Coffee Manufacturers; National Institutes of Health; Ness Motley and Associates; Neuromedical Technologies, Inc.; Neuroscience Ventures; New England Journal of Medicine; New York State; Nissen &amp; Lumsden; Orbis, Inc.; Palo Alto Center for Disease Prevention; Parke-Davis, Division of Warner-Lambert; Patient Care; Pharmacia &amp; Upjohn Company, Inc.; AB Leo Pharmaceuticals; Kabi Pharmacia; Pharmacia Consumer; Pinney Associates/Corporate Health Policies; Plenum Press; Porter Novelli; Princeton Scientifics; Proctor &amp; Gamble; SmithKline Beecham Pharmaceuticals; Southern Medical Association; Springer-Verlag; St. Peters Medical Center; Symedco; Washington University; Weil, Gotshal &amp; Manges; Wilkerson Group; Wilmer, Cutler &amp; Pickering</td>
<td>33</td>
</tr>
<tr>
<td>Richard D. Hurt, M.D.</td>
<td>Glaxo Wellcome Inc.; McNeil Pharmaceuticals; SANO; SmithKline Beecham Pharmaceuticals; Ciba Geigy Corporation, Pharmaceuticals Division; Marion-Merrell Dow; Eli Lilly and Company; Dupont Pharma; Merck &amp; Co.; DynaGen</td>
<td>9, 48, 117</td>
</tr>
<tr>
<td>Steven E. Hyles, M.D.</td>
<td>Nilo Software &amp; Video</td>
<td>5, 6, 39, 44, 54, 56, 59, 88, 99</td>
</tr>
<tr>
<td>Waguh W. Ishak, M.D.</td>
<td>Redtop, L.L.C.</td>
<td>19, 56, 91</td>
</tr>
<tr>
<td>Jerome H. Jaffe, M.D.</td>
<td>Merck &amp; Co.; Pfizer Inc.; Johnson and Johnson; Bristol-Myers Squibb; Roxanne; Schering-Plough; Algos</td>
<td>51, 87</td>
</tr>
<tr>
<td>Kay R. Jamison, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Abbott Laboratories</td>
<td>72</td>
</tr>
<tr>
<td>Philip G. Janicak, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Glaxo Wellcome Inc.; Abbott Laboratories; Pfizer Inc.; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Pratt; Novartis Pharmaceuticals Corporation</td>
<td>41, 68</td>
</tr>
<tr>
<td>James W. Jefferson, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Eli Lilly and Company; Organon Inc.; Janssen Pharmaceutica and Research Foundation; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Watson Laboratories, Inc.; Bristol-Myers Squibb; Ciba Geigy Corporation, Pharmaceuticals Division; Sealer; Pharmacia &amp; Upjohn Company, Inc.; Roche Laboratories, a member of the Roche Group; Novartis Pharmaceuticals Corporation; Wyeth-Ayerst Laboratories</td>
<td>10</td>
</tr>
<tr>
<td>Rachel Jenkins, M.D.</td>
<td>Johnson and Johnson; Eli Lilly and Company</td>
<td>38, 63</td>
</tr>
<tr>
<td>Dilip V. Jeste, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Zenea Pharmaceuticals</td>
<td>38, 67</td>
</tr>
<tr>
<td>Russell T. Joffe, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Abbott Laboratories; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories</td>
<td>16</td>
</tr>
<tr>
<td>Xenia H. Johnson, M.D.</td>
<td>Zenea Pharmaceuticals</td>
<td>114</td>
</tr>
<tr>
<td>Billy E. Jones, M.D.</td>
<td>Greenspring Health Services; Maryland Health Partners</td>
<td>62, 63</td>
</tr>
<tr>
<td>Lewis L. Judd, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
</tbody>
</table>

XXIII
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>David A. Kahn, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>6, 38</td>
</tr>
<tr>
<td>Ned H. Kolin, M.D.</td>
<td>Wyeth-Ayerst Laboratories; DuPont Pharma; Merck &amp; Co.; Solvay Pharmaceuticals, Inc.</td>
<td>11</td>
</tr>
<tr>
<td>John M. Kane, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Lundbeck; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; McNeil Pharmaceuticals; Zeneca Pharmaceuticals</td>
<td>69</td>
</tr>
<tr>
<td>Andres Kanner, M.D.</td>
<td>Parke-Davis, Division of Warner-Lambert Company; Novartis Pharmaceuticals Corporation</td>
<td>95</td>
</tr>
<tr>
<td>Ira R. Katz, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Zeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>13, 100</td>
</tr>
<tr>
<td>David J. Katzelnick, M.D.</td>
<td>Ciba Geigy Corporation, Pharmaceuticals Division; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.; Abbott Laboratories; Astra/Merck Group, Division of Merck &amp; Co.; Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Watson Laboratories, Inc.; Pfizer Inc.; Upjohn Company, Inc.</td>
<td>30</td>
</tr>
<tr>
<td>Richard J. Kavoussi, M.D.</td>
<td>Abbott Laboratories; Alza; Parke-Davis, Division of Warner-Lambert Company; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Glaxo Wellcome Inc.; Eli Lilly and Company; Worldwide; Janssen Pharmaceutica and Research Foundation; Stanley Foundation; National Institute of Drug Abuse; National Institute of Mental Health; Pfizer Inc.; Zeneca Pharmaceuticals</td>
<td>3, 12, 52</td>
</tr>
<tr>
<td>Paul E. Keck, Jr., M.D.</td>
<td>Lilly Research Laboratories, a division of Eli Lilly and Company</td>
<td>67</td>
</tr>
<tr>
<td>Gabor I. Keilner, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>7, 103</td>
</tr>
<tr>
<td>Martin B. Keller, M.D.</td>
<td>Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Pfizer Inc.; Bristol-Myers Squibb; Eli Lilly and Company</td>
<td>9, 99</td>
</tr>
<tr>
<td>James L. Kennedy, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Terence A. Ketter, M.D.</td>
<td>Abbott Laboratories; Parke-Davis, Division of Warner-Lambert Company; Wyeth-Ayerst Laboratories; SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Eli Lilly and Company</td>
<td>16, 96</td>
</tr>
<tr>
<td>Paul A. Kettl, M.D.</td>
<td>Pfizer Inc.; Wyeth-Ayerst Laboratories; Manor Health Care; Abbott Laboratories</td>
<td>47</td>
</tr>
<tr>
<td>Steven A. King, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>30</td>
</tr>
<tr>
<td>Herbert D. Kleber, M.D.</td>
<td>Dupont Pharma</td>
<td>18, 97, 120</td>
</tr>
<tr>
<td>Donald F. Klein, M.D.</td>
<td>Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome Inc.; Pharmacia &amp; Upjohn Company, Inc.; Eli Lilly and Company; Interneuron; Pfizer Inc.; Bristol-Myers Squibb; Abbott Laboratories</td>
<td>12, 29, 37</td>
</tr>
<tr>
<td>James H. Kocsis, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Abbott Laboratories</td>
<td>37, 69</td>
</tr>
<tr>
<td>George F. Koob, Ph.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>9</td>
</tr>
<tr>
<td>Lili C. Kopala, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>99</td>
</tr>
<tr>
<td>Susan G. Kornstein, M.D.</td>
<td>Bristol-Myers Squibb; Pfizer, Inc.</td>
<td>7</td>
</tr>
<tr>
<td>Edward M. Kovachy, Jr., M.D.</td>
<td>Therapy Enhancement Associates</td>
<td>102</td>
</tr>
<tr>
<td>K. Ranga Rama Krishnan, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Hoffman-LaRoche</td>
<td>2</td>
</tr>
<tr>
<td>Vinod Kumar, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Hoffman-LaRoche</td>
<td>88</td>
</tr>
<tr>
<td>David J. Kupfer, M.D.</td>
<td>Eli Lilly and Company</td>
<td>2</td>
</tr>
<tr>
<td>Stanley P. Kutcher, M.D.</td>
<td>Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Eli Lilly and Company</td>
<td>23, 42</td>
</tr>
<tr>
<td>Raymond W. Lam, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Otsuka; ICN Canada; Eli Lilly Canada; ICN Canada; Chelsea Pharmaceuticals; Merck &amp; Co.; Mylan Pharmaceuticals; Pfizer Inc.; Upjohn Company, Inc.</td>
<td>62, 92, 99</td>
</tr>
<tr>
<td>William B. Lawson, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Abbott Laboratories; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Otsuka; Pfizer Inc.; Upjohn Company, Inc.</td>
<td>63</td>
</tr>
<tr>
<td>Barry D. Lebowitz, Ph.D.</td>
<td>Merck &amp; Co.; Mylan Pharmaceuticals</td>
<td>109</td>
</tr>
<tr>
<td>Douglas S. Lehrer, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Abbott Laboratories; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Otsuka; Pfizer Inc.; Upjohn Company, Inc.</td>
<td>19, 31, 117</td>
</tr>
<tr>
<td>Allen Lechtenflucht, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Abbott Laboratories; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Otsuka; Pfizer Inc.; Upjohn Company, Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Andrew F. Leuchter, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Freda C. Lewis-Hall, M.D.</td>
<td>Psychiatry's Purchasing Group, Inc.</td>
<td>54</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Peter F. Liddle, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceuticals Corporation and Research Foundation; Ortho Inc.</td>
<td>63</td>
</tr>
<tr>
<td>Jeffrey A. Lieberman, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Janssen Pharmaceuticals Corporation and Research Foundation; Zeneca Pharmaceuticals; Pfizer Inc.</td>
<td>7, 10, 68</td>
</tr>
<tr>
<td>Michael R. Liebowitz, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Eli Lilly and Company; Synthelabo; Roche Laboratories, a member of the Roche Group; Solvay Pharmaceuticals, Inc.; Pfizer Inc.; Boehringer Ingelheim; Bristol-Myers Squibb</td>
<td>6, 64, 68, 121</td>
</tr>
<tr>
<td>Russell F. Lin, M.D.</td>
<td>Eli Lilly and Company</td>
<td>8, 19, 44, 56, 76, 88, 99, 110</td>
</tr>
<tr>
<td>Keh-Ming Lin, M.D.</td>
<td>Zeneca Pharmaceuticals; Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company</td>
<td>80, 94</td>
</tr>
<tr>
<td>Jean-Pierre Lindenmayer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals and Research Foundation</td>
<td>10, 86</td>
</tr>
<tr>
<td>Marsha M. Linehan, Ph.D.</td>
<td>Guilford Publications, Inc.</td>
<td>6, 64</td>
</tr>
<tr>
<td>John R. Lion, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>12</td>
</tr>
<tr>
<td>Richard B. Lipton, M.D.</td>
<td>Bristol-Myers Squibb; Abbott Laboratories; Glaxo Wellcome Inc.; Zambon; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Merck U.S. Health</td>
<td>69</td>
</tr>
<tr>
<td>R. Bruce Lydiard, M.D.</td>
<td>Bristol-Myers Squibb</td>
<td>10</td>
</tr>
<tr>
<td>Mario Maj, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Jose R. Maldonado, M.D.</td>
<td>Glaxo Wellcome Inc.; Eli Lilly and Company; Pfizer Inc.</td>
<td>1</td>
</tr>
<tr>
<td>Husseini K. Manji, M.D.</td>
<td>Pharmac &amp; Upjohn Company, Inc.; Organon Inc.; Abbott Laboratories; Lilly Research Laboratories, a division of Eli Lilly and Company; Glaxo Wellcome Inc.</td>
<td>116</td>
</tr>
<tr>
<td>Lauren B. Mangell, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb</td>
<td>73</td>
</tr>
<tr>
<td>Stephen R. Marder, M.D.</td>
<td>Janssen Pharmaceuticals and Research Foundation; Novartis Pharmaceuticals Corporation and Research Foundation; Eli Lilly and Company; Abbott Laboratories; Zeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Bristol-Myers Squibb; National Institute of Mental Health; Eli Lilly and Company; American Psychiatric Press, Inc.</td>
<td>1, 16, 35, 42, 78</td>
</tr>
<tr>
<td>Randall D. Marshall, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>91</td>
</tr>
<tr>
<td>Daniel B. Martinez, M.D.</td>
<td>Zeneca Pharmaceuticals</td>
<td>114</td>
</tr>
<tr>
<td>Prakash S. Marand, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceuticals and Research Foundation; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>6, 12, 118</td>
</tr>
<tr>
<td>Ninan T. Mathew, M.D.</td>
<td>Bristol-Myers Squibb; Glaxo Wellcome Inc.; Abbott Laboratories; Merck U.S. Health</td>
<td>69</td>
</tr>
<tr>
<td>Richard H. McCarthy, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company</td>
<td>86</td>
</tr>
<tr>
<td>Susan L. McElroy, M.D.</td>
<td>Abbott Laboratories; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Glaxo Wellcome Inc.; Alza; Wyeth-Ayerst Laboratories; Parke-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals</td>
<td>80</td>
</tr>
<tr>
<td>Bruce S. McEwen, Ph.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>4</td>
</tr>
<tr>
<td>Benton H. McFarland, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals</td>
<td>47, 52</td>
</tr>
<tr>
<td>Patrick J. McGrath, M.D.</td>
<td>Pharmacia &amp; Upjohn Company, Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Susan R. McGurk, Ph.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceuticals and Research Foundation; Eli Lilly and Company</td>
<td>3, 99</td>
</tr>
<tr>
<td>Dennis J. McKenna, Ph.D.</td>
<td>Modern Alchemy; Mauna Kea Nutraceuticals</td>
<td>94</td>
</tr>
<tr>
<td>William T. McKinney, Jr., M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.; Eli Lilly and Company; Abbott Laboratories</td>
<td>79, 117</td>
</tr>
<tr>
<td>Thomas D. McRoe, M.D.</td>
<td>Pfizer Inc.</td>
<td>86</td>
</tr>
<tr>
<td>David Mee-Lee, M.D.</td>
<td>New Standards, Inc.</td>
<td>41</td>
</tr>
<tr>
<td>Herbert Y. Meltzer, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Pfizer Inc.; Abbott Laboratories; Zeneca Pharmaceuticals; Eli Lilly and Company; Otsuka</td>
<td>3, 10</td>
</tr>
<tr>
<td>Julien Mendlewicz, M.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Roger E. Meyer, M.D.</td>
<td>United Behavioral Health Care</td>
<td>9</td>
</tr>
<tr>
<td>Barnett S. Meyers, M.D.</td>
<td>Forest Laboratories, Inc.</td>
<td>100</td>
</tr>
<tr>
<td>David Michelson, M.D.</td>
<td>Eli Lilly and Company</td>
<td>84</td>
</tr>
</tbody>
</table>

XXV
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivan W. Miller, Ph.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Organon Inc.; Eli Lilly and Company</td>
<td>27</td>
</tr>
<tr>
<td>Lisa J.F. Miller, Ph.D.</td>
<td>Pfizer Inc.</td>
<td>111</td>
</tr>
<tr>
<td>Jacobo E. Mintzer, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.</td>
<td>86, 95, 105</td>
</tr>
<tr>
<td>Darío F. Minski, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>95</td>
</tr>
<tr>
<td>James E. Mitchell, M.D.</td>
<td>Eli Lilly and Company; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals</td>
<td>16, 118</td>
</tr>
<tr>
<td>Kerry E. Mitchell, M.D.</td>
<td>Pfizer Inc.</td>
<td>24</td>
</tr>
<tr>
<td>John Monahan, Ph.D.</td>
<td>ProMental Group</td>
<td>5</td>
</tr>
<tr>
<td>Maureen Mondor, R.N.</td>
<td>Orson Inc.</td>
<td>7</td>
</tr>
<tr>
<td>Stuart A. Montgomery, M.D.</td>
<td>Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Eisai Inc.; Forest Laboratories, Inc.</td>
<td>100</td>
</tr>
<tr>
<td>Benoit H. Mulsant, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Zeneca Pharmaceuticals Corporation</td>
<td>10</td>
</tr>
<tr>
<td>Henry A. Nasrallah, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; Zeneca Pharmaceuticals</td>
<td>4, 53</td>
</tr>
<tr>
<td>Devdutt V. Nayak, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>68</td>
</tr>
<tr>
<td>J. Craig Nelson, M.D.</td>
<td>Abbott Laboratories; Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Wyeth-Ayerst Laboratories; Ciba Geigy Corporation, Pharmaceuticals Division; Organon Inc.; Hoechst Marion Rousell; SmithKline Beecham Pharmaceuticals; Pfizer Inc.</td>
<td>10, 69</td>
</tr>
<tr>
<td>Charles B. Nemeroff, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>2</td>
</tr>
<tr>
<td>Peter J. Neumann, Sc.D.</td>
<td>Pfizer Inc.; Eisai Inc.</td>
<td>100</td>
</tr>
<tr>
<td>Raymond S. Niaura, Ph.D.</td>
<td>Glaxo Wellcome Inc.; Sano Corporation</td>
<td>15, 117</td>
</tr>
<tr>
<td>Andrew A. Nierenberg, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Sano Corporation</td>
<td>13, 98, 99</td>
</tr>
<tr>
<td>Keith H. Nuechterlein, Ph.D.</td>
<td>Pfizer Inc.; Sanofi-Winthrop; Searle; Parke-Davis, Division of Warner-Lambert Company; Hoechst Marion Rousell; National Institutes of Health; Dupont Pharma; Merck &amp; Co.; Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; Cardiologic Systems; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Astra/Merck Group, Division of Merck &amp; Co.</td>
<td>113</td>
</tr>
<tr>
<td>Christopher O'Connor, M.D.</td>
<td>Pfizer Inc.; Sanofi-Winthrop; Searle; Parke-Davis, Division of Warner-Lambert Company; Hoechst Marion Rousell; National Institutes of Health; Dupont Pharma; Merck &amp; Co.; Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; Cardiologic Systems; Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Astra/Merck Group, Division of Merck &amp; Co.</td>
<td>2</td>
</tr>
<tr>
<td>Samuel O. Okpaku, M.D.</td>
<td>Abbott Laboratories</td>
<td>63</td>
</tr>
<tr>
<td>Mark Olsson, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>65, 116</td>
</tr>
<tr>
<td>Lewis A. Opler, M.D.</td>
<td>Multi-Health Systems, Inc.</td>
<td>5, 46, 67</td>
</tr>
<tr>
<td>C. Richard Orndoff, M.Ed.</td>
<td>Greenspring Health Services, Inc.; Advacare</td>
<td>63</td>
</tr>
<tr>
<td>Robert B. Ostroff, M.D.</td>
<td>Psych Management, Inc.</td>
<td>95</td>
</tr>
<tr>
<td>Michael W. Otto, Ph.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Parke-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; Roche Laboratories, a member of the Roche Group</td>
<td>9</td>
</tr>
<tr>
<td>Barbara L. Parry, M.D.</td>
<td>Pfizer Inc.</td>
<td>62, 122</td>
</tr>
<tr>
<td>Michele T. Pato, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>3, 15</td>
</tr>
<tr>
<td>Robert D. Patterson, M.D.</td>
<td>Mental Health Connections Inc.</td>
<td>65, 76</td>
</tr>
<tr>
<td>David Pauls, Ph.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Diana O. Perkins, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Hoechst Marion Rousell; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Zeneca Pharmaceuticals; Novartis Pharmaceuticals Corporation</td>
<td>50, 60</td>
</tr>
<tr>
<td>Eric D. Peselow, M.D.</td>
<td>Pfizer Inc.</td>
<td>113</td>
</tr>
<tr>
<td>Katharine A. Phillips, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Solvay Pharmaceuticals, Inc.; Gate Pharmaceuticals</td>
<td>11</td>
</tr>
<tr>
<td>Robert T.M. Phillips, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>12, 47, 80</td>
</tr>
<tr>
<td>David Pickar, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>10</td>
</tr>
<tr>
<td>Teresa A. Pigott, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Eli Lilly and Company; Parke-Davis, Division of Warner-Lambert Company; Bristol-Myers Squibb; Wyeth-Ayerst Laboratories; Glaxo Wellcome Inc.; Interneuron, Inc.; Organon Inc.; RW Johnson; Obsessive-Compulsive Foundation; Pharmacia &amp; Upjohn Company, Inc.; Ciba Geigy Corporation, Pharmaceuticals Division</td>
<td>6</td>
</tr>
<tr>
<td>Harold Alan Pincus, M.D.</td>
<td>American Psychiatric Association (employer)</td>
<td>29, 46, 65, 95</td>
</tr>
</tbody>
</table>

XXVI
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark H. Pollack, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Solvay Pharmaceuticals, Inc.; Bristol-Myers Squibb; Parke-Davis, Division of Warner-Lambert Company</td>
<td>9, 112</td>
</tr>
<tr>
<td>Bruce G. Pollock, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Forest Laboratories, Inc.; National Institutes of Health</td>
<td>100</td>
</tr>
<tr>
<td>Michael Pontecorvo, M.D.</td>
<td>Johnson and Johnson; Janssen Pharmaceutica and Research Foundation (employer)</td>
<td>86</td>
</tr>
<tr>
<td>Charles W. Popper, M.D.</td>
<td>Mary Ann Liebert, Inc.; Abbott Laboratories; Richwood; Pharmacia &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb</td>
<td>71</td>
</tr>
<tr>
<td>Robert M. Post, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.</td>
<td>6, 96</td>
</tr>
<tr>
<td>Ronald A. Rabin, M.D.</td>
<td>Abbott Laboratories</td>
<td>84</td>
</tr>
<tr>
<td>Peter V. Rabins, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>7, 38</td>
</tr>
<tr>
<td>Jiri Raboch, M.D.</td>
<td>Roche Laboratories, a member of the Roche Group; Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Giorgio Racagni, Ph.D.</td>
<td>International Academy for Biomedical and Drug Research</td>
<td>4</td>
</tr>
<tr>
<td>Susan Rako, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.</td>
<td>97</td>
</tr>
<tr>
<td>Mark H. Rapaport, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; Pharmacia &amp; Upjohn Company, Inc.; Lilly Research Laboratories, a division of Eli Lilly and Company; Pfizer Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Alan M. Rapoport, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Abbott Laboratories; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Merck U.S. Health</td>
<td>69</td>
</tr>
<tr>
<td>Murray A. Raskind, M.D.</td>
<td>Bayer; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Janssen Pharmaceutica and Research Foundation</td>
<td>13</td>
</tr>
<tr>
<td>Scott L. Rauch, M.D.</td>
<td>Glaxo Wellcome Inc.; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>6</td>
</tr>
<tr>
<td>Noreen A. Reilly-Harrington, Ph.D.</td>
<td>Glaxo Wellcome Inc.; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>12</td>
</tr>
<tr>
<td>Domeena C. Renshaw, M.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>66, 91</td>
</tr>
<tr>
<td>Phillip J. Resnick, M.D.</td>
<td>Novartis Pharmaceuticals Corporation</td>
<td>5, 12, 16, 41, 73</td>
</tr>
<tr>
<td>Victor I. Reus, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Pfizer Inc.</td>
<td>97</td>
</tr>
<tr>
<td>S. Craig Risch, M.D.</td>
<td>Abbott Laboratories; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Novartis Pharmaceuticals Corporation; Seattle</td>
<td>27</td>
</tr>
<tr>
<td>Steven J. Romano, M.D.</td>
<td>Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.</td>
<td>2, 70, 94</td>
</tr>
<tr>
<td>Steven P. Roose, M.D.</td>
<td>Pfizer Inc.; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Forest Laboratories, Inc.</td>
<td>2, 70, 94</td>
</tr>
<tr>
<td>Jerrold F. Rosenbaum, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Forest Laboratories, Inc.; Sanofi; Roche Laboratories, a member of the Roche Group</td>
<td>2</td>
</tr>
<tr>
<td>Anthony J. Rothschild, M.D.</td>
<td>Zeneca Pharmaceuticals; Eli Lilly and Company; Glaxo Wellcome Inc.; Otsuka; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.</td>
<td>41</td>
</tr>
<tr>
<td>Bruce J. Rounsaville, M.D.</td>
<td>Dupont Pharma</td>
<td>64, 120</td>
</tr>
<tr>
<td>Sean B. Routke, Ph.D.</td>
<td>Glaxo Wellcome Inc.</td>
<td>112</td>
</tr>
<tr>
<td>Barry W. Rovner, M.D.</td>
<td>Abbott Laboratories</td>
<td>13</td>
</tr>
<tr>
<td>David R. Rubinow, M.D.</td>
<td>Dist; TAP Pharmaceuticals; Ciba Geigy Corporation, Pharmaceuticals Division; Upshure-Smith; Eli Lilly and Company</td>
<td>6</td>
</tr>
<tr>
<td>A. John Rush, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Abbott Laboratories; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Organon Inc.</td>
<td>2, 7, 65</td>
</tr>
<tr>
<td>Gary S. Sachs, M.D.</td>
<td>Roche Laboratories, a member of the Roche Group; Glaxo Wellcome Inc.; Parke-Davis, Division of Warner-Lambert Company; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories; Solvay Pharmaceuticals, Inc.; Sanofi; Pfizer Inc.</td>
<td>6, 65</td>
</tr>
<tr>
<td>Harold A. Sackei, M.D.</td>
<td>Glaxo Wellcome Inc.; Abbott Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>23, 99</td>
</tr>
<tr>
<td>Kenneth M. Sakauye, M.D.</td>
<td>Pfizer Inc.; Bristol-Myers Squibb; Janssen Pharmaceutica and Research Foundation</td>
<td>120</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Carl Salzman, M.D.</td>
<td>Zeneca Pharmaceuticals; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Protodigm; Janssen Pharmaceutica and Research Foundation; Forest Laboratories, Inc.; Wyeth-Ayerst Laboratories</td>
<td>99</td>
</tr>
<tr>
<td>Gerard Sanacora, M.D.</td>
<td>Pfizer Inc.</td>
<td>112</td>
</tr>
<tr>
<td>Nat H. Sandler, M.D.</td>
<td>Eli Lilly and Company; Zeneca Pharmaceuticals; Warner-Lambert; Pfizer Inc.; Glaxo Wellcome Inc.; Watson Laboratories, Inc.</td>
<td>83</td>
</tr>
<tr>
<td>Joel Saper, M.D.</td>
<td>Bristol-Myers Squibb; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Merck U.S. Health; Glaxo Wellcome Inc.; Eli Lilly and Company; Pfizer Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Alan F. Schatzberg, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories; Pfizer Inc.; Bristol-Myers Squibb; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories</td>
<td>7, 12</td>
</tr>
<tr>
<td>Steven J. Schleifer, M.D.</td>
<td>Greenspring Health Services of New Jersey</td>
<td>114</td>
</tr>
<tr>
<td>Lon S. Schneider, M.D.</td>
<td>Bayer; Eisai Inc.; Pfizer Inc.; Novartis Pharmaceuticals Corporation; Parke-Davis, Division of Warner-Lambert Company; Somerset; SmithKline Beecham Pharmaceuticals; American Association for Geriatric Psychiatry; Johnson and Johnson; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation</td>
<td>13, 68</td>
</tr>
<tr>
<td>S. Charles Schulz, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Pfizer Inc.; Zeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation</td>
<td>6</td>
</tr>
<tr>
<td>Dean Schuyler, M.D.</td>
<td>Eli Lilly and Company</td>
<td>2</td>
</tr>
<tr>
<td>R. Taylor Segraves, M.D.</td>
<td>Organon Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Edmund C. Settle, Jr., M.D.</td>
<td>Glaxo Wellcome Inc.; SmithKline Beecham Pharmaceuticals; Bristol-Myers Squibb; Organon Inc.; Pharmacia &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.</td>
<td>10</td>
</tr>
<tr>
<td>Jerold L. Shapiro, Ph.D.</td>
<td>Therapy Enhancement Associates</td>
<td>102</td>
</tr>
<tr>
<td>Shawn C. Shea, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>5, 42</td>
</tr>
<tr>
<td>M. Katherine Shear, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Glaxo Wellcome; Hoffman-LaRoche; Bristol-Myers Squibb; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>12</td>
</tr>
<tr>
<td>David V. Sheehan, M.D.</td>
<td>American Medical Association; Anclote Foundation; Bristol-Myers Squibb; National Institutes of Health; Glaxo Wellcome Inc.; Eisai Inc.; ICR; Janssen Pharmaceutica and Research Foundation; Kali Duphar Laboratories, Inc.; Eli Lilly and Company; Wyeth-Ayerst Laboratories; Merck Sharp &amp; Dohme Ltd.; National Institute on Drug Abuse; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Quintiles Pacific; Novartis Pharmaceuticals Corporation; SmithKline Beecham Pharmaceuticals; TAP Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Zeneca Pharmaceuticals; Warner Chilcott Pharmaceutical Company; Tampa General Hospital, University Psychiatric Center; Abbott Laboratories; Organon Inc.; Philadelphia College of Pharmacy &amp; Science; Lilly Research Laboratories, a division of Eli Lilly and Company; Connecticut &amp; Ohio Academies of Family Physicians; CPC Coliseum Medical Center; USF Friends of Research in Psychiatry; National Anxiety Awareness Program; Anxiety Disorders Resource Center; APA Task Force on Treatments of Psychiatric Disorders; APA Task Force on Benzodiazepine Dependency; National Depressive &amp; Manic Depressive Association; Council on Anxiety Disorders; Division of Drugs &amp; Technology; American Medical Association; Ad Hoc Committee, Treatment Drug &amp; Assessment Research Review Committee of National Institute of Mental Health on Anxiety and Phobic Disorder Projects; APA Work Group to revise DSM-III Anxiety Disorders Section; Anxiety Drug Efficacy Case, U.S. Food &amp; Drug Administration; Boehringer Ingelheim; Boots; Charter Hospitals; Ciba Geigy Corporation, Pharmaceuticals Division; Dista; Rhone-Poulenc Rorer Pharmaceuticals; Roche Laboratories, a member of the Roche Group; Schering Corporation; Excetpa Medica Asia; Hospital Corporation of America; Humana; ICI; Marion-Merrell Dow; McNeil Pharmaceuticals</td>
<td>6</td>
</tr>
<tr>
<td>Fred D. Sheftell, M.D.</td>
<td>Wyeth-Ayerst Laboratories; Proctor &amp; Gamble Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>69</td>
</tr>
<tr>
<td>Barbara B. Sherwin, Ph.D.</td>
<td>Merck U.S. Health</td>
<td></td>
</tr>
<tr>
<td>Marjorie L. Shuer, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>4, 13</td>
</tr>
<tr>
<td>Larry J. Steer, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Wyeth-Ayerst Laboratories</td>
<td>4, 56</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4, 39, 61, 103</td>
</tr>
<tr>
<td>Presenter</td>
<td>Manufacturer(s)</td>
<td>Program Page #</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Samuel G. Siris, M.D.</td>
<td>Pfizer Inc.</td>
<td>67, 92</td>
</tr>
<tr>
<td>Gary W. Small, M.D.</td>
<td>Pfizer Inc.; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Eli Lilly and Company; Bayer; Janssen Pharmaceutica and Research Foundation</td>
<td>13, 68</td>
</tr>
<tr>
<td>Michael W. Smith, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Organon Inc.; Zeneca Pharmaceuticals; Scios Nova Pharmaceuticals</td>
<td>8, 94</td>
</tr>
<tr>
<td>Thomas J. Spencer, M.D.</td>
<td>Wyeth-Ayerst Laboratories</td>
<td>7, 8</td>
</tr>
<tr>
<td>David A. Spiegel, M.D.</td>
<td>Pfizer Inc.</td>
<td>12</td>
</tr>
<tr>
<td>Margaret G. Spinelli, M.D.</td>
<td>Eli Lilly and Company</td>
<td>9, 27, 36</td>
</tr>
<tr>
<td>Stephen M. Stahl, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.; Solvay Pharmaceuticals, Inc.; Janssen Pharmaceutica and Research Foundation; Bayer; Yamanouchi; Glaxo Wellcome Inc.; Wyeth-Ayerst Laboratories; Roche Laboratories, a division of the Roche Group; Ciba Geigy Corporation, Pharmaceuticals Division; Pharma &amp; Upjohn Company, Inc.; Hoechst Marion Roussel; Takeda; Abbott Laboratories; Organon Inc.; Neurocrine Biosciences, Inc.</td>
<td>15</td>
</tr>
<tr>
<td>Murray B. Stein, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.; Hoffman-LaRoche; Pharma &amp; Upjohn Company, Inc.; Bristol-Myers Squibb; Patke-Davis, Division of Warner-Lambert Company</td>
<td>9, 64, 92, 121</td>
</tr>
<tr>
<td>Meir Steiner, M.D.</td>
<td>MRC-PMAC; Pfizer Canada Inc.</td>
<td>37</td>
</tr>
<tr>
<td>Andrew L. Stoll, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Pfizer Inc.; Janssen Pharmaceutica and Research Foundation; Glaxo Wellcome Inc.; Abbott Laboratories; SmithKline Beecham Pharmaceuticals; Organon Inc.; Solvay Pharmaceuticals, Inc.; Eli Lilly and Company</td>
<td>65, 98</td>
</tr>
<tr>
<td>Nada L. Stotland, M.D.</td>
<td>Pfizer Inc.; Solvay Pharmaceuticals, Inc.; Zeneca Pharmaceuticals</td>
<td>42, 54, 108, 113</td>
</tr>
<tr>
<td>Stephen M. Strakowski, M.D.</td>
<td>Zeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Otsuka America Pharmaceuticals; Hoechst Marion Roussel; Abbott Laboratories; Pfizer Inc.</td>
<td>7</td>
</tr>
<tr>
<td>John Strang, M.D.</td>
<td>Britannia Pharmaceuticals (England)</td>
<td>120</td>
</tr>
<tr>
<td>Jamie S. Street, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>86</td>
</tr>
<tr>
<td>David L. Sulfzer, M.D.</td>
<td>Pfizer Inc.; Eisai Inc.</td>
<td>100, 105</td>
</tr>
<tr>
<td>Trey Sunderland, M.D.</td>
<td>Pfizer Inc.; Eisai Inc.</td>
<td>62, 100</td>
</tr>
<tr>
<td>Norman Susman, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Pfizer Inc.; SmithKline Beecham Pharmaceuticals</td>
<td>15, 82, 92</td>
</tr>
<tr>
<td>Eva M. Szegethy, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>56</td>
</tr>
<tr>
<td>Carol A. Tamminga, M.D.</td>
<td>Abbott Laboratories; Eli Lilly and Company; Pfizer Inc.; Wyeth-Ayerst Laboratories; Janssen Pharmaceutica and Research Foundation; Lundbeck</td>
<td>69</td>
</tr>
<tr>
<td>Roy Tamura, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>83</td>
</tr>
<tr>
<td>Rajiv Tandon, M.D.</td>
<td>Abbott Laboratories; Zeneca Pharmaceuticals; Janssen Pharmaceutica and Research Foundation; Novartis Pharmaceuticals Corporation</td>
<td>10</td>
</tr>
<tr>
<td>Terri L. Tanieland, M.A.</td>
<td>American Psychiatric Association (employer)</td>
<td>29</td>
</tr>
<tr>
<td>Pierre N. Tariot, M.D.</td>
<td>Eisai Inc.; Pfizer Inc.; Takeda; SmithKline Beecham Pharmaceuticals; Zeneca Pharmaceuticals; Somesent; Abbott Laboratories; Novartis Pharmaceuticals Corporation; Pharma &amp; Upjohn Company, Inc.; Bayer; Janssen Pharmaceutica and Research Foundation; Astra/Merck Group, Division of Merck &amp; Co.; Alza; Ipsen; Sanofi</td>
<td>13, 68</td>
</tr>
<tr>
<td>Donald E. Tarver, M.D.</td>
<td>Transgender Care (co-author)</td>
<td>55</td>
</tr>
<tr>
<td>Martin H. Teicher, M.D.</td>
<td>CirceSoft Inc.; Glaxo Wellcome Inc.; Watson Laboratories, Inc.</td>
<td>42</td>
</tr>
<tr>
<td>Clifton R. Tennison, Jr., M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; SmithKline Beecham Pharmaceuticals</td>
<td>103</td>
</tr>
<tr>
<td>Michael E. Thase, M.D.</td>
<td>Bristol-Myers Squibb; Eli Lilly and Company; Organon Inc.; Pfizer Inc.; Wyeth-Ayerst Laboratories; Glaxo Wellcome Inc.; Cerenex; Lhipharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>1, 7, 16, 38, 41, 42, 93, 118, 119</td>
</tr>
<tr>
<td>John W. Thompson, Jr., M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>113</td>
</tr>
<tr>
<td>Troy L. Thompson II, M.D.</td>
<td>Distar; SmithKline Beecham Pharmaceuticals; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb; Glaxo Wellcome Inc.</td>
<td>12, 53</td>
</tr>
<tr>
<td>Mauricio Tohen, M.D.</td>
<td>Eli Lilly and Company (employer)</td>
<td>12, 53</td>
</tr>
<tr>
<td>Herman A. Tolbert, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation</td>
<td>4</td>
</tr>
</tbody>
</table>

XXIX
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Martin G. Tracy, J.D.</td>
<td>Professional Risk Management Services, Inc.</td>
<td>20, 29, 85</td>
</tr>
<tr>
<td>Paula T. Trzepecz, M.D.</td>
<td>Pfizer Inc.</td>
<td>78</td>
</tr>
<tr>
<td>Fred Turek, Ph.D.</td>
<td>Merck &amp; Co.; Servier</td>
<td>117</td>
</tr>
<tr>
<td>George E. Vaillant, M.D.</td>
<td>Pfizer Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Daniel P. van Kammen, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Pfizer Inc.; Zeneca Pharmaceuticals; Abbott Laboratories</td>
<td>41</td>
</tr>
<tr>
<td>Richard C. Velth, M.D.</td>
<td>Pfizer Inc.</td>
<td>99</td>
</tr>
<tr>
<td>Bruce S. Victor, M.D.</td>
<td>Eli Lilly and Company; Pfizer Inc.; Wyeth-Ayerst Laboratories; Bristol-Myers Squibb</td>
<td>1</td>
</tr>
<tr>
<td>Ivan C.A. Walks, M.D.</td>
<td>Options Health Care Inc.</td>
<td>28, 63</td>
</tr>
<tr>
<td>Joel J. Wallack, M.D.</td>
<td>Bristol-Myers Squibb; Pfizer Inc.; Merck &amp; Co.</td>
<td>52</td>
</tr>
<tr>
<td>B. Timothy Walsh, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories</td>
<td>33, 69</td>
</tr>
<tr>
<td>Peter J. Welden, M.D.</td>
<td>Zeneca Pharmaceuticals; Eli Lilly and Company; Pfizer Inc.</td>
<td>7, 27</td>
</tr>
<tr>
<td>Daniel R. Weinberger, M.D.</td>
<td>Pfizer Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Lisa S. Weinstock, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals</td>
<td>9</td>
</tr>
<tr>
<td>Myrna M. Weissman, Ph.D.</td>
<td>Eli Lilly and Company</td>
<td>9, 35, 78</td>
</tr>
<tr>
<td>Bryant Welch, J.D.</td>
<td>Merck &amp; Co.</td>
<td>22</td>
</tr>
<tr>
<td>K.A. Welsh-Bohmer, Ph.D.</td>
<td>Bayer</td>
<td>68</td>
</tr>
<tr>
<td>Scott A. West, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Pfizer Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Hoechst Marion Roussel; Janssen Pharmaceutica and Research Foundation; Otsuka; Zeneca Pharmaceuticals</td>
<td>42</td>
</tr>
<tr>
<td>Peter J. Whitehouse, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Eisai Inc.</td>
<td>86</td>
</tr>
<tr>
<td>Diane K. Whitney, M.D.</td>
<td>Bristol-Myers Squibb; Abbott Laboratories</td>
<td>86</td>
</tr>
<tr>
<td>Timothy E. Wilens, M.D.</td>
<td>Eli Lilly and Company; Glaxo Wellcome Inc.; Abbott Laboratories; Wyeth-Ayerst Laboratories</td>
<td>8</td>
</tr>
<tr>
<td>John W. Winkelman, M.D.</td>
<td>Cephalon, Inc.</td>
<td>16</td>
</tr>
<tr>
<td>Daniel K. Winstead, M.D.</td>
<td>Abbott Laboratories; Boots; Bristol-Myers Squibb; Watson Laboratories, Inc.; Distacol; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Solvay Pharmaceuticals, Inc.; Wyeth-Ayerst Laboratories</td>
<td>11, 23</td>
</tr>
<tr>
<td>Donna A. Wishing, M.D.</td>
<td>Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Pfizer Inc.; Abbott Laboratories; Otsuka</td>
<td>4</td>
</tr>
<tr>
<td>William C. Wishing, M.D.</td>
<td>Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company; Otsuka; Hoechst Marion Roussel; Novartis Pharmaceuticals Corporation; Abbott Laboratories; Pfizer Inc.</td>
<td>41, 69, 99</td>
</tr>
<tr>
<td>Katherine L. Wisner, M.D.</td>
<td>Pfizer Inc.</td>
<td>26</td>
</tr>
<tr>
<td>John J. Worthington III, M.D.</td>
<td>American Cyanamid; Bristol-Myers Squibb; Glaxo Wellcome Inc.; Hoffman-LaRoche; Eli Lilly and Company; Lorex; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Pharmacia &amp; Upjohn Company, Inc.; SmithKline Beecham Pharmaceuticals; Solvay Pharmaceuticals, Inc.</td>
<td>27</td>
</tr>
<tr>
<td>Janet Wozniak, M.D.</td>
<td>Eli Lilly and Company; Abbott Laboratories; Wyeth-Ayerst Laboratories</td>
<td>8</td>
</tr>
<tr>
<td>Jesse H. Wright, M.D.</td>
<td>Mindstreet</td>
<td>37, 48, 57, 77</td>
</tr>
<tr>
<td>Joel Yager, M.D.</td>
<td>Eli Lilly and Company; Wyeth-Ayerst Laboratories; Pfizer Inc.</td>
<td>16, 106, 118</td>
</tr>
<tr>
<td>Peter Yellowlees, M.D.</td>
<td>ICI Zeneca; Eli Lilly and Company; High Performance Healthcare Ltd.</td>
<td>36</td>
</tr>
<tr>
<td>Kimberly A. Yonkers, M.D.</td>
<td>SmithKline Beecham Pharmaceuticals; Forest Laboratories, Inc.</td>
<td>9, 65, 70</td>
</tr>
<tr>
<td>Alexander S. Young, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica and Research Foundation; Eli Lilly and Company</td>
<td>111</td>
</tr>
<tr>
<td>L. Trevor Young, M.D.</td>
<td>Abbott Laboratories; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation</td>
<td>96</td>
</tr>
<tr>
<td>Stuart C. Yudofsky, M.D.</td>
<td>Bristol-Myers Squibb; Diamond Health Care; Pfizer Inc.; Eli Lilly and Company</td>
<td>15, 23, 41, 73, 121</td>
</tr>
<tr>
<td>John M. Zajeczka, M.D.</td>
<td>Abbott Laboratories; Boehringer Ingelheim; Bristol-Myers Squibb; Eli Lilly and Company; Glaxo Wellcome Inc.; Organon Inc.; Parke-Davis, Division of Warner-Lambert Company; Pfizer Inc.; Wyeth-Ayerst Laboratories; Zeneca Pharmaceuticals; SmithKline Beecham Pharmaceuticals; Pharmacia &amp; Upjohn Company, Inc.; Forest Laboratories, Inc.</td>
<td>3, 7</td>
</tr>
<tr>
<td>Carlos A. Zarate, Jr., M.D.</td>
<td>Pfizer Inc.; Zeneca Pharmaceuticals; Parke-Davis, Division of Warner-Lambert Company; Glaxo Wellcome Inc.; Eli Lilly and Company; Janssen Pharmaceutica and Research Foundation; Abbott Laboratories</td>
<td>65</td>
</tr>
</tbody>
</table>

XXX
### DISCLOSURE INDEX

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Manufacturer(s)</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deborah A. Zarin, M.D.</td>
<td>American Psychiatric Association (employer)</td>
<td>29, 46, 78, 95, 117</td>
</tr>
<tr>
<td>Elsa M. Zayas, M.D.</td>
<td>Novartis Pharmaceuticals Corporation; Wyeth-Ayerst Laboratories; Pfizer Inc.; Glaxo Wellcome Inc.; Bristol-Myers Squibb; Abbott Laboratories; Eli Lilly and Company</td>
<td>7</td>
</tr>
<tr>
<td>Phyllis Zee, M.D.</td>
<td>Searle</td>
<td>117</td>
</tr>
<tr>
<td>Douglas M. Ziedonis, M.D.</td>
<td>Pfizer Inc.; Glaxo Wellcome Inc.; Janssen Pharmaceutica and Research Foundation; Bristol-Myers Squibb</td>
<td>48, 92, 108, 117</td>
</tr>
<tr>
<td>Joseph Zohar, M.D.</td>
<td>Solvay Pharmaceuticals, Inc.; SmithKline Beecham Pharmaceuticals; Pfizer Inc.; Eli Lilly and Company; Pharmacia &amp; Upjohn Company, Inc.</td>
<td>3, 34, 91, 92</td>
</tr>
</tbody>
</table>

Voting members of the Board of Trustees, Assembly officers, and members of the Scientific Program Committee cannot receive honoraria or travel reimbursement for participation in Industry-Supported Symposia. In accordance with this policy, the following members are participating in Industry-Supported Symposia and will not receive any compensation:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Balon, M.D.</td>
<td>3, 30, 47, 56, 74, 83</td>
</tr>
<tr>
<td>Charles L. Bowden, M.D.</td>
<td>3, 63</td>
</tr>
<tr>
<td>Rodrigo A. Muñoz, M.D.</td>
<td>4, 11</td>
</tr>
<tr>
<td>Carol A. Tamminga, M.D.</td>
<td>69</td>
</tr>
</tbody>
</table>

The following presenters on this year's scientific program failed to return the APA disclosure form. The presenter's name and the page number(s) the presenter appears on in this Program Book are listed below:

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Program Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>David P. Bernstein, Ph.D.</td>
<td>39</td>
</tr>
<tr>
<td>William M. Buzogany, M.D.</td>
<td>78</td>
</tr>
<tr>
<td>Howard A. Davison, J.D.</td>
<td>62</td>
</tr>
<tr>
<td>Ronald R. Fieve, M.D.</td>
<td>26</td>
</tr>
<tr>
<td>Martin E. Glaser, M.D.</td>
<td>114</td>
</tr>
<tr>
<td>Karl Goodkin, M.D.</td>
<td>21</td>
</tr>
<tr>
<td>Neeta Jain, M.D.</td>
<td>71</td>
</tr>
<tr>
<td>Kenneth A. Kessler, M.D.</td>
<td>47</td>
</tr>
<tr>
<td>Howard D. Kibel, M.D.</td>
<td>21</td>
</tr>
<tr>
<td>Janet Knoefal, Ph.D.</td>
<td>120</td>
</tr>
<tr>
<td>Kyu-Hang Lee, M.D.</td>
<td>87</td>
</tr>
<tr>
<td>Patrick Lemoine, M.D.</td>
<td>80</td>
</tr>
<tr>
<td>Larry Maayan, M.S.</td>
<td>46</td>
</tr>
<tr>
<td>Zhang Mingyuan, M.D.</td>
<td>87</td>
</tr>
<tr>
<td>Thomas Peterson, J.D.</td>
<td>78</td>
</tr>
<tr>
<td>Daniel S. Pine, M.D.</td>
<td>33</td>
</tr>
</tbody>
</table>

Richard K. Ries, M.D. 9
Benedetto Saraceno, M.D. 38
Dr. Pascal Singy 48
Dudley M. Stewart, Jr., M.D. 115
Julio Vallejo, M.D. 54
Susan Woodward, M.D. 91

XXXI
SATURDAY, MAY 30, 1998

151ST ANNUAL MEETING

8:00 a.m. Sessions

COURSES 1-4
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 1 8:00 a.m.-12 noon
Room 707, 700 Level, Convention Centre
BEYOND MUNCHAUSEN: FACTITIOUS DISORDERS TODAY
Director: Marc D. Feldman, M.D.
Faculty: Stuart J. Eisenbrandt, M.D., Charles V. Ford, M.D.

COURSE 2 8:00 a.m.-12 noon
Room 709, 700 Level, Convention Centre
INTERPERSONAL PSYCHOTHERAPY
Director: John C. Markowitz, M.D.
Faculty: Kathleen F. Clougherty, M.S.W.

COURSE 3 8:00 a.m.-12 noon
Room 711, 700 Level, Convention Centre
COGNITIVE THERAPY FOR SEVERE MENTAL DISORDERS
Co-Directors: Michael E. Thase, M.D., Monica A. Basco, Ph.D.

COURSE 4 8:00 a.m.-12 noon
Room 714B, 700 Level, Convention Centre
ADD IN CHILDREN AND ADOLESCENTS
Director: Thomas E. Brown, Ph.D.
Faculty: James J. McGough, M.D.

9:00 a.m. Sessions

COURSES 5-10
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 5 9:00 a.m.-4:00 p.m.
Room 703, 700 Level, Convention Centre
PERSONALITY AND POLITICAL BEHAVIOR
Joint Session with the International Society of Political Psychology
Director: Jerrold M. Post, M.D.

COURSE 6 9:00 a.m.-4:00 p.m.
Room 704, 700 Level, Convention Centre
TRANSPERSONAL PSYCHIATRY: THEORY AND PRACTICE
Co-Directors: Allan B. Chinen, M.D., Bruce W. Scotton, M.D.
Faculty: Seymour Boorstein, M.D., Sylvia Boorstein, Ph.D., John F. Hiatt, M.D., Francis G. Lu, M.D., William W. Foote, M.D., Bruce S. Victor, M.D.

COURSE 7 9:00 a.m.-4:00 p.m.
Room 706, 700 Level, Convention Centre
DISSOCIATIVE DISORDER NOT OTHERWISE SPECIFIED: DIAGNOSIS AND TREATMENT WITH EGO STATE THERAPY
Co-Directors: Marlene Steinberg, M.D., Charles H. Rousell, M.D.

COURSE 8 9:00 a.m.-4:00 p.m.
Room 708, 700 Level, Convention Centre
ASSESSING THREATS AND VIOLENCE AT HOME AND WORK
Director: James R. Missett, M.D.
Faculty: Paul S.D. Berg, Ph.D.

COURSE 9 9:00 a.m.-4:00 p.m.
Room 712, 700 Level, Convention Centre
INTRODUCTION TO PSYCHODYNAMIC GROUP PSYCHOTHERAPY
Joint Session with the American Group Psychotherapy Association, Inc.
Director: Hillel I. Swiller, M.D.
Faculty: Milton L. Wainberg, M.D.

COURSE 10 9:00 a.m.-4:00 p.m.
Rooms 717A/B, 700 Level, Convention Centre
HYPNOSIS IN PSYCHIATRY
Director: Jose R. Maldonado, M.D.
Faculty: Marcia Greenleaf, Ph.D., David Spiegel, M.D., Herbert Spiegel, M.D.
SATURDAY

1:00 p.m. Sessions

COURSES 11-14
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 11 1:00 p.m.-5:00 p.m.
Room 702, 700 Level, Convention Centre
PRACTICAL TOOLS FOR QUALITY IMPROVEMENT
Director: Richard L. Elliott, M.D.

COURSE 12 1:00 p.m.-5:00 p.m.
Room 709, 700 Level, Convention Centre
PSYCHIATRIC DISORDERS IN PREGNANCY AND POSTPARTUM
Co-Directors: Shaila Misri, M.D., Kristin S. Sivertz, M.D.
Faculty: Diana Carter, M.D., Deirdre M. Ryan, M.D.

COURSE 13 1:00 p.m.-5:00 p.m.
Room 713A, 700 Level, Convention Centre
HOW TO MEASURE OUTCOMES WITHOUT BREAKING THE BANK
Co-Directors: Gabriel Kaplan, M.D., James R. Westphal, M.D.
Faculty: Jill A. Rush, M.D.

COURSE 14 1:00 p.m.-5:00 p.m.
Room 714B, 700 Level, Convention Centre
COGNITIVE THERAPY: THE BASICS
Director: Dean Schuyler, M.D.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 1-9

INDUSTRY-SUPPORTED SYMPOSIUM 1
7:00 p.m.-10:00 p.m.
Auditorium, Lower Level, Convention Centre
MAINTENANCE TREATMENT OF DEPRESSION: THE FINAL EPISODE
Supported by Eli Lilly and Company
Chp.: Jerrold F. Rosenbaum, M.D.

A       Depression Is a Recurrent and Chronic Illness
        David J. Kupfer, M.D.

B       Morbidity of Depression: Major Causes, Targeted Responses
        John F. Greden, M.D.

C       Antidepressant Maintenance Therapies: Improving Outcomes
        A. John Rush, M.D.

D       The Reality of Current Antidepressant Maintenance Treatment
        Ellen Frank, Ph.D.

E       The SSRI Discontinuation Syndrome
        Jerrold F. Rosenbaum, M.D., Maurizio Fava, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 2
7:00 p.m.-10:00 p.m.
Room 106, Lower Level, Convention Centre
DEPRESSION AS A RISK FACTOR FOR CARDIOVASCULAR AND CEREBROVASCULAR DISEASE: EMERGING DATA AND CLINICAL PERSPECTIVES
Supported by SmithKline Beecham Pharmaceuticals
Chp.: Charles B. Nemeroff, M.D.

A       The Clinical Course and Medical Management of Depressed Patients with Ischemic Heart Disease
        Christopher O'Connor, M.D.

B       Are Platelets the Link Between Depression and Ischemic Heart Disease?
        Charles B. Nemeroff, M.D.

C       Depression As a Contributing Factor in Cerebrovascular Disease
        K. Ranga Rama Krishnan, M.D.

D       Heart Rate Variability in Depressive and Anxiety Disorders
        Jack M. Gorman, M.D., Richard Sloan, Ph.D., Peter A. Shapiro, M.D.

E       Considerations for the Use of Antidepressants in Patients with Ischemic Heart Disease
        Steven P. Roose, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 3
7:00 p.m.-10:00 p.m.
Hall G, 800 Level, Convention Centre

MANAGEMENT OF IATROGENIC SEXUAL DYSFUNCTION
Supported by Glaxo Wellcome Inc.

Chp.: Adam K. Ashton, M.D.

A Etiology and Incidence
R. Taylor Segraves, M.D.

B Assessment of Sexual Functioning
Anita L.H. Clayton, M.D.

C Management of SRI-Induced Sexual Dysfunction
Adam K. Ashton, M.D.

D SSRIs in Premature Ejaculation and Paraphilias
Richard Balon, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 4
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

COGNITION IN SCHIZOPHRENIA: THE NEW THERAPEUTIC GOAL
Supported by Pfizer Inc.

Chp.: Herbert Y. Meltzer, M.D.

A Dimensions of Cognitive Dysfunction in Schizophrenia: The Kraepelinian Legacy
Philip D. Harvey, Ph.D.

B Cortical Circuitry and Cognition in Schizophrenia
David A. Lewis, M.D.

C Functional MRI Studies of Cognitive Function in Schizophrenia
Daniel R. Weinberger, M.D., Venkata Mattay, M.D., Joseph H. Callicott III, M.D., Kathryn J. Kotira, M.D., Attanagoda Santha, Ph.D., Peter Van Gelderen, Ph.D., Jeff Duyn, Ph.D.

D Effect of Antipsychotic Drugs on Cognition in Schizophrenia
Herbert Y. Meltzer, M.D., Susan R. McGurk, Ph.D.

E Cognitive Impairment and Psychopathology As Determinants of Ability to Work in Schizophrenia
Susan R. McGurk, Ph.D., Herbert Y. Meltzer, M.D.

Discussant: David L. Braff, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 5
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

OCD SUBTYPES: FROM CLINICAL TO MOLECULAR GENETICS
Supported by Solvay Pharmaceuticals, Inc. and Pharmacia & Upjohn Company, Inc.

Chp.: Michele T. Pato, M.D.
Co-Chp.: Eric Hollander, M.D.

A Phenotypic Components of OCD
David Pauls, Ph.D.

B Are OCD Spectrum Disorders Different Phenotypes of OCD?
Eric Hollander, M.D., Cheryl M. Wong, M.D., Charles Cartwright, M.D., Concetta M. DeCaria, Ph.D., Bonnie A. Aronowitz, Ph.D., Lisa Margolin, Ph.D., Tomer Begaz, B.A.

C OCD and Schizophrenia: Diagnostic and Treatment Considerations
Joseph Zohar, M.D.

D Molecular Genetics of OCD and Response to SRS
James L. Kennedy, M.D.

E Autoimmunity and OCD
Mark H. Rapaport, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 6
7:00 p.m.-10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

PHARMACOTHERAPY OF BIPOLAR DISORDER: NEWEST ADVANCES
Supported by Abbott Laboratories

Chp.: Paul E. Keck, Jr., M.D.

A Rapid Loading Strategies in the Treatment of Acute Mania
Paul E. Keck, Jr., M.D., Susan L. McElroy, M.D.

B Bipolar Depression
John M. Zajecka, M.D.

C Maintenance Treatment in Bipolar Disorder
Charles L. Bowden, M.D., Joseph R. Calabrese, M.D., Susan L. McElroy, M.D., Robert M.A. Hirschfeld, M.D., Frederick Petty, M.D., Lazzlo Gyulai, M.D.

D Substance Abuse Complicating Manic Depression
Kathleen T. Brady, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 7
7:00 p.m.-10:00 p.m.
Frontenac Ballroom, Street Level, Westin Harbour Castle

MOOD DISORDERS IN SCHIZOPHRENIA: UNITED STATES AND EUROPEAN PERSPECTIVES
Supported by the International Academy for Biomedical and Drug Research
Chp.: Lewis L. Judd, M.D.
Co-Chp.: Giorgio Racagni, Ph.D.

A Depressive Symptomatology in Schizophrenia: Comorbid Disorders or Negative Symptoms?
Lewis L. Judd, M.D.

B The Interface Between Bipolar and Schizophrenic Disorders: The United States Approach
Hagop S. Akiskal, M.D.

C The Interface Between Bipolar and Schizophrenic Disorders: The European Approach
Helmut Beckmann, M.D.

D New Therapeutic Approaches in the Management of Mood Disorders in Schizophrenia
W. Wolfgang Fleischhacker, M.D., Armand Hausmann, M.D.

E New Therapeutic Approaches in the Management of Mood Disorders in Schizophrenia: United States Perspectives
William T. Carpenter, Jr., M.D.

F The Use of New Antipsychotics in the Treatment of Schizoaffective Disorders
Mario Maj, M.D.

Discussants: Julien Mendlewicz, M.D., Rodrigo A. Munoz, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 8
7:00 p.m.-10:00 p.m.
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle

NOVEL ANTIPSYCHOTICS: USE IN NONPSYCHOTIC DISORDERS ACROSS THE LIFE CYCLE
Supported by Janssen Pharmaceutica and Research Foundation
Chp.: Henry A. Nasrallah, M.D.

A Novel Antipsychotics in Children and Adolescents
Herman A. Tolbert, M.D., Henry A. Nasrallah, M.D., Noelle K. Gehm, B.S., Nicholas A. Votolato, R.Ph.

B Novel Antipsychotics in Personality Disorders
Larry J. Siever, M.D.

C Efficacy of Novel Antipsychotics in Basal Ganglia Disorders
Henry A. Nasrallah, M.D.

D Role of Novel Antipsychotics in Treatment of Mood Disorders
Donna A. Wirshing, M.D.

E Use of Atypical Antipsychotics in Dementia and Delirium
Prakash S. Masand, M.D., Henry A. Nasrallah, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 9
7:00 p.m.-10:00 p.m.
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

ESTROGEN ENHANCEMENT OF MOOD AND MEMORY IN POSTMENOPAUSAL WOMEN
Supported by Wyeth-Ayerst Laboratories
Chp.: Marjorie L. Shuer, M.D.
Co-Chp.: Uriel Halbreich, M.D.

A Estrogens and Synapses: Basic Neurobiology of Ovarian Steroids
Bruce S. McEwen, Ph.D.

B Sexual Dimorphism, Memory and Menopause
Marjorie L. Shuer, M.D.

C Estrogen and Cognition in Postmenopausal Women
Barbara B. Sherwin, Ph.D.

D Hormone-Replacement Therapy: Cognition and Alzheimer’s Dementia
Uriel Halbreich, M.D.

E Practical Implications of Hormone-Replacement Therapy: Using Natural Hormones
Joel T. Hargrove, M.D.
SUNDAY, MAY 31, 1998

151ST ANNUAL MEETING

8:00 a.m. Sessions

COURSES 15-20
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 15  8:00 a.m.-12 noon
Room 702, 700 Level, Convention Centre
TEACHING PSYCHIATRY? LET HOLLYWOOD HELP!
Director: Steven E. Hyler, M.D.
Faculty: Carol A. Bernstein, M.D., Michael B. First, M.D.

COURSE 16  8:00 a.m.-12 noon
Room 711, 700 Level, Convention Centre
ASSESSING POSITIVE AND NEGATIVE SYMPTOMS WITH THE POSITIVE AND NEGATIVE SYNDROME SCALE
Co-Directors: Lewis A. Opler, M.D., Paul M. Ramirez, Ph.D.

COURSE 17  8:00 a.m.-12 noon
Room 712, 700 Level, Convention Centre
MANAGING THE STRESS OF MALPRACTICE LITIGATION
Co-Directors: Sara C. Charles, M.D., Miguel A. Leibovich, M.D.
Faculty: Maureen Mondor, R.N., Ronald L. Hofeldt, M.D.

COURSE 18  8:00 a.m.-12 noon
Room 714B, 700 Level, Convention Centre
ADD IN ADULTS
Director: Thomas E. Brown, Ph.D.
Faculty: James J. McGough, M.D.

COURSE 19  8:00 a.m.-12 noon
Rooms 717A/B, 700 Level, Convention Centre
RISK ASSESSMENT FOR VIOLENCE
Director: Phillip J. Resnick, M.D.

COURSE 20  8:00 a.m.-12 noon
Room 718B, 700 Level, Convention Centre
COMPUTER SURVIVAL GUIDE 1998
Co-Directors: Robert S. Kennedy, M.A., Thomas A.M. Kramer, M.D.

9:00 a.m. Sessions

COURSES 21-26
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 21  9:00 a.m.-4:00 p.m.
Room 703, 700 Level, Convention Centre
THE ADVANCED PRACTICE OF PSYCHOTHERAPY
Director: T. Byram Karasu, M.D.

COURSE 22  9:00 a.m.-4:00 p.m.
Room 704, 700 Level, Convention Centre
ADVANCED INTERVIEWING TECHNIQUES
Director: Shawn C. Shea, M.D.

COURSE 23  9:00 a.m.-4:00 p.m.
Room 707, 700 Level, Convention Centre
MANAGEMENT AND TREATMENT OF THE VIOLENT PATIENT
Director: Gary J. Maier, M.D.
Faculty: William R. Dubin, M.D.

COURSE 24  9:00 a.m.-4:00 p.m.
Room 706, 700 Level, Convention Centre
INTEGRATIVE COUPLE THERAPY: SKILLS AND TECHNIQUES
Co-Directors: Lois S. Slovik, M.D., James L. Griffith, M.D.

COURSE 25  9:00 a.m.-4:00 p.m.
Room 713A, 700 Level, Convention Centre
THE PRACTICAL MANAGEMENT OF PERSONALITY DISORDER
Director: John Livesley, M.D.
SUNDAY

COURSE 26  9:00 a.m.-4:00 p.m.
Room 716A, 700 Level, Convention Centre

DIALECTICAL BEHAVIOR THERAPY FOR PATIENTS WITH BPD

Director: Charles R. Swenson, M.D.
Faculty: Marsha M. Linehan, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 10-17

INDUSTRY-SUPPORTED SYMPOSIUM 10
9:00 a.m.-12 noon
Auditorium, Lower Level, Convention Centre

WOMEN AND PSYCHOSIS: FROM LAB BENCH TO CLINICAL PRACTICE
Supported by Eli Lilly and Company

Chp.: Lee S. Cohen, M.D.
Co-Chp.: Ruth A. Dickson, M.D.

A Effects of Gonadal Steroids on Brain and Behavior
David R. Rubinow, M.D., Peter J. Schmidt, M.D.

B Sex and Brain Abnormalities in Schizophrenia
Jill M. Goldstein, Ph.D., Larry J. Seidman, Ph.D.,
Julie M. Goodman, Ph.D., Nikos Makris, M.D.,
David Kennedy, Ph.D., Verne Caviness, M.D.,
Stephen V. Farzaneh, Ph.D.

C Sex and Neuroendocrine Differences Following Treatment with Typical and Atypical Antipsychotics
Lee S. Cohen, M.D., Jill M. Goldstein, Ph.D., Hang Lee, Ph.D., Mauricio Tohen, M.D., Scott Andersen, M.S., Gary D. Tollefson, M.D.

D Women, Prolactin and the New Neuroleptics
Ruth A. Dickson, M.D.

E Atypical Antipsychotics in Women with Bipolar and Other Psychiatric Disorders
Susan L. McElroy, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 11
9:00 a.m.-12 noon
Room 106, Lower Level, Convention Centre

NEW TREATMENTS FOR ANXIETY DISORDERS: CLINICAL APPOACHES FOR SUCCESSFUL OUTCOMES
Supported by SmithKline Beecham Pharmaceuticals

Chp.: David V. Sheehan, M.D.

A Gender Differences in the Epidemiology and Treatment of Anxiety Disorders
Teresa A. Pigott, M.D.

B Current Concepts in the Treatment of Panic Disorder
David V. Sheehan, M.D., Kathy Harnett-Sheehan, Ph.D., Ashok Raj, M.D.

C Update on the Diagnosis and Treatment of Social Phobia
Michael R. Liebowitz, M.D., Richard G. Heimberg, Ph.D., Franklin R. Schneier, M.D.

D OCD: Diagnosis and Treatment
Wayne K. Goodman, M.D.

E Management of PTSD: Diagnostic and Therapeutic Issues
Jonathan R.T. Davidson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 12
9:00 a.m.-12 noon
Hall G, 800 Level, Convention Centre

INTERVENTION FOR REFRACTORY BIPOLAR DISORDER
Supported by Glaxo Wellcome Inc.

Chp.: Gary S. Sachs, M.D.

A Bipolar Disorder: Expert Consensus Survey Results
David A. Kahn, M.D.

B Management of Treatment-Refractory Bipolar Depression
Gary S. Sachs, M.D.

C Options for Treatment-Refractory Rapid Cycling
Joseph R. Calabrese, M.D.

D Alternative Treatment for Refractory Mania/Cycling
Robert M. Post, M.D., Mark A. Frye, M.D., Kirk D. Denicoff, M.D., Timothy A. Kirmile, M.D.,
Robert T. Dunn, M.D., Gabrielle S. Leverich, M.S.

E Cognitive Behavioral Strategies for Bipolar Patients
Noreen A. Reilly-Harrington, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 13
9:00 a.m.-12 noon
Canadian Room, Convention Floor, Royal York

INDIVIDUALIZING THE TREATMENT OF PSYCHOSES
Supported by Zeneca Pharmaceuticals

Chp.: S. Charles Schulz, M.D.

A Impact of Phases and Severity of Illness on Treatment Decisions Across the Age Spectrum
Robert L. Findling, M.D., S. Charles Schulz, M.D.,
Mahmoud A. Parsa, M.D.
B  Management of Psychotic Aspects of Schizoaffective Disorder
   Stephen M. Strakowski, M.D.

C  Treating Symptoms Comorbid with Psychosis in Schizophrenia
   Jeffrey A. Lieberman, M.D.

D  Treatment Issues with the Use of Antipsychotic Medications
   Sharon G. Dott, M.D.

E  After Responding: What Happens Next?
   Peter J. Weiden, M.D., Ralph Aquila, M.D., Laura J. Dalheim, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 14
9:00 a.m.-12 noon
Concert Hall, Convention Floor, Royal York

ALZHEIMER'S DISEASE: PRACTICAL TREATMENT APPROACHES
Supported by Novartis Pharmaceuticals Corporation
Chp.: George T. Grossberg, M.D.

A  The Natural History of Alzheimer's Disease and the Evolution of Psychiatric Symptoms
   George T. Grossberg, M.D.

B  The Alzheimer's Disease Patient and Family: Communication, Evaluation and Management Issues
   Steven H. Ferris, Ph.D.

C  The Psychiatrist's Role in Day to Day Management
   Peter V. Rabins, M.D.

D  The APA Practice Guidelines: Implications for the Practitioner
   Elsa M. Zayas, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 15
9:00 a.m.-12 noon
Grand Ballroom, Lower Concourse, Sheraton Centre

CHRONIC DEPRESSION: OPTIMIZING LONG-TERM TREATMENT
Supported by Bristol-Myers Squibb
Chp.: Alan F. Schatzberg, M.D.

A  Epidemiology and Clinical Course of Chronic Depression
   Martin B. Keller, M.D.

B  Enhancing Compliance with Antidepressant Treatment: Identification and Management of Side Effects
   John M. Zajecka, M.D.

C  Chronic Depression: Managing Emerging Bipolar Symptoms
   David L. Dunner, M.D.

D  Gender Issues in Chronic Depression: Implications for Treatment
   Susan G. Kornstein, M.D.; Alan F. Schatzberg, M.D., Michael E. Thase, M.D., Alan J. Gelenberg, M.D.,
   Gabor I. Keitner, M.D.

E  Combining Pharmacotherapy with Psychosocial Treatments
   Gabor I. Keitner, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 16
9:00 a.m.-12 noon
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle

ISSUES IN THE LONG-TERM MANAGEMENT OF DEPRESSION
Supported by Organon Inc.
Chp.: Robert M.A. Hirschfeld, M.D.

A  Long-Term Nature of Depression
   Michael E. Thase, M.D.

B  New Developments in Acute Treatment of Depression
   Stuart A. Montgomery, M.D.

C  Antidepressant Drug Mechanism of Action: Relationship to Efficacy
   Dennis S. Charney, M.D.

D  Management Issues in Maintenance Treatment
   A. John Rush, M.D.

E  Management of Sexual Side Effects of Antidepressant Therapy
   Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 17
9:00 a.m.-12 noon
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

JUVENILE MOOD DISORDERS: FROM RESEARCH TO CLINICAL PRACTICE
Supported by Wyeth-Ayerst Laboratories
Chp.: Joseph Biederman, M.D.
Co-Chp.: Thomas J. Spencer, M.D.

A  ADHD and Juvenile Mania: An Overlooked Comorbidity?
   Joseph Biederman, M.D.

(Continued on next page)
SUNDAY

B Mania-Like Symptoms Suggestive of Childhood-Onset Bipolar Disorder in Clinically Referred Children
Janet Wozniak, M.D.

C ADHD with Bipolar Disorder: A Familial Subtype?
Stephen V. Faraone, Ph.D.

D Juvenile Bipolar Disorder and the Risk for Substance Abuse
Timothy E. Wilens, M.D.

E The Naturalistic Course of Pharmacologic Treatment of Children with Manic-Like Symptoms: A Systematic Chart Review
Thomas J. Spencer, M.D.

12:30 p.m. Session

BUSINESS MEETING

(Voting Members Only*)
12:30 p.m.-1:30 p.m. (Refreshments Served)
Room 105, Lower Level, Convention Centre

CALL TO ORDER
Herbert S. Sacks, M.D., President

ANNOUNCEMENT OF ELECTION OF OFFICERS AND TRUSTEES; AND RESULTS OF BALLOTING ON AMENDMENTS TO THE CONSTITUTION AND BY-LAWS
Jeffrey S. Akman, M.D., Chairperson, Committee of Tellers

REPORTS TO THE MEMBERSHIP
Secretary: Paul S. Appelbaum, M.D.
Treasurer: Fred Gottlieb, M.D.
Speaker, Assembly:
Jeremy A. Lazarus, M.D.
Speaker-Elect, Assembly:
Donna M. Norris, M.D.
Chairperson, Constitution and By-Laws Committee: Robert J. McDevitt, M.D.
Chairperson, Elections Committee:
Sheldon L. M. Lee, M.D.
Chairperson, Membership Committee:
Bernard A. Katz, M.D.
Medical Director: Steven M. Man, M.D.
Chairpersons of the Eleven Councils

FORUM

ADJOURNMENT
*Members-in-Training, General Members, Fellows, Life Fellows and Life Members. Badge or APA membership card necessary for admission. No cameras or tape recorders will be permitted.

1:00 p.m. Sessions

COURSES 27-33
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 27 1:00 p.m.-5:00 p.m.
Room 706, 700 Level, Convention Centre

THE PSYCHIATRIST’S ROLE IN SEXUAL HARASSMENT

Director: Gail E. Robinson, M.D.
Faculty: Renee L. Binder, M.D.; Sharyn A. Lenchart, M.D.; Michael F. Myers, M.D.

COURSE 28 1:00 p.m.-5:00 p.m.
Room 712, 700 Level, Convention Centre

DSM-IV CULTURAL FORMULATION: DIAGNOSIS AND THERAPY

Director: Russell F. Lim, M.D.
Faculty: Francis G. Lu, M.D.; Candace M. Fleming, Ph.D.; J. Charles Ndilela, M.D.; Roberto Lewis-Fernandez, M.D.; Michael W. Smith, M.D.

COURSE 29 1:00 p.m.-5:00 p.m.
Room 713B, 700 Level, Convention Centre

PSYCHIATRIC DISORDERS RELATED TO EPILEPSY

Director: Dietrich P. Blumer, M.D.
Faculty: John J. Barry III, M.D.

COURSE 30 1:00 p.m.-5:00 p.m.
Room 714B, 700 Level, Convention Centre

TESTING FOR DRUG USE: POLICY, SCIENCE AND LIABILITY

Director: John T. Pichot, M.D.

COURSE 31 1:00 p.m.-5:00 p.m.
Room 716B, 700 Level, Convention Centre

HOW TO PASS THE BOARDS! THE PART II ORAL EXAM

Co-Directors: Steven E. Hyler, M.D., James C.Y. Chou, M.D.
COURSE 32  1:00 p.m.-5:00 p.m.
Room 718A, 700 Level, Convention Centre

ADDITION TREATMENT IN PSYCHIATRIC POPULATIONS

Director: Norman S. Miller, M.D.
Faculty: Robert M. Antenelli, M.D.,
          Kenneth Minkoff, M.D., Richard K. Ries, M.D.

COURSE 33  1:00 p.m.-5:00 p.m.
Room 718B, 700 Level, Convention Centre

HOW TO APPLY THE INTERNET: ADVANCED TOPICS

Director: Robert C. Hsiung, M.D.
Faculty: Francoise Gilbert, J.D., Ivan K. Goldberg, M.D.,
          Storm A. King, B.A., Gilbert Levin, Ph.D., William M.
          Silberg, Leonard Holmes, Ph.D.

1:30 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 18-25

INDUSTRY-SUPPORTED SYMPOSIUM 18
1:30 p.m.-4:30 p.m.
Auditorium, Lower Level, Convention Centre

THE DEPRESSED WOMAN: CONTEMPORARY
TREATMENTS
Supported by Eli Lilly and Company
Chp.: Myrna M. Weissman, Ph.D.

A  Treatment of Psychiatric Illness During Pregnancy
   and the Postpartum Period
   Lee S. Cohen, M.D.

B  Interpersonal Psychotherapy for Antepartum
   Depression
   Margaret G. Spinelli, M.D.

C  The Treatment of Depressed Women and Their
   Children
   Myrna M. Weissman, Ph.D.

D  Preventing Recurrence of Depression in Women
   Ellen Frank, Ph.D.

E  New Treatments for Prenatal Dysphoric
   Disorder
   Kimberly A. Yankers, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 19
1:30 p.m.-4:30 p.m.
Room 106, Lower Level, Convention Centre

NEW FRONTIERS IN THE MANAGEMENT OF SOCIAL
PHOBIA: DIAGNOSIS, TREATMENT AND CLINICAL
COURSE
Supported by SmithKline Beecham Pharmaceuticals
Chp.: Mark H. Pollack, M.D.

A  The Differential Diagnosis of Social Phobia
   Murray B. Stein, M.D.

B  Gender Differences in the Presentation and
   Management of Social Phobia
   Lisa S. Weinstock, M.D.

C  Cognitive-Behavior Therapy for Social Phobia:
   Theory, Outcome and Future Directions
   Michael W. Otto, Ph.D.

D  Social Phobia: Designing a Pharmacologic
   Treatment Strategy
   Mark H. Pollack, M.D.

E  Comorbid Social Anxiety and Body Dysmorphic
   Disorder: Managing the Complicated Patient
   Eric Hollander, M.D., Charles Cartwright, M.D.,
   Bonnie A. Aronowitz, Ph.D., Cheryl M. Wong, M.D.,
   Concetta M. DeCario, Ph.D., Tomer Begaz, B.A.,
   Jee Kwon, B.A.

INDUSTRY-SUPPORTED SYMPOSIUM 20
1:30 p.m.-4:30 p.m.
Hall G, 800 Level, Convention Centre

NICOTINE: AN ENEMY OR AN ALLY?
Supported by Glaxo Wellcome Inc.
Chp.: Alexander H. Glassman, M.D.
Co-Chp.: Robert Freedman, M.D.

A  Depressive Relapse Provoked by Smoking
   Cessation
   Alexander H. Glassman, M.D., Toby A. Cohen, M.S.

B  A Nicotinic Receptor Deficit in Schizophrenia
   Robert Freedman, M.D., Lawrence E. Adler, M.D.,
   Ann Olincy, M.D., Herbert T. Nagamoto, M.D.,
   Sherry Leonard, Ph.D., Paula Bickford, Ph.D.,
   Karen Stevens, Ph.D.

C  The Neurobiology of Nicotine Dependence
   George F. Koob, Ph.D., Shelly Watkins, M.A., Mark
   Epping-Jordan, Ph.D., Ana Maria Basso, Ph.D.,
   Athina Markou

D  Treating Heavily Dependent and Comorbid
   Smokers
   John R. Hughes, M.D.

E  Nicotine Dependence in Alcoholics
   Richard D. Hurt, M.D.
SUNDAY

INDUSTRY-SUPPORTED SYMPOSIUM 21
1:30 p.m.-4:30 p.m.
Canadian Room, Convention Floor, Royal York

NEW ATYPICALS: DATA VERSUS CLINICAL EXPERIENCE
Supported by Zeneca Pharmaceuticals

Chp.: Ira D. Glick, M.D.
Co-Chp.: Stephen R. Marder, M.D.

A Therapeutic Implications of Etiological Research
Robin M. Murray, M.B.

B Atypical Antipsychotics: How Well Do They Really Work?
Rajiv Tandon, M.D.

C Newer Antipsychotics: Side-Effect Profiles
Stephen R. Marder, M.D.

D Services Research and Use of Atypical Antipsychotics
Lisa B. Dixon, M.D.

E Combining Atypicals with Psychosocial Interventions
Ira D. Glick, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 22
1:30 p.m.-4:30 p.m.
Concert Hall, Convention Floor, Royal York

OPTIMIZING PATIENT OUTCOMES WITH NOVEL ANTIPSYCHOTICS: CHANGING EXPECTATIONS
Supported by Novartis Pharmaceuticals Corporation

Chp.: Alan I. Green, M.D.

A Antipsychotic Drugs: Translating Pharmacology into Clinical Effects
David Pickar, M.D.

B Early Intervention: Can We Change the Course of Illness?
Jeffrey A. Lieberman, M.D.

C Aggression, Violence and Suicide in Schizophrenia
Peter F. Buckley, M.D.

D Comorbid Substance Abuse: Do Antipsychotic Drugs Have a Role?
Alan I. Green, M.D.

E Beyond Symptoms: Optimizing Real-World Outcomes
Jean-Pierre Lindenmayer, M.D.

Discussant: Herbert Y. Meltzer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 23
1:30 p.m.-4:30 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

THE ANXIETY LABYRINTH: FINDING A PATHWAY TO THE SOLUTIONS
Supported by Bristol-Myers Squibb

Chp.: Jonathan R.T. Davidson, M.D.

A Course and Psychosocial Impairment in GAD
Jane L. Eisen, M.D., Martin B. Keller, M.D.

B GAD: Unloved and Misunderstood and Its Relevance to Psychiatry
James G. Barbee IV, M.D.

C Comorbidity: Bad News and Good News
R. Bruce Lydiard, M.D.

D PTSD: Who Responds to What Treatment?
Jonathan R.T. Davidson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 24
1:30 p.m.-4:30 p.m.
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle

DEPRESSIVE DISORDERS: ADVANCES IN CLINICAL MANAGEMENT
Supported by Organon Inc.

Chp.: James W. Jefferson, M.D.

A Depression Subtyping: Treatment Implications
Paula J. Clayton, M.D.

B Strategies for Overcoming Treatment Resistance
J. Craig Nelson, M.D.

C Assessment and Treatment of Depression by Computer
John H. Greist, M.D.

D Dealing with Dangerous and Disturbing Side Effects
Edmund C. Settle, Jr., M.D.

E Drug and Diet Interactions: Avoiding Therapeutic Paralysis
James W. Jefferson, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 25
1:30 p.m.-4:30 p.m.
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

TREATMENT OF DEPRESSION IN DIFFICULT SITUATIONS
Supported by Wyeth-Ayerst Laboratories

Chp.: Dwight L. Evans, M.D.
A Depression Adversely Affects Mental and Physical Health
Dwight L. Evans, M.D.

B Treatment of Severe Unipolar and Bipolar Depression
Neal H. Kani, M.D.

C Treatment of Depression and Comorbid Anxiety
Dennis S. Charney, M.D.

D Recognizing and Treating Body Dysmorphic Disorder in Depressed Patients
Katherine A. Phillips, M.D.

E The Study of Affects with Neuroimaging
Raquel E. Gur, M.D.

2:30 p.m. Session

LECTURE 1
2:30 p.m.-4:00 p.m.
Room 205, Street Level, Convention Centre
AAPL/APA'S MANFRED S. GUTTMACHER AWARD LECTURE
Larry H. Strasburger, M.D., Thomas G. Gutheil, M.D., Archie Brodsky, B.A.

Two Hats Revisited: Contexts, Complications and Compromises Between Clinical and Forensic Roles
Chp.: Robert L. Sadoff, M.D.,
Co-Chp.: Brain Crowley, M.D.

For the treating psychiatrist, the role of expert (forensic) witness is fraught with clinical, ethical and legal conflicts. Larry H. Strasburger, M.D., Thomas G. Gutheil, M.D., and Archie Brodsky, B.A., review these conflicts using a case example from the patient's perspective. They also examine clinical pitfalls of treating a patient who has previously been involved in litigation, offer guidelines for situations where separation of clinical and forensic roles is impossible and discuss specific challenges posed by so-called "recovered memory" cases. Dr. Strasburger is Assistant Clinical Professor of Psychiatry at Harvard Medical School and a past president of the American Board of Forensic Psychiatry. He has been extensively involved in setting standards for the practice of forensic psychiatry and has written extensively on the prevention of sexual misconduct by psychotherapists.

OFFICIAL OPENING SESSION
5:00 p.m.-6:30 p.m.
Hall F, 800 Level, Convention Centre

CALL TO ORDER
Herbert S. Sacks, M.D.
President

INTRODUCTION OF STAGE GUESTS
INTRODUCTION OF CHAIRPERSONS OF THE SCIENTIFIC PROGRAM COMMITTEE AND THE TASK FORCE ON LOCAL ARRANGEMENTS
Daniel K. Winstead, M.D.
Chairperson, Scientific Program Committee
D. Raymond Freebury, M.D.
Chairperson, Task Force on Local Arrangements

INTRODUCTION OF VISITING DIGNITARIES
PRESIDENTIAL ADDRESS
Herbert S. Sacks, M.D.
To be introduced by Steven M. Mirin, M.D.
RESPONSE OF THE PRESIDENT-ELECT
Rodrigo A. Muñoz, M.D.
To be introduced by Harold I. Est, M.D.

ADJOURNMENT
Music Performed by The Great Lakes Brass
INDUSTRY-SUPPORTED SYMPOSIUM 26-32

INDUSTRY-SUPPORTED SYMPOSIUM 26
7:00 p.m.-10:00 p.m.
Auditorium, Lower Level, Convention Centre

EXPANDING THE SPECTRUM OF PSYCHOSES: THE INTERFACE OF AFFECT
Supported by Eli Lilly and Company

Chp.: William M. Glazer, M.D.
Co-Chp.: Paul E. Keck, Jr., M.D.

A Biological Basis for Overlap of Mood in Psychotic Disorders
Paul E. Keck, Jr., M.D.

B The Psychopharmacologic Treatment of Schizoaffective Disorder
Susan L. McElroy, M.D.

C Psychotic Major Depression
Alan F. Schatzberg, M.D., Joel A. Posener, M.D.,
Charles DeBattista, M.D.

D Experience Using Olanzapine in the Treatment of Acute Bipolar Mania
Mauricio Tohen, M.D., Todd Sanger, Ph.D.,
Gary D. Tollefson, M.D., Susan L. McElroy, M.D.,
Michael G. Greaney, M.S., Verna Toma

E Affective Disorders, Tardive Dyskinesia and Atypical Antipsychotics
William M. Glazer, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 27
7:00 p.m.-10:00 p.m.
Hall G, 800 Level, Convention Centre

SEXUAL DYSFUNCTION, DEPRESSION AND ANTIDEPRESSANTS
Supported by Glaxo Wellcome Inc.

Chp.: Troy L. Thompson II, M.D.

A Avoiding and Managing Sexual Side Effects of Antidepressants
Troy L. Thompson II, M.D.

B The Sexual Side Effects of Commonly Prescribed Drugs
Theresa L. Crenshaw, M.D.

C A Comprehensive Approach to Sexuality and Depression
Domeena C. Renshaw, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 28
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

TREATMENT STRATEGIES FOR SUCCESSFUL OUTCOMES IN PATIENTS WITH PANIC DISORDER
Supported by Pfizer Inc.

Chp.: Jack M. Gorman, M.D.

A Reduction of Panic Attacks, As a Single Measure, Is Insufficient for Assessing Treatment Efficacy in Panic Disorder
David A. Spiegel, M.D.

B Clinical Treatment Strategies for Successful Outcomes in Panic
Donald F. Klein, M.D.

C Pharmacotherapy of Panic Disorder
Jack M. Gorman, M.D., Laslo A. Papp, M.D.,
Jeremy D. Coplan, M.D., Justine M. Kent, M.D.,
Gregory M. Sullivan, M.D.

D Cognitive-Behavioral Therapy of Panic Disorder
M. Katherine Shear, M.D.

Discussant: Robert M.A. Hirschfeld, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 29
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

CLINICAL ASPECTS OF VIOLENCE
Supported by Novartis Pharmaceuticals Corporation

Chp.: Phillip J. Resnick, M.D.

A Risk Assessment for Violence
Phillip J. Resnick, M.D.

B Assessment of Violent Threats
Park E. Dietz, M.D.

C Child and Adolescent Violence
Robert T.M. Phillips, M.D.

D Violence Against Psychiatrists
John R. Lion, M.D.

E Pharmacologic Approaches to Violence
Renee L. Binder, M.D.

Discussant: John Monahan, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 30
7:00 p.m.-10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

PRACTICAL APPROACHES TO THE TREATMENT OF PSYCHOSES IN THE ELDERLY
Supported by Abbott Laboratories
A Chronic and Late-Onset Psychotic Disorders  
Ira R. Katz, M.D.

B Organic Disorders with Psychotic Features in the Elderly  
Jeffrey L. Cummings, M.D.

C Treatment Options and Practical Issues for Elderly Patients with Psychoses  
Pierre N. Tariot, M.D.

D Psychotic Disorders Among Patients in Long-Term-Care Facilities  
Barry W. Rovner, M.D.

E Nonpharmacologic Approaches in Managing Elderly Patients with Psychoses  
Soo Borsoo, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 31  
7:00 p.m.-10:00 p.m.  
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle  

AGE-RELATED MEMORY LOSS: DETECTION AND TREATMENT  
Supported by Janssen Pharmaceutica and Research Foundation  

Chp.: Gary W. Small, M.D.  
Co-Chp.: Lon S. Schneider, M.D.

A From Age-Related Cognitive Decline to Dementia  
Steven H. Ferris, Ph.D., Alan Kluger, Ph.D.

B Does Depression Predict Cognitive Decline in the Elderly?  
Davangere P. Devanand, M.D., Mary Sano, Ph.D., Ming-X Tang, Ph.D., Karen Marder, M.D., Karen Bell, M.D., Yaakov Stern, Ph.D., Richard P. Mayeux, M.D.

C Methods for Early Detection of Memory Loss  
Gary W. Small, M.D.

D From Neurobiology to Novel Treatments  
Murray A. Raskind, M.D.

E Current Memory Treatments: Challenges and Prospects  
Lon S. Schneider, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 32  
7:00 p.m.-10:00 p.m.  
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle  

CONTEMPORARY ISSUES IN TREATMENT-RESISTANT DEPRESSION  
Supported by Wyeth-Ayerst Laboratories  

Chp.: Jay D. Amsterdam, M.D.

A Overview of Treatment-Resistant Depression  
Andrew A. Nierenberg, M.D.

B Algorithms in Treatment-Refractory Depression  
Jan A. Fawcett, M.D.

C Estrogen: What Is the Magnitude of the Effect?  
Barbara B. Sherwin, Ph.D.

D Combination Treatment in Resistant Depression  
David Bakish, M.D., Cynthia L. Hooper, M.A.

E Treatment-Resistant Depression: Pushing Out the Edges of the Envelope  
Jay D. Amsterdam, M.D.

MEDIA SESSION 1  
7:00 p.m.-10:00 p.m.  
Civic Ballroom, Second Floor, Sheraton Centre  

TOWARDS HEALING OF RACIAL AND RELIGIOUS DIVISIONS  

Chp.: Elmore F. Rigamer, M.D.

1 Blacks & Jews  
(85 minutes)

Distributor: California Newsreel  
149 9th Street, Suite 420  
San Francisco, CA 94103

The fault line between blacks and Jews is one of the most visible symbols of America's racial divide. Now a new film, Blacks & Jews, made collaboratively by Jewish and black filmmakers, goes behind the headlines and the rhetoric. It was acclaimed at the 1997 Sundance Film Festival for initiating a frank yet constructive nationwide dialogue to overcome the mistrust. Blacks & Jews reexamines key conflicts including the Crown Heights riots; "block busting" in Chicago and the interracial coalition that opposed it; the controversy around Louis Farrakhan and the Nation of Islam; and the press frenzy over a group of black students who laughed during a screening of Schindler's List. Blacks & Jews offers no assurances of easy racial harmony, but

(Continued on next page)
SUNDAY

Screenings of this film can cut through the anger and emotion on both sides by demonstrating that dialogue and cooperation must be based in a serious effort to understand and value the experience of others.

2 Daughters of the Troubles: Belfast Stories
(56 minutes)

Distributor: Derry Video Productions
Attn.: Marcia Rock
100 Blecker Street, 13E
New York, NY 10012

Daughters of the Troubles provides a personal narrative of the lives of two working-class Belfast women, told against the backdrop of the last 25 years of political turmoil in Northern Ireland. Women have been forced to transcend the traditional roles assigned to them by a conservative male-dominated society in order to meet the challenges of their shattered country. They painfully piece together different lives for themselves and their children as they tackle new problems today such as teenage pregnancy, drug use and alienated youth caught in the inexorable cycle of dependency. With wit and humor, the women, Catholic and Protestant, convey a sense of hope.
MONDAY, JUNE 1, 1998

151ST ANNUAL MEETING

7:00 a.m. Sessions

INDUSTRY-SUPPORTED BREAKFAST
SYMPOSIUM 33
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

PRACTICAL CLINICAL STRATEGIES FOR MANAGING REFRACTORY DEPRESSION, AGITATION AND ANTI-DEPRESSANT SIDE EFFECTS: PRACTICAL CLINICAL PSYCHOPHARMACOLOGY FOR THE PHYSICIAN
Supported by Bristol-Myers Squibb
Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Combined Treatment: A Rational Approach for Physicians
Stephen M. Stahl, M.D.

B Practical Tips in Managing Common Side Effects of Antidepressants
Norman Sussman, M.D.

RESIDENTS’ SESSION
7:00 a.m.-8:30 a.m.
Essex Room, Mezzanine, Sheraton Centre

MEET THE EXPERTS: SUNNY SIDE-UP
Chp.: Herbert S. Sacks, M.D., APA President
Co-Chp.: Rodrigo A. Muñoz, M.D., APA President-Elect

Nationally recognized "experts" will sit at tables with small groups of residents and discuss a variety of career issues and opportunities in psychiatry. Topic areas include child and adolescent psychiatry, minority issues, organizational psychiatry, private practice, psychiatry and the law, public and community psychiatry, research, writing and publishing, women’s issues, issues related to managed care and many more.

8:00 a.m. Sessions

COURSES 34-43
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 34 8:00 a.m.-12 noon
Room 702, 700 Level, Convention Centre
OUTPATIENT GROUP THERAPY FOR THE SERIOUSLY MENTALLY ILL
Joint Session with the American Group Psychotherapy Association, Inc.
Director: Walter N. Stone, M.D.

COURSE 35 8:00 a.m.-12 noon
Room 703, 700 Level, Convention Centre
SPECIAL PROBLEMS IN TREATING BORDERLINE PATIENTS
Director: Otto F. Kernberg, M.D.
Faculty: Sonia Kulchycky, M.D.

COURSE 36 8:00 a.m.-12 noon
Room 704, 700 Level, Convention Centre
DOING RESEARCH ON A SHOESTRING BUDGET
Director: Mantosh J. Dewan, M.D.
Faculty: Michele T. Pato, M.D., Edward K. Silberman, M.D.

COURSE 37 8:00 a.m.-12 noon
Room 706, 700 Level, Convention Centre
ASSESSMENT AND TREATMENT OF NICOTINE DEPENDENCE
Director: Michael G. Goldstein, M.D.
Faculty: Raymond S. Niaura, Ph.D.

COURSE 38 8:00 a.m.-12 noon
Room 707, 700 Level, Convention Centre
PSYCHIATRIC TRAINING FOR DISASTER
Co-Directors: Michael Blumenthal, M.D., Ann E. Norwood, M.D.
Faculty: Robert J. Ursano, M.D., Jon A. Shaw, M.D.

COURSE 39 8:00 a.m.-12 noon
Room 708, 700 Level, Convention Centre
FAMILIES AND MEDICAL ILLNESS: AN INTEGRATIVE TREATMENT APPROACH
Director: John S. Rolland, M.D.
MONDAY

COURSE 40  8:00 a.m.-12 noon
Room 714B, 700 Level, Convention Centre
OVERVIEW AND UPDATE OF SLEEP DISORDERS
MEDICINE
Director: Karl Doghramji, M.D.
Faculty: Thomas D. Hurwitz, M.D., John W.
Winkelmann, M.D.

COURSES 44-49
Course descriptions are available in
the CME Course Brochure included in
your registration packet. Admission by
ticket only.

COURSE 40  8:00 a.m.-12 noon
Room 714B, 700 Level, Convention Centre
OVERVIEW AND UPDATE OF SLEEP DISORDERS
MEDICINE
Director: Karl Doghramji, M.D.
Faculty: Thomas D. Hurwitz, M.D., John W.
Winkelmann, M.D.

COURSE 41  8:00 a.m.-12 noon
Room 715A/B, 700 Level, Convention Centre
ANTICONVULSANTS IN CHILD, ADOLESCENT AND
ADULT PSYCHIATRY
Co-Directors: Joseph R. Calabrese, M.D., Russell T.
Joffe, M.D.
Faculty: Kathleen T. Brady, M.D., Robert L. Findling, M.D.,
Mark A. Frye, M.D., Terence A. Ketner, M.D.

COURSE 42  8:00 a.m.-12 noon
Room 716A, 700 Level, Convention Centre
DUAL DIAGNOSIS: BASIC PRINCIPLES OF SUCCESSFUL
INTERVENTION
Director: Kenneth Minkoff, M.D.

COURSE 43  8:00 a.m.-12 noon
Room 717A/B, 700 Level, Convention Centre
THE PSYCHIATRIST AS EXPERT WITNESS
Director: Phillip J. Resnick, M.D.

COURSE 44  9:00 a.m.-4:00 p.m.
Room 705, 700 Level, Convention Centre
THERAPEUTIC INTERVENTIONS IN EATING DISORDERS
Director: David C. Jimerson, M.D.
Faculty: W. Stewart Agras, M.D., Katherine A.
Halmi, M.D., James E. Mitchell, M.D., Joel Yager, M.D.

COURSE 45  9:00 a.m.-4:00 p.m.
Room 709, 700 Level, Convention Centre
DISORDERS OF THE SELF: DIFFERENTIAL DIAGNOSIS
AND TREATMENT
Director: James F. Masterson, M.D.

COURSE 46  9:00 a.m.-4:00 p.m.
Room 711, 700 Level, Convention Centre
TRAUMA, DISSOCIATION AND MEMORY
Director: James A. Chu, M.D.

COURSE 47  9:00 a.m.-4:00 p.m.
Room 713B, 700 Level, Convention Centre
PERSONNEL MANAGEMENT FOR CLINICIAN-
MANAGERS
Director: Stephen M. Saltys, M.D.
Faculty: William Noyes, M.P.A., Joseph J. Parks III, M.D.,
Roberta Gardine, M.P.A., James Impey, J.D., Mark
Binkley, J.D.

COURSE 48  9:00 a.m.-4:00 p.m.
Room 714A, 700 Level, Convention Centre
INTRODUCTION TO BEHAVIOR THERAPY
Co-Directors: Robert M. Goisman, M.D., Philip G.
Levendusky, Ph.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Caledon Room, Lobby Level, Crowne Plaza
PSYCHOTHERAPY OF A SUBSTANCE-ABUSING PATIENT
Moderator: Richard J. Frances, M.D.
Presenter: Frances R. Levin, M.D.

CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART I
9:00 a.m.-12 noon
Ontario Room, Lower Level, Crowne Plaza
PSYCHOTHERAPIES IN RESIDENCY TRAINING: PART I

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 1
9:00 a.m.-10:30 a.m.
Caledon Room, Lobby Level, Crowne Plaza
PSYCHOTHERAPY OF A SUBSTANCE-ABUSING PATIENT
Moderator: Richard J. Frances, M.D.
Presenter: Frances R. Levin, M.D.

CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART I
9:00 a.m.-12 noon
Ontario Room, Lower Level, Crowne Plaza
PSYCHOTHERAPIES IN RESIDENCY TRAINING: PART I

Moderator: Lisa A. Mellman, M.D.
Presenter: Steven P. Hamilton, M.D.
Discussants: Michael E. Thase, M.D., John C.
Markowitz, M.D., Glen O. Gabbard, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE
REGISTRATION BADGE OR APA MEMBERSHIP CARD
REQUIRED FOR ADMITTANCE.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE
REGISTRATION BADGE OR APA MEMBERSHIP CARD
REQUIRED FOR ADMITTANCE.
COURSE 49  
9:00 a.m.-4:00 p.m.  
Room 718A, 700 Level, Convention Centre

ADVANCES IN NEUROPSYCHIATRY  
Joint Session with the American Neuropsychiatric Association

Co-Directors: C. Edward Coffey, M.D., Jeffrey L. Cummings, M.D.  
Faculty: Mark S. George, M.D., John J. Campbell III, M.D., James D. Duffy, M.D.

DEBATE 1  
9:00 a.m.-10:40 a.m.  
Room 104A, Lower Level, Convention Centre

RESOLVED: PHARMACEUTICAL SUPPORT FOR UNDERGRADUATE, GRADUATE AND POSTGRADUATE EDUCATIONAL PROGRAMS SHOULD BE ENCOURAGED

Moderator: Peter B. Gruenberg, M.D.  
Affirmative: Michael A. Schwartz, M.D., Paul C. Mohl, M.D.  
Negative: Myrl R.S. Manley, M.D., Irwin N. Hassenfeld, M.D.  
THIS SESSION WILL BE AUDIOTAPED.

DISCUSSION GROUPS 1-2

These sessions are limited to 25 participants on a first-come, first-served basis.

DISCUSSION GROUP 1  
9:00 a.m.-10:30 a.m.  
Confederation Room 4, Mezzanine, Royal York

Rodrigo A. Muñoz, M.D., on Psychiatry in the Year 2010

DISCUSSION GROUP 2  
9:00 a.m.-10:30 a.m.  
Confederation Room 6, Mezzanine, Royal York

Charles R. Schuster, Ph.D., on Behavioral Approaches to the Treatment of Drug Dependence  
Collaborative Session with the National Institute on Drug Abuse

LECTURES 2-4

Days of Creation Session
LEcTURE 2  
9:00 a.m.-10:30 a.m.
Research advances in treatments for major mental disorders are often difficult to apply in clinical practice because of the heterogeneity of patients outside research settings, providers' reluctance to adopt manualized treatments and limits on treatment regimens imposed by managed care. Barbara J. Burns, Ph.D., explores challenges to determining the clinical effectiveness of promising interventions and discusses strategies for disseminating effective treatments, monitoring the fidelity of interventions and documenting outcomes. Dr. Burns holds academic appointments at Duke University Medical Center as Professor of Medical Psychology in the Department of Psychiatry and Behavioral Sciences, Associate Research Professor in the Center for Health Policy Research and Education and Senior Fellow in the Center for the Study of Aging and Human Development. She is a Research Fellow at the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill (UNC) and an Adjunct Professor at the University of Arkansas for Medical Sciences. Dr. Burns directs the Services Effectiveness Research Program at Duke and co-directs the Postdoctoral Research Training Program in Mental Health Services and Systems at Duke and UNC. A nationally recognized mental health services researcher with more than 140 publications in this specialty area, Dr. Burns has received numerous awards, including the Carl A. Taube Award for Excellence in Mental Health Services Research from the American Public Health Association and a Special Presidential Commendation from the American Psychiatric Association. Dr. Burns received her doctoral degree from Boston College.

Floyd E. Bloom, M.D., reviews these findings and discusses current research to clarify the long-term changes that cause humans to become tolerant of commonly abused drugs. Dr. Bloom is Chairman of the Department of Neuropharmacology at the Scripps Research Institute in La Jolla, California, and Editor-in-Chief of Science. One of the major architects of modern neuroscience, Dr. Bloom was the first to appreciate the need for in-depth study of comprehensive neurotransmitter systems at the anatomical, physiological and pharmacological levels. A member of the National Academy of Sciences and the Institute of Medicine, he has received numerous awards, including the Pasarow Award in Neuropsychiatry, the Hermann von Helmholtz Award, the William R. McAlpin, Jr., Award from the National Association of Mental Health and the Distinguished Research Award from the American Society of Addiction Medicine. He is a Distinguished Fellow of the American Psychiatric Association, a Fellow and former president of the American College of Neuropsychopharmacology, and the former president of the Society for Neuroscience and the Research Society for Alcoholism. A graduate of the Washington University School of Medicine in St. Louis, Dr. Bloom trained in pharmacology at the National Institute of Mental Health's Clinical Neuropharmacological Research Center in Washington, DC, and completed a postdoctoral fellowship in anatomy at Yale University School of Medicine.

**Frontiers of Science Lecture Series**

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 4**

9:00 a.m.-10:30 a.m.

Dominion Ballroom, Second Floor, Sheraton Centre

Floyd E. Bloom, M.D.

Substance Abuse and Reward Systems in the Brain

Collaborative Session with the National Institute on Drug Abuse

Chp.: Herbert D. Kleber, M.D.

Co-Chp.: Marianne T. Guschwan, M.D.

Over the past decade, neuroscientific research has identified several important synaptic sites which underlie the reward sites in the brain where drugs that are abused by humans (opioids, psychostimulants, alcohol and nicotine) are known to act. These drugs act by various primary mechanisms to activate the ventral tegmental dopaminergic projections to the nucleus accumbens, and in particular the shell of this nucleus, known to maintain substantial interconnections to the amygdaloid complex.

**MASTER EDUCATOR CLINICAL CONSULTATIONS 1-2**

9:00 a.m.-10:30 a.m.

These are limited to 25 participants on a first-come, first-served basis.

18
1 Kyle D. Pruett, M.D., on the Father in Psycho-pathology and Psychotherapy: Case Discussions Where Fathering and Being Fathered Affect Recovery from Mental Illness: Dynamic and Developmental Considerations
   New Brunswick Room, Mezzanine, Royal York

2 Ellen Leibenluft, M.D., on Rapid-Cycling Bipolar Disorder
   Nova Scotia Room, Mezzanine, Royal York

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 2-5

MEDIA SESSION 2 9:00 a.m.-5:00 p.m.
   Room 718B, 700 Level, Convention Centre

COMPUTERIZED PATIENT RECORDS: STATE-OF-THE-ART
Co-Chps.: Tal Burt, M.D., Waguih Ishak, M.D.

3 Computerized Patient Records
   Russell F. Urn, M.D., Zebulon C. Taintor, M.D.

This all day session will focus on the use of computer technology in psychiatric practice. Waguih Ishak, M.D., of New York University, and Tal Burt, M.D., of Harvard University, will demonstrate state-of-the-art software specifically created for psychiatry. Participants will have the opportunity to appreciate how user-friendly and comprehensive the new age of software is. Emphasis will be placed on the specific ways in which the use of specialized software can improve the quality of psychiatric care, administration, education, research and communication. There will be some power strips available for attendees who bring their own laptop computers to “plug in.” No pre-registration is required.

MEDIA SESSION 3 9:00 a.m.-10:30 a.m.
   Ontario Room, Convention Floor, Royal York

REMARKABLE COURAGE OF THE PHYSICALLY CHALLENGED
Chp.: John M. Dluhy, M.D.

4 Breathing Lessons: The Life and Work of Mark O’Brien
   (35 minutes)

Distributor: Fanlight Productions
   47 Halifax Street
   Boston, MA 02130

According to the poet-journalist Mark O’Brien, “The two mythologies of disabled people break down to: one, we can’t do anything, or two, we can do everything. But the truth is, we’re just human.” This award-winning documentary offers a challenging look into the mind of a man who can’t do a lot of things that most of us take for granted, but who does other things superbly well. Mr. O’Brien writes regularly for Pacific News Service and contributes to National Public Radio. He is the author of a collection of poetry entitled Breathing and has had poems featured in numerous literary publications and anthologies. Mark O’Brien contracted polio in childhood. Due to post-polio syndrome as a young adult, he now spends much of his life in an iron lung. Yet for more than 40 years he has fought against illness and bureaucracy for his right to lead an independent life. By presenting life from Mr. O’Brien’s point of view, this documentary provides an intimate window into the reality of a life with severe disability, as well as an illuminating portrait of a remarkable artist.

Best Short Documentary, South by Southwest Film Festival
Juror’s Choice Award, Charlotte Film and Video Festival
Audience Award, Aspen Shortsfest
Golden Gate Awards, Silver Spire, San Francisco International Film Festival

5 Untold Desires
   (53 minutes)

Distributor: Filmaekers Library
   124 East 40th Street
   New York, NY 10016

Untold Desires highlights the struggle that people with disabilities face in their quest to be recognized as sexual beings, free to express their sexuality and lead sexually active lives. In the sometimes sensitive area of sexuality, people with disabilities find that their own needs are often subverted by the conservative values of those who provide essential care. They are also sharply conscious of how they are seen by others. Untold Desires allows these people to speak about issues that confront them: choice, privacy, the right to have sexual relationships, and the right to have children. They speak frankly about their experiences in search of sexually fulfilled lives. Their honesty is sometimes raw, but always deeply moving. The film offers positive images for people with disabilities and breaks down stereotypes that render the disabled person nonsexual in the eyes of the nondisabled world.

Best Documentary, Human Rights Award, 1995
Best Documentary, Australian Film Institute Awards, 1995
Silver Medal, Prix Leonardo, Italy, 1995
MEDIA SESSION 4
9:00 a.m.-11:00 a.m.
Confederation Room 5, Mezzanine, Royal York

VIDEO PRODUCTION CLINIC
Chp.: Richard E. D’Alli, M.D.

This clinic, chaired by a former TV news reporter and producer, will illustrate basic principles of shooting, lighting and sound in video production. Editing, technical and target audience issues will be discussed. Participants are STRONGLY encouraged to bring their own video materials, finished, in progress, or in concept, for discussion during this highly interactive session. VHS record/playback equipment will be available on site.

MEDIA SESSION 5
9:00 a.m.-10:30 a.m.
Civic Ballroom, Second Floor, Sheraton Centre

TRUTH AND RECONCILIATION IN SOUTH AFRICA
Chp.: J. Charles Ndlela, M.D.

6 Cry, The Beloved Country
(108 minutes)

Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787-4305

On attending the world premier of Cry, The Beloved Country, President Nelson Mandela made an astounding statement, "A monument to the future. I enjoyed every moment of it. Cry, The Beloved Country and its message reinforce our friendship across the oceans and add value to the treasure house of culture. It vividly captures Alan Paton’s eloquent faith in the essential goodness of people." The first feature film from the new democratic South Africa shows the healing process of forgiveness and reconciliation. Born on a 1946 worldwide best-selling novel, it depicts the sociopolitical forces that were already in existence in the pre-apartheid era; blacks and whites existed in diametrically opposed worlds yet were completely oblivious to one another. The two main protagonists are played magnificently by James Earl Jones and Richard Harris; from the tragedy of one son killing the other’s son arose compassion and forgiveness. Cry, The Beloved Country demonstrates parallels with the current process of the Truth and Reconciliation Commission in South Africa. Both the film and the Truth and Reconciliation Commission can be regarded as guideposts in the history of South Africa spanning the pre-apartheid, apartheid, and post-apartheid periods. The rest of the world may yet learn how the deep wounds of division and racism can be healed through forgiveness.

NEW RESEARCH

YOUNG INVESTIGATORS’ POSTER
SESSION 1
9:00 a.m.-10:30 a.m.
Room 106, Lower Level, Convention Centre

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

WORKSHOPS

COMPONENTS 1-8

COMPONENT WORKSHOP 1 9:00 a.m.-10:30 a.m.
Room 205C, Street Level, Convention Centre

MALPRACTICE AND LITIGATION IN PSYCHIATRIC RESIDENCY
APA New York State Psychiatric Association’s Committee of Members-in-Training

Chp.: Cletus S. Carvalho, M.D.
Participants: Paul S. Appelbaum, M.D., Martin G. Tracy, J.D.

COMPONENT WORKSHOP 2 9:00 a.m.-10:30 a.m.
Room 205D, Street Level, Convention Centre

NURSING HOME PSYCHIATRY: PROBLEMS AND SOLUTIONS
APA New Jersey Psychiatric Association

Chp.: Marc I. Rothman, M.D.
Participants: Istvan J.E. Boksay, M.D., Patricia A.J. Kay, M.D.

COMPONENT WORKSHOP 3 9:00 a.m.-10:30 a.m.
Room 206A, Street Level, Convention Centre

HOW YOUR PATIENTS’ DISABLEMENT WILL BE EVALUATED
APA Committee on Psychiatric Diagnosis and Assessment

Co-Chps.: Frederick G. Guggenheim, M.D., Bedirhan Ustun, M.D.
Participants: Cille Kennedy, Ph.D., Dale N. Cox, B.S., Laura Lee Hall
<table>
<thead>
<tr>
<th>Component Workshop 4</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 206B, Street Level, Convention Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Political Violence in the Post-Cold War Era</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Jerrold M. Post, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Stevan M. Weine, M.D., David A. Rothstein, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 5</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Humber Room, Lobby Level, Crowne Plaza</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New and Alternative Treatments in HIV Care</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Commission on AIDS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Francisco Fernandez, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Francine Cournois, M.D., John H. O'Donnell, M.D., Karl Goodkin, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 6</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Alberta Room, Mezzanine, Royal York</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Guidelines for Collaborative Treatment in Psychiatry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Consortium on Treatment Issues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Jerome A. Collins, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Michelle Riba, M.D., Joseph J. Westermeyer, M.D., Richard J. Kessler, D.O., Howard D. Kibel, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 7</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Huron Room, Second Floor, Sheraton Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dealing with Violence in Schools</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Committee on Psychiatry and Mental Health in the Schools and APA Task Force on Psychiatric Aspects of Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Lois T. Flaherty, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Carl C. Bell, M.D., Paul Jay Fink, M.D., Joan E. Kinlan, M.D., Joseph J. Palombi, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component Workshop 8</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 3285, Third Floor, Medical Sciences Building, University of Toronto, 8 Tattle Creek Road (Transportation not provided)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hands-On Web Work: Part I</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Committee on Information Systems</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Bertram Warren, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Cheryl A. Chessick, M.D., Ivan K. Goldberg, M.D., Sol Herman, M.D., Ronnie S. Stangler, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issues 1-18</th>
<th></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 1</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 205A, Street Level, Convention Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Insight into Illness: A Detriment or an Enhancement?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Thankamma Mathew, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: John F. Crilly, M.S.W., Elizabeth DiMartino, M.S.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 2</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 205B, Street Level, Convention Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiac Psychiatry</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Susan E. Abbey, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Francois Lesperance, M.D., Brian Baker, M.D., Paul Dorian, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 3</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 206D, Street Level, Convention Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Medical Careers and Mid-Life Transition</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Anna G. Engel, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Hera J. Cohn-Haft, M.D., Virginia L. Susman, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 4</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Room 104B, Lower Level, Convention Centre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Treating Mental Illness in Prisons</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: James E. Dillon, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Richard S. Jackson, M.D., Lee H. Rome, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 5</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Grenadier Room, Lobby Level, Crowne Plaza</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>How to Teach the Biopsychosocial Model Effectively</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Hoyle Leigh, M.D., Trevor D. Glenn, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Don R. Lipsitt, M.D., Jon M. Steltzer, M.D.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Issue Workshop 6</th>
<th>9:00 a.m.-10:30 a.m.</th>
<th>Kingsway Room, Lobby Level, Crowne Plaza</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Collaboration in Eastern and Southern Africa</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>APA Task Force on National and International Terrorism and Violence</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chp.: Lawson R. Wulsin, M.D.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Participants: Athanase Hagengimana, M.D., Pius Akivaga Kiganwa, M.D., Alan S. Bergsma, O.D., Clifford W. Allwood, M.D., Dr. Margaret Makanyengo</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
ISSUE WORKSHOP 7 9:00 a.m.-10:30 a.m.
Oakville Room, Lobby Level, Crowne Plaza

THE HAMILTON-WENTWORTH HSO MENTAL HEALTH PROGRAM
Chp.: Nick S. Kates, M.B.
Participants: Anne Marie Crustolo, B.Sc.N., Marilyn Craven, M.D., Lambrina Nikolaou, Sheryl Farrar

ISSUE WORKSHOP 8 9:00 a.m.-10:30 a.m.
Toronto Room, Convention Floor, Royal York

OUR FUTURE: MEDICINE, CULTURE AND HUMAN RIGHTS ISSUES
Joint Session with the American Association of Psychiatric Administrators
Chp.: Paul A. Rodenhauser, M.D.
Participants: Humberto L. Martinez, M.D., L. Mark Russakoff, M.D., Pedro Ruiz, M.D.

ISSUE WORKSHOP 9 9:00 a.m.-10:30 a.m.
British Columbia Room, Mezzanine, Royal York

VALUES IN THE PHYSICIAN/PATIENT MANAGED HEALTH CARE RELATIONSHIP
Chp.: Harold J. Bursztajn, M.D.
Participants: Alan A. Stone, M.D., Patricia Illingworth, J.D., Bryant Welch, J.D.

ISSUE WORKSHOP 10 9:00 a.m.-10:30 a.m.
Manitoba Room, Mezzanine, Royal York

THE PSYCHODYNAMIC FORMULATION: WHY BOTHER?
Co-Chps.: Carlos Blanco-Jerez, M.D., Donna T. Chen, M.D.
Participants: Gita Vaid, M.D., Robert Michels, M.D., Paul H. Ornstein, M.D.

ISSUE WORKSHOP 11 9:00 a.m.-10:30 a.m.
Territories Room, Mezzanine, Royal York

FAITH AND COPING IN PATIENTS AND Psychiatrists
Chp.: Elizabeth S. Bowman, M.D.
Participants: Francis G. Lu, M.D., Terry Bard, Ph.D., Roger C. Sider, M.D., Linda K. George, Ph.D.

ISSUE WORKSHOP 12 9:00 a.m.-10:30 a.m.
Tudor Room 7, Mezzanine, Royal York

GROUP TREATMENT FOR TRAUMATIZED DRUG-USING WOMEN
Chp.: Paula G. Panzer, M.D.

ISSUE WORKSHOP 13 9:00 a.m.-10:30 a.m.
Conference Room B, Mezzanine, Sheraton Centre

ENHANCING SUPERVISOR-RESIDENT RELATIONSHIPS TO FACILITATE LEARNING
Co-Chps.: Richard G. Tiberius, Ph.D., Janet M. deGroot, M.D.
Participants: Joanne Sinai, M.D., Peter Voore, M.D., Aileen S. Brunet, M.D.

ISSUE WORKSHOP 14 9:00 a.m.-10:30 a.m.
Conference Room F, Mezzanine, Sheraton Centre

CHALLENGES TO CONFIDENTIALITY IN CHILD PSYCHIATRY
Co-Chps.: Daniel M.A. Freeman, M.D., Peter D. Ganime, M.D.
Participants: Marshall D. Schechter, M.D., David M. Ellis, M.D., Leroy J. Byerly, M.D., Barbara B. Zulick, Esq.

ISSUE WORKSHOP 15 9:00 a.m.-10:30 a.m.
Windsor Room, Mezzanine, Sheraton Centre

MODEL FOR MULTIPLE AFFILIATIONS FOR PSYCHIATRIC PRACTICE
Co-Chps.: Anil G. Godbole, M.D., Anthony M. D'Agostino, M.D.

ISSUE WORKSHOP 16 9:00 a.m.-10:30 a.m.
York Room, Mezzanine, Sheraton Centre

USING STANDARDIZED PATIENTS TO EVALUATE PSYCHIATRIC CLINICAL CLERKS
Chp.: Debra L. Klamen, M.D.
Participant: Kathleen R. Merikangas, Ph.D.

ISSUE WORKSHOP 17 9:00 a.m.-10:30 a.m.
City Hall Room, Second Floor, Sheraton Centre

HELLO DOLLY: PSYCHIATRY AND ASSISTED REPRODUCTION
Chp.: Martha J. Kirkpatrick, M.D.
Participants: Jane L. Rosenthal, M.D., Miriam B. Rosenthal, M.D., Ian E. Alger, M.D.

ISSUE WORKSHOP 18 9:00 a.m.-10:30 a.m.
Kent Room, Second Floor, Sheraton Centre

NEW ROLES FOR PSYCHIATrists RESOLVING COMMUNITY CONFLICTS
Chp.: Stuart W. Twemlow, M.D.
Participant: Frank C. Sacco, Ph.D.
WORKSHOP ON PRIVATE PRACTICE ISSUES
9:00 a.m.-12 noon
Room 103B, Lower Level, Convention Centre

THE FUTURE OF PRIVATE PRACTICE
APA Committee on Private Practice
Chp.: Michael C. Hughes, M.D.
Participants: Herbert S. Sacks, M.D., Ronald A. Shellow, M.D., Norman A. Clemens, M.D., Tracy R. Gordy, M.D.

10:30 a.m. Session

ADVANCES IN RESEARCH
10:30 a.m.-12:30 p.m.
Room 105, Lower Level, Convention Centre

RESEARCH ADVANCES IN PSYCHIATRY: AN UPDATE FOR THE CLINICIAN
Co-Sponsored by the APA Scientific Program Committee and the APA Council on Research
Chp.: Herbert Pardes, M.D.
Co-Chp.: Daniel K. Winstead, M.D.
Participants: Alan Leshner, Ph.D., on Substance Abuse
Collaborative Presentation with the National Institute on Drug Abuse
Jimmie C. Holland, M.D., on Psychiatrists' Role in Medical Illness
Stuart C. Yudofsky, M.D., on Advances in Neuropsychiatry
Harold A. Sackeim, Ph.D., on Use of Transcranial Magnetic Stimulation in Psychiatry

11:00 a.m. Sessions

DISCUSSION GROUPS 3-4
These sessions are limited to 25 participants on a first-come, first-served basis.

DISCUSSION GROUP 3 11:00 a.m.-12:30 p.m.
Confederation Room 4, Mezzanine, Royal York
Carol A. Bernstein, M.D., on the Future of Psychiatric Education in the 21st Century

DISCUSSION GROUP 4 11:00 a.m.-12:30 p.m.
Confederation Room 6, Mezzanine, Royal York
Richard C.W. Hall, M.D., on Legal and Ethical Issues in Dealing with Managed Care

LECTURES 5-6

Days of Creation Session
LECTURE 5
11:00 a.m.-12:30 p.m.
Room 107, Lower Level, Convention Centre
Wolf Kahn
Artists' Inspiration: Sentiment, Sentimentality or Neither of the Above
Chp.: Herbert S. Sacks, M.D.
Co-Chp.: Eve Leeman, M.D.
To explore how artists are inspired to create their work, one must first put aside the superficial, sentimental ideas that dominate conventional thinking about this topic. Drawing on a lifetime of practice as an artist, Wolf Kahn discusses the sources of his appetite for work and explores the deeper motivations that may be the basis of the artist's endeavor. He questions the popular idea that equates inspiration with a momentary excess of feeling and examines whether art is of value to mental health and whether contemporary art reflects the current culture. Art practiced on a serious level invariably aims at transcendence of the every day, and opens the mind to unconventional thinking and feeling. Mr. Kahn travels extensively and has painted landscapes in such diverse locales as Mexico, Italy, Egypt, Greece and Kenya. He has had solo exhibits at numerous galleries in the United States, including the Beadleston Gallery and the Grace Borgenicht Gallery in New York City, as well as in Canada and England. His work has been displayed at major museums across the United States and is included in major corporate and public collections. Mr. Kahn has received a Fulbright grant and the John Simon Guggenheim Fellowship. He has been elected to membership in the National Academy of Design, the National Board of the College Art Association, and the National Academy and Institute of Arts and Letters. He is the author of several articles for periodicals in the art field.

Mr. Kahn was born in Stuttgart, Germany, in 1927, and came to the United States in 1940. A graduate of the University of Chicago, Mr. Kahn studied painting with Hans Hofmann in New York and Provincetown, Massachusetts. Psychiatry and the Arts Lecture Series

THIS SESSION WILL BE AUDIOTAPED.
The past 30 years have seen dramatic changes in approaches to treatment of eating disorders. Paul E. Garfinkel discusses empirical research that has increased the understanding of anorexia and bulimia nervosa and has improved clinical care. Multifactorial models for conceptualizing these illnesses have become accepted, although each factor that contributes to the model must stand up to independent empirical scrutiny. In both anorexia nervosa and bulimia nervosa, depression avoidance of a normal body size is related to fears of being able to control oneself independently. This problem in turn is rooted in other events in the individual, family and culture, including difficulties in emotional separation and self-perception, genetic factors and styles of family interaction, as well as the culture's idealization of thinness. Our new level of understanding has helped us move towards a goal of step care, which involves providing interventions that have proven effective beginning with the least costly, least intrusive form and working up to more intensive care as the patient's need requires. Dr. Garfinkel is Professor and Chair of the Department of Psychiatry at the University of Toronto and President and Psychiatrist-in-Chief of the Clarke Institute of Psychiatry. Particularly well respected for his clinical and research expertise in the field of eating disorders, Dr. Garfinkel established a comprehensive eating disorders program at Toronto General Hospital and has received numerous research and clinical awards in support of his work, including the Gold Achievement Award from the American Psychiatric Association and the Canadian Psychiatric Research Foundation Annual Award. In 1996, he was elected Fellow in the Royal Society of Canada. He is also a Fellow of the Canadian College of Neuropsychopharmacology and the American College of Psychiatrists and a member of the Canadian Institute of Academic Medicine. Dr. Garfinkel is the author of Anorexia Nervosa: A Multidimensional Perspective and has edited seven other books on eating disorders. He has contributed numerous articles to the professional literature and lectures widely in his areas of expertise. He is a member of the editorial boards of several journals and is an Associate Editor of the Canadian Journal of Psychiatry and the Journal of Eating and Weight Disorders.

MASTER EDUCATOR CLINICAL CONSULTATIONS 3-4

11:00 a.m.-12:30 p.m.
These are limited to 25 participants on a first-come, first-served basis.

3 Alan J. Gelenberg, M.D., on Depression
New Brunswick Room, Mezzanine, Royal York

4 Kerry E. Mitchell, M.D., on Evaluation of Depression in the Medically Ill
Nova Scotia Room, Mezzanine, Royal York

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY.
BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 6-7

MEDIA SESSION 6 11:00 a.m.-2:00 p.m.
Ontario Room, Convention Floor, Royal York

MULTICULTURAL AND GENDER PERSPECTIVES ON DEVELOPMENT

Chp.: Ian E. Alger, M.D.

7 Girls Like Us
(60 minutes)

Distributor: Women Make Movies, Inc.
Distribution Department
462 Broadway, Suite 500 E
New York, NY 10013
In Girls Like Us, a documentary on female teenage sexuality, a fluid hand-held camera follows an ethnically diverse group of four working-class teenage girls over a period of four years (ages 14 to 18). Filmed in South Philadelphia, Girls Like Us exposes the conflicts of growing up female and the impact of class, sexism and violence on the dreams and expectations of teenage girls. Exploiting the intersection of cultural values and pop culture, family pressures and personal identity, Girls Like Us stimulates dialogue between youth, adults and educators.

Grand Jury Prize, Best Documentary, 1997 Sundance Film Festival
Golden Apple Award, National Educational Media Market
Grand Jury Prize, 1997 Charlotte Film Festival
Honorable Mention, 1997 Atlanta Film/Video Festival
Human Rights Watch Film Festival
Nationally Broadcast on Public Television (P.O.V.)

8 Nobody's Business
(60 minutes)

Distributor: Milestone Film & Video, Inc.
275 West 96th Street, Suite 28C
New York, NY 10013

"My life is no different from, I don’t know how many, billions of people, who the hell am I?” asks Oscar Berliner. “You’re my father” his filmmaker son answers. So begins a fascinating, if reluctant, partnership to create a portrait of a family by sifting through myth, memories, fact and fiction—the cautious exchange of information and affection between father and son.

MEDIA SESSION 7 11:00 a.m.-2:00 p.m.
Civic Ballroom, Second Floor, Sheraton Centre

AN INNOVATIVE PSYCHOLOGICAL MUSICAL: PENNIES FROM HEAVEN
Joint Session with the Forum for the Psychoanalytic Study of Films

Co-Chps.: Francis G. Lu, M.D., Bruce H. Sklarew, M.D.

9 Pennies from Heaven
(120 minutes)

Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787-4305

Songs of the Great Depression momentarily offered hope and possibility to many who were otherwise filled with despair as they went from soup kitchens to apple stands. So did escapist movies such as those made by Astaire/Rogers, Rooney/Garland, and Busbee Berkeley.

Dennis Potter, the British TV dramatist, wrote a six-part series for the BBC called Pennies From Heaven which MGM made into an American musical directed by Herb Ross and starring Steve Martin, Bernadette Peters, and Christopher Walken. The movie Pennies From Heaven stands escapism on its head and offers the audience a musical tour into the unconscious lives of its characters. In a highly entertaining yet bleak comedy about a down-and-out liar and philanderer, we see how the unconscious is always active and experiencing the material world simultaneously with conscious experience. In classical psychoanalytic therapy, one digs into the past, lifting repression, ultimately hoping to reveal psychic drives which underlie disturbed defenses. When characters burst into song we in the audience get a different view of how the mind works, as songs from the distant past suddenly illuminate the present while they simultaneously offer ways of escaping. Suddenly the past feels alive in the present, something which puts therapists more in the mind of Betty Joseph’s ideas about “the total situation” than Freud’s of peeling an onion. Music offers immediate recall, reaction and interpretation of events hitherto hidden. Discussion at the end of this film will examine new ways to think about the unconscious process and means of accessing it. Too often films depicting the painful realities of the 1930s lend themselves merely to sociological interpretation. In this film, however, the audience can explore the individual psychology of the leading characters and how they are each shaped in unique ways by overtly common cultural experiences.

Discussant: Justin A. Frank, Jr., M.D.

MEDICAL UPDATE 1
11:00 a.m.-12:30 p.m.
Room 104C, Lower Level, Convention Centre

CONGESTIVE HEART FAILURE

Chp.: Brian Baker, M.D.
Presenter: Howard Levin, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSIONS 1-10

SCIENTIFIC AND CLINICAL REPORT SESSION 1
11:00 a.m.-12:30 p.m.
Room 205B, Street Level, Convention Centre

COMORBIDITY AND TREATMENT ISSUES IN PERSONALITY DISORDERS

(Continued on next page)
MONDAY

Chp.: Conrad V. Schmitt, M.D.
Co-Chp.: Rownak Ahmed, M.D.

2 Personality in Different Anxiety Disorders
James H. Reich, M.D. 11:00 a.m.

3 Personality Traits and Response to Antidepressants
Ronald R. Fieve, M.D., Michael Sobel, M.D.,
Eric D. Peselow, M.D. 11:30 a.m.

4 Schizotypy and Cognition in Borderline Personality
Rosemary Toomey, Ph.D., Michael J. Lyons, Ph.D.,
Rebecca Hartley, B.A., Mary C. Zanarini, Ed.D.,
Stephen V. Faraone, M.D., Larry J. Seidman, Ph.D.,
Ming T. Tsuang, M.D. 12 noon

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 2
11:00 a.m.-12:30 p.m.
Room 205D, Street Level, Convention Centre

MOOD DISORDERS IN WOMEN
Chp.: Barbara D. Bartlik, M.D.
Co-Chp.: Sharon C. Harvey, M.D.

5 Prevention of Postpartum Episodes in Bipolar Women
Katherine L. Wisner, M.D. 11:00 a.m.

6 Alcohol Dependency and Affective Illness Among Women
Kathleen S. Feindt, Ph.D., Katherine L. Wisner, M.D. 11:30 a.m.

7 Dysphoric Moods in Women: Menopause or Myth?
Howard M. Kravitz, D.O., Joyce T. Bromberger, Ph.D.,
Lynda H. Powell, Ph.D. 12 noon

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 3
11:00 a.m.-12:30 p.m.
Room 206C, Street Level, Convention Centre

SUICIDE: CAUSES IN PATIENTS AND EFFECTS ON DOCTORS
Chp.: James E. Dillon, M.D.
Co-Chp.: Daniel P. Chapman, M.D.

8 Kevorkian's List: Psychosocial or Medical Factors?
Kalman J. Kaplan, Ph.D., Flint Lachenmeier, M.A.,
Jyll O'Dell, M.A., Diana Caragacianu 11:00 a.m.

9 Psychological Impact of a Patient's Suicide on Psychiatrists
Charito V. Quintero, M.D. 11:30 a.m.

10 Covariates of Suicidality in Dysphoric Mania
Jessica L. Garno, B.S., Joseph F. Goldberg, M.D.,
James H. Kocsis, M.D., Laura Portera, M.S. 12 noon

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 4
11:00 a.m.-12:30 p.m.
Room 206F, Street Level, Convention Centre

ADOLESCENT MENTAL HEALTH ISSUES
Chp.: Sidney H. Weissman, M.D.
Co-Chp.: Cassandra E. Harewood, M.D.

11 PTSD in Adolescent Survivors of Ethnic Cleansing
Daniel F. Becker, M.D., Stevan M. Weine, M.D.,
Dolores Vojvoda, M.D., Thomas H. McGlashan, M.D. 11:00 a.m.

12 Pathological Gambling Among Louisiana Adolescents
James R. Westphal, M.D., J Jill A. Rush, M.D.,
Lee Stevens, M.D. 11:30 a.m.

13 Depressed Mood in Conduct-Disordered Inpatients
Dwain C. Fehon, Psy.D., Carlos M. Grilo, Ph.D.,
Steve Martino, Ph.D. 12 noon

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 5
11:00 a.m.-12:30 p.m.
Caledon Room, Lobby Level, Crowne Plaza

CHANGING PATTERNS OF MENTAL HEALTH PRACTICE
Chp.: Roger Peele, M.D.
Co-Chp.: Alpa A. Patel, M.D.

14 County Funding of Mental Health Services
Barbara M. Rohland, M.D., James E. Rohrer, Ph.D. 11:00 a.m.

15 Results of Capitated Behavioral Health Care in a Primary Care Based Academic Health System
Donald M. Hilty, M.D., Robert E. Hales, M.D.,
Thomas F. Anders, M.D., Anthony Smith, Ph.D.,
Sera Cosentino-Long 11:30 a.m.

16 Practice Profile of Canadian Psychiatrists
Elizabeth Lin, Ph.D., D. Blake Woodside, M.D.,
Anne E. Rhodes, M.Sc. 12 noon

THIS SESSION WILL BE AUDIOTAPE.
MONDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 6
11:00 a.m.-12:30 p.m.
Confederation Room 3, Mezzanine, Royal York

NEUROLEPTICS: COSTS AND BENEFITS
Chp.: Peter J. Weiden, M.D.
Co-Chp.: Patricia K. Leebeens, M.D.
17 Haloperidol Versus Clomipramine in Autistic Disorder
11:00 a.m.
Leon Sloman, M.D., Gary Remington, M.D., Mary Konstantareas, Ph.D., Kathryn Parker, B.A.
18 Cost of Olanzapine Treatment Compared with Haloperidol for Schizophrenia: Results from a Randomized Clinical Trial
11:30 a.m.
Susan H. Hamilton, Dennis Revicki, Ph.D., Laura A. Genduso, Gary D. Tollefson, M.D.
19 NMS and Catatonia: Comparative Features
12 noon
Patricia I. Rosebush, M.D., Michael F. Mazurek, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 7
11:00 a.m.-12:30 p.m.
Quebec Room, Mezzanine, Royal York

CHALLENGES IN DIAGNOSIS
Chp.: Howard W. Telson, M.D.
Co-Chp.: L. Lee Tynes, M.D.
20 Incarceration: What Does It Do to Psychiatric Diagnosis?
11:00 a.m.
Balbir S. Coshal, M.D.
21 Psychiatric Diagnosis in Clinical Practice
11:30 a.m.
Mark Zimmerman, M.D., Jill I. Mattia, Ph.D.
22 The Evaluation Process in Obstructive Sleep Apnea
12 noon
Milton Kramer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 8
11:00 a.m.-12:30 p.m.
Tudor Room 7, Mezzanine, Royal York

SEX, ADDICTION AND ETHICS OF TREATMENT
Chp.: Saul M. Levin, M.D.
Co-Chp.: Paul Gaist, Ph.D.
23 Sexual Abuse by Clergy: Clinical and Forensic Issues
11:00 a.m.
Diane H. Schefsky, M.D.
24 Sexual Addiction: An Integrated Understanding
11:30 a.m.
Aviel Goodman, M.D.
25 Ethics in the Practice of Psychiatry in South Africa
12 noon
Christopher P. Szabo, M.D., Robert Kohn, M.D., Alan L. Gordon, M.D., Itzhak Leven, M.D., George A. Hart, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 9
11:00 a.m.-12:30 p.m.
City Hall Room, Second Floor, Sheraton Centre

DEPRESSION: OUTCOMES AND COMORBIDITIES
Chp.: Mark J. Rapoport, M.D.
Co-Chp.: Rizwan M. Mufti, M.D.
26 Matched Versus Mismatched Treatment for Depressed Inpatients
11:00 a.m.
Ivan W. Miller, Ph.D., Gabor I. Keitner, M.D., Christine E. Ryan, Ph.D., David A. Solomon, M.D.
27 Sociodemographic and Clinical Predictors of Lifetime History of Alcohol and Drug Abuse in Depressed Outpatients
11:30 a.m.
John J. Worthington III, M.D., Bronwyn R. Keefe, B.A., Andrew A. Nierenberg, M.D., Jonathan E. Alpert, M.D., Joel Pava, Ph.D., Jerrold F. Rosenbaum, M.D., Maurizio Fava, M.D.
28 A Systematic Review of the Mortality of Depression
12 noon
Lawson R. Wulsin, M.D., George E. Vaillant, M.D., Victoria E. Wells, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 10
11:00 a.m.-12:30 p.m.
Huron Room, Second Floor, Sheraton Centre

TREATMENT ISSUES IN DEPRESSION
Chp.: Margaret G. Spinelli, M.D.
Co-Chp.: Katalin J. Margittai, M.D.
29 Birth Outcomes Following Prenatal Exposure to Fluoxetine
11:00 a.m.
Lynn R. Grush, M.D., Lee S. Cohen, M.D., Vicki L. Heller, M.D., Jennie W. Bailey, B.S., Jerrold F. Rosenbaum, M.D.
30 Venlafaxine in the Treatment of Postpartum Depression
11:30 a.m.
Lee S. Cohen, M.D., Cassandra P. Morabito, M.Ed., Mary H. Collins, M.D.
31 Changes in Insomnia During the Treatment of Depression
12 noon
Steven J. Romano, M.D., Rosalinda Tepner, R.Ph., Bruce Basson, M.S.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY WORKSHOPS

COMPONENTS 9-15

COMPONENT WORKSHOP 9 11:00 a.m.-12:30 p.m.
Kingsway Room, Lobby Level, Crowne Plaza

IMPROVING MANAGED CARE IN THE PUBLIC SECTOR
APA Committee on Managed Care and APA Committee of Black Psychiatrists

Chp.: Altha J. Stewart, M.D.
Participants: Gloria Pitts, D.O., Ivan C.A. Walks, M.D.

COMPONENT WORKSHOP 10 11:00 a.m.-12:30 p.m.
Toronto Room, Convention Floor, Royal York

USE OF CULTURE IN INTERVENTIONS FOR YOUNG CHILDREN
APA Committee on Pre-School Children

Chp.: Harry H. Wright, M.D.
Participants: Irene Chatoor, M.D., David S. Rue, M.D., William Arroyo, M.D.

COMPONENT WORKSHOP 11 11:00 a.m.-12:30 p.m.
Alberta Room, Mezzanine, Royal York

LOVE LETTERS: SHORT DRAMA WITH ANALYTICAL INTERPRETATION AND DISCUSSION
APA Auxiliary

Co-Chps.: Catherine Kirschner, Elizabeth A. Reade, M.D.
Participants: Venie B. Palasota, Pete C. Palasota, M.D.

COMPONENT WORKSHOP 12 11:00 a.m.-12:30 p.m.
Conference Room C, Mezzanine, Sheraton Centre

SOLVING PROBLEMS IN PSYCHIATRIC ADMINISTRATION
APA Council on Medical Education and Career Development

Co-Chps.: W. Walter Menninger, M.D., Philip E. Veenhuit, M.D.
Participant: William H. Reid, M.D.

COMPONENT WORKSHOP 13 11:00 a.m.-12:30 p.m.
York Room, Mezzanine, Sheraton Centre

BEYOND COMING OUT
APA Committee on Gay, Lesbian and Bisexual Issues

Chp.: Lowell D. Tong, M.D.
Participants: Steven J. Lee, M.D., Howard C. Rubin, M.D., Karine J. Igartua, M.D., Diana C. Miller, M.D.

COMPONENT WORKSHOP 14 11:00 a.m.-12:30 p.m.
Simcoe Room, Second Floor, Sheraton Centre

LIFE AFTER RESIDENCY: MAKING A CAREER CHOICE
APA Assembly's Committee of Area Member-in-Training Representatives

Chp.: Judythe S. McKay, M.D.
Participants: Allan Tasman, M.D., Suzhanna M. Bar, M.D., George A. Furas, M.D., Mary Kay Smith, M.D.

COMPONENT WORKSHOP 15 11:00 a.m.-12:30 p.m.
Room 3285, Third Floor, Medical Sciences Building, University of Toronto, 8 Tattle Creek Road (Transportation not provided)

HANDS-ON WEB WORK: PART II
APA Committee on Information Systems

Chp.: Thomas A.M. Kramer, M.D.
Participants: David F. McMahon, M.D., James L. Day, M.D., Norman E. Alessi, M.D., Bertram Warren, M.D.

ISSUES 19-30

ISSUE WORKSHOP 19 11:00 a.m.-12:30 p.m.
Room 205A, Street Level, Convention Centre

PSYCHIATRISTS' CHILDREN SPEAK ABOUT UNIQUE ISSUES

Co-Chps.: Leah J. Dickstein, M.D., Michelle Riba, M.D.
Participants: Daniel P. Dickstein, M.D., Alissa Riba, Michael F. Myers, M.D., Briana Myers, Donna M. Norris, M.D., Marlaina Norris, Kailie R. Shaw, M.D., Daniel Shaw, Carolyn B. Robinowitz, M.D., David Robinowitz

ISSUE WORKSHOP 20 11:00 a.m.-12:30 p.m.
Room 205C, Street Level, Convention Centre

CULTURALLY RELEVANT SERVICES FOR AFRICAN AMERICANS

Chp.: Reta D. Floyd, M.D.
Participants: Michelle O. Clark, M.D., Jack M. Barbour, M.D., Linda L. Conney, M.S.W.

ISSUE WORKSHOP 21 11:00 a.m.-12:30 p.m.
Room 206A, Street Level, Convention Centre

NMS: DIAGNOSIS, TREATMENT AND AFTERCARE

Chp.: Gerard C. Addonizio, M.D.
Participants: Virginia L. Susman, M.D., Stanley N. Caroff, M.D.
<table>
<thead>
<tr>
<th>Issue Workshop</th>
<th>Time</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 206A, Street Level, Convention Centre</td>
<td>Forensic Risks in the New Age of Psychopharmacology, Chp.: David W. Preven, M.D., Participants: Donald F. Klein, M.D., Michael M. Weiner, M.D., Martin G. Tracy, J.D., Amy B. Rowan, M.D.</td>
</tr>
<tr>
<td>23</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Room 206D, Street Level, Convention Centre</td>
<td>Issues in Negotiating a Managed Care Contract, Chp.: Nancy H. Halleck, J.D., Participants: C. Deborah Cross, M.D., Andrea Lefton, M.D., Jay L. Zucker, J.D.</td>
</tr>
<tr>
<td>24</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Grenadier Room, Lobby Level, Crowne Plaza</td>
<td>Protease Inhibitors in the Mentally Ill with HIV, Chp.: Dan H. Karasic, M.D., Participants: George H. Harrison, M.D., Charles T. Robinson III, M.D.</td>
</tr>
<tr>
<td>25</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Humber Room, Lobby Level, Crowne Plaza</td>
<td>Short-Term Integrative Therapy for Personality Disorders, Chp.: Miguel A. Leibovich, M.D.</td>
</tr>
<tr>
<td>26</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Oakville Room, Lobby Level, Crowne Plaza</td>
<td>Consultation-Liaison Psychiatry: Problem Solving and Lifelong Learning, Chp.: Barbara A. Schindler, M.D., Participants: Marlan A. Ormont, M.D., Donald J. Kushon, Jr., M.D., Randy A. Inkles, M.D.</td>
</tr>
<tr>
<td>27</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>British Columbia Room, Mezzanine, Royal York</td>
<td>Human Rights and Mental Health System Reform, Chp.: Eric Rosenthal, J.D., Participants: Humberto L. Martinez, M.D., Robert L. Okin, M.D.</td>
</tr>
<tr>
<td>28</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Manitoba Room, Mezzanine, Royal York</td>
<td>Mental Health of Elderly Asian Indians: Issues and Solutions, Joint Session with the Indo-American Psychiatric Association, Chp.: Jagannathan Srinivasaraghavan, M.D., Participants: Seetharaman Vivek, M.D., Ganesan Gopalakrishnan, M.D., Ajaya K. Upadhyaya, M.D.</td>
</tr>
<tr>
<td>29</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Conference Room B, Mezzanine, Sheraton Centre</td>
<td>Adolescents and Popular Culture, Co-Chps.: Debra S. Rosenblum, M.D., Lawrence Hartmann, M.D., Participants: Neal S. Kass, M.D., Peter T. Danilos, M.D.</td>
</tr>
<tr>
<td>30</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Conference Room F, Mezzanine, Sheraton Centre</td>
<td>Homeopathic Medicine and Psychiatry, Chp.: Edward B. Gogek, M.D., Participants: Todd A. Rowe, M.D., Sandra N. Kamiak, M.D., Arlin E. Brown, M.D.</td>
</tr>
</tbody>
</table>

12 noon Sessions

<table>
<thead>
<tr>
<th>Forum</th>
<th>Time</th>
<th>Location</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>12 noon-1:30 p.m.</td>
<td>Room 104B, Lower Level, Convention Centre</td>
<td>What's Really Going on in Psychiatry? The APA Practice Research Network, Chp.: John S. McIntyre, M.D., Participants: Harold Alan Pincus, M.D., Deborah A. Zarin, M.D., Terri L. Tanielian, M.A.</td>
</tr>
<tr>
<td>2</td>
<td>12 noon-1:30 p.m.</td>
<td>Windsor Room, Mezzanine, Sheraton Centre</td>
<td>Meet the APA Medical Director, Chp.: Steven M. Mirin, M.D.</td>
</tr>
</tbody>
</table>
1:00 p.m. Sessions

COURSES 50-58
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 50
1:00 p.m.-5:00 p.m.
Room 704, 700 Level, Convention Centre
MEDICATION BACKUP: A PRACTICAL GUIDE
Co-Directors: Michelle Riba, M.D., Richard Balon, M.D.
Faculty: Joseph A. Himle, Ph.D., Jeremy A. Lazarus, M.D., JoAnn E. Macbeth, J.D.; Kenneth R. Silik, M.D., Kevin B. Kerber, M.D.

COURSE 51
1:00 p.m.-5:00 p.m.
Room 706, 700 Level, Convention Centre
TREATING MEDICAL STUDENTS AND PHYSICIANS
Co-Directors: Michael F. Myers, M.D., Leah J. Dickstein, M.D.

COURSE 52
1:00 p.m.-5:00 p.m.
Room 707, 700 Level, Convention Centre
ADVANCED TOPICS IN SLEEP MEDICINE FOR PSYCHIATRISTS
Director: Thomas D. Hurwitz, M.D.
Faculty: Paul A. Fredrickson, M.D., Max Hirshkowitz, Ph.D.

COURSE 53
1:00 p.m.-5:00 p.m.
Room 708, 700 Level, Convention Centre
WRITING ABOUT CLINICAL EXPERIENCES
Director: John S. Strauss, M.D.

COURSE 54
1:00 p.m.-5:00 p.m.
Room 713A, 700 Level, Convention Centre
PSYCHIATRY AND PRIMARY CARE: MANAGED CARE MODELS
Director: Steven A. Cole, M.D.
Faculty: Michael A. Freeman, M.D., Wayne J. Katon, M.D., David J. Katzelnick, M.D., David J.M. Whitehouse, M.D.

COURSE 55
1:00 p.m.-5:00 p.m.
Room 714B, 700 Level, Convention Centre
AUTISM AND ASPERGER'S SYNDROME ACROSS THE LIFE SPAN
Co-Directors: Kerim M. Munir, M.D., Ludwik S. Szymanski, M.D.
Faculty: Peter Szatmari, M.D.

COURSE 56
1:00 p.m.-5:00 p.m.
Rooms 715A/B, 700 Level, Convention Centre
ADVANCED ASSESSMENT AND TREATMENT OF ADD
Director: Thomas E. Brown, Ph.D.
Faculty: James J. McGough, M.D.

COURSE 57
1:00 p.m.-5:00 p.m.
Room 716A, 700 Level, Convention Centre
DUAL DIAGNOSIS: ADVANCED CLINICAL APPLICATION, PROGRAMMATIC INNOVATION AND TREATMENT STRATEGIES
Director: Kenneth Minkoff, M.D.

COURSE 58
1:00 p.m.-5:00 p.m.
Room 716B, 700 Level, Convention Centre
THE EVALUATION AND MANAGEMENT OF PAIN
Director: Steven A. King, M.D.

NEW RESEARCH

YOUNG INVESTIGATORS' ORAL/SLIDE SESSIONS 2-3
1:00 p.m.-2:30 p.m.

2 SUICIDE, SUBSTANCE ABUSE AND DEPRESSION
Room 205B, Street Level, Convention Centre

3 PSYCHOPHARMACOLOGY AND MOOD DISORDERS
Room 205D, Street Level, Convention Centre

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
Days of Creation Session
A Musical Presentation
by
The Guarnieri String Quartet

2:00 p.m. - 3:30 p.m.
Room 107, Lower Level, Convention Centre

Chairperson: Herbert S. Sacks, M.D.

The Guarnieri String Quartet is one of the most revered quartets in the world today. During the 1994-95 season the four members celebrated their 30th year together. Violinists Arnold Steinhardt and John Dailey, violist Michael Tree and cellist David Soyer have circled the globe countless times together, playing the world's most prestigious halls in North and South America, Mexico, Europe, the Far East and Australia. In their home town of New York City, they have maintained their two special series: "Guarnieri and Friends" at Lincoln Center since 1973, and recital programs at the Metropolitan Museum of Art since 1965. They have been the subject of the full-length critically acclaimed film "High Fidelity - the Guarnieri String Quartet" and several books, including Quartet by Helen Drees Ruttencutter and The Art of Quartet Playing: The Guarnieri in Conversation with David Blum. The Guarnieri String Quartet records exclusively for the Philips Classics label. Many of their recordings have won international awards on both RCA Red Seal and Philips.

LECTURES 7-8

LECTURE 7
2:00 p.m.-3:30 p.m.
Ballroom B, Lower Level, Crowne Plaza

APA'S ADMINISTRATIVE PSYCHIATRY AWARD LECTURE
Michael J. Vergare, M.D.

Follow the Leader:
From Institutions to Systems of Care

Chp.: William H. Reid, M.D.
Co-Chp.: Paul A. Rodenhauser, M.D.

LECTURE 8
2:00 p.m.-3:30 p.m.
Dominion Ballroom, Second Floor, Sheraton Centre

Andrew Chess, M.D.

Olfaction As a Window into Brain Function

Chp.: Ellen Leibenluft, M.D.
Co-Chp.: Ron M. Winchel, M.D.

One percent of the human genome, more than 1,000 genes, is devoted to a single task: making sure humans can distinguish among a vast number of odorant molecules. Although it is often overlooked in analyses of human behavior, the sense of smell developed very early in evolution and is vital to the function and survival of most animals. Understanding how we respond to the vast array of odors is not only interesting in its own right, it also provides information about how the human brain operates more generally. Andrew Chess, M.D.,
MONDAY

discusses insights about the functioning of the olfactory system that have come from recent studies using the tools of molecular biology. He also examines the impact of these findings on the understanding of the rest of the nervous system. Dr. Chess is the Robert A. Swanson Career Development Professor in the Department of Biology and an associate member of the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. In 1993 he received the Clinical Investigator Development Award from the National Institute of Deafness and Communication Disorders. Dr. Chess is a graduate of Columbia University of Physicians and Surgeons in New York City, where he received the Dr. Alfred Steiner Award for Medical Student Research. He was a postdoctoral fellow at the Center for Neurobiology and Behavior at Columbia University.

Frontiers of Science Lecture Series

MEDIA SESSIONS 8-9

MEDIA SESSION 8 2:00 p.m.-5:00 p.m.
Ontario Room, Convention Floor, Royal York

FROM HOMOPHOBIC VIOLENCE TO GAY/LESBIAN ACCEPTANCE

Chp.: Dan H. Karasic, M.D.

10 Licensed to Kill
(80 minutes)

Distributor: Deep Focus Productions
4506 Palermo Drive
Los Angeles, CA 90065-4237

Despite increasing societal acceptance of homosexuality, antigay violence remains one of the most frequently reported hate crimes. Attempts to understand the ubiquity of antigay violence includes an exploration of both societal and psychological underpinnings of homophobia, as well as prejudice in general. Arthur Dong, whose acclaimed films have documented historical episodes of antigay and anti-Asian discrimination, provides a unique and compelling perspective on antigay violence in Licensed to Kill. In this unsettling documentary, Dong interviews seven men imprisoned for murdering homosexuals. The interviews allow the convicts to describe in their own words their motivations for killing. Winner of the Filmmakers Trophy and Best Documentary Director at the 1997 Sundance Film Festival, Licensed to Kill provides an unusual window into the minds of these seven men, allowing the psychiatric audience to draw its own conclusions about the psychology of the killers of gay men.

11 I Shall Not Be Removed: The Life of Marlon Riggs
(50 minutes)

Distributor: California Newsreel
149 9th Street, Suite 420
San Francisco, CA 94103

This loving biography chronicles the heroic life of black, gay filmmaker Marlon Riggs, who died of AIDS in 1994. A fierce advocate of free expression, Marlon created soul-searching art at a furious pace. Clips from all eight of Marlon’s works are shown and discussed. Marlon was a lightning rod in the civil war over funding for the arts in America. He also waged a passionate battle against AIDS.

12 All God’s Children
(20 minutes)

Distributor: Transit Media Film Library
22-D Hollywood Avenue
Hohokus, NJ 07423

All God’s Children is a short documentary about the black church’s embrace of African-American lesbians and gay men as dedicated members of its spiritual family. Prominent religious, intellectual and political leaders, family members and activists speak out about the role of the church and the importance of a commitment to equal rights and social justice for all people. Intertwined with music, the intricately layered stories unfold on the screen creating a tapestry with the theme of spiritual understanding. Rev. Jesse Jackson, Rev. Ceci L. Murray, Bishop Carl Bean, Rev. James Forbes and Rev. Waylon Melton join theologian Cornel West in his call for fellow Christians “to not confuse the blood of Calvary with the Kool-Aid of homophobia in America.” All God’s Children includes strong statements of recognition and support from prominent African-American political leaders like Congresswoman Maxine Waters, Senator Carol Moseley-Braun and Mayor Ken Reeves. They reiterate the need to build a better society based on the common ground of civil equality. Families, church members and gay activists weigh in with heartfelt stories about exclusion and discrimination, then about inclusion and a call for healing. One mother, Dorothy Beam, says, “If most people could understand that if you’re gay, you’re beautiful! If you’re straight, you’re beautiful! Let’s put all this beauty together. It would be a better world.” A Woman Vision Production in association with The National Gay and Lesbian Task Force and The National Black Lesbian and Gay Leadership Forum; produced and directed by Academy Award nominees Dr. Dee Mosbacher, Frances Reid and Dr. Sylvia Rhue.
Shine is the mythical story of a Jewish father whose overbearing pride, possessiveness and envy ruined his talented son, and an astrologer wife whose unconditional love eventually resurrected the victim and launched his professional career as a concert pianist. The film leaves no doubt that David Helfgott suffered a "nervous breakdown" and a very serious, prolonged mental illness. But much of the story is left implicit. We see Helfgott collapsing and passing out as he finishes a performance but are not told what led to his first hospitalization, which is crucial to our understanding of his illness. The screenplay also suggests that David was further victimized by unseen psychiatrists who gave him shock treatment, and in their ignorance, ordered him to stay away from the piano, his only route to salvation. For people who love David Helfgott's concerts and this movie, perhaps one important consideration is that Helfgott has made the journey from the back ward of a mental hospital to the stage of great concert halls. Helfgott's innocence is the psychological backbone of Shine. It insures that we see him as a pure victim. The tyrannical father tormenting his son out of his own egoism gives the audience its insight into how Helfgott was driven mad. In the film he relentlessly drives his only son to succeed at the piano, resents his success and refuses to let him pursue studies abroad. He puts a father's triple curse on his son: no one will ever love you as I do; if you disobey me you will be punished for the rest of your life; you can never come home again. Unfortunately, this film makes us weep for the wrong reasons. It is a docudrama that recycles old myths of mental illness.

NIDA/NIH GRANTSMSHIPS WORKSHOP
2:00 p.m.-5:00 p.m.
Room 205C, Street Level, Convention Centre

DOS AND DONTS IN WRITING YOUR FIRST NIH GRANT
Collaborative Session with the National Institute on Drug Abuse

Co-Chps.: Andrea Baruchin, Ph.D., Lucinda Miner, Ph.D.
Participants: Teresa Levitin, Ph.D., David Shore, M.D.

REVIEW OF PSYCHIATRY: PART I
2:00 p.m.-5:30 p.m.
Room 105, Lower Level, Convention Centre

CHILD PSYCHOPHARMACOLOGY

Chp.: Laurence L. Greenhill, M.D.

1 Tics and OCD
F. Xavier Castellanos, M.D.

2 ADHD
Laurence L. Greenhill, M.D.

3 Psychosis
Sanjiv Kumra, M.D.

4 Affective Disorders
Stanley P. Kutcher, M.D.

5 Anxiety Disorders
Daniel S. Pine, M.D.

6 Eating Disorders
Laurel Mayer, M.D.

SYMPOSIA 1-23

SYMPOSIUM 1 2:00 p.m.-5:00 p.m.
Room 205A, Street Level, Convention Centre

EVALUATING GROUP INTERVENTIONS FOR CANCER PATIENTS
Chp.: Cheryl Koopman, Ph.D.
Co-Chp.: Peter M. Silberfarb, M.D.

A Structured Psychiatric Intervention for Melanoma Patients
Fawzy I. Fawzy, M.D.

B The Breast Expressive-Supportive Therapy (BEST) Study: Randomized Controlled Trial of Group Support in Metastatic Breast Cancer
Pamela J. Goodwin, M.D., Mlyn Leszcz, M.D., Jan Koopman, M.S.W., Harvey M. Chochinov, M.D., Margaret Navarro, M.D., Richard Doll, M.S.W., Julia A. Masterson, M.D., Narilyn Hundleby, Ph.D.

C Group Therapy and Survival in Breast Cancer
Michael E. Stefanek, Ph.D., Andrea Barsevick, D.N.Sc., David Cella, Ph.D.

D Multicenter Trial: Group Therapy for Breast Cancer
David Spiegel, M.D., Gary R. Morrow, Catherine Classen, Ph.D., R. Raubertas

(Continued on next page)
E Australian Randomized Controlled Trial of Cognitive-Existential Group Therapy for Women with Early-Stage Breast Cancer
David W. Kissane, M.D., David Clarke, Ph.D., Sydney Bloch, M.D., Patricia Miach, Ph.D., Jillian F. Ikin, B.A., Graeme Smith, M.D., Dean McKenzie, B.A.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 2 2:00 p.m.-5:00 p.m.
Room 206A, Street Level, Convention Centre

IS THERE AN OBSESSIVE-COMPULSIVE SUBTYPE OF SCHIZOPHRENIA?

Chp.: Ileana Berman, M.D.

A Prevalence and Prognosis of Obsessive-Compulsive Symptoms in Schizophrenia
Paul C. Bermanzhohn, M.D., Linda Porto, M.S.N., Samuel G. Siris, M.D.

B Relationship Between Obsessions and Delusions: Insight in OCD
Jane L. Eisen, M.D.

C Cognitive Function in Patients with Obsessive-Compulsive Symptoms and Schizophrenia
Ileana Berman, M.D., Demetra Pappas, B.S., Alan I. Green, M.D.

D Treatment of Obsessive-Compulsive Symptoms in Schizophrenia
Joseph Zohar, M.D., Yehuda Sasson, M.D.

E Obsessive-Compulsive Symptoms in Relatives of Schizophrenia Patients
Alan I. Green, M.D., Stephen V. Faraone, Ph.D., Hang Lee, Ph.D., C. Robert Cloninger, M.D., Charles A. Kaufmann, M.D., Ming T. Tsuang, M.D.

Discussant: Ming T. Tsuang, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 3 2:00 p.m.-5:00 p.m.
Room 206B, Street Level, Convention Centre

VIOLENCE AND ABUSE: FULL CIRCLE
APA Auxiliary

Chp.: Catherine Kirschner
Co-Chp.: Ronald A. Pond, M.D.

A Violence in the Workplace
Harold I. Eist, M.D.

B Mission-Driven Families: Primary Prevention of Family Violence
Carl C. Bell, M.D.

C Violence and Abuse: Full Circle
David C. Wright, M.D.

D Starting the Cycle of Violence: The Effects of Trauma in Childhood
Sandra L. Bloom, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 4 2:00 p.m.-5:00 p.m.
Room 206C, Street Level, Convention Centre

TRAINING AT THE INTERFACE OF PSYCHIATRY AND PRIMARY CARE
Joint Session with the Association for Academic Psychiatry

Chp.: Edward K. Silberman, M.D.

A Training Psychiatrists to Provide Primary Care
Edward K. Silberman, M.D.

B Teaching Psychiatry Residents in Primary Care Settings
Stephen J. Weiler, M.D.

C Teaching Psychiatry to Family Physicians
Elizabeth H. Rand, M.D.

D Training Psychiatrists in Family-Centered Care
James L. Griffith, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 5 2:00 p.m.-5:00 p.m.
Room 206D, Street Level, Convention Centre

CRITICAL ISSUES IN PSYCHIATRIC NOSOLOGY

Chp.: John Livesley, M.D.
Co-Chp.: Roger K. Blashfield, Ph.D.

A An Alternative Approach to Classifying Personality Disorder
John Livesley, M.D.

B The Internal Structure of the DSM-IV
John Livesley, M.D., Roger K. Blashfield, Ph.D.

C Biological Classification and Psychiatric Nosology
Roger K. Blashfield, Ph.D.

D Openness in the DSM-IV Process
John Z. Sadler, M.D.

E Gender Differences in the DSM-IV: Conclusions and Controversies
Thomas A. Widiger, Ph.D.

Discussant: Robert L. Spitzer, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 6 2:00 p.m.-5:00 p.m.
Room 206E, Street Level, Convention Centre

A REVIEW OF EMPATHY IN PSYCHIATRY AND PSYCHOTHERAPY
Chp.: Vladan Starcevic, M.D.
Co-Chp.: Richard D. Chessick, M.D.

A A Review of Empathy in Psychiatry and Psychotherapy
Richard D. Chessick, M.D.

B Philosophical Underpinnings of Empathy
Hermann Lang, M.D.

C Understanding and Empathy in the Diagnostic Process
Professor Dr. Alfred Kraus

D Empathic Understanding in Psychotherapy
Vladan Starcevic, M.D.

E The Limits of Empathy and the Value of Misunderstanding
Arnold I. Goldberg, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 7 2:00 p.m.-5:00 p.m.
Room 206F, Street Level, Convention Centre

INTERPERSONAL PSYCHOTHERAPY IN THE MEDICALLY ILL
Chp.: Susan E. Abbey, M.D.
Co-Chp.: Laurie Gillies, Ph.D.

A Interpersonal Psychotherapy and the Medically Ill: A Rationale
Laurie Gillies, Ph.D.

B Interpersonal Psychotherapy for Depressed HIV-Positive Patients
John C. Markowitz, M.D., Gerald L. Klerman, M.D., Kathleen F. Clougherty, M.S.W., Lisa A. Spielman, Ph.D., Lawrence B. Jacobsberg, M.D., Samuel W. Perry, M.D., Baruch Fishman, Ph.D.

C Interpersonal Psychotherapy in Breast Cancer Patients
Susan E. Abbey, M.D.

D Interpersonal Psychotherapy and Chronic Physical Disabilities
Edward McAnanama, BMR(OT)

Discussant: Myrna M. Weissman, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 8 2:00 p.m.-5:00 p.m.
Room 104A, Lower Level, Convention Centre

DEVELOPING MENTAL HEALTH CARE IN A POST-TOTALITARIAN SOCIETY
Chp.: Dr. Robert van Voren
Co-Chp.: Dr. James L.T. Birley

A Mental Health Care Development in Belarus: Forth or Back?
Dr. Vladimir Poznyak

B Reforming Mental Health Care in the Ukraine: A Report from Practice
Dr. Viktor Shumlyansky

C Mental Health and Medical Insurance: A Lithuanian Experience
Dr. Dainius Puras, Dr. Raimundas Milasiunas

D Families in Transition: Relations Between Families and Mental Health Workers in a Post-Totalitarian Society
Dr. Carmen Andresch, Dr. Gabriela Grigoresch

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 9 2:00 p.m.-5:00 p.m.
Room 104B, Lower Level, Convention Centre

RISK AND VULNERABILITY TO DRUG ABUSE
Collaborative Session with the National Institute on Drug Abuse
Chp.: Meyer D. Glantz, Ph.D.

A Behavioral Genetic Approach to Drug Abuse Liability
Ralph E. Tarter, Ph.D.

B Familial Transmission of Drug Abuse and Comorbid Disorders
Kathleen R. Merikangas, Ph.D.

C Extent of Drug Use and Dependence in the Population
Denise Kandel, Ph.D.

D First Grade Classrooms: Course of Aggression and Prevention
Sheppard G. Kellam, M.D., Xiangge Ling, M.S., Rolande Merisca, Ph.D., C. Hendricks Brown, Ph.D., Nicholas I. Ialongo, Ph.D.

Discussant: Meyer D. Glantz, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 10 2:00 p.m.-5:00 p.m.
Room 104C, Lower Level, Convention Centre

GAY MEN, LESBIANS AND BISEXUALS: CONTROVERSIAL ISSUES
Joint Session with the Association of Gay and Lesbian Psychiatrists

Chp.: Robert P. Cabaj, M.D.

A Childhood Development of Gay Men: What Is Known
Graeme Hanson, M.D.

B Assaulting Ourselves: Domestic Violence in Lesbian Relationships
Amy E. Banks, M.D.

C Mid-Life Development in Gay Men: AIDS and Age Revisited
Robert M. Kertzner, M.D.

D Culture Clash: Latinos and the Failures of Gay Identity
Francisco J. Gonzalez, M.D.

E Lesbian Rules: What's Sex Got to Do with It?
Maggie Magee, M.S.W., Diana C. Miller, M.D.

F Institutional Homophobia: The Making of a Gay Psychiatrist
Robert P. Cabaj, M.D.

Discussant: Terry S. Stein, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 11 2:00 p.m.-5:00 p.m.
Room 104D, Lower Level, Convention Centre

INTERNATIONAL HEALTH CARE AND TELEPSYCHIATRY
APA Committee on Telemental Health Services

Co-Chps.: Ellen N. Rothchild, M.D., Peter Yellowlees, M.D.

A Mental Health in Canada: Changes and Challenges
Pierre A. Beauchesne, M.D.

B Psychiatric Care in New Zealand
Janice M. Wilson, M.D.

C Psychiatric Health Care in Australia
Harvey A. Whiteford, M.D.

D Approaching the Millennium: Psychiatric Care in the United States
Herbert S. Sacks, M.D.

Discussant: Theodore Marmor, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 14 2:00 p.m.-5:00 p.m.
Niagara Room, Lower Level, Crowne Plaza

PSYCHIATRIC FORMULATION: WHAT'S ESSENTIAL?
Chp.: Roger Peele, M.D.
Co-Chp.: Donna M. Norris, M.D.
A Formulation from the Perspective of Child and Adolescent Psychiatry
Jerry M. Wiener, M.D.
B Configurational Analysis
Mardi J. Horowitz, M.D.
C Case Formulations from the Perspective of Cognitive-Behavioral Therapy
Jerry M. Wiener, M.D.
D Evaluation Indicators in Psychopharmacology
Donald F. Klein, M.D.
E Acute Care Psychiatry: The Four Questions
Lloyd I. Sederer, M.D.
Discussants: Melvin Sabshin, M.D., Robert Michels, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 15 2:00 p.m.-5:00 p.m.
Ontario Room, Lower Level, Crowne Plaza

DYSTHYMIA: THE FORGOTTEN DEPRESSION
Chp.: Meir Steiner, M.D.
A Standardized Assessment of Dysthymia
Harry E. Gwirtsman, M.D., Mary C. Blehar, Ph.D., James P. McCullough, Jr., Ph.D., James H. Kocsis, M.D., Robert F. Prien, Ph.D.
B The Prevalence of Dysthymia in Primary Care
Barbara Bell, M.D., Gina Browne, Ph.D., Meir Steiner, M.D., Jacqueline Roberts, M.S.C., Amiram Gafni, Ph.D., Carolyn Byrne, R.N., Edward Dunn, Ph.D.
C Pharmacotherapy of Dysthymia
James H. Kocsis, M.D.
D IPT and Sertraline in Dysthymia: Six-Month Follow-Up
Gina Browne, Ph.D., Meir Steiner, M.D., Jacqueline Roberts, M.S.C., Amiram Gafni, Ph.D., Carolyn Byrne, R.N., Barbara Bell, M.D., Edward Dunn, Ph.D.
E Cognitive-Behavior Therapy and Sertraline in Dysthymia: Efficacy and Physiology
Arun V. Ravindran, M.B., Hymie Anisman, Ph.D., Jenna Griffiths, M.Sc., Zul Merali, Ph.D., Yolanda Charbonneau, M.D.
Discussant: Joseph J. Westermeyer, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 16 2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine, Royal York

ARE EATING AND SUBSTANCE ABUSE DISORDERS RELATED?
Chp.: Timothy D. Brewerton, M.D.
A Familial Association of Bulimia Nervosa and Substance Dependence
Lisa R. Lilengfeld, Ph.D., Walter H. Kaye, M.D., Catherine G. Greeno, Ph.D., Kathleen R. Merikangas, Ph.D., Katherine Plotnikov, Ph.D., Michael Strober, Ph.D., Cynthia M. Bulik, Ph.D.
B Eating Disorders and Substance Abuse: Family and Follow-up Data
Michael Strober, Ph.D.
C Weight Control As a Motivation for Cocaine Abuse
Carolyn E. Cochrane, Ph.D., Robert J. Malcolm, Ph.D., Timothy D. Brewerton, M.D.
D Victimization and Substance Abuse: Risk Factors for Bulimia Nervosa
Bonnie S. Danksy, Ph.D., Timothy D. Brewerton, M.D., Dean G. Kilpatrick, Ph.D.
E Bulimia and Alcohol Abuse: Proposed Linkage Mechanism
Dean D. Krahn, M.D., Blake A. Gosnell, Ph.D.
Discussant: Paul E. Garfinkel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 17 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine, Royal York

MULTIGENERATIONAL ASPECTS OF TRAUMA
Chp.: Andrei Novac, M.D.
Co-Chp.: Rita R. Newman, M.D.
A Multigenerational Legacies of Trauma
Yael Danielli, Ph.D.
B Intergenerational Effects of Stress in Rhesus Monkeys
Stephen J. Suomi, Ph.D.
C Assessing Intergenerational Traumatic Stress
Andrei Novac, M.D.
D Offspring of Holocaust Survivors' Vulnerability to PTSD
Rachel Yehuda, Ph.D., Milton L. Wainberg, M.D., Karen Binder-Brynes, Ph.D., Sheila Elrich, Ph.D., Dan Aferiot, M.S.W., Stacey Namm, Tamar Duvdevani
E Culture and Familial Transmission of Trauma
Cecile Rousseau, M.D., Aline Drapeau, M.S.C.
Discussant: Joseph J. Westermeyer, M.D.
THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 18  2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine, Royal York

NOVEL PREDICTORS OF VULNERABILITY TO MAJOR DEPRESSION

Chp.: Sidney H. Kennedy, M.D.
Co-Chp.: Franco J. Vaccarino, Ph.D.

A Preclinical Behavioral Predictors of Anhedonia
Franco J. Vaccarino, Ph.D., Zindel V. Segal, Ph.D.,
Robert D. Levitan, M.D., Sidney H. Kennedy, M.D.

B Cognitive Response to a Mood Prime Predicts Depressive Relapse
Zindel V. Segal, Ph.D., Michael Gemar, Ph.D.,
Susan Williams, M.Sc.

C Childhood Abuse Predicts Major Depressive Subtypes in Adults
Robert D. Levitan, M.D., Sagar V. Parikh, M.D.,
Alain D. Lesage, M.D., Kathleen Hegadoren, Ph.D.,
Martha Adams, M.D., Sidney H. Kennedy, M.D.,
Paula N. Goering, Ph.D.

D Negative Attributional Style As a Predictor of Treatment Response in Seasonal and Nonseasonal Depression
Neil Rector, Ph.D., Robert D. Levitan, M.D.,
Michael Bagby, Ph.D.

E Psychobiological Predictors of Partial Drug Response
Sidney H. Kennedy, M.D., Michael Bagby, Ph.D.,
Zindel V. Segal, Ph.D., Kenneth R. Evans, Ph.D.,
Robert D. Levitan, M.D., Franco J. Vaccarino, Ph.D.

Discussant: Michael E. Thase, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 19  2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine, Royal York

LATE-ONSET SCHIZOPHRENIA: NEW INSIGHTS

Chp.: Dilip V. Jeste, M.D.
Co-Chp.: Mary V. Seeman, M.D.

A Is Late-Onset Schizophrenia Really Schizophrenia?
Dilip V. Jeste, M.D., M. Jackuesyn Harris, M.D.,
Laurie A. Lindamer, Ph.D., Barton W. Palmer, Ph.D.,
Julie A. Gladesjo, Ph.D., Jovier D. Evans, Ph.D.,
Robert K. Heaton, Ph.D.

B Can Schizophrenia Begin After the Age of 60?
Robert J. Howard, M.D.

C Schizophreniform Disorder in Elderly Public Housing Residents
Peter V. Rabins, M.D., Betty S. Black, Ph.D.

D Schizophrenia of Late-Onset: Simply a Variant of Early-Onset Disorder?
David J. Castle, M.D., Robert J. Howard, M.D.,
Robin M. Murray, M.B.

E Is Late-Onset Schizophrenia an Organic Mental Disorder?
Perminder S. Sachdev, M.D., Henry Brodaty, M.D.,
Noelene Rose, M.C.

Discussant: Mary V. Seeman, M.D.

SYMPOSIUM 20  2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine, Royal York

AGITATION IN THE ELDERLY

Chp.: John P. Docherty, M.D.

A Guidelines and the Transmission of Knowledge
John P. Docherty, M.D.

B Methodology of Expert Consensus Guidelines
Daniel Carpenter, Ph.D.

C Agitation of Dementia: Treatment Principles
George S. Alexopoulos, M.D.

D Agitation: A Neuropsychiatric Perspective
Jonathan M. Silver, M.D.

E Summary of the Practice Guidelines
David A. Kahn, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 21  2:00 p.m.-5:00 p.m.
Tudor Room 7, Mezzanine, Royal York

THE BURDEN OF WORLD MENTAL HEALTH: THE WORLD HEALTH ORGANIZATION AND THE WORLD FEDERATION FOR MENTAL HEALTH RESPONSES

Chp.: Marten W. deVries, M.D.

A Nations for Mental Health: Tackling the Global Burden of Mental Disorders
Rachel Jenkins, M.D.

B World Federation for Mental Health in World Mental Health: Science, Consumers and Providers
Marten W. deVries, M.D.

Discussants: Arthur Kleinmann, M.D., Eugene B. Brody, M.D., Benedetto Saraceno, M.D.

THIS SESSION WILL BE AUDIOTAPED.
MONDAY

SYMPOSIUM 22  2:00 p.m.-5:00 p.m.
Windsor Room, Mezzanine, Sheraton Centre

STRESS AND PERSONALITY DISORDERS
Joint Session with the Association for Research in Personality Disorders

Chp.: James H. Reich, M.D.
A Effect of Treatment of Panic on Personality
Stefan Hofmann, Ph.D., David H. Barlow, Ph.D.,
M. Katherine Shear, M.D., Scott W. Woods, M.D.,
Jack M. Gorman, M.D.
B Personality Dysfunction Appearing Under Stress
James H. Reich, M.D.
C Early Abuse, Later Personality Disorders
David P. Bernstein, Ph.D.
D PTSD Predisposing to Personality Disorders
Charles R. Marmar, M.D.
E Personality and Stress Among Young Physicians:
A Longitudinal Study
Per Vaglum, M.D., Reidar Tyssen, M.D., Oivind
Ekeberg, M.D., Nina Gronvold
Discussant: Joel F. Paris, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 23  2:00 p.m.-5:00 p.m.
City Hall Room, Second Floor, Sheraton Centre

PERSONALITY: NEUROBIOLOGY AND LIFE EXPERIENCE

Chp.: Harold W. Koenigsberg, M.D.
A Neuromodulators and Development of
Personality Disorders
Larry J. Siever, M.D.
B Serotonin-Related Genes and Impulsive
Aggression
Antonia S. New, M.D., Joel Gelernter, M.D.,
Robert L. Trestman, M.D., Harold W.
Koenigsberg, M.D., Larry J. Siever, M.D.
C Biological and Psychosocial Correlates of
Affective Instability
Harold W. Koenigsberg, M.D.
D The Psychobiology of Developmental Trauma
Bessel A. van der Kolk, M.D.
THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 16-17

COMPONENT WORKSHOP 16  2:00 p.m.-3:30 p.m.
Room 3285, Third Floor, Medical Sciences Building,
University of Toronto, 8 Tattle Creek Road
(Transportation not provided)

HANDS-ON COMPUTER LEARNING: USING CLINICAL
APPLICATIONS/DEMONSTRATIONS
APA Committee on Information Systems

Chp.: Steven E. Hyler, M.D.
Participants: Daniel A. Deutschman, M.D.,
Stuart Gitlow, M.D., Carlyle Hung-Lun Chan, M.D.,
Robert S. Kennedy, M.A.

COMPONENT WORKSHOP 17  2:00 p.m.-5:00 p.m.
Room 3285, Third Floor, Medical Sciences Building,
University of Toronto, 8 Tattle Creek Road
(Transportation not provided)

PRODUCING A WEB PAGE: INTRODUCTION
APA Committee on Information Systems

Chp.: Robert C. Hsiung, M.D.

3:00 p.m. Session

NEW RESEARCH

YOUNG INVESTIGATORS' POSTER SESSION 4
3:00 p.m.-5:00 p.m.
Room 106, Lower Level, Convention Centre
For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:30 p.m. Session

CONVOCATION OF FELLOWS
7:30 p.m.
Hall F, 800 Level, Convention Centre
All Fellows, members and registered guests are invited.
MONDAY

Presiding: Herbert S. Sacks, M.D., President

Grand Marshals: Gerald H. Flamm, M.D., D. Raymond Freebury, M.D.

Marshals: Jack S. Brandes, M.D., Arthur L. Lesser, M.D.

INTRODUCTION OF LIFE FELLOWS
Rodrigo A. Muñoz, M.D., President-Elect

INDUCTION OF FELLOWS
Rodrigo A. Muñoz, M.D.

INTRODUCTION OF FIFTY-YEAR LIFE FELLOWS, LIFE MEMBERS, CORRESPONDING FELLOWS, DISTINGUISHED FELLOW, AND HONORARY FELLOW
Herbert S. Sacks, M.D.

PRESENTATION OF SPECIAL PRESIDENTIAL COMMENDATIONS
Herbert S. Sacks, M.D.

PRESENTATION OF DISTINGUISHED SERVICE AWARDS
Herbert S. Sacks, M.D.

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE
INTRODUCTION OF THE MEMBERSHIP COMMITTEE CHAIRPERSON AND AWARD BOARD CHAIRPERSONS
Herbert S. Sacks, M.D.

PRESENTATION OF AWARDS
Herbert S. Sacks, M.D.

APA Awards for Research in Psychiatry
APA/Lilly Resident Research Awards
Francis J. Braceland Award for Public Service
Alexander Granick Award for Research in Schizophrenia
Human Rights Award
Blanche F. Ittleson Award for Research in Child Psychiatry
Agnes Purcell McGavin Award
Robert T. Morse Writers Awards
Isaac Ray Award
Robert L. Robinson Awards
Jack Weinberg Memorial Award for Geriatric Psychiatry

Music Performed by The Great Lakes Brass

LECTURE 9
7:30 p.m.-9:00 p.m.
Hall F, 800 Level, Convention Centre

WILLIAM C. MENNINGER MEMORIAL CONVOCATION LECTURE

Justice Richard Goldstone

The Prevention of Human Rights Abuses and the Healing of Victims: Is There a Role for Psychiatry?

Justice Richard Goldstone was appointed to the Constitutional Court of South Africa in 1994. He is head of the board of the Human Rights Institute of South Africa and president of the National Institute of Crime Prevention and the Rehabilitation of Offenders. In addition, he is Chancellor of the University of Witwatersrand in Johannesburg and a member of the board of the university’s School of Law. From 1991 to 1994 he served as chairperson of the Commission of Inquiry Regarding Public Violence and Intimidation, which became known as the Goldstone Commission. From 1994 to 1996 he served as the chief prosecutor of the United Nations International Criminal Tribunals for the former Yugoslavia and Rwanda. He is a member of the International Panel established in 1997 by the Government of Argentina to monitor that country’s inquiry into Nazi activities in the Argentine Republic since 1938.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY, JUNE 2, 1998

151ST ANNUAL MEETING

7:00 a.m. Session

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 34
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

PRACTICAL CLINICAL STRATEGIES FOR MANAGING
REFRACTORY DEPRESSION, AGITATION AND ANTI-
DEPRESSANT SIDE EFFECTS: PRACTICAL STRATEGIES FOR
MANAGING SLEEP DISTURBANCES AND SEXUAL DYS-
FUNCTION WHEN TREATING DEPRESSED PATIENTS
Supported by Bristol-Myers Squibb

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Managing Sleep Disturbances When Treating
Depressed Patients
Michael E. Thase, M.D.

B Management of Antidepressant-Induced Sexual
Dysfunction
Anthony J. Rothschild, M.D.

8:00 a.m. Sessions

COURSES 59-64
Course descriptions are available in
the CME Course Brochure included in
your registration packet. Admission by
ticket only.

COURSE 59 8:00 a.m.-12 noon
Room 704, 700 Level, Convention Centre
DEALING WITH RESISTANCE IN ADDICTION PATIENTS
Director: David Mee-Lee, M.D.

COURSE 60 8:00 a.m.-12 noon
Room 705, 700 Level, Convention Centre
ECT PRACTICE UPDATE
Director: Charles H. Kelner, M.D.
Faculty: Richard Weintraub, M.D., W. Vaughn
McCall, M.D., Richard L. Jaffe, M.D.

COURSE 61 8:00 a.m.-12 noon
Room 706, 700 Level, Convention Centre
BRIEF PSYCHODYNAMIC PSYCHOTHERAPY: THE CORE
CONFLICTUAL RELATIONSHIP THEME METHOD
Director: Howard E. Book, M.D.

COURSE 62 8:00 a.m.-12 noon
Room 712, 700 Level, Convention Centre
MEDICAL AND LEGAL ASPECTS OF ASSESSMENT IN THE
WORKPLACE
Director: Ronald Schouten, M.D., J.D.
Faculty: Sara Eddy, J.D., Brian L. Grant, M.D.,
C. Donald Williams, M.D.

COURSE 63 8:00 a.m.-12 noon
Room 714B, 700 Level, Convention Centre
THE DETECTION OF MALINGERED MENTAL ILLNESS
Director: Phillip J. Resnick, M.D.

COURSE 64 8:00 a.m.-12 noon
Room 716B, 700 Level, Convention Centre
DRUG TREATMENT OF SCHIZOPHRENIA
Co-Directors: Philip G. Janicak, M.D., John M. Davis, M.D.
Faculty: Stephen R. Marder, M.D., Daniel P.
van Kammen, M.D., William C. Wirshing, M.D.

9:00 a.m. Sessions

AIDS EDUCATION PROGRAM 1
9:00 a.m.-12 noon
Ballroom A, Lower Level, Crowne Plaza

CLINICAL AND NEUROPSYCHIATRIC DIMENSIONS OF
HIV DISEASE
Co-Sponsored by the APA Commission on AIDS and
the APA Education Steering Committee on AIDS

Chp.: Marshall Forstein, M.D.

A AIDS and HIV Disease: A Medical Update
Sharon Walsmley, M.D.

B Neuropsychiatric Manifestations and Their
Treatments: A Review
Mark H. Halman, M.D., Francisco Fernandez, M.D.,
J. Stephen McDaniel, M.D.
TUESDAY

CLINICAL CASE CONFERENCE 2
9:00 a.m.-10:30 a.m.
Caledon Room, Lobby Level, Crowne Plaza

PSYCHOTHERAPY WITH WOMEN WHO HAVE EXPERIENCED DOMESTIC VIOLENCE

Moderator: Donna E. Stewart, M.D.
Presenter: Gail E. Robinson, M.D.
Discussant: Nada L. Stotland, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

CONTINUOUS CLINICAL CASE CONFERENCE 1:
PART II
9:00 a.m.-12 noon
Ontario Room, Lower Level, Crowne Plaza

PSYCHOTHERAPIES IN RESIDENCY TRAINING: PART II

Moderator: Lisa A. Mellman, M.D.
Presenter: Deborah L. Kralick, M.D.
Discussants: Glen O. Gabbard, M.D., John C. Markowitz, M.D., Michael E. Thase, M.D., Norman A. Clemens, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

COURSES 65-71

Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 65
9:00 a.m.-4:00 p.m.
Room 702, 700 Level, Convention Centre

SKILLS FOR BUILDING AND LEADING SUCCESSFUL TEAMS

Co-Directors: des Anges Cruser, Ph.D., Alan L. Podawiltz, D.O.
Faculty: Harold R. Veits, M.D.

COURSE 66
9:00 a.m.-4:00 p.m.
Room 707, 700 Level, Convention Centre

THERAPEUTIC PUZZLE: OCD

Director: Jose A. Yaryura-Tobias, M.D.
Faculty: Fugen A. Neziroglu, Ph.D., Jonathan H. Hoffman, Ph.D.

COURSE 67
9:00 a.m.-4:00 p.m.
Room 708, 700 Level, Convention Centre

MEDICAL ETHICS 101

Director: Edmund G. Howe, M.D.

COURSE 68
9:00 a.m.-4:00 p.m.
Room 709, 700 Level, Convention Centre

ASSESSMENT AND TREATMENT OF PATIENTS WITH MENTAL RETARDATION

Director: Ruth M. Ryan, M.D.

COURSE 69
9:00 a.m.-4:00 p.m.
Room 710, 700 Level, Convention Centre

INTERPERSONAL PSYCHOTHERAPY

Director: Scott P. Stuart, M.D.
Faculty: Stephen P. Webb, M.D.

COURSE 70
9:00 a.m.-4:00 p.m.
Room 711, 700 Level, Convention Centre

RAPID SINGLE-SESSION ASSESSMENT IN THE AGE OF MANAGED CARE

Director: Shawn C. Shea, M.D.

COURSE 71
9:00 a.m.-4:00 p.m.
Room 712, 700 Level, Convention Centre

PRACTICAL TECHNIQUES IN CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY

Director: Charles W. Popper, M.D.
Faculty: Barbara J. Coffey, M.D., Daniel F. Connor, M.D., Robert D. Hunt, M.D., Graham J. Emslie, M.D., Stanley P. Kutcher, M.D., Martin H. Teicher, M.D., Elizabeth B. Weller, M.D., Scott A. West, M.D.

DISCUSSION GROUPS 5-6

These are limited to 25 participants on a first-come, first-served basis.

DISCUSSION GROUP 5
9:00 a.m.-10:30 a.m.
Confederation Room 4, Mezzanine, Royal York

Philip R. Muskin, M.D., on Patients Who Deny Medical Illness or Refuse Treatment
TUESDAY

DISCUSSION GROUP 6
9:00 a.m.-10:30 a.m.
Confederation Room 6, Mezzanine, Royal York
Carlos Blanco-Jerez, M.D., and Donna T. Chen, M.D.,
on Effective Use of a Mentor

LECTURES 10-11

LECTURE 10
9:00 a.m.-10:30 a.m.
Room 107, Lower Level, Convention Centre
APA'S PATIENT ADVOCACY AWARD LECTURE

Professor Arthur R. Miller
Chp.: Samuel B. Guze, M.D.
Co-Chp.: Julie K. Schulman, M.D.

Arthur R. Miller is the Bruce Bromley Professor of Law at Harvard Law School, where he has taught since 1971. Among lawyers he is nationally known for his work on court procedure, a subject on which he has authored or coauthored more than 25 books, and for his work on copyright and unfair competition. The general public, however, knows him for his work on the right of privacy. His book, Assault on Privacy: Computers, Data Banks, and Dossiers (1971) has been extremely influential. Professor Miller carries on an active law practice and has worked in the public interest in the fields of privacy, computers, copyright and the courts. He has been a Commissioner on the United States Commission on New Technological Uses of Copyrighted Works, a member of the Advisory Committee on Civil Rules for the United States Supreme Court and a reporter for the American Law Institute's Project on Complex Litigation. For many years he has appeared on "ABC's Good Morning America" as the program's legal editor. He is the host of the weekly "Miller's Law" program on the Courtroom Television Network and appears frequently on other Court TV programs. He has also conducted Socratic dialogues for several acclaimed PBS series, including "The Constitution: That Delicate Balance," "Managing Our Miracles: Health Care in America" and "The Presidency." He won an Emmy award for "The Sovereign Self." Professor Miller received his law degree from Harvard Law School.

LECTURE 11
9:00 a.m.-10:30 a.m.
Dominion Ballroom, Second Floor, Sheraton Centre
APA'S ADOLF MEYER AWARD LECTURE

Sir David Paul Goldberg, D.M.
The Course of Common Mental Disorders: Vulnerability, Destabilization and Restitution
Chp.: Carolyn B. Robinowitz, M.D.
Co-Chp.: Susan M. Deakins, M.D.

A dimensional model for common mental disorders is used to argue that symptoms of anxiety and depression lie along two correlated dimensions, and that most episodes of disorders that are common in the community will include admixtures of these two symptoms. Sir David Paul Goldberg, D.M., explores the course of these illnesses and factors which determine individual vulnerability, including genetic characteristics and modifying events in childhood and adolescence. Destabilization of episodes is mainly related to stressful life events and characteristics of the current social setting, including social support, self-esteem and coping behaviors. Restitution or recovery is determined by the level of initial vulnerability, the presence of social stressors, the availability of social support and the occurrence of various types of life events during the episode. Dr. Goldberg is Professor of Psychiatry and Director of Research and Development at the Institute of Psychiatry and Director of Medical Education at the Maudsley Hospital in London. He designed the General Health Questionnaire, which has been translated into 48 languages and is one of the most widely used screening questionnaires in the world. He is the author of numerous scientific papers and the co-author of Common Mental Disorders: A Biosocial Model. In 1996 he was knighted for services to medicine. Dr. Goldberg trained as a psychologist at Oxford before studying medicine at St. Thomas's Hospital. He trained in psychiatry at the Maudsley Hospital.

THIS SESSION WILL BE AUDIOTAPED.
MASTER EDUCATOR CLINICAL CONSULTATIONS 5-6

9:00 a.m.-10:30 a.m.

These are limited to 25 participants on a first-come, first-served basis.

5 James L. Griffith, M.D., on Patients with Symptoms of Somatization
New Brunswick Room, Mezzanine, Royal York

6 Robert E. Hales, M.D., on the Treatment of Agitation and Aggression in Neuropsychiatric Patients
Nova Scotia Room, Mezzanine, Royal York

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 10-12

MEDIA SESSION 10 9:00 a.m.-12 noon
Room 718B, 700 Level, Convention Centre

COMPUTERIZED MEDICAL RECORDS/PRACTICE MANAGEMENT SOFTWARE: PART I
Co-Chps.: Steven E. Hyler, M.D., Russell F. Lim, M.D.

14 Practice Management Software on the Cheap!
Steven E. Hyler, M.D.

There is little argument against using computer programs to help manage your practice. One option is the purchase of an "all-in-one" practice management program. The disadvantages of this option are: 1) it can be expensive; 2) it may not be easy to customize for your practice; 3) it might be difficult or expensive to upgrade to keep up with the ever-changing forms of insurance companies, managed care companies and government agencies; and 4) there is a good chance that the company who sold you the software may not exist as long as your practice does! A less expensive option for anyone who doesn't mind (or who even likes) tinkering with software programs is to create your own "practice management" program using commercially available software that is either already on your hard disc or inexpensive to purchase. Using the combination of a contact management program, scheduling program, office suite (word processor/spreadsheet), and database program you can create a program that will be custom tailored to your own practice. These programs will be demonstrated.

15 Computer Psychiatric Record Creation and Use for Solo Psychiatrists (CPR-CUSP)
Cary L. Hamlin, M.D.

Psychiatrist data input of observations and classifications requires a method that will not distract attention from the patient and will permit mapping to a normalized database. The CPR-CUSP method fulfills those goals and has been used to create a database of over 2,000 patients. CPR-CUSP uses a Win32Intel PC, Wordpad.exe, datajunction.exe, and a single psychiatrist to create patient interview notes and to put those notes into a database case repository. Procedures of CPR-CUSP include: how to type encounter notes in a text editor; how to write an extraction script in DataJunction Extraction Language; how to use extraction script.dip in DataJunction.exe to tokenize concepts in patient.txt and extract values from them; how to write a datamodel for the values; and how to populate the database with the values from patient.txt. Once created, a computer patient record is an argument to powerful functions, such as report macros, SQL queries, neural networks, and fuzzy cognitive maps. Insurance companies and other large corporations have spent millions of dollars to develop computer patient records. A solo psychiatrist can implement an office computer patient record for about two thousand dollars.

16 Psych Script: Software to Create Typed Psych Notes
Auby H. Axler, M.D.

This demonstration will show a new software (Psych Script) for the Newton hand-held computer. This software creates typed psychiatric consults and notes. This is done by a unique combination of templates and handwriting recognition, converting handwritten notes into type. These notes are created on the Newton hand-held computer and can be printed out directly or transferred to a PC. This allows the user to quickly write a note and have a completed typed note for enhanced communication and medical record keeping. All this can be done with a computer that receives e-mail and Internet and fits in the palm of a hand.

MEDIA SESSION 11 9:00 a.m.-11:00 a.m.
Ontario Room, Convention Floor, Royal York

DIVERSITY: A CASE FOR MINORITY FACULTY
Chp.: Francis G. Lu, M.D.

17 Shattering the Silences
(86 minutes)
Distributor: California Newsreel
149 9th Street, Suite 420
San Francisco, CA 94103

"Diversity" may be the word of the hour on the nation's campuses, but faculty of color remain a rare sight, making up only 9.2% of full professors. At the same time, affirmative action is under attack across the country. Shattering the Silences, broadcast by PBS, tells the story of these academic pioneers, their scholarly contributions, how they've helped open campuses to students of color, and the stresses and
challenges they face every day. Shattering the Silences wends its way through the culture wars and battles over multiculturalism to provide a unique look at campus life from the perspective of minority scholars from the humanities and social sciences, including Darlene Clark Hine, Alex Saragoza, Robin Kelley, Shawn Wong and others. This video may have lessons for psychiatry where the underrepresentation of ethnic minority faculty continues to exist in academic departments of psychiatry.

MEDIA SESSION 12  
9:00 a.m.-10:30 a.m.  
Civic Ballroom, Second Floor, Sheraton Centre

URBAN AND RURAL SYSTEMS OF CARE FOR THE CHRONIC MENTALLY ILL

Chp.: Elmore F. Rigamer, M.D.

18 Schizophrenia: The Community’s Response  
(41 minutes)

Distributor: Concept Media  
2493 DuBridge Avenue  
Irvine, CA 92714-5022

This documentary describes the deinstitutionalization movement and its impact. It discusses the community’s response from several viewpoints including those clients, parents, medical and nursing professionals, law enforcement personnel, psychiatric personnel in the penal system and outreach workers. The program will examine issues such as importance of the family, ad-  
herence to medication regimens, stigmatization, dangerousness, and need for community outreach and support. Commentary by E. Fuller Torrey, M.D.

National Educational Film and Video Festival’s Gold Apple Award Winner, 1996, in the Mental Health category.

19 In Their Shoes: Community Mental Health in Texas  
(29 minutes)

Distributor: Mental Health Needs Council  
P.O. Box 270205  
Houston, TX 77277-0205

In Their Shoes is a video documenting the prevalence and problems of persons with severe and persistent mental illness in the greater Houston area. It presents an overview of the nature of severe mental illness, as well as problems associated with homelessness and involvement in the criminal justice system. It captures the first person perspectives of persons with mental illness, their families, clinicians and public officials. Although primarily produced for lay audiences, this video has didactic value for students and faculty. It has received awards from the Texas Alliance for the Mentally Ill and the Houston Psychological Association.

20 Never Too Far: Rural Outreach for Serious Mental Illness  
(18 minutes)

Distributor: Duke University Medical Center  
Division of Social and Community Psychiatry  
Box 3173  
Durham, NC 27710

Severely mentally ill individuals are often poorly served in rural areas. Lack of transportation and cultural barriers often make treatment inaccessible. This video depicts a model of mobile outreach treatment in rural South Carolina that visits the homes and communities of rural mentally ill individuals and aggressively mobilizes treatment efforts.


ORAL/SLIDE SESSIONS 6-7  
9:00 a.m.-10:30 a.m.

5 MOOD DISORDERS
Room 205B, Street Level, Convention Centre

6 PSYCHOPHARMACOLOGY
Room 205D, Street Level, Convention Centre

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

RESEARCH ADVANCES IN MEDICINE  
9:00 a.m.-11:00 a.m.  
Ballroom B, Lower Level, Crowne Plaza

RESEARCH ADVANCES IN MEDICINE: THE EFFECTS OF PERINATAL EXPOSURE TO COCAINE
Collaborative Session with the National Institute on Drug Abuse

Chp.: Frances R. Levin, M.D.
Participants: Deborah Frank, M.D., on Cocaine in Babies: Who’s Cracked  
Linda Mayes, M.D., on Neurodevelopmental Outcome of Prenatal Cocaine Exposure  
Loretta P. Finnegan, M.D., on Perinatal Cocaine Exposure Is a Persistent Phenomenon: What Can We Do to Make a Difference?

THIS SESSION WILL BE AUDIOTAPE.
TUESDAY

REVIEW OF PSYCHIATRY: PART II
9:00 a.m.-12:30 p.m.
Room 105, Lower Level, Convention Centre

PSYCHOPATHOLOGY AND VIOLENT CRIME
Chp.: Andrew E. Skodol II, M.D.

7 Violent Crime and Axis I Psychopathology
James C. Beck, M.D.

8 The Personalities of Murderers: Sadistic Personality Revisited
Michael H. Stone, M.D.

9 Violent Crime and Axis II Psychopathology
Jeremy W. Coid, M.D.

10 Biology of Aggression: Relevance to Crime
Emil F. Coccaro, M.D.

11 Psychopathology, Crime and Law
Paul S. Appelbaum, M.D.

ROUND TABLE DISCUSSION
9:00 a.m.-10:30 a.m.
Room 104A, Lower Level, Convention Centre

COERCION IN PSYCHIATRY
Moderator: Robert Michels, M.D.
Participants: Alan D. Felix, M.D., Katherine Falk, M.D., Joseph Rogers, Laurie M. Flynn, M.A., Howard W. Telson, M.D., Marvin S. Swartz, M.D., Lewis A. Opler, M.D.

This format is designed to establish a dialogue between psychiatrists and other citizens about controversial issues of special interest to our profession. The moderator presents a panel of experts with hypothetical scenarios that highlight controversial and problematic situations with which psychiatrists interface.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS

COMPONENTS 18-27

COMPONENT WORKSHOP 18 9:00 a.m.-10:30 a.m.
Room 205A, Street Level, Convention Centre

THE NEW SOCIAL SECURITY INCOME RULE FOR CHILDREN: PRACTICAL ISSUES
APA Committee on Chronically Ill and Emotionally Handicapped Children
Chp.: Graeme Hanson, M.D.
Participants: Deborah A. Zarin, M.D., Joseph R. Mawhinney, M.D., Duncan S. Wallace, M.D.

COMPONENT WORKSHOP 19 9:00 a.m.-10:30 a.m.
Room 206C, Street Level, Convention Centre

RECRUITMENT AND RETENTION
APA Membership Committee
Chp.: Bernard A. Katz, M.D.
Participants: Rodrigo A. Muñoz, M.D., Harold Alan Pincus, M.D., R. Dale Walker, M.D.

COMPONENT WORKSHOP 20 9:00 a.m.-10:30 a.m.
Room 206E, Street Level, Convention Centre

ADVANCES IN VETERANS AFFAIRS SCHIZOPHRENIA RESEARCH
APA Consortium on Organized Service Systems
Co-Chps.: Laurent S. Lehmann, M.D., Frederick G. Guggenheim, M.D.
Participants: Robert Freedman, M.D., Robert W. McCarley, M.D., Dennis S. Charney, M.D., Paul Hoffman, M.D.

COMPONENT WORKSHOP 21 9:00 a.m.-10:30 a.m.
Grenadier Room, Lobby Level, Crowne Plaza

CERTIFICATION IN PSYCHIATRIC ADMINISTRATION
APA Committee on Psychiatric Administration and Management
Co-Chps.: William H. Reid, M.D., Carmel A. Foley, M.D.
Participants: Dave M. Davis, M.D., W. Walter Menninger, M.D., Philip E. Veerhuis, M.D., Paul A. Rodenhausen, M.D., Horace G. Whittington, M.D.

COMPONENT WORKSHOP 22 9:00 a.m.-10:30 a.m.
Humber Room, Lobby Level, Crowne Plaza

ACCESS TO PATIENTS: ARE RESIDENTS BEING CARVED OUT?
APA Glaxo Wellcome Fellows
Chp.: Diana R. Sanderson, M.D.
Participants: James H. Scully, Jr., M.D., John H. Lloyd, M.D., Steven P. Hamilton, M.D., Sukhmani K. Gill, M.D.

COMPONENT WORKSHOP 23 9:00 a.m.-10:30 a.m.
Oakville Room, Lobby Level, Crowne Plaza

CURRENT ISSUES IN MEDICAL STUDENT EDUCATION
APA Committee on Medical Student Education
Co-Chps.: Michael J. Vergare, M.D., Ronald L. Martin, M.D.
Participants: Carlyle Hung-Lun Chan, M.D., Christopher M. Palmer, M.D., Larry Maayan, M.S.
COMPONENT WORKSHOP 24 9:00 a.m.-10:30 a.m.
Quebec Room, Mezzanine, Royal York
SUCCESSFUL PRACTICE IN LONG-TERM CARE
APA Committee on Long-Term Care and Treatment for the Elderly and the American Association for Geriatric Psychiatry
Co-Chps.: George Dyck, M.D., Gary S. Moak, M.D.
Participants: James A. Greene, M.D., J. Pierre Loebel, M.D., Jeanne M. Jackson, M.D., David K. Conn, M.B.

COMPONENT WORKSHOP 25 9:00 a.m.-10:30 a.m.
Tudor Room 7, Mezzanine, Royal York
THE HISTORY OF MANAGED CARE IN PSYCHIATRY
APA Committee on History and Library
Co-Chps.: Etham S. Rofman, M.D., Dilip Ramchandani, M.D.
Participants: Miles F. Shore, M.D., Ronald I. Dozoretz, M.D., Kenneth A. Kessler, M.D.

COMPONENT WORKSHOP 26 9:00 a.m.-10:30 a.m.
Conference Room F, Mezzanine, Sheraton Centre
WOMEN PSYCHIATRISTS: THEIR TRIUMPHS AND TRAGEDIES
APA Committee of Asian-American Psychiatrists, APA Committee on Women, and APA Committee on Religion and Psychiatry
Co-Chps.: Geetha Jayaram, M.D., C. Deborah Cross, M.D.
Participants: Cecilia Tang, M.D., Patel Alpha, M.D., Nalini V. Juthani, M.D.

COMPONENT WORKSHOP 27 9:00 a.m.-10:30 a.m.
Kent Room, Second Floor, Sheraton Centre
MEDICAL MANPOWER ISSUES: ARE IMGS SCAPEGOATS?
APA Committee on International Medical Graduates
Chp.: Jambur V. Ananth, M.D.
Participants: Richard Balon, M.D., Nyapati R. Rao, M.D.

ISSUE WORKSHOP 31 9:00 a.m.-10:30 a.m.
Room 206C, Street Level, Convention Centre
DYNAMIC THERAPY WITH SELF-DESTRUCTIVE BORDERLINE PATIENTS
Chp.: Eric M. Plakun, M.D.

ISSUE WORKSHOP 32 9:00 a.m.-10:30 a.m.
Room 206A, Street Level, Convention Centre
VIDEO CASE STUDIES OF COUPLES IN TREATMENT
Chp.: Ian E. Alger, M.D.

ISSUE WORKSHOP 33 9:00 a.m.-10:30 a.m.
Room 206B, Street Level, Convention Centre
JCAHO AND HCFA ACCREDITATION AND QUALITY CARE
Chp.: Richard L. Elliott, M.D.
Participants: Helene M. Vartelas, M.S.N., Margaret Higgins, R.N.C., Anthony Nucifora, C.N.A.

ISSUE WORKSHOP 34 9:00 a.m.-10:30 a.m.
Room 206D, Street Level, Convention Centre
CREATING AND USING ADDICTION TREATMENT GUIDELINES, CONTINUED
Chp.: Richard J. Frances, M.D.
Participants: Sheldon I. Miller, M.D., Steven M. Mirin, M.D., Robert B. Millman, M.D., Sheila B. Blume, M.D., Lionel P. Solunsh, M.D., John S. Tamerin, M.D., Allen J. Frances, M.D.

ISSUE WORKSHOP 35 9:00 a.m.-10:30 a.m.
Room 206F, Street Level, Convention Centre
UPDATE ON MENTAL HEALTH IN THE OREGON HEALTH PLAN
Chp.: David A. Pollack, M.D.
Participants: Bentson H. McFarland, M.D., Robert A. George, M.D., Richard H. Angell, M.D., Magnus Lakovics, M.D.

ISSUE WORKSHOP 36 9:00 a.m.-10:30 a.m.
Room 103A, Lower Level, Convention Centre
FACING TELEVISION VIOLENCE IN CLINICAL PRACTICE
Chp.: Paul A. Kettl, M.D.
Participant: Robert T.M. Phillips, M.D.

ISSUE WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 104B, Lower Level, Convention Centre
SWIMMING WITH THE SHARKS
Chp.: Michelle Riba, M.D.
Participants: John S. McIntyre, M.D., Elissa P. Benedek, M.D., Marcia Slomowitz, M.D.
<table>
<thead>
<tr>
<th>Issue Workshop</th>
<th>Time</th>
<th>Location</th>
<th>Title</th>
<th>Chair(s)</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Room 104D, Lower Level, Convention Centre</td>
<td>ABPN Examinations and Canadians: Joint Session with the American Board of Psychiatry and Neurology, Inc., and the APA Board of Trustees</td>
<td>Michael F. Myers, M.D.</td>
<td>Stephen C. Scheiber, M.D., William Bebchuk, M.D., Stella L. Blackshaw, M.D., Peter E. Tanguay, M.D., Emmanuel Persad, M.B., Carol A. Bernstein, M.D., J.P. Des Grosilliers, M.D.</td>
</tr>
<tr>
<td>39</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Kingsway Room, Lobby Level, Crowne Plaza</td>
<td>COGNITIVE THERAPY FOR PERSONALITY DISORDERS</td>
<td>Judith S. Beck, Ph.D.</td>
<td>Jesse H. Wright, M.D.</td>
</tr>
<tr>
<td>40</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Alberta Room, Mezzanine, Royal York</td>
<td>THE STANDARDIZED PATIENT IN PSYCHIATRIC EDUCATION</td>
<td>Susan E. Abbey, M.D.</td>
<td>Brian D. Hodges, M.D., Jodi S. Lofchy, M.D., Nancy McNaughton, B.A.</td>
</tr>
<tr>
<td>41</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>British Columbia Room, Mezzanine, Royal York</td>
<td>PREDAOTRY ABUSE: EXPLOITATION OF THE ELDERLY</td>
<td>Michael J. Tueth, M.D.</td>
<td>Vikram Mehra, M.D.</td>
</tr>
<tr>
<td>42</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Territories Room, Mezzanine, Royal York</td>
<td>ISSUES IN TOBACCO USE AND SCHIZOPHRENIA</td>
<td>Peter E. Cook, M.D.</td>
<td>Douglas M. Ziedonis, M.D., Joel O. Goldberg, Ph.D., Sandra Moll, M.Sc.</td>
</tr>
<tr>
<td>43</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Tudor Rooms 8/9, Mezzanine, Royal York</td>
<td>CULTURAL ISSUES IN CONSULTATION-LIAISON PSYCHIATRY</td>
<td>Jon M. Streitzer, M.D., Wen-Shing Tseng, M.D.</td>
<td>James J. Strain, M.D., Norman B. Levy, M.D., Hoyle Leigh, M.D.</td>
</tr>
<tr>
<td>44</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Conference Room B, Mezzanine, Sheraton Centre</td>
<td>MANAGEMENT OF SEXUAL PREDATORS AFTER THE SUPREME COURT RULING IN KANSAS VS. HENDRICKS</td>
<td>James E. Dillon, M.D.</td>
<td>Melvin Guyer, Ph.D., J.D., Lee H. Rome, M.D.</td>
</tr>
<tr>
<td>45</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Windsor Room, Mezzanine, Sheraton Centre</td>
<td>ACADEMIC MEDICAL CENTERS MANAGING CARE</td>
<td>Arthur L. Lazarus, M.D., M.B.A.</td>
<td>Thomas Carli, M.D., Allen Daniels, Ed.D., Bruce J. Schwartz, M.D.</td>
</tr>
<tr>
<td>46</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>York Room, Mezzanine, Sheraton Centre</td>
<td>INTERNATIONAL PERSPECTIVES ON GAY PSYCHIATRY</td>
<td>Gene A. Nakajima, M.D., Siegmund Dannecker, M.D.</td>
<td>Pierre Cochand, M.D., Oyvind E. Jensen, M.D., Ruedi Gloor, M.D., Dr. Pascal Singy</td>
</tr>
<tr>
<td>47</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>City Hall Room, Second Floor, Sheraton Centre</td>
<td>HOW TO HELP YOUR PATIENTS STOP SMOKING</td>
<td>John R. Hughes, M.D., Susan J. Fiester, M.D.</td>
<td></td>
</tr>
<tr>
<td>48</td>
<td>9:00 a.m.-10:30 a.m.</td>
<td>Wentworth Room, Second Floor, Sheraton Centre</td>
<td>PHARMACOTHERAPY OF ADDICTIVE DISORDERS</td>
<td>Norman S. Miller, M.D.</td>
<td>Roye Litten, Ph.D.</td>
</tr>
</tbody>
</table>

11:00 a.m. Sessions

DISCUSSION GROUPS 7-8

These are limited to 25 participants on a first-come, first-served basis.

DISCUSSION GROUP 7

11:00 a.m.-12:30 p.m.  
Confederation Room 4, Mezzanine, Royal York

Roslyn Seligman, M.D., on Development and Psychopathology: Clinical Perspectives
**DISCUSSION GROUP 8**

11:00 a.m.-12:30 p.m.
Confederation Room 6, Mezzanine, Royal York

Pedro Ruiz, M.D., on Cultural Psychiatry

**LECTURES 12-14**

**Days of Creation Session**

**LECTURE 12**

11:00 a.m.-12:30 p.m.
Room 107, Lower Level, Convention Centre

Rabbi Burton L. Visotzky

The Dysfunctional Family As Moral Exemplar: Studying Genesis

Chp.: Maurice D. Steinberg, M.D.

Co-Chp.: Bonnie R. Saks, M.D.

The study of the biblical book of Genesis outside the realm of religious hermeneutics gives rise to the possibility that the first book of the Bible is an ugly little soap opera about a dysfunctional family. Why have religious communities and even secular writers in the Western tradition afforded such pride of place to the work? Rabbi Professor Burton L. Visotzky applies Lawrence Kohlberg’s theories of moral development to the study of Genesis and concludes that the several stories in the biblical book serve as moral dilemmas that are appropriate for group study and discussion to spur moral development. This interactive, nonjudgmental study of Genesis not only strengthens moral reasoning, but also strengthens community bonds and promotes the growth of listening skills. Burton L. Visotzky holds the Nathan and Janet Appleman Chair in Midrash and Interreligious Studies at the Jewish Theological Seminary of America. He is also Adjunct Professor of Biblical Studies at Union Theological Seminary in New York City. Professor Visotzky is the author of three scholarly books and two popular works, Reading the Book: Making the Bible a Timeless Text and the best-selling The Genesis of Ethics. With Bill Moyers, he developed the ten-hour television series “Genesis: A Living Conversation,” for the Public Broadcasting Station and was featured as an on-screen participant. Professor Visotzky received a Master of Education degree from Harvard University and his Master of Arts, Rabbinic ordination and doctoral degree from the Jewish Theological Seminary.

**THIS SESSION WILL BE AUDIOTAPED.**

**LECTURE 13**

11:00 a.m.-12:30 p.m.
Ballroom, Convention Floor, Royal York

APA'S SOLOMON CARTER FULLER AWARD LECTURE

Deborah B. Prothrow-Stith, M.D.

Violence Prevention: A Public Health Mandate to Save Our Children

Chp.: Gloria Pitts, D.O.

Co-Chp.: Michelle O. Clark, M.D.

Violence takes a heavy toll on our nation’s spirit, health and economy. However, the disparity between the high rate of homicide among young men in the United States and the much lower rates in other developed countries suggests that violence is preventable. Deborah Prothrow-Stith, M.D., discusses youth violence in the U.S. from a public health perspective, examines the risk factors that predispose certain children to act violently and explores violence prevention strategies that are available to communities.

Dr. Prothrow-Stith is Associate Dean for Faculty Development, Director of the Division of Public Health Practice and Professor of Public Health Practice at Harvard School of Public Health in Boston. She formerly was Commissioner of Public Health for the Commonwealth of Massachusetts. She developed and wrote the first violence prevention curriculum for schools and communities, entitled, Violence Prevention Curriculum for Adolescents and coauthored Deadly Consequences, a book for general readers that presented the view that violence is a public health problem. Dr. Prothrow-Stith has been instrumental in several local and national initiatives, including the Community Violence Prevention Project and the National Coalition of Survivors for Violence Prevention. She has received the Secretary’s Award for Exceptional Achievement in Public Service from the United States Department of Health and Human Services and was appointed to the National Commission on Crime Control and Prevention in 1995. Dr. Prothrow-Stith received her medical degree from Harvard Medical School and trained in internal medicine at Boston City Hospital.

**THIS SESSION WILL BE AUDIOTAPED.**
The field of psychiatry needs a unified national approach for psychotherapy education to ensure that psychotherapy continues to be a significant part of the field’s core identity. James H. Shore, M.D., proposes a unified educational model for the psychotherapies and discusses other critical issues in psychiatric education, including the need for more specific educational standards for accreditation of residency training programs and for certification of individual psychiatrists. Dr. Shore is Professor and Chairman of the Department of Psychiatry at the University of Colorado Health Sciences Center and Superintendent of the Colorado Psychiatric Hospital. He has served as chairman of the APA Council on Medical Education and Career Development, president of the American Board of Psychiatry and Neurology and president of the American Association of Chairmen of Departments of Psychiatry. A member of the Editorial Board of Psychiatric Services, Dr. Shore is the author of more than 125 scientific papers and book chapters and coauthor of the book Certification, Recertification and Lifetime Learning in Psychiatry. He has received the Commendation Medal from the United States Public Health Service, the Fellowship of the Foundation’s Fund for Research in Psychiatry and the Distinguished Service Award from the Indian Health Service. Dr. Shore received his medical degree from Duke University and completed his psychiatric residency at the University of Washington in Seattle.

This session will be audiotaped.

MASTER EDUCATOR CLINICAL CONSULTATIONS 7-9

11:00 a.m.-12:30 p.m.
Nova Scotia Room, Mezzanine, Royal York

These are limited to 25 participants on a first-come, first-served basis.

7 Donald W. Black, M.D., on OCD and the Obsessive-Compulsive Spectrum
New Brunswick Room, Mezzanine, Royal York

8 Eugene V. Beresin, M.D., on Anorexia and Bulimia Nervosa
Nova Scotia Room, Mezzanine, Royal York

9 Sheldon I. Miller, M.D., on Dual Diagnosis: Cases and Discussion
Collaborative Session with the National Institute on Drug Abuse
Saskatchewan Room, Mezzanine, Royal York

These sessions are open to APA members only. Blue registration badge or APA membership card required for admittance.

MEDIA SESSIONS 13-14

MEDIA SESSION 13 11:00 a.m.-2:00 p.m.
Ontario Room, Convention Floor, Royal York

RAPE AND RECONCILIATION

Chp.: Cheryl A. Kennedy, M.D.

21 Rape: A Crime of War (60 minutes)

Distributor: National Film Board of Canada
P.O. Box 6100 Station Centreville
Montreal, PQ, Canada H3C 3H5

This documentary follows the story of some extraordinary women and their battle to ensure that rape is understood by the world as a crime against humanity. It has been estimated that between 20,000 and 50,000 rapes were committed during fighting in the former Yugoslavia. From the perspective of victims, prosecutors and perpetrators, we are drawn into the horrors of rape as a weapon of war. Four women tell their story of forced confinement, rape and degradation in Bosnia and share how their experiences have influenced their perceptions of their partners, society as a whole and themselves. The rapists claim they were acting upon a higher authority. Legal consultants at The Hague where the International
Tribunal is investigating war crimes, discuss the implications of the trial of a former camp boss, the first person to be indicted for rape as a war crime. Interviews and archival footage of war crimes hearings in Nuremberg, Nanking, Bosnia and Rwanda are interspersed with images of Western art and culture which have romanticized, eroticized and legitimized rape.

**National Educational Media Network's Silver Apple Award, 1997**

**22 Glimmer of Hope**

(52 minutes)

**Distributor:** National Film Board of Canada  
P.O. Box 6100 Station Centreville  
Montreal, PQ, Canada H3C 3H5

The death of a child is tragedy enough, but when the cause of death is random, brutal murder, the pain can be insurmountable. In the aftermath of horror, the greatest challenge can be to come to terms with grief and get on with life. For those who can't, anger and vengeance may take over, making them victims of a crime that never ends. *Glimmer of Hope* shows the Streufert family trying to come to terms with the rape and murder of their 19-year-old daughter, Carin. Across North America, individuals and groups, many of them volunteer, are actively working to change the concept of justice through innovative, community-based initiatives such as offender community service programs, victim/offender mediation and healing circles. These people are part of the restorative justice movement, founded on the principle of individual and community responsibility, which brings healing to both victims and offenders. The Streuferts are part of a growing movement of victims of violence. They are taking healing into their own hands by confronting those who have hurt them in a effort to understand the tragedy that has shattered their lives. By meeting the killers of their daughter they can ask the questions that plague them, hear the killers' version first-hand, and bring a monstrous act and its perpetrators into human focus, all in the hope of coming to terms with inexpressible loss and grief.

**MEDIA SESSION 14**  
**11:00 a.m.-2:00 p.m.**  
Civic Ballroom, Second Floor, Sheraton Centre

**FAMILY/CONSUMER PERSPECTIVES ON COPING WITH STIGMA**  
**Chp.: Ian E. Alger, M.D.**

**23 Conversations at the Carter Center: Coping with the Stigma of Mental Illness**  
(27 minutes)

**Distributor:** Carter Center Mental Health Program  
One Copenhill  
Atlanta, GA 30307

This moving videotape is hosted by Mrs. Rosalynn Carter and features the powerful testimony of author Kathy Cronkite and actor Rod Steiger. This video is designed to educate and to be used as a tool to reduce stigma and discrimination against persons with mental illness and their families.

**24 Mental Illness: The Family's Story**  
(30 minutes)

**Distributor:** AMI of S.W. Pennsylvania  
4721 McKnight Road, Suite 216  
Pittsburgh, PA 15237

The anguish of living with a family member who has a serious mental illness is described by four parents. This video moves from the initial shock, disbelief and grief that accompany the diagnosis of a loved one's serious mental illness to an eventual acceptance and a hope for a brighter future, recognizing the ongoing benefits of research, including the availability of new and better medications.

**25 I'm Still Here, the Truth About Schizophrenia: A Non-Fiction Film**  
(67 minutes)

**Distributor:** Direct Cinema  
P.O. Box 1003  
Santa Monica, CA 90401

*I'm Still Here, The Truth About Schizophrenia* strips away the ignorance and fear associated with schizophrenia, reminding us that despite the distortions of personality and perception induced by a chemical imbalance of the brain, many of those living with this illness lead lives of extraordinary courage and accomplishment, deserving of our compassion and admiration.

**MEDICAL UPDATE 2**  
**11:00 a.m.-12:30 p.m.**  
Room 104C, Lower Level, Convention Centre

**HERBAL MEDICINE**  
**Chp.: Philip R. Muskin, M.D.**  
**Presenter:** Richard P. Brown, M.D.

THIS SESSION WILL BE AUDIOTAPED.

**RESEARCH CONSULTATION WITH**  
**11:00 a.m.-12:30 p.m.**  
York Room, Mezzanine, Royal York

**1 Jerome H. Jaffe, M.D., on Choosing the Right Treatment for Opiate Dependence**  
Collaborative Session with the National Institute on Drug Abuse

This session is limited to 25 participants on a first-come, first-served basis.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT
SESSIONS 11-19

SCIENTIFIC AND CLINICAL REPORT SESSION 11
11:00 a.m.-12:30 p.m.
Room 205B, Street Level, Convention Centre

THE SPECTRUM OF SUBSTANCE ABUSE: RESEARCH FROM THE BRAIN TO THE STREETS
Chp.: David W. Brook, M.D.
Co-Chp.: Vishwas Mashalkar, M.D.

32 Psychopathology and the Risk of Homelessness
Collaborative Presentation with the National Institute on Drug Abuse
11:00 a.m.
Carol L.M. Caton, Ph.D., Deborah S. Hasin, Ph.D.,
Patrick E. Shrout, Ph.D., Alan D. Felix, M.D.,
Lewis A. Opler, M.D.

33 Addiction: Professionals' Perception of Nicotine Use
11:30 a.m.
Baljit S. Gill, M.D., Dwayne L. Bennett, M.D.,
Mohammad Abu-Salha, M.D., Lisa G. Fore-Arcand, Ed.D.

34 Mu-Opioid Receptor Binding During Cocaine Abstinence
Collaborative Presentation with the National Institute on Drug Abuse
12 noon
David A. Gorelick, M.D., Badreddine Bencherif, M.D.,
Richard A. Nelson, M.D., Robin Stauffer, R.N.,
Hayden Ravert, M.D., Robert Dannals, M.D.,
J. James Frost, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 12
11:00 a.m.-12:30 p.m.
Room 205C, Street Level, Convention Centre

THE SOMATIC SPECTRUM
Chp.: Joel J. Wallack, M.D.
Co-Chp.: Cyril Hoschl, M.D.

38 Effects of Trauma Events in GAD Patients
11:00 a.m.
Olga Brawman-Mintzer, M.D., Sherry Falsetti, Ph.D.,
R. Bruce Lysiard, M.D., Naresh P. Emmanuel, M.D.,
Sarah W. Book, M.D., Michael R. Johnson, M.D.

39 Chronic Pain Disorder Following Injury
11:30 a.m.
Jon M. Streitzer, M.D., Byron A. Elashof, M.D.,
Amy F. Klime, Ph.D.

40 A Family Study of Fibromyalgia
12 noon
Catherine L. Woodman, M.D., Russell Noyes, Jr., M.D.,
Kenneth Saag, M.D., Hulda Hardardottir, Lori Stout, R.N.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 13
11:00 a.m.-12:30 p.m.
Caledon Room, Lobby Level, Crowne Plaza

RISK FACTORS FOR CHILDHOOD PSYCHOPATHOLOGY
Chp.: Stephen J. Millman, M.D.
Co-Chp.: Derek G. Puddester, M.D.

41 Some Long-Term Consequences of Orphanage Care
11:00 a.m.
John J. Sigal, Ph.D., Michael Rossignol, M.D.,
J. Christopher Perry, M.D.

42 Attachment Security of Mothers and Adolescents
11:30 a.m.
Elie R. Broussard, M.D.

43 Shyness and Behavioral Inhibition: Relationship to Anxiety Disorders
12 noon
Michael A. Van Ameringen, M.D., Catherine L. Mancini, M.D.,
Jonathan Oakman, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
TUESDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 15
11:00 a.m.-12:30 p.m.
Confederation Room 3, Mezzanine, Royal York

MENTAL HEALTH DELIVERY ISSUES
Chp.: Marshall E. Lewis, M.D.
Co-Chp.: K. Shazad, M.D.

44 Maximizing Community Resources in a Rural Setting
   11:00 a.m.
   Janet E. Ordway, M.D.

45 Managed Care Principles Applied to Indigent Mental Health Care
   11:30 a.m.
   F. Kevin Butler, M.D.

46 Integrating Physical Rehabilitation Services into an Inpatient Psychiatric Unit
   12 noon
   Edward M. Phillips, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 16
11:00 a.m.-12:30 p.m.
Quebec Room, Mezzanine, Royal York

BIOLOGICAL STUDIES OF MENTAL ILLNESS
Chp.: Henry A. Nasrallah, M.D.
Co-Chp.: Suzanne M. Renaud, M.D.

47 PET Analysis of Antidepressant Effects of Paroxetine
   11:00 a.m.
   Sidney H. Kennedy, M.D., Kenneth R. Evans, Ph.D.,
   Sylvain Houle, M.D., Franco J. Vaccarino, Ph.D.

48 Abnormal Diurnal 5-HIAA with Premenstrual Syndrome and Premenstrual Dysphoric Disorder
   11:30 a.m.
   Anita L.H. Clayton, M.D., Adrienne R. Sheldon-Keller, Ph.D.,
   Catharine A. Leslie, M.D., William Evans, M.D.

49 Expanding Versus Static Ventricile Schizophrenia
   12 noon
   David L. Garver, M.D., Thamilarasi R. Nair, M.D.,
   Janet L. Tekell, M.D., James D. Christensen,
   Jennifer Holcomb, B.A., Steven J. Kingsbury, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 17
11:00 a.m.-12:30 p.m.
Tudor Room 7, Mezzanine, Royal York

INNOVATIONS IN PRIMARY CARE
Chp.: Ellen N. Rothchild, M.D.
Co-Chp.: Beverly N. Jones, M.D.

50 Use of the PRIME-MD in a University Student Health Service
   11:00 a.m.
   Elizabeth H. Rand, M.D., Lee W. Badger, Ph.D.,
   Scott Batey, M.S.W., Allison Winters, M.S.W.,
   Julia Hartman, B.A., Marian Swindoll, B.A.

51 Telepsychiatry in Georgia: A Multichanneled Approach
   11:30 a.m.
   Rhonda G. Vought, M.D., R. Kevin Grigsby, D.S.W.,
   Laura N. Adams, B.S., Stewart A. Shevitz, M.D.

52 Care Models Guide Primary Care Psychiatry Teaching
   12 noon
   Troy L. Thompson II, M.D., Elizabeth H. Rand, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 18
11:00 a.m.-12:30 p.m.
City Hall Room, Second Floor, Sheraton Centre

NEW ISSUES WITH ATYPICAL ANTIPSYCHOTICS
Chp.: Bernard I. Grosser, M.D.
Co-Chp.: Dr. Vaiapuri Palaniappun

53 Olanzapine Versus Placebo in the Treatment of Acute Mania
   11:00 a.m.
   Mauricio Tohen, M.D., Todd Sanger, Ph.D.,
   Gary D. Tollefson, M.D., Susan L. McElroy, M.D.,
   Michael G. Greaney, M.S., Verna Toma

54 Olanzapine Versus Risperidone and Haloperidol in the Treatment of Schizophrenia
   11:30 a.m.
   Barry Jones

55 The Differential Risk of Tardive Dyskinesia with Olanzapine
   12 noon
   Charles M. Beasley, Jr., M.D., Gary D. Tollefson, M.D.,
   Maryanne Deliva, M.S., Roy Tamura, Ph.D.,
   William M. Glazer, M.D., Hal Morgenstern, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 19
11:00 a.m.-12:30 p.m.
Huron Room, Second Floor, Sheraton Centre

GERIATRIC PSYCHIATRY
Chp.: David G. Bienenfeld, M.D.
Co-Chp.: Sharon S. Levine, M.D.

56 Clinical Response to Valproate in Geriatric Patients
   11:00 a.m.
   Julie A. Niedermier, M.D., Henry A. Nasrallah, M.D.,
   Nicholas A. Votolato, R.Ph.

57 Nortriptyline for Grief-Related Depression in Elders
   11:30 a.m.
   Mark D. Miller, M.D., Charles F. Reynolds III, M.D.

58 Two-Year Outcome of Psychotic Depression in Late-Life
   12 noon
   Alastair J. Flint, M.B., Sandra L. Rifat, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

53
TUESDAY

WORKSHOPS

COMPONENTS 28-36

COMPONENT WORKSHOP 28 11:00 a.m.-12:30 p.m.
Room 205A, Street Level, Convention Centre

OCD: SPANISH PERSPECTIVE
APA Committee of Hispanic Psychiatrists

Chp.: Silvia W. Olarte, M.D.
Participants: Angela Pedraza, M.D., Jesus De La Gandara, M.D., Julio Bobes, M.D., Julio Vallejo, M.D., Jose M. Menchon, M.D., Roberto A. Dominguez, M.D.

COMPONENT WORKSHOP 29 11:00 a.m.-12:30 p.m.
Room 205C, Street Level, Convention Centre

PROMISES AND PROBLEMS WITH NEW TREATMENTS FOR HIV
APA New York County District Branch's AIDS Committee

Co-Chps.: Elizabeth V. Getter, M.D., John A. Sahs, M.D.
Participants: Stephen J. Ferrando, M.D., John A.R. Grimaldi, Jr., M.D., Kyle S. Kato, M.D.

COMPONENT WORKSHOP 30 11:00 a.m.-12:30 p.m.
Room 206A, Street Level, Convention Centre

PSYCHIATRY FELLOWSHIPS: RESIDENT TO RESIDENT
APA New York County District Branch's Residents Committee

Chp.: Evaristo O. Akerele, M.D.

COMPONENT WORKSHOP 31 11:00 a.m.-12:30 p.m.
Room 206D, Street Level, Convention Centre

FILM CLUBS: HOW TO HAVE FUN WHILE LEARNING PSYCHIATRY
APA Media Subcommittee

Co-Chps.: Francis G. Lu, M.D., Steven E. Hyler, M.D.
Participant: Tal Burt, M.D.

COMPONENT WORKSHOP 32 11:00 a.m.-12:30 p.m.
Room 206E, Street Level, Convention Centre

PATIENTS' RIGHTS: AN INTERNATIONAL PERSPECTIVE
APA Committee on International Abuse of Psychiatry and Psychiatrists

Chp.: Alan L. Gordon, M.D.

COMPONENT WORKSHOP 33 11:00 a.m.-12:30 p.m.
Room 104D, Lower Level, Convention Centre

PSYCHIATRY AND THE PHARMACEUTICAL INDUSTRY
APA Joint Commission on Public Affairs

Chp.: Nada L. Stotland, M.D.
Participants: Freda C. Lewis-Hall, M.D., Laurie M. Flynn, M.A., Michael Faenza, M.S.W., Stephen M. Goldfinger, M.D.

COMPONENT WORKSHOP 34 11:00 a.m.-12:30 p.m.
Kingsway Room, Lobby Level, Crowne Plaza

CHANGING PSYCHIATRIC COMPENSATION
APA Committee on Psychiatric Administration and Management

Co-Chps.: Carmel A. Foley, M.D., Philip E. Veenhuis, M.D.
Participant: W. Walter Menninger, M.D.

COMPONENT WORKSHOP 35 11:00 a.m.-12:30 p.m.
Oakville Room, Lobby Level, Crowne Plaza

HOT OFF THE PRESS: NEW GUIDELINES FOR JAILS AND PRISONS
APA Task Force to Revise the APA Report on Jails and Prisons

Chp.: Henry C. Weinstein, M.D.
Participants: Kathryn A. Burns, M.D., Joel A. Dvoskin, Ph.D., Cassandra F. Newkirk, M.D., John S. Zil, M.D., J.D.

COMPONENT WORKSHOP 36 11:00 a.m.-12:30 p.m.
Conference Room C, Mezzanine, Sheraton Centre

EFFECTIVE PSYCHIATRIC WORK IN THE JUVENILE JUSTICE SYSTEM
APA Committee on Juvenile Justice Issues

Chp.: Wade C. Myers, M.D.
Participants: Patrice A. Harris, M.D., Diane E. Heisel, M.D., Ledro Justice, M.D., Debra K. DePrato, M.D.

ISSUES 49-61

ISSUE WORKSHOP 49 11:00 a.m.-12:30 p.m.
Room 206B, Street Level, Convention Centre

THE ROLE OF ENACTMENT IN PSYCHIATRIC TREATMENT

Co-Chps.: Eric M. Plakun, M.D., Edward R. Shapiro, M.D.

ISSUE WORKSHOP 50 11:00 a.m.-12:30 p.m.
Room 103A, Lower Level, Convention Centre

CONCEPTUALIZATION AND BOUNDARIES OF TRAUMA

Chp.: Malkah T. Notman, M.D.
Participants: Carl P. Malmquist, M.D., Elissa P. Benedek, M.D.
<table>
<thead>
<tr>
<th>Issue Workshop</th>
<th>Time</th>
<th>Location</th>
<th>Topic</th>
<th>Chair(s)</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>51</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Grenadier Room, Lobby Level, Crowne Plaza</td>
<td>Sexual Activity in Long-Term Psychiatric Facilities</td>
<td>Thomas P. Welch, M.D.</td>
<td>Allan W. Wood, M.S.W.</td>
</tr>
<tr>
<td>52</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Humber Room, Lobby Level, Crowne Plaza</td>
<td>How to Write and Publish in Psychiatry</td>
<td>Carol C. Nadalon, M.D.</td>
<td>Sydney Bloch, M.D., Nancy C. Andreasen, M.D.</td>
</tr>
<tr>
<td>53</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Niagara Room, Lower Level, Crowne Plaza</td>
<td>George Gershwin at 100: A Creative Genius Re-Examined</td>
<td>Richard Kogan, M.D.</td>
<td>William A. Frosch, M.D.</td>
</tr>
<tr>
<td>54</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Alberta Room, Mezzanine, Royal York</td>
<td>Art and Audience: The Creative Interaction</td>
<td>Albert Rothenberg, M.D.</td>
<td>Ellen H. Spitz, Ph.D., Richard Selzer, M.D.</td>
</tr>
<tr>
<td>55</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>British Columbia Room, Mezzanine, Royal York</td>
<td>Toning and Chanting: Accessing and Expressing the Nonverbal</td>
<td>Leah J. Dickstein, M.D., Alice H. Cash, Ph.D.</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Manitoba Room, Mezzanine, Royal York</td>
<td>Severe Mental Illness in Family Medicine Settings</td>
<td>Rebecca S. Lewin, M.D.</td>
<td>Deborah Seymour, Psy.D.</td>
</tr>
<tr>
<td>57</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Tudor Rooms 8/9, Mezzanine, Royal York</td>
<td>Transgender Issues</td>
<td>Dan H. Karasic, M.D.</td>
<td>James W. Dotson, M.D., Shoshmanna W. Gillick, M.D., Donald E. Tarver, M.D.</td>
</tr>
<tr>
<td>58</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Conference Room B, Mezzanine, Sheraton Centre</td>
<td>Acupuncture, Oriental Medicine and Psychiatry</td>
<td>Antoinette W. Jakobi, M.D.</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Conference Room F, Mezzanine, Sheraton Centre</td>
<td>Women's Issues in Drug Abuse: Violence, Trauma and Victimization</td>
<td>Dan H. Karasic, M.D.</td>
<td>James W. Dotson, M.D., Shoshmanna W. Gillick, M.D., Donald E. Tarver, M.D.</td>
</tr>
<tr>
<td>60</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>York Room, Mezzanine, Sheraton Centre</td>
<td>Transgender Awareness</td>
<td>David E. Seil, M.D.</td>
<td>Laura P. Perri, M.D.</td>
</tr>
<tr>
<td>61</td>
<td>11:00 a.m.-12:30 p.m.</td>
<td>Dufferin Room, Second Floor, Sheraton Centre</td>
<td>Behavioral Independent Provider Association: A Look at the Future?</td>
<td>Bruce J. Schwartz, M.D.</td>
<td>Robert B. Ostroff, M.D., Ronnie S. Stangler, M.D., Andrea J. Weiss, M.D.</td>
</tr>
</tbody>
</table>

**12 noon Sessions**

<table>
<thead>
<tr>
<th>Forum</th>
<th>Time</th>
<th>Location</th>
<th>Topic</th>
<th>Chair(s)</th>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>12 noon-1:30 p.m.</td>
<td>Room 206F, Street Level, Convention Centre</td>
<td>Psychiatry: 25 Years Since Depathologizing Homosexuality</td>
<td>Lowell D. Tong, M.D.</td>
<td>James P. Krajekis, M.D.</td>
</tr>
<tr>
<td>4</td>
<td>12 noon-1:30 p.m.</td>
<td>Tudor Rooms 8/9, Mezzanine, Royal York</td>
<td>Transgender Issues</td>
<td>Melvin Sabshin, M.D., Carolyn B. Robinowitz, M.D., Robert P. Cabaj, M.D., Diana C. Miller, M.D., Howard C. Rubin, M.D.</td>
<td></td>
</tr>
</tbody>
</table>
TUESDAY

FORUM 4  12 noon-1:30 p.m.
Room 104B, Lower Level, Convention Centre
TOWARD A NEUROBIOLOGY OF PSYCHOTHERAPY
APA Commission on Psychotherapy by Psychiatrists
Chp.: Bernard D. Beitman, M.D.
Participants: Barton J. Blinder, M.D., Glen O. Gabbard, M.D., Jerald Kay, M.D.

FORUM 5      12 noon-1:30 p.m.
Territories Room, Mezzanine, Royal York
THE FUTURE OF THE PSYCHIATRIC WORKFORCE
Chp.: Allan Tasman, M.D.
Participants: Larry R. Faulkner, M.D., Gloria Pitts, D.O., Nyapati R. Rao, M.D., James H. Scully, Jr., M.D., Mary Kay Smith, M.D., Eva M. Szigethy, M.D., Sir David Paul Goldberg, D.M.

FORUM 6  12 noon-1:30 p.m.
Windsor Room, Mezzanine, Sheraton Centre
CHALLENGES IN TEACHING PSYCHIATRY IN THE NEXT CENTURY
APA George Tarjan Award
Chp.: Richard Balon, M.D.

NEW RESEARCH

POSTER SESSION 7
12 noon-2:00 p.m.
Room 106, Lower Level, Convention Centre
MOOD, FMDD, PERSONALITY AND EATING DISORDERS;
PSYCHOIMMUNOLOGY; BEHAVIOR/COGNITIVE AND SOMATIC THERAPIES; PSYCHOTHERAPY AND PHARMACOTHERAPY; SUICIDE; EPIDEMIOLOGY; RESEARCH ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

1:00 p.m. Sessions

COURSES 72-76
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 72  1:00 p.m.-5:00 p.m.
Room 703, 700 Level, Convention Centre
ENHANCING MARITAL INTIMACY THERAPY
Co-Directors: Edward M. Waring, M.D., John S. Leverette, M.D.

COURSE 73  1:00 p.m.-5:00 p.m.
Room 704, 700 Level, Convention Centre
CLINICAL MANAGEMENT OF REGRESSIVE DEPENDENCY
Director: John O. Beahrs, M.D.
Faculty: Claudette H. Beahrs, M.S.S.W.

COURSE 74  1:00 p.m.-5:00 p.m.
Room 705, 700 Level, Convention Centre
CONTEMPORARY MALPRACTICE LIABILITY: A CASE STUDY
Co-Directors: Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.
Faculty: Richard G. Hersh, M.D.

COURSE 75  1:00 p.m.-5:00 p.m.
Room 712, 700 Level, Convention Centre
RATIONAL USE OF HORMONE-REPLACEMENT THERAPY AND ANTIDEPRESSANTS IN POSTMENOPAUSAL WOMEN
Director: Marjorie L. Shuer, M.D.
Faculty: Joel T. Hargrove, M.D.

COURSE 76  1:00 p.m.-5:00 p.m.
Room 716B, 700 Level, Convention Centre
ESTABLISHING A FORENSIC PSYCHIATRIC PRACTICE
Joint Session with the American Academy of Psychiatry and the Law
Director: Robert P. Granacher, Jr., M.D.
Faculty: Steven Berger, M.D., Emily A.H. Keram, M.D., Steven E. Pitt, D.O., Christiane Tellefsen, M.D.

MEDIA SESSION 15
1:00 p.m.-5:00 p.m.
Room 718B, 700 Level, Convention Centre
COMPUTERIZED MEDICAL RECORDS/PRACTICE MANAGEMENT SOFTWARE: PART II
Co-Chps.: Russell F. Lim, M.D., Steven E. Hyler, M.D.

56 Comprehensive Clinician's Desktop
Waguih Ishak, M.D., Tal Burt, M.D.
This presentation demonstrates how computer technology can be used in the service of the ultimate goal of medicine, which is to alleviate patient suffering. The introduction of computers in the second half of the 20th century has led to the development of tools that can help achieve this goal by optimizing patient care, enhancing psychiatric education, and promoting meaningful research. The Comprehensive Clinician's Desktop will be demonstrated. This application provides an all-in-one tool of charting, reference and communication, reducing the time spent on paperwork and repetitive tasks, and improving diagnostic and management skills in addition to performing billing functions. Participants will learn how to make use of stored data in generating information useful for administrative decision making, meeting educational requirements in training and simplifying managed care demands. An opportunity will be available to learn about the use of computers in education and training, including its promises and limitations. Participants will have the opportunity to participate in a debate over the future of such systems and their benefits and limitations including, but not limited to, confidentiality.

27 An Electronic Medical Record for Psychiatry
Jesse H. Wright, M.D., G. Randolph Schrodt, Jr., M.D., Glen D. Williams, R.N., Thomas E. Hedden, L.C.S.W.

The adaptation of commercially available software for a psychiatric electronic medical record is described and demonstrated. This system is based on Logician™ (produced by Medicalogic®), an electronic medical record widely used in general medical practice. Logician™ had not previously been equipped with modules for recording psychiatric evaluations and treatment records, but this software has several important advantages including a Windows format and the potential to be used in general hospital settings and multidisciplinary clinics. The psychiatric version of Logician™ presented here has been in use in a networked group of outpatient services in Louisville, Kentucky, for over one year. Clinicians and patients have responded very favorably to the introduction of this electronic medical record. Psychiatric records for Logician™, including initial evaluations, treatment session notes, prescription writing, laboratory testing and managed care reports are demonstrated. Results of clinician and patient surveys are also described.

28 Computer-Assisted Service Planning (CASP)
Kemal Sagduyu, M.D.

CASP is a new Windows-based software application created for use by mental health clinicians, MR/DD staff, physicians, or anyone who needs to write plans for patients or clients. CASP helps you from start to finish by providing a structured planning environment, targeting specific problem areas, suggesting treatments, and allowing the staff to develop individualized plans while continuously monitoring the progress. CASP meets all JCAHO and HCFA treatment plan requirements. CASP supports both clinical and nonclinical staff. It helps you to create a treatment plan that fits each individual by offering a variety of suggestions for possible diagnosis, associated problems, probable symptoms and potential treatments, all from a database that has been customized for your program. CASP has a multilevel security access system and a user-controlled, plan-locking system.

2:00 p.m. Sessions

LECTURES 15-18

Days of Creation Session
LECTURE 15
2:00 p.m.-3:30 p.m.
Room 107, Lower Level, Convention Centre
Sherwin B. Nuland, M.D.

Ward Stories: Writing About Medicine
Cht.: Elissa P. Benedek, M.D.
Co-Cht.: Elizabeth C. Druss, M.D.

For patients to be knowledgeable partners with physicians on the journey of their illness, they need at least a basic understanding of the disordered physiology being treated. Lucid, enjoyable narratives of human physiology and pathology written from the personal experiences of physicians who deal with patients every day can contribute much to fulfilling this need. Drawing on 15 years of experience in medical writing for scholarly and general audiences, Sherwin B. Nuland, M.D., author of the prize-winning book How We Die, discusses his methods of writing and his experiences in publishing and publicizing his work. Dr. Nuland is Clinical Professor of Surgery at the Yale University School of Medicine. His book, Doctors: the Biography of Medicine, which told the story of the profession through biographies of 14 of its most prominent practitioners, was published in 1988. His 1994 book, How We Die, a study (Continued on next page)
of the modern way of death, became a bestseller and received the National Book Award. Dr. Nuland's latest book, *The Wisdom of the Body: Discovering the Human Spirit*, a wide-ranging study of history, human biology, ethics and the nature of humanity, was published in 1997. A Fellow of the American Association for the Advancement of Science, Dr. Nuland has received the Person of the Year Award from the National Center for Death Education and the John P. McGovern Medal of the American Osler Society. Dr. Nuland graduated from Yale University School of Medicine and trained in surgery at Yale-New Haven Medical Center.

**THIS SESSION WILL BE AUDIOTAPE**

**LECTURE 16**

2:00 p.m.-3:30 p.m.
Ballroom B, Lower Level, Crowne Plaza

Dr. Alexandra Symonds' Legacy of Advancing Women Psychiatrists and Promoting Women's Mental Health: Sailing Toward the Next Millennium

Chp.: Carol C. Nadelson, M.D.
Co-Chp.: Peter M. Steiner, M.D.

Alexandra Symonds, M.D., co-founder in 1983 of the Association of Women Psychiatrists, was its first president and newsletter editor, as well as a successful dual-career wife and sailor. She pioneered a number of programs and processes to advance professional opportunities for women psychiatrists and proposed new insights into women's unique psychiatric symptoms, syndromes and treatment needs. Leah J. Dickstein, M.D., examines the history of Dr. Symonds' professional contributions and recommends actions to secure equitable opportunities for women psychiatrists in all areas of professional activity. Dr. Dickstein is Professor, Associate Chair for Academic Affairs and Director of the Division of Attitudinal and Behavioral Medicine and Arts in Medicine Program in the Department of Psychiatry and Behavioral Sciences at the University of Louisville School of Medicine. She is also Associate Dean for Faculty and Student Advocacy and Founder and Chair of the Committee of Women Faculty at the school. She is a former vice president of the American Psychiatric Association and current president of the American Association for Social Psychiatry. A member of the Consulting Editorial Board of American Psychiatric Press, Inc., she is the author of numerous scientific papers and the editor of five books. Dr. Dickstein received her medical degree from the University of Louisville and completed her residency in psychiatry at Norton Psychiatric Clinic and Louisville General Hospital in Louisville and Maudsley Hospital in London.

**APA'S Alexandra Symonds Award Winner Distinguished Psychiatrist Lecture Series**

**THIS SESSION WILL BE AUDIOTAPE**

**LECTURE 17**

2:00 p.m.-3:30 p.m.
Ballroom, Convention Floor, Royal York

Charles P. O'Brien, M.D.

The Surprising Efficacy of Treatments for Addictive Disorders
Collaborative Session with the National Institute on Drug Abuse

Chp.: Patricia I. Ordonaca, M.D.
Co-Chp.: Teresa Frausto, M.D.

The high rate of relapse after treatment for addiction has led to the widely held belief among physicians and policy-makers that treatment is ineffective. Charles P. O'Brien, M.D., draws on a conceptualization of addiction as a chronic disorder to discuss data from controlled outcome studies showing that efficacy of treatment for addiction is comparable to that for other mental disorders and other chronic medical disorders. He also reviews modern treatments that use combinations of pharmacologic and behavioral approaches to prevent relapse. Dr. O'Brien is Professor and Vice Chairman of the Department of Psychiatry at the University of Pennsylvania and Chief of the Psychiatry Service at the Veterans Affairs Medical Center in Philadelphia. The author of more than 325 publications in the areas of addictive disorders and biological psychiatry, Dr. O'Brien is a member of the Editorial Boards of *Archives of General Psychiatry* and the *British Journal of Addiction*. He has received the Wikler Prize for excellence in drug abuse research, the MERIT Award and the Pacesetter Research Award from the National Institute on Drug Abuse. A Fellow of the College of Problems of Drug Dependence, he has been elected to the Institute of Medicine of the National Academy of Sciences. Dr. O'Brien received his medical degree and
TUESDAY

LECTURE 18

2:00 p.m.-3:30 p.m.
Dominion Ballroom, Second Floor,
Sheraton Centre

Philip Seeman, M.D.

Schizophrenia, Dopamine Receptors and Antipsychotic Drugs

Chp.: Andrew J. Cutler, M.D.
Co-Chp.: Robert L. Hendren, D.O.

Examination of dopamine pathways provides a useful approach to understanding the symptoms and treatment of schizophrenia and other psychotic disorders. Subtyping of dopamine receptors provides additional information. Philip Seeman, M.D., reviews the actions of antipsychotic drugs on the D2 receptor, examines what these actions reveal about psychotic symptoms and compares the effects of traditional and newer antipsychotic drugs on dopamine pathways. Dr. Seeman is Professor in the Departments of Pharmacology and Psychiatry at the University of Toronto. He also holds the Anne and Max Tanenbaum Chair in Neurosciences at the university. His research on the membrane actions of drugs led to the discovery of the antipsychotic receptor, now renamed the dopamine D2 receptor, and provided the experimental basis for the dopamine hypothesis of schizophrenia. A Fellow of the Royal Society of Canada, Dr. Seeman has received numerous awards, including the Lieber Award from the National Alliance for Research on Schizophrenia and Depression, the Stanley Dean Award of the American College of Psychiatrists, the Tanenbaum Award for Schizophrenia Research from the Canadian Psychiatric Research Foundation, the first Prix Galien Award in North America and the Pasarow Foundation Award in Neuropsychiatry. Dr. Seeman received his medical degree from McGill University in Montreal and his doctorate in life sciences from Rockefeller University in New York City. Frontiers of Science Lecture Series

MEDIA SESSIONS 16-17

MEDIA SESSION 16

2:00 p.m.-5:00 p.m.
Ontario Room, Convention Floor, Royal York

INNOVATIVE TEACHING OF PSYCHOPATHOLOGY

Chp.: Steven E. Hyler, M.D.

29 Paranoia

(23 minutes)

Distributor: University of California Extension Center for Media and Independent Learning
2000 Center Street, 4th Floor
Berkeley, CA 94704

This innovative, thought-provoking visual essay explores one of the most intriguing and characteristic aspects of the American national psyche: our propensity to distrust virtually everything around us. The film examines the forces that influence our every day lives and ponders the extent to which we should, or should not, feel threatened by them. Distrust of authority is a traditional part of the American psyche, but today, people seem more disillusioned than ever with the institutions and values that underpin our society. At the same time, we all accept hundreds of dubious assumptions each day without ever questioning their legitimacy.

A Henri Langlois International Film Festival (Poitiers, France) honoree.

30 Step on a Crack

(29 minutes)

Distributor: Fanlight Productions
47 Halifax Street
Boston, MA 02130

Obsessive-Compulsive Disorder or OCD was once thought to be rare. It is now estimated to affect between 2-4% of the population, nearly five million people in this country alone. In this outstanding new video, six individuals with OCD talk about their feelings of isolation and lack of control and about being misunderstood by families, friends and the community. They also discuss the ways they have come to manage the disorder through medication, psychotherapy and behavioral therapy. Speaking out about the disease has helped them to educate an often skeptical public and empower others to seek help. Step on a Crack will be a valuable resource for patient and staff education, counseling and support groups, community outreach, and for schools of nursing, psychology and social work.
People with Munchausen's Disorder invent illnesses in order to be admitted to a hospital. They repeatedly turn up in emergency rooms, claiming to be in acute distress and falsifying their medical histories. So convincing is their deception that they may even be operated on needlessly. This powerful documentary follows 41-year-old Nina and 26-year-old Simon. Nina has made over 500 hospital visits in her lifetime. Having once suffered a genuine ectopic pregnancy, she has faked many such emergencies and been operated on seven times. While Nina's case is tragic, Simon is an even more complex individual who exhibits a dangerous combination of medical obsessions and habitual lying. He often goes directly from the medical library, where he researches symptoms, to the hospital. Psychiatrist Dr. Ben John admits the medical profession is largely defeated by Munchausen's Disorder. These people divert valuable health resources from the truly sick in their endless drive to gain attention. Psychiatrist Dr. Michael Murphy of Queen Mary's Hospital observes that the typical Munchausen patient has few peer relationships and uses nursing and medical staff for social contact that does not become too intimate.

In the inpatient situation. The use of video technology can provide temporary, safe and creative spaces where these young women can engage in effective dialogue with their captors in the war about weight. Although other patients were initially reluctant to participate, some provided the graphics that effectively illustrate the questions posed. Staff were required to welcome the unexpected and to reveal something of themselves in the scrutiny of Sally and Amanda, turning the tables.

Discusant: Janice Russell, M.D.

MEDIA SESSION 17  2:00 p.m.-5:00 p.m.
Civic Ballroom, Second Floor, Sheraton Centre

FILM AND HEALING: HOPE ARISING FROM DESPAIR

Chp.: Francis G. Lu, M.D.

Contact (150 minutes)

Distributor: Swank Motion Pictures, Inc
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787-4305

Contact tells the story of Ellie Arroway (Jodie Foster), a scientist who has devoted her life to the search for extraterrestrial life (SETL) and finds it. Based on the late Carl Sagan's 1985 novel, Contact originates from the distinguished astronomer's lifelong study of planetary science and the radio search for extraterrestrial intelligence. Early in the film we come to understand Ellie's ambition as poignantly related to despair arising from the early loss of her father, who had encouraged her interest in radio communication. She perseveres against infinite odds in her hope of discovering radio signals of extraterrestrial life, which actually happens one day in the Arizona desert. Their signals provide blueprints for a machine that will transport one person to that world. After fate intervenes, Ellie takes that remarkable journey out to the very edge of the universe where her fondest hope is realized. When she returns to Earth, she (as well as we, the audience) is left to ponder with reverence the magnificence of the universe.

REVIEW OF PSYCHIATRY: PART III
2:00 p.m.-5:30 p.m.
Room 105, Lower Level, Convention Centre

PSYCHOBIOLOGY OF PERSONALITY DISORDERS

Chp.: Kenneth R. Silk, M.D.

12 Genetics and Psychobiology of the Seven-Factor Model of Personality
C. Robert Cloninger, M.D.
13 Psychopharmacologic Management of Personality Disorders: An Outcome-Focused Model
Paul S. Links, M.D.

14 The Significance of Biological Research for a Biopsychosocial Model of Personality Disorders
Joel F. Paris, M.D.

15 New Strategies for Psychobiologic Investigation
Larry J. Siever, M.D.

SYMPOSIA 24-51

SYMPOSIUM 24 2:00 p.m.-5:00 p.m.
Room 205A, Street Level, Convention Centre
GENDER ISSUES IN CANCER TREATMENT

Chp.: Debra L. Fertig, M.D.
Co-Chp.: John R. Peteet, M.D.

A Adolescents with Cancer: Gender and Intimacy
   Daniel Shapiro, Ph.D., Joan Haase, Ph.D.

B Counseling Men with Testicular and Prostate Cancer
   Patricia P. Rieker, Ph.D.

C Sequeleae of Treatment in Women's Cancers
   Debra L. Fertig, M.D.

D Group Therapy That Narrows the Gender Gap
   Genevieve A. Mason, M.S.W.

E Gender Aspects of Marital Strain in Oncology
   John R. Peteet, M.D.

Discussant: Jimmie C. Holland, M.D.
THIS SESSION WILL BE AUDIOTAPEO.

SYMPOSIUM 25 2:00 p.m.-5:00 p.m.
Room 205B, Street Level, Convention Centre
CONUNDRUMS OF COMORBIDITY
Collaborative Session with the National Institute on Drug Abuse

Chp.: Frances R. Levin, M.D.
Co-Chp.: David M. McDowell, M.D.

A Treatment of PTSD and Substance Use Disorders
   Kathleen T. Brady, M.D.

B Evaluation of Depression in Substance Abusers
   David M. McDowell, M.D., Frances R. Levin, M.D.,
   Edward V. Nunes, M.D., Angela Serracini, Ph.D.,
   Herbert D. Kleber, M.D.

C Diagnosis and Treatment of Substance Abusers with ADHD
   Frances R. Levin, M.D., David M. McDowell, M.D.,
   Suzette Evans, Ph.D., Herbert D. Kleber, M.D.,
   Daniel J. Brooks, M.A.

D Overcoming Obstacles for Treating Dual Disorders
   Andrew L. Shaner, M.D., Lisa J. Roberts, M.A.,
   Thad Eckman, Ph.D., John W. Tsuang, M.D.,
   Andrew P. Ho, M.D.

E Comorbidity and Outcomes in Substance Abusers
   John S. Cacciola, Ph.D., Arthur I. Alterman, Ph.D.,
   Megan J. Rutherford, Ph.D., James R. McKay, Ph.D.

Discussant: Edward V. Nunes, M.D.
THIS SESSION WILL BE AUDIOTAPEOE.

SYMPOSIUM 26 2:00 p.m.-5:00 p.m.
Room 205C, Street Level, Convention Centre
CONTROVERSY IN CORRECTIONAL PSYCHIATRY

Chp.: James E. Dillon, M.D.

A Mental Illness and Delinquency
   Norman E. Alessi, M.D., James E. Dillon, M.D.,
   Euphemie A. Brown, M.D.

B Implications of Mandatory Statutes
   Peter Ash, M.D.

C Punk Prisons and Juvenile Justice Reform
   Lee H. Rome, M.D.

D Psychiatry, Predators and the Law
   Melvin Guyer, Ph.D., J.D.

E Implications of Sexual Predator Laws
   Lee H. Rome, M.D.

F Treatment of Sexual Predators After the Supreme Court Ruling on Kansas Versus Hendricks
   Gene G. Abel, M.D.

G Criminalization of the Mentally Ill: Is It Such a Bad Idea?
   James E. Dillon, M.D.

Discussant: Edward V. Nunes, M.D.
THIS SESSION WILL BE AUDIOTAPEOE.

SYMPOSIUM 27 2:00 p.m.-5:00 p.m.
Room 205D, Street Level, Convention Centre
EMERGING TRENDS IN THE TREATMENT OF DEMENTIA
Chp.: Gary J. Kennedy, M.D.

A Horizon Drugs and the Concept of Excess Disability
   Gary J. Kennedy, M.D.

B Estrogen Replacement Therapy for Dementia:
   Prophylaxis or Repair?
   Gary J. Kennedy, M.D.

(Continued on next page)
C Cognitive Enhancers in the Clinic and on the Horizon
Trey Sunderland, M.D.

D Antipsychotics in the Treatment of Dementia Complicated by Psychosis
Davangere P. Devanand, M.D., Kristin Michaels, M.A., Harold A. Sackeim, Ph.D., Karen Marler, M.D., Richard P. Mayeux, M.D.

E Comorbidity of Depression in Dementia
Patricia Parmelee, Ph.D.

Discussant: Hugh C. Hendrie, M.B.

SYMPOSIUM 28 2:00 p.m.-5:00 p.m.
Room 206A, Street Level, Convention Centre
THE CHANGING ROLE OF PSYCHIATRISTS IN THE HOSPITAL
APA Consultation Service Board
Chp.: Robert K. Schreter, M.D.
Co-Chp.: Steven S. Sharfstein, M.D.

A The Changing Role of Clinicians in Hospitals
Benjamin Liptzin, M.D.

B Employee to Partner: Hospital Psychiatrist in Transition
Steven S. Sharfstein, M.D.

C The Psychiatrist As Employer and Academician
Sheldon I. Miller, M.D.

D The Psychiatrist As Employer or Organization Man
Peter J. Panzarino, Jr., M.D.

E The Psychiatrist As Teacher
Robert Michels, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 29 2:00 p.m.-5:00 p.m.
Room 206B, Street Level, Convention Centre
BIOLOGICAL RHYTHMS: NEW FRONTIER FOR PSYCHIATRY
Chp.: Dan A. Oren, M.D.

A Seasonality of Mood and Related Symptoms
Anthony J. Levitt, M.D., Michael Boyle, M.S.W.

B Circadian Alterations in Premenstrual Dysphoric Disorder
Barbara L. Parry, M.D., Richard L. Hauger, M.D., J. Christian Gillin, M.D., Jeffrey Elliott, Ph.D.

C Serotonin and SAD: Implications for Treatment
Raymond W. Lam, M.D.

D Shifting Circadian Phase Using Light and Melatonin
Alfred J. Lewy, M.D., Neil L. Cutler, B.A., Robert L. Sack, M.D.

E How Does Light Regulate Body and Brain?
Dan A. Oren, M.D., Robert M. Berman, M.D., Amit Anand, M.D., Angela C. Cappiello, M.D., Dennis S. Charney, M.D.

Discussant: Dennis S. Charney, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 30 2:00 p.m.-5:00 p.m.
Room 206C, Street Level, Convention Centre
FAMILY VIOLENCE AND PSYCHIATRY: CANADA AND THE UNITED STATES
Joint Session with the United States Department of Justice and the APA Committee on Family Violence and Sexual Abuse
Chp.: Sandra J. Kaplan, M.D.
Co-Chp.: Edward K. Rynearson, M.D.

A Canadian Law: Psychiatry and Family Violence
Professor Alison Harvison Young

B United States Legal Reforms on Child and Family Violence
Howard A. Davison, J.D.

C Child Abuse: A Review of Canadian Studies
David A. Wolfe, Ph.D.

D United States Treatment Outcome Studies
William M. Friedrich, Ph.D.

E Funding for the Family Violence Service in the United States: Office for Crime Victims
Carolyn A. Hightower, Joye Whatley

F Funding for the Violence Service in Canada: CAVEAT (Canadians Against Violence Everywhere Advocating Its Termination)
Priscilla de Villiers

Discussant: Sandra J. Kaplan, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 31 2:00 p.m.-5:00 p.m.
Room 206D, Street Level, Convention Centre
MODELS OF MANAGED CARE IN THE PUBLIC SECTOR
APA Consortium on Organized Service Systems
Chp.: Billy E. Jones, M.D.
Co-Chp.: Karen G. Drexler, M.D.
A Maryland’s Public Mental Health System
Billy E. Jones, M.D., Brian M. Hepburn, M.D.,
Karen A. Oliver, Ph.D., Marilyn L. Martin, M.D.

B SALUD! A Hybrid Model of Managed Care for
New Mexico Mental Health
James N. Jacobson, M.D., M.B.A.

C Carve-Outs for Behavioral Health Care: Trend or
Passe?
C. Richard Orndoff, M.Ed., Henry T. Harbin, M.D.

D Psychiatrists As Managers in Public Sector
Partnerships
Ivan C.A. Walks, M.D.

E Models of Managed Care in the Public Sector
Kurt A. Patton, M.S., John M. Oldham, M.D.

Discussants: Altha J. Stewart, M.D.,
Colette Croze, M.S.W.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 33 2:00 p.m.-5:00 p.m.
Room 206F, Street Level, Convention Centre

COMPLEXITY OF BIPOLAR DISORDER

Chp.: William B. Lawson, M.D.

A Toward an Animal Model of Bipolar Disorder
Aimee R. Mayeda, M.D., John R. Hofstetter, Ph.D.,
John I. Nurnberger, Jr., M.D.

B Recent Genetic Findings in Bipolar Disorder
John I. Nurnberger, Jr., M.D., J. Raymond
DePaula, Jr., M.D., Mary C. Blehar, Ph.D., Elliott S.
Gershon, M.D., Theodore Reich, M.D.

C Ethnic Issues in Bipolar Disorder
William B. Lawson, M.D.

D The New Uses for Valproic Acid
Samuel O. Okpaku, M.D., Elizabeth Spivey, R.N.

Discussant: Charles L. Bowden, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 34 2:00 p.m.-5:00 p.m.
Room 103A, Lower Level, Convention Centre

AFFECTIVE DYSFUNCTIONS IN SCHIZOPHRENIA
Joint Session with the World Psychiatric Association
and the German Society of Psychiatry,
Psychotherapy and Nervous Diseases

Chp.: Professor Dr. Wolfgang Gaebel
Co-Chp.: Wolfgang Woelwer, Ph.D.

A Affective Dysfunctions: Concepts and
Assessment
Wolfgang Woelwer, Ph.D., Professor Dr. Wolfgang
Gaebel

B Affective and Neuromotor Deficits in
Schizophrenia: What’s What?
Robert H. Dworkin, Ph.D., Xavier F. Amador, Ph.D.,
Scott C. Clark, M.D., Jack M. Gorman, M.D.

C Brain Mechanisms of Affective and Social
Behaviors
John F.W. Deakin

D Brain Mechanisms of Affective Disorder in
Schizophrenia
Peter F. Liddle, M.D.

E Affective Dysfunctions in Schizophrenia:
Treatment Strategies
Professor Dr. Hans D. Brenner, Bettina Hodel, Ph.D.

Discussant: Alan S. Bellack, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 35 2:00 p.m.-5:00 p.m.
Room 104A, Lower Level, Convention Centre

DEALING WITH PSYCHOPATHY: THE UNITED STATES SUPREME COURT'S KANSAS VS. HENDRICKS DECISION AND BEYOND

Chp.: William M. Tucker, M.D.

A Don Juan: Myths, Milestones and Management of the Paraphilias
John M.W. Bradford, M.B.

B Psychopathy As a Risk Factor for Violence
Robert D. Hare, Ph.D.

C The Aggressive Patient: Beyond Denial
Gary J. Maier, M.D.

D Mad Versus Bad Revisited: Managing Predatory Behavior
William M. Tucker, M.D.

Discussant: Jeffrey L. Geller, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 36 2:00 p.m.-5:00 p.m.
Room 104B, Lower Level, Convention Centre

RECENT FINDINGS IN SOCIAL PHOBIA

Chp.: Michael R. Liebowitz, M.D.
Co-Chp.: Murray B. Stein, M.D.

A Diagnostic and Assessment Issues
Richard G. Heimberg, Ph.D.

B Epidemiology, Morbidity, Comorbidity and Disability
Murray B. Stein, M.D.

C Recent Psychological Findings in Social Phobia
Franklin R. Schneier, M.D.

D Familial and Temperamental Factors in Social Phobia
Abby J. Fyer, M.D.

E Treatment of Social Phobia
Michael R. Liebowitz, M.D., Richard G. Heimberg, Ph.D., Franklin R. Schneier, M.D.

F The Offensive Type of Social Phobia: Cross-Cultural Perspectives
Si-Hyung Lee, M.D., Kang-Seob Oh
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 37 2:00 p.m.-5:00 p.m.
Room 104D, Lower Level, Convention Centre

PSYCHOTHERAPEUTIC ISSUES IN PSYCHIATRIC CARE
Joint Session with the American Psychoanalytic Association

Chp.: Miriam F. Tasini, M.D.

A Psychotherapeutic Issues in Medication Management
Allan Tasman, M.D.

B Psychodynamic Psychotherapy of Panic Disorder
Barbara L. Mirold, M.D., Fredric N. Busch, M.D.

C Psychotherapy in Managing the Medically Ill
David Spiegel, M.D.

D Psychotherapeutic Modalities in the Treatment of PTSD
Melvin R. Lansky, M.D.

E Dynamic Therapy in the Treatment of Depression
Glen O. Gabbard, M.D.

SYMPOSIUM 38 2:00 p.m.-5:00 p.m.
Caledon Room, Lobby Level, Crowne Plaza

PSYCHOSOCIAL INTERVENTIONS FOR DRUG ABUSE
Collaborative Session with the National Institute on Drug Abuse

Chp.: Stephen T. Higgins, Ph.D.
Co-Chp.: Thomas McLellan, Ph.D.

A Contingency-Management Therapy with Drug Abusers
Stephen T. Higgins, Ph.D.

B Therapy for Borderline Personality and Drug Abuse
Marsha M. Linehan, Ph.D.

C Efficacy of Psychosocial Services for Drug Abuse
Thomas McLellan, Ph.D.

D Behavioral Couples Therapy for Substance Abuse
Timothy J. O'Farrell, Ph.D.

E Structured Psychotherapies for Drug Abuse
Bruce J. Rounsaville, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 39  2:00 p.m.-5:00 p.m.  
Kingsway Room, Lobby Level, Crowne Plaza  
HARVARD PSYCHOPHARMACOLOGY EXPERT SYSTEMS PROJECT  
Chp.: David N. Osser, M.D.  
Co-Chp.: Robert D. Patterson, M.D.  
A  Inventing an Information Support System  
Robert D. Patterson, M.D.  
B  Psychopharmacology of Depression Expert System  
David N. Osser, M.D.  
C  Psychopharmacology of Psychosis Expert System  
Carlos A. Zarate, Jr., M.D.  
D  Anxiety in Patients with Chemical Abuse and/or Dependence  
Rogelio D. Bayog, M.D.  
E  Psychopharmacological Algorithms: Mental Retardation  
Edwin J. Mikkelsen, M.D., Leo McKenna, R.P.H.  
Discussant: Miles F. Shore, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 41  2:00 p.m.-5:00 p.m.  
Niagara Room, Lower Level, Crowne Plaza  
PRACTICING EVIDENCE-BASED PSYCHIATRY: MDD  
Chp.: John S. McIntyre, M.D.  
Co-Chp.: Harold Alan Pincus, M.D.  
A  Major Depressive Disorder: Using Psychiatric Measures in Clinical Care  
Kimberly A. Yonkers, M.D., Jacqueline Samson, Ph.D., Laurie McQueen, M.S.W.  
B  Clinical Practice Guidelines for Treatment  
T. Byram Karasu, M.D., Deborah A. Zarin, M.D., Leslie Seigle  
C  What's Really Going on in the Treatment of MDD?  
Mark Olton, M.D., Harold Alan Pincus, M.D., Deborah A. Zarin, M.D., Julie L. Johnson, M.A.  
Discussant: A. John Rush, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 42  2:00 p.m.-5:00 p.m.  
Ontario Room, Lower Level, Crowne Plaza  
NEW INSIGHTS ON BIPOLAR DISORDER  
Chp.: Bruce M. Cohen, M.D.  
A  Bipolar Mood Disorder: Overview of Illness and Management  
Gary S. Sachs, M.D.  
B  Novel Treatment Strategies for Refractory Bipolar Disorder  
Andrew L. Stoll, M.D.  
C  Child and Adolescent Bipolar Disorder: A Review  
Ronald J. Steingard, M.D.  
D  MRS Studies of Brain Chemistry in Bipolar Disorder  
Perry F. Renshaw, M.D., Deborah Yurgelun-Todd, Ph.D., Constance M. Moore, Ph.D., Suzanne Babb, M.S., Bruce M. Cohen, M.D.  
Discussant: Bruce M. Cohen, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

SYMPOSIUM 43  2:00 p.m.-5:00 p.m.  
Alberta Room, Mezzanine, Royal York  
ETIOLOGY OF EATING DISORDERS: HIGH-RISK GROUPS  
Chp.: Gary M. Rodin, M.D.  
A  Epidemiologic Studies of Eating Disorders  
Paul E. Garfinkel, M.D.  
B  Eating Disorders and Sexual Abuse: What is the Link?  
Janet M. deGroot, M.D.  
Discussants: Richard J. Frances, M.D., Stephen L. Dilts, M.D.  
THIS SESSION WILL BE AUDIOTAPED.  

(Continued on next page)
TUESDAY

C Compulsive Exercising As a Risk for Eating Disorders
Caroline A. Davis, Ph.D.

D The Relationship Between Obesity and Eating Disorders
Allan S. Kaplan, M.D., Donna Ciliska, Ph.D.

E Eating Disorders in Gay Males: Double Stigma
Arnold E. Andersen, M.D.

F Eating Disorders and Diabetes: Iatrogenic?
Gary M. Rodin, M.D., Marion P. Olmsted, Ph.D.,
Anne Rydall, M.S.C., Shari I. Maharaj, M.A.,
Patricia Colton, M.D., Jennifer M. Jones, B.A.,
Denis Daneman, M.B.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 44 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine, Royal York

DEVASTATING EFFECTS OF CHILDHOOD ABUSE ON MIND AND BRAIN
Chp.: J. Douglas Bremner, M.D.

A Clinical Presentation of Dissociative Disorders Related to Abuse
Dorothy O. Lewis, M.D.

B Effects of Childhood Abuse on Psychopathology and Brain Anatomy
J. Douglas Bremner, M.D.

C The Neuro-Anthropology of Child Abuse and Neglect: Use and Disuse of Dependent Neurodevelopment
Bruce D. Perry, M.D.

D Stressor Reactivity in Abused and Nonabused Girls
Frank W. Putnam, Jr., M.D., Penelope Trickett, Ph.D.,
Jennie Noll, Ph.D.

E Childhood and Other Traumas in the Etiology of Depression
Carolyn M. Mazure, Ph.D., J. Douglas Bremner, M.D.

SYMPOSIUM 45 2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine, Royal York

NEUROANATOMY OF NORMAL AND PATHOLOGICAL EMOTION
Chp.: Richard D. Lane, M.D.

A Neural Correlates of Normal Human Emotion
Richard D. Lane, M.D., Eric M. Reiman, M.D.,
Margaret M. Bradley, Ph.D., Peter J. Lang, Ph.D.,
Raymond J. Dolan, M.D.

B Mood Lateralization: Transcranial Magnetic Stimulation
Mark S. George, M.D., Ziad H. Nahas, M.D.,
Wendol A. Williams, M.D., Andrew M. Speer, M.D.,
Benjamin D. Greenberg, M.D., Robert M. Post, M.D.

C Anatomical Correlates of Familial Mood Disorders
Wayne C. Drevets, M.D.

D Functional Neuroimaging Studies in Anxiety Disorders
Scott L. Rauch, M.D., Paul J. Whalen, Ph.D.,
Lisa M. Shin, Ph.D.

Discussant: Eric M. Reiman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 46 2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine, Royal York

RECOGNITION, MANAGEMENT AND REPORTING OF DRUG-INDUCED DISEASE: A CLINICAL PHARMACOLOGIC APPROACH FOR PSYCHIATRISTS
Chp.: Stephen A. Goldman, M.D.

A Premarketing Drug Safety Evaluation
Thomas P. Laughren, M.D.

B Drug-Induced Disease: Pharmacokinetic and Pharmacodynamic Consideration
John D. Balian, M.D.

C Clinical Assessment, Work-Up and Reporting of Adverse Drug Events
Stephen A. Goldman, M.D.

Discussant: Jack M. Gorman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 47 2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine, Royal York

SCHIZOPHRENIA: A NEURODEVELOPMENTAL PERSPECTIVE
Chp.: Alan S. Brown, M.D.
Co-Chp.: Ezra S. Susser, M.D.

A Prenatal Rubella and Adult Schizophrenia
Alan S. Brown, M.D.

B Neuroendocrine and Behavioral Change in Schizotypal Adolescents
Elaine F. Walker, Ph.D.

C Genes, Prenatal Factors and IQ of Offspring at High Risk for Psychosis
Jill M. Goldstein, Ph.D., Stephen L. Buka, Sc.D.,
Larry J. Seidman, Ph.D., Hang Lee, Ph.D.,
Gwen L. Zomberg, M.D., Lisa Denny, B.A., Ming T. Tsuang, M.D.
TUESDAY

A Rat Model of Schizophrenia: Neonatal Hippocampal Damage
Barbara K. Lipska, Ph.D.

Low Specificity for Developmental Precursors of Psychosis
Peter B. Jones, Ph.D.

Discussant: Ezra S. Susser, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 48 2:00 p.m.-5:00 p.m.
Tudor Room 7, Mezzanine, Royal York

MANAGEMENT OF SCHIZOPHRENIA WITH COMORBID DISORDERS
Chp.: Michael Y. Hwang, M.D.
Co-Chp.: Lewis A. Opler, M.D.

A Management of Comorbid Depression in Schizophrenia
Samuel G. Siris, M.D.

B Management of Obsessive-Compulsive Patients with Schizophrenia
Michael Y. Hwang, M.D., Miklos F. Losonczy, M.D.,
Edward Steinberg, M.D.

C Violence in Schizophrenia
Leslie L. Citrome, M.D., Jan Volavka, M.D.

D Management of Cognitive Impairment in Schizophrenia
Dilip V. Jeste, M.D., Barton W. Palmer, Ph.D.,
Javier D. Evans, Ph.D., Julie A. Gladso, Ph.D.,
M. Jackueyn Harris, M.D., Robert K. Heaton, Ph.D.

Discussants: Lewis A. Opler, M.D., Eric Hollander, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 49 2:00 p.m.-5:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

SINGLE PAYER OR COMPETITION? CANADIAN AND UNITED STATES VIEWS
Chp.: James L. Pendleton, M.D.

A Canada's Single Payer System
Arthur L. Lesser, M.D.

B Why a Private Alternative Is Essential
Joseph Berger, M.B.

C Advantages of a Single Payer System
Captane P. Thomson, M.D.

D Managed Care Versus Medical Savings Accounts: Fact and Fiction
Frederick K. Goodwin, M.D.

Discussant: Rodrigo A. Muñoz, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 50 2:00 p.m.-5:00 p.m.
Windsor Room, Mezzanine, Sheraton Centre

PHARMACOLOGICAL TREATMENTS IN SCHIZOPHRENIA AND THEIR EFFECT ON COGNITIVE FUNCTION
Chp.: Ileana Berman, M.D.

A Cognition and Atypical Antipsychotics in Schizophrenia
Richard S.E. Keefe, Ph.D., Susan G. Silva, Ph.D.,
Diana O. Perkins, M.D., Jeffrey A. Lieberman, M.D.

B Effects of Clozapine on Cognition in Schizophrenia
Larry J. Seidman, Ph.D., William S. Stone, Ph.D.,
Anthony Kalinowski, Ph.D., Win Sachs, Ph.D.,
Joseph J. Schildkraut, M.D., Alan I. Green, M.D.

C Effects of Risperidone on Cognitive Function in Schizophrenia
Ileana Berman, M.D., Demetra Pappas, B.S.,
Charu Patel, M.D., Howard Chang, M.D.,
Donald C. Goff, M.D.

D Effects of Glutamatergic Agents on Cognitive Function
Donald C. Goff, M.D., Ileana Berman, M.D.,
Thomas Posever, M.D.

Discussant: Philip D. Harvey, Ph.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 51 2:00 p.m.-5:00 p.m.
City Hall Room, Second Floor, Sheraton Centre

EARLY DETECTION AND THE TREATMENT OF FIRST PSYCHOSIS
Chp.: Thomas H. McGlashan, M.D.

A The TIPS Project: An International Multicenter Site for Early Detection
Per Vaglum, M.D., Thomas H. McGlashan, M.D.,
Erik Simonsen, M.D., Jan O. Johannessen, M.D.,
Stein Opjordsmoen, M.D., Svein Friis, M.D.

B Early Detection in the Experimental Sector
Jan O. Johannessen, M.D., Marthe Homeland, M.D.,
Gerd R. Bloch-Thorsen, M.D.,
Tor K. Larsen, M.D., Cato A. Guldberg, M.D.,
Sigurd Mardal, Ph.D.

C TIPS: The Norwegian Comparison Site, Ulleval Hospital
Ingrid Melle, M.D., Svein Friis, M.D., Eva Sortland, M.D.,
Stein Opjordsmoen, M.D.,
Emily Ellefsen, M.D., Kjersti S. Tvete
(Continued on next page)
TUESDAY

D  TIPS: The Danish Comparison Site, Roskilde County, Denmark
Erik Simonsen, M.D., Ulrik Haahr, M.D., Anne Dahl, M.D., Lis Olsen, M.D.

E  Duration of Untreated Psychosis: Can It Be Reduced?
Tor K. Larsen, M.D., Cato A. Guldberg, M.D., Kjetil Hustoft, M.D., Svein Aspoy, R.N., Marthe Homeland, M.D., Knut Gabrielsen, R.N., Jan O. Johannessen, M.D.

F  Family Intervention in Prodromal and Early Psychosis
William R. McFarlane, M.D.

Discussant: Jeffrey A. Lieberman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

3:00 p.m. Session

NEW RESEARCH

POSTER SESSION 8
3:00 p.m.-5:00 p.m.
Room 106, Lower Level, Convention Centre
GERIATRIC, BIOLOGICAL, ADDICTION, AND CROSS-CULTURAL AND MINORITY PSYCHIATRY; COGNITIVE, SEXUAL AND GENDER DISORDERS; BRAIN IMAGING; AIDS; GENETICS; NEUROBIOLOGY; NEUROPSYCHIATRY; AND VIOLENCE

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 35-41

INDUSTRY-SUPPORTED SYMPOSIUM 35
7:00 p.m.-10:00 p.m.
Auditorium, Lower Level, Convention Centre
PHARMACOTHERAPY COMBINATION STRATEGIES IN CLINICAL PRACTICE
Supported by Janssen Pharmaceutica and Research Foundation

Chp.: Philip G. Janicak, M.D.
Co-Chp.: Jan A. Fawcett, M.D.

A  Skillful Polypharmacy Is the Current Practice
Devdutt V. Nayak, M.D.

B  Clinical Strategies in Intractable Depression
Jan A. Fawcett, M.D.

C  Rational Copharmacy for Bipolar Disorder
Philip G. Janicak, M.D.

D  Copharmacy in Treatment-Resistant Anxiety States
Michael R. Liebowitz, M.D.

E  Treatment of Drug-Refractory Schizophrenia
Sidney Fein, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 36
7:00 p.m.-10:00 p.m.
Hall F, 800 Level, Convention Centre
HOT TOPICS IN ALZHEIMER'S DISEASE
Supported by Bayer Pharmaceuticals

Chp.: Lon S. Schneider, M.D.
Co-Chp.: Gary W. Small, M.D.

A  Apolipoprotein E-ß and Alzheimer's Disease: Search for Truth
Kathleen Welsh-Bohmer, Ph.D., Bonita W. Wyse, Ph.D., David C. Steffens, M.D., Joann Ischanz, Ph.D., Maria C. Norton, Michael J. Helms, M.A., John C.S. Breitner, M.D.

B  Diagnostic Testing: Benefits or Just Costs?
Gary W. Small, M.D.

C  Prevention of Alzheimer's Disease: Non-Steroid, Anti-Inflammatory Agents, Estrogens and H² Blockers
John C.S. Breitner, M.D.

D  Antioxidants in Selegiline: Are They Ready for the Clinic?
Pierre N. Tariot, M.D.

E  Cholinesterase Inhibitors: Greater Therapeutic Possibilities?
Martin R. Farlow, M.D., Debmoy K. Lahiri, Ph.D., Anne M. Hake, M.D.

Discussant: Lon S. Schneider, M.D.
INDUSTRY-SUPPORTED SYMPOSIUM 37
7:00 p.m.-10:00 p.m.
Hall G, 800 Level, Convention Centre

UPDATE ON DIAGNOSIS: PATHOPHYSIOLOGY AND TREATMENT OF PRIMARY HEADACHE DISORDERS FOR THE PRACTICING PSYCHIATRIST
Supported by Merck U.S. Human Health

Chp.: Fred D. Sheftell, M.D.
Co-Chp.: Alan M. Rapoport, M.D.

A Epidemiology and Comorbidity of Primary Headache Disorders
Richard B. Lipton, M.D.

B The Diagnosis and Classification of Primary Headache Disorders
Alan M. Rapoport, M.D.

C Pathophysiology of Primary Headache Disorders
Ninan T. Mathew, M.D.

D Pharmacologic Treatment of Primary Headache Disorders
Joel Saper, M.D.

E Menstrual and Menopausal Migraine
Ivy Fettes, M.D.

F Behavioral and Psychophysiological Approaches to Primary Headache Disorders
Steven M. Baskin, Ph.D.

INDUSTRY-SUPPORTED SYMPOSIUM 38
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

EXPLORING THE COURSE OF SCHIZOPHRENIA
Supported by Pfizer Inc.

Chp.: Daniel E. Casey, M.D.

A Rapidly Controlling Acute Psychotic Symptoms with Antipsychotic Drugs
William C. Wirshing, M.D.

B Relapse Prevention
John M. Kane, M.D.

C Long-Term Studies in Schizophrenia: Improving Functional Outcomes
Mihaly Arato, M.D.

D Assessment and Treatment of Depression in Schizophrenia
Donald E. Addington, M.D.

E Adverse Effects Profile of New Antipsychotic Agents
Daniel E. Casey, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 39
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

CLINICAL CHALLENGES IN THE TREATMENT OF DEPRESSION SUBTYPES
Supported by Solvay Pharmaceuticals, Inc. and Pharmacia & Upjohn Company, Inc.

Chp.: Maurizio Fava, M.D.

A Minor and Subsyndromal Depression and Their Treatment
Mark H. Rapaport, M.D., Lewis L. Judd, M.D.

B Dysthymic Disorder
David L. Dunner, M.D.

C Anxious Depression: Treatment Approaches
Maurizio Fava, M.D.

D Depression with Alcohol and/or Drug Abuse
Patrick J. McGrath, M.D., Edward V. Nunes, M.D., Frederic M. Quitkin, M.D.

E Psychotic Depression
Barbara Hochstrasser, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 40
7:00 p.m.-10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

RECENT ADVANCES IN PSYCHOPHARMACOLOGY
Joint Session with the American Society of Clinical Psychopharmacology, Inc.
Supported by Abbott Laboratories

Chp.: J. Craig Nelson, M.D.

A New Treatments for Schizophrenia
Carol A. Tamminga, M.D.

B Anticonvulsants in Bipolar Disorder
Joseph R. Calabrese, M.D.

C Treatment of Chronic Depression
James H. Kocsis, M.D.

D Current Treatments for Eating Disorders
B. Timothy Walsh, M.D.

E Advances in Geriatric Psychiatry
J. Craig Nelson, M.D.
TUESDAY

INDUSTRY-SUPPORTED SYMPOSIUM 41
7:00 p.m.-10:00 p.m.
Frontenac Ballroom, Street Level, Westin Harbour Castle

TREATING THE DIFFICULT-TO-TREAT DEPRESSED PATIENT
Supported by Forest Laboratories, Inc.

Chp.: Steven P. Roose, M.D.

A When the Depressed Patient Is Not Responding
Steven P. Roose, M.D.

B Antidepressant Use in Patients with Heart Disease
Alexander H. Glassman, M.D., Peter A. Shapiro, M.D.,
Steven P. Roose, M.D.

C Treatment of Depression with Comorbid
Personality Disorders
Glen O. Gabbard, M.D.

D Estrogens and Progestins: Do They Cause or Treat
Mood Disorders?
Kimberly A. Yonkers, M.D., Karen Bradshaw, M.D.

E Treatment of Depressed Patients with Cognitive
Impairment
Carl G. Gottfries, Ph.D.

MEDIA SESSIONS 18-19

MEDIA SESSION 18 7:00 p.m.-10:00 p.m.
Ontario Room, Convention Floor, Royal York

VIOLENCE AGAINST WOMEN

Chp.: Keith Cheng, M.D.

34 Responses in Music to Violence Against Women
Distributor: Keith Cheng, M.D.
Adolescent Psychiatry
Emanuel Hospital
3001 North Gantenbein Avenue
Portland, OR 97201-3011

This media presentation is composed of 10 songs that
depict women's responses to the subject of women as
victims of violence. Eight songs will be presented using
compact discs accompanied by 35mm slides of
album cover art, and two songs will be presented on
videotape. Some common themes in these songs are:
1) feeling helpless and passive; 2) fighting violence
with violence; 3) victimization by society; and 4) an
advocacy of self-defense. All 10 songs were written
by women and include a variety of views like the self-
depicting experiences of victimization as a bystander
while another woman is being harmed. Songs have
been collected from rap, popular and alternative
music genres. Artists include Tori Amos, Bikini Kill, Tracy
Chapman, Dione Farris, Hole, Joan Jett, Sara
McLachlan, Heather Nova, Queen Latifah and Tribe 8.
Some songs graphically describe violent acts or
contain adult language.

Discussant: Cynthia R. Pfeffer, M.D.

35 Packing Heat
(50 minutes)
Distributor: National Film Board of Canada
P.O. Box 6100 Station Centre Ville
Montreal, PQ, Canada H3C 3H5

In a culture of fear where women are assaulted by
images of themselves as victims, the idea of picking up
a gun and getting even is tempting. Women who
carry firearms don't fit stereotypes: they can be soft-
spoken liberals, doctoral students, or nurses. They see
the right to pack a gun as an issue of women's em-
powerment; many call themselves feminists. Packing
Heat profiles women of this emerging gun culture, from
self-styled guru Paxton Quigley to a University of
Toronto psychology professor who spends her week-
ends at the gun club. This video also features self-
defense advocates and anti-gun feminists who say
that security doesn't come from the barrel of a gun,
and that weapons makers are profiting from fear.
Most of the women featured in Packing Heat say they
feel safer armed. But with guns far more likely to kill a
child than an intruder, is that a sense of safety or
illusion? This lively documentary looks at why women
want to carry firearms, and at the ethical and
practical implications of a gun in every purse.

MEDIA SESSION 19 7:00 p.m.-10:00 p.m.
Civic Ballroom, Second Floor, Sheraton Centre

SUBSTANCE ABUSE IN YOUTH: A BRITISH PERSPECTIVE
Collaborative Session with the National Institute on
Drug Abuse

Chp.: Timothy P. Condon, Ph.D.

36 Trainspotting
(93 minutes)
Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787-4305

Based on a cult novel by Scottish author Irvine Welsh,
Trainspotting is a riveting character study of five junkies
who drift in and out of an uncharmed circle of losers,
liars and thieves in a rundown English suburb. Directed
by Danny Boyle (Shallow Grave) and featuring Jonny
Lee Miller (Hackers), this emotional drama of betrayal
and friendship is also a humorous tale of morality.
SYMPOSIUM 52  7:00 p.m.-10:00 p.m.
Room 205B, Street Level, Convention Centre

A WORLDWIDE CHALLENGE: WORLD PSYCHIATRIC ASSOCIATION'S RESPONSES
Chp.: Roger M. Montenegro, M.D.

A World Psychiatric Association Educational Programs in the Czech Republic: A Model
Jiri Raboch, M.D.

B World Psychiatric Association Educational Programs on Teaching and Learning About Schizophrenia
Driss Moussaoui, M.D.

C A Worldwide Challenge: Education Efforts by the World Psychiatric Association
Pedro Ruiz, M.D.

D International Guidelines for Diagnostic Assessment
Juan E. Mezzich, M.D.

E ICD-10 for Psychiatrists and Primary Care Physicians
Juan J. Lopez-Ibor, Jr., Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 53  7:00 p.m.-10:00 p.m.
Room 205C, Street Level, Convention Centre

CULTURE AND ETHNICITY: AN ARAB PERSPECTIVE
Joint Session with the Arab-American Psychiatric Association
Chp.: Ossama T. Osman, M.D.
Co-Chp.: Abdel A. Salama, M.D.

A Ethnic and Cultural Influence in the Psychiatric Diagnosis
Ossama T. Osman, M.D.

B Group Therapy: An Islamic Approach
Osama M. Al-Radi, M.D.

C Ethnicity and Psychopharmacology
Ahmed M.F. Okasha, M.D.

D Ethnicity and Transcultural Aspects of ECT
Tarek A. Okasha, M.D.

E Educating Trainees to Care for Persons of Other Cultures
Earl L. Loschen, M.D.

Discussants: Afaf H. Khall, M.D., William H. Nelson, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 56  7:00 p.m.-10:00 p.m.
Quebec Room, Mezzanine, Royal York

ADMINISTRATIVE PSYCHIATRY: HOW CLINICIAN EXECUTIVES CAN SURVIVE THESE TURBULENT TIMES!

Chp.: John A. Talbott, M.D.

A  An Overview of the Evolving Behavioral Health System
   Michael A. Freeman, M.D.

B  Core Administrative Concepts
   Miles F. Shore, M.D.

C  New Roles for Behavioral Health Players
   Judith Browne, R.N.

D  How Selected Behavioral Health Systems Are Moving Toward Integration
   Jose M. Santiago, M.D.

E  Law and Ethics
   Donald H. Williams, M.D.

F  Future Issues for Administrative Psychiatry
   John A. Talbott, M.D.

Discussant: Melvin Sabshin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 57  7:00 p.m.-10:00 p.m.
Territories Room, Mezzanine, Royal York

ARTISTS AT MID LIFE: CONFRONTATIONS WITH DEATH

Chp.: Joseph J. Schildkraut, M.D.

A  The Mid-Life Crisis in Artists
   Elliott Jacques, M.D.

B  Rembrandt at Mid Life: St. Jerome in a Dark Chamber
   Joseph J. Schildkraut, M.D.

C  Lord Byron: A Fevered Dying
   Kay R. Jamison, Ph.D.

D  Arshile Gorky: Terminal Agonies and Abstract Expressionism
   Karen Akiskal, B.A., Hagop S. Akiskal, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 58  7:00 p.m.-10:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

WHEN SPORTS GOES OVER THE LINE
Joint Session with the International Society for Sport Psychiatry

Chp.: Ronald L. Kamm, M.D.

A  Violence On and Off the Field
   Antonia L. Baum, M.D.

B  The Effects of Verbal Abuse in Sports
   Robert W. Burton, M.D.

C  Athlete to Athlete Violence
   Ronald L. Kamm, M.D.

D  The Relevance of the Sports Psyche in the Legal Arena
   Thane Campbell, Esq.

Expert Panel: Bobby Czyz, World Champion boxer; Stewart Gavin, professional hockey player with the National Hockey League; Jill Ross Woolley Olympic Track and Field participant; and Daniel M. Begel, M.D., President of the International Society for Sport Psychiatry.

THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY, JUNE 3, 1998

151ST ANNUAL MEETING

7:00 a.m. Session

INDUSTRY-SUPPORTED BREAKFAST SYMPOSIUM 42
7:00 a.m.-8:30 a.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

PRACTICAL CLINICAL STRATEGIES FOR MANAGING REFRACTORY DEPRESSION, AGITATION AND ANTI-DEPRESSANT SIDE EFFECTS: NEW ADVANCES IN AUGMENTATION AND AGITATION TREATMENT STRATEGIES
Supported by Bristol-Myers Squibb

Chp.: Robert E. Hales, M.D.
Co-Chp.: Stuart C. Yudofsky, M.D.

A Augmentation Strategies for the Newer Antidepressants
Lauren B. Marangell, M.D.

B Clinical Pearls in Managing Agitation in the Elderly
George T. Grossberg, M.D.

8:00 a.m. Sessions

COURSES 77-82
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 77 8:00 a.m.-12 noon
Room 703, 700 Level, Convention Centre
CONCEPTUAL TOOLS FOR PSYCHOTHERAPY SUPERVISION

Director: Paul A. Rodenhauser, M.D.
Faculty: John R. Rudisill, Ph.D., Albert F. Painter, Psy.D.

COURSE 78 8:00 a.m.-12 noon
Room 708, 700 Level, Convention Centre
DELIRIUM IN THE GENERAL HOSPITAL

Director: Peter J. Manos, M.D.
Faculty: Frank Adams, M.D., J. Hampton Atkinson, Jr., M.D., Edwin H. Cassem, M.D.

AN INTRODUCTION TO THE BUSINESS OF MENTAL HEALTH

Director: James M. Schuster, M.D.
Faculty: Arthur L. Lazarus, M.D., M.B.A., Ole J. Thienhaus, M.D., David J.M. Whitehouse, M.D.

COURSE 80 8:00 a.m.-12 noon
Room 711, 700 Level, Convention Centre
ECT: NEW DIRECTIONS IN PRACTICE AND RESEARCH
Joint Session with the Association for Convulsive Therapy

Director: Richard L. Jaffe, M.D.
Faculty: C. Edward Coffey, M.D., Max Fink, M.D.

COURSE 81 8:00 a.m.-12 noon
Room 713A, 700 Level, Convention Centre
INSANITY DEFENSE EVALUATIONS

Director: Phillip J. Resnick, M.D.

COURSE 82 8:00 a.m.-12 noon
Room 714B, 700 Level, Convention Centre
UPDATE ON THE TREATMENT OF SUBSTANCE USE DISORDERS

Director: Dara A. Charney, M.D.
Faculty: Juan C. Negrete, M.D., Jorge A. Palacios-Boix, M.D., Kathryn J. Gill, Ph.D.

9:00 a.m. Sessions

AIDS EDUCATION PROGRAM 2
9:00 a.m.-12 noon
Ballroom A, Lower Level, Crowne Plaza

AIDS AMONG SPECIAL PATIENT POPULATIONS
Co-Sponsored by the APA Commission on AIDS and the APA Education Steering Committee on AIDS

Chp.: Marshall Forstein, M.D.

A Special Issues of Women with AIDS and HIV Disease
Cheryl J. Rowe, M.D.

B Children and Adolescents
Ariette M.L. Lefebvre, M.D.

C Multicultural Issues in HIV/AIDS Care
Joyce Y. Chung, M.D.
CLINICAL CASE CONFERENCE 3
9:00 a.m.-10:30 a.m.
Caledon Room, Lobby Level, Crowne Plaza
PSYCHOTHERAPY WITH A PATIENT WITH DISSOCIATIVE
IDENTITY DISORDER
Presenter: Harold E. Bronheim, M.D.
Discussant: Margaret Huntley, M.D.
THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE
REGISTRATION BADGE OR APA MEMBERSHIP CARD
REQUIRED FOR ADMITTANCE.

COURSES 83-88
Course descriptions are available in
the CME Course Brochure included in
your registration packet. Admission by
ticket only.

COURSE 83  9:00 a.m.-4:00 p.m.
Room 704, 700 Level, Convention Centre
STRUCTURED CLINICAL INTERVIEW FOR DSM-IV-CV:
TRAINING FOR CLINICIANS
Director: Michael B. First, M.D.
Faculty: Miriam Gibbon, M.S.W.

COURSE 84  9:00 a.m.-4:00 p.m.
Room 705, 700 Level, Convention Centre
DEPRESSION: INDIVIDUAL/GROUP INTERPERSONAL
THERAPY
Joint Session with the American Group
Psychotherapy Association, Inc.
Director: K. Roy MacKenzie, M.D.

COURSE 85  9:00 a.m.-4:00 p.m.
Room 706, 700 Level, Convention Centre
THE ASSESSMENT AND TREATMENT OF CHILD
MOLESTERS
Director: John M.W. Bradford, M.B.
Faculty: Gene G. Abel, M.D., David M.
Greenberg, M.B.

COURSE 86  9:00 a.m.-4:00 p.m.
Room 707, 700 Level, Convention Centre
SOUND AND FURY: TREATING BPD PATIENTS WHO ACT
OUT
Director: Ralph Klein, M.D.

COURSES 87  9:00 a.m.-4:00 p.m.
Room 712, 700 Level, Convention Centre
OUTCOMES ASSESSMENT: USE OF RATING SCALES
Co-Directors: Luis F. Ramirez, M.D., Martha
Sajatovic, M.D.
Faculty: Paul Thompson, Ph.D.

COURSE 88  9:00 a.m.-4:00 p.m.
Room 716A, 700 Level, Convention Centre
TRAUMATIC BRAIN INJURY: NEUROPSYCHIATRIC
ASSESSMENT
Joint Session with the American Academy of
Psychiatry and the Law
Director: Robert P. Granacher, Jr., M.D.

DISCUSSION GROUPS 9-10
These are limited to 25 participants on a first-come,
first-served basis.

DISCUSSION GROUP 9  9:00 a.m.-10:30 a.m.
Confederation Room 4, Mezzanine, Royal York
Mark H. Townsend, M.D., on the Treatment of
Lesbians and Gay Men: Are the Psychiatric Issues
Really Different? (For Residents Only)

DISCUSSION GROUP 10  9:00 a.m.-10:30 a.m.
Confederation Room 6, Mezzanine, Royal York
Stephen J. Ferrando, M.D., on Substance Use
Disorders and HIV Infection in 1998: Where Are We
with Prevention and Treatment?
Collaborative Session with the National Institute on
Drug Abuse

LECTURES 19-21

LECTURE 19
9:00 a.m.-10:30 a.m.
Room 107, Lower Level, Convention Centre
Maurice H.J. Dongier, M.D.
The Convergence of Neurobiology and
Psychodynamics
Chp.: Jennifer L. Downey, M.D.
Co-Chp.: Richard Balon, M.D.
In spite of Freud’s anticipation, it is no more likely that psychodynamic theory will be reducible by neurosciences than the contrary. Maurice H.J. Dongier, M.D., contends that psychodynamic theory and the neurosciences have converged more than diverged, despite differences in concepts and techniques. Neurobiology is transnosographic and more congruent with psychodynamic dimensions than with the diagnostic entities delineated by DSM-IV or ICD-10. Psychic reality, fantasy life, and anxiogenic conflicts are regulated by genes and neurohormonal functions and in turn modify brain structures and functions. The basic task of psychiatric research is to go beyond nosology to explore the mechanisms of such interactions. Dr. Dongier is Co-Director of the Alcohol Research Center at McGill University in Montreal. Previously he was Professor and Chairman of the Department of Psychiatry at McGill University and Director of Allan Memorial Institute. The author of more than 175 scientific papers and book chapters, Dr. Dongier has consistently viewed the dynamics of psychopathology simultaneously from the psychological and neurobiological perspectives. Among his many honors is election as a Fellow to the Royal College of Physicians and Surgeons of Canada. He is a Founding Member of the International College of Psychosomatic Medicine. Dr. Dongier received his medical degree from the Université de Marseille and trained in psychiatry at McGill University and the Université de Marseille.

Distinguished Psychiatrist Lecture Series
THIS SESSION WILL BE AUDIOTAPE.

LECTURE 20
9:00 a.m.-10:30 a.m.
Ballroom B, Lower Level, Crowne Plaza
APA'S SIMON BOLIVAR AWARD LECTURE
Javier I. Escobar, M.D.

Immigration and Psychopathology: Is There a Connection?
Chp.: Silvia W. Olarte, M.D.
Co-Chp.: Angela Pedraza, M.D.

The expectation that immigrants would be more susceptible to mental health problems than native-born citizens has been based on social theory and early research on acculturation. Javier I. Escobar, M.D., reviews data from a study of Mexican Americans that suggest the prevalence of psychopathology and disability may actually be lower among immigrants than among their U.S.-born counterparts. He also discusses recent data on a large multi-ethnic sample of primary care patients in which interesting differences in psychopathology and disability that favored immigrants over nonimmigrants were observed. Dr. Escobar is Professor and Chairman of the Department of Psychiatry at the University of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical School and Psychiatrist-in-Chief of the University’s Community Mental Health Center in Piscataway, New Jersey. He is also Professor in the Graduate School of Applied Psychology at Rutgers University and Chief of the Department of Psychiatry at Robert Wood Johnson University Hospital in New Brunswick, New Jersey. Dr. Escobar is a current member of the APA Council on International Affairs and has been an advisor to the Division of Mental Health of the World Health Organization in Geneva. He is the author of more than 150 scientific publications. A native of Colombia, Dr. Escobar received his medical degree from the University of Antioquia School of Medicine in Medellin, and did his residency in psychiatry and completed a research fellowship in psychiatric genetics at the University of Minnesota.

THIS SESSION WILL BE AUDIOTAPE.

LECTURE 21
9:00 a.m.-10:30 a.m.
Ballroom, Convention Floor, Royal York
APA'S OSKAR PFISTER AWARD LECTURE
Allen E. Bergin, Ph.D.

Spiritual and Religious Issues in Psychopathology and Psychotherapy
Chp.: George T. Harding IV, M.D.
Co-Chp.: Reverend Clark S. Eist, Ph.D.

The gap between the assumptions of psychiatric, medical and behavioral sciences and spiritual perspectives is being bridged by developments in physics, philosophy, research on the brain and consciousness, and spiritual conceptions of personality and therapeutic change. Allen E. Bergin, Ph.D., discusses ways...
of resolving problems in applying spiritual perspectives to the treatment of serious psychopathology. He distinguishes healthy and unhealthy ways of being religious, discusses methods for assessing religiousness and its positive and negative aspects, and describes spiritual interventions that show promise when integrated with standard therapies. Dr. Bergin is Professor of Psychology at Brigham Young University in Provo, Utah. He is the editor of five books and the author of numerous papers and two books, including A Spiritual Strategy for Counseling and Psychotherapy. A Fellow of the American Psychological Association, Dr. Bergin has received the association’s Distinguished Professional Contribution to Knowledge Award. He has also received the Biggs-Pine Award for outstanding scholarly contributions to counseling and values from the Association for Religious and Values Issues in Counseling. Dr. Bergin is a past president of the Society for Psychotherapy Research and the Association of Mormon Counselors and Psychotherapists. He received his doctorate in clinical psychology from Stanford University and did post-doctoral research in psychotherapy at the University of Wisconsin Psychiatric Institute.

THE INTERNET AND PSYCHOTHERAPY

Chp.: Russell F. Lim, M.D.

37 Psychotherapy on the Internet
Russell F. Lim, M.D.

The Internet is a dynamic, rapidly evolving and enlarging international computer network that enables the exchange of most forms of data, including text, graphics, audio and video among geographically distant mental health clinicians and their patients. The recent development of graphical interfaces to the Internet has made access to its resources much easier for individual users. In addition, the Internet’s explosive growth has given consumers and mental health service providers greater access to its resources and capabilities. The Internet and how it can be used to provide treatment to patients will be described and demonstrated. The use of electronic support groups on the USENET, the use of Internet Relay Chat (IRC) for real-time support groups run by consumers, the use of video conferencing in psychiatry and the use of specialized software for treatment of specific groups of patients will be reviewed. In addition, consultation and psychotherapy are available on the Internet, and websites for both will be demonstrated. Issues of security and confidentiality, liability and licensure also will be discussed.

38 Cytochrome Interactions via the Web
Robert D. Patterson, M.D.

Psychiatric and other drugs frequently interact with the cytochromes. The interaction has the potential to increase or decrease blood levels and therefore seriously affect drug benefits and side effects. The numerous interactions and rapidly emerging knowledge about them are too great for clinicians to keep in mind. This program aims to provide a means to sort this information for use in clinical situations, and searches a comprehensive database about cytochrome interactions for potential effects among drugs. It can help spot potential problems when a new drug is added and it can help to choose the best drug to add from a group (such as antihypertensives). Ratings, clinical relevance and confidence are included as references. The program accesses the latest information via the Web. The database can be updated at the time a search is made or periodically when a Web connection is convenient. The “engine” for using the database is downloaded only once from the Web. This affords rapid program response, no necessity to be
connected to the Web at the time of use, and yet completely updated information. This program can be incorporated into clinical record keeping or other large programs.

39 Computer-Assisted Psychotherapy

Jesse H. Wight, M.D., Scott P. Stuart, M.D.,
Monica A. Basco, Ph.D., Peter M. Steiner, M.D.

Recently developed software for computer-assisted psychotherapy may offer opportunities for improving efficiency and reducing cost of treatment. Early attempts to stimulate traditional therapeutic interviews have been supplanted with computer programs that use the unique features of computers to assist the human therapist. Contemporary programs for computer-assisted psychotherapy typically employ easy-to-use interfaces that are suitable for a wide range of patients. Examples include multimedia computer programs, behavioral systems to promote exposure and response prevention, and interactive voice response. This presentation will provide an overview of programs developed for computer-assisted therapy and will demonstrate methods for clinical use of therapeutic software. Advantages and limitations of the different forms of computer-assisted psychotherapy will be discussed. Participants will be able to gain experience in using a multimedia program for cognitive therapy through a CD-ROM demonstration and discussion of cases of patients treated with this type of computer-assisted therapy. The final segment will focus on advances in technology and software development that may lead to increased use of computer tools in psychotherapy.

MEDIA SESSION 21 9:00 a.m.-10:30 a.m.
Ontario Room, Convention Floor, Royal York

PREVENTION OF SUBSTANCE ABUSE
Collaborative Session with the National Institute on Drug Abuse

Chp.: Ian E. Alger, M.D.

40 Prevention of Substance Abuse Risk for Families at Risk
(66 minutes)

Distributor: Lawrence J. Hatterer, M.D.
Department of Public Health
Cornell Medical Center
167 E. 79th Street
New York, NY 10021-0421

Three urban multiethnic families at risk for substance abuse on Thanksgiving, Easter and New Years Day holidays respond to their adolescent members’ drug-related auto accidents. Their common interactions and resolutions educate the viewer to etiologic factors that raise their consciousness of their denials of the multiple dimensions of the addictive process. These videotapes are currently in use for a National Institute on Drug Abuse prevention research study of Caucasian, African-American and Hispanic populations in New York City over a three-year period.

Discussant: Lawrence J. Hatterer, M.D.

MEDIA SESSION 22 9:00 a.m.-10:30 a.m.
Civic Ballroom, Second Floor, Sheraton Centre

HEALING FROM GRIEF: CHILD AND PARENT LOSSES

Chp.: John M. Dluhy, M.D.

41 A Mother’s Grief
(45 minutes)

Distributor: Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

This intensely moving documentary follows a support group for mothers struggling to deal with the unthinkable—the death of a child. In this support group, you meet courageous women of various ages and backgrounds and watch as they are bound together by their sense of loss. Excellent for bereavement counselors, support groups and staff training.

Winner, Loss & Transition Category, Aquarius Film Festival

42 Grown-Up Tears
(28 minutes)

Distributor: Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

Losing a parent can be one of the most difficult and painful times in our lives, despite how old we are. This video explores how adults feel about, and cope with, the loss of a parent through the eyes and experiences of seven individuals who are supported by three professionals. The participants share stories of what life was like at the actual moment of their parent’s death, as well as their anticipation of the death of the parent. Excellent for professionals, training, bereavement groups and area agencies on aging.
NEW RESEARCH

ORAL/SLIDE SESSIONS 9-10
9:00 a.m.-10:30 a.m.

9 HEALTH SERVICES
Room 205B, Street Level, Convention Centre

10 PSYCHOPHARMACOLOGY AND ANXIETY
Room 205D, Street Level, Convention Centre

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

PRACTICE GUIDELINES UPDATE
9:00 a.m.-11:00 a.m.
Essex Room, Mezzanine, Sheraton Centre

PRACTICE GUIDELINES: DELIRIUM AND HIV/AIDS
APA Steering Committee on Practice Guidelines

Co-Chps.: John S. McIntyre, M.D., Deborah A. Zarin, M.D.
Participants: Sara C. Charles, M.D., Paula T. Trzepacz, M.D., Philip S. Wang, M.D., J. Stephen McDaniel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

PRESIDENTIAL SESSION: A TIME OF VIOLENCE, PART I
9:00 a.m.-12 noon
Room 104D, Lower Level, Convention Centre

JUVENILE JUSTICE

Chp.: Lawrence A. Stone, M.D.
Participants: William M. Buzogany, M.D., Louis J. Kraus, M.D., Helen Sacks, Thomas Peterson, J.D., Carl P. Malmquist, M.D.

REVIEW OF PSYCHIATRY: PART IV
9:00 a.m.-12:30 p.m.
Room 105, Lower Level, Convention Centre

INTERPERSONAL PSYCHOTHERAPY

Chp.: John C. Markowitz, M.D.

16 Interpersonal Psychotherapy: An Overview
Myrna M. Weissman, Ph.D.

17 Maintenance Interpersonal Psychotherapy: A Preventive Treatment for Depression
Cynthia Spanier, Ph.D.

18 Interpersonal Psychotherapy for the Treatment of Depression in HIV-Positive Men and Women
Holly A. Swartz, M.D.

19 Interpersonal Psychotherapy for Depressed Adolescents
Laura Mufson, Ph.D.

20 Interpersonal Psychotherapy for Patients with Bulimia
Denise E. Wilfley, Ph.D.

SOCIAL SECURITY WORKSHOP
9:00 a.m.-12 noon
City Hall Room, Second Floor, Sheraton Centre

DISABILITY EVALUATION UNDER SOCIAL SECURITY: A PRESENTATION FOR TREATING PSYCHIATRISTS
Sponsored by the Social Security Administration, APA Office of Psychiatric Services and APA Consortium on Organized Service Systems

Chp.: Jerome E. Shapiro, M.D.
Co-Chp.: Dale N. Cox, B.S.

WORKSHOPS

COMPONENTS 37-41

COMPONENT WORKSHOP 37 9:00 a.m.-10:30 a.m.
Room 205C, Street Level, Convention Centre

NAVAJO PSYCHOLOGY
APA Committee of American Indian/Alaskan Native and Native Hawaiian Psychiatrists and APA Council on National Affairs

Co-Chps.: Mary H. Roessel, M.D., Edward J. Neidhardt, M.D.
Participant: Ruth Roessel, M.A.

COMPONENT WORKSHOP 38 9:00 a.m.-10:30 a.m.
Room 205A, Street Level, Convention Centre

CODING CHANGES AND NEW DOCUMENTATION REQUIREMENTS
APA Work Group on Codes and Reimbursements and APA Work Group on Harvard Resource-Based Relative Value Scale Study
COMPONENT WORKSHOP 39  9:00 a.m.-10:30 a.m.
Room 206B, Street Level, Convention Centre

PHYSICIANS UNDER FIRE: UNDERSTANDING AND HELP
APA Committee on Physician Health, Illness and Impairment

Co-Chps.: Stephen L. Dilts, M.D., Malkah T. Notman, M.D.
Participants: Richard F. Limoges, M.D., Michael F. Myers, M.D., Patti Tighe, M.D., Carmen T. Webb, M.D.

COMPONENT WORKSHOP 40  9:00 a.m.-10:30 a.m.
Humber Room, Lobby Level, Crowne Plaza

THE EXPERIENCE OF COMING OUT IN PSYCHIATRY
APA Southern California Psychiatric Society's Committee on Gay, Lesbian and Bisexual Issues

Chp.: Nick M. Gutierrez, M.D.
Participants: William Arroyo, M.D., Robert Dasher, M.D., William E. Callahan, Jr., M.D., Vernon A. Rosario, M.D.

COMPONENT WORKSHOP 41  9:00 a.m.-10:30 a.m.
Alberta Room, Mezzanine, Royal York

THE SEARCH COMMITTEE AND ISSUES FOR WOMEN
APA Committee on Women

Chp.: Donna E. Stewart, M.D.
Participants: Cheryl F. McCartney, M.D., Carol C. Nadelson, M.D.

ISSUE WORKSHOP 62  9:00 a.m.-10:30 a.m.
Room 205A, Street Level, Convention Centre

IMGS IN THE UNITED STATES: PROBLEM OR SOLUTION?

Co-Chps.: Renato D. Alarcon, M.D., Alejandra Hallin, M.D.
Participants: Inomata Tomomi, M.D., Nyapati R. Rao, M.D., Frederick C. Miller, M.D.

ISSUE WORKSHOP 63  9:00 a.m.-10:30 a.m.
Room 206C, Street Level, Convention Centre

SPIRITUALITY/RELIGION IN THE MEDICAL SCHOOL CURRICULUM
WEDNESDAY

ISSUE WORKSHOP 69 9:00 a.m.-10:30 a.m.
Toronto Room, Convention Floor, Royal York

TESTIMONY: A FORMER POLITICAL PRISONER FROM HAITI
Joint Session with the Haitian-American Psychiatric Association

Chp.: Jacques Vital-Herne, M.D.
Participants: Patrick Plante, M.D., Patrick Lemoine, M.D., Pierre A. Jean-Noel, M.D.

ISSUE WORKSHOP 70 9:00 a.m.-10:30 a.m.
British Columbia Room, Mezzanine, Royal York

CHALLENGES IN RESOCIALIZING PSYCHIATRIC EDUCATION

Chp.: Kenneth S. Thompson, M.D.
Participants: Bradley E. Lewis, M.D., David A. Pollack, M.D., Stephen M. Goldfinger, M.D., Linda G. Gochfeld, M.D.

ISSUE WORKSHOP 71 9:00 a.m.-10:30 a.m.
Manitoba Room, Mezzanine, Royal York

CULTURAL ISSUES IN THE PSYCHIATRIC PATIENT

Chp.: Cletus S. Carvalho, M.D.
Participants: Juan E. Mezzich, M.D., Manoj R. Shah, M.D., Pamela Y. Collins, M.D., Keh-Ming Lin, M.D.

ISSUE WORKSHOP 72 9:00 a.m.-10:30 a.m.
Territories Room, Mezzanine, Royal York

PUCK PRISONS AND JUVENILE JUSTICE REFORM IN THE 1990S

Chp.: James E. Dillon, M.D.
Participants: Peter Ash, M.D., Lee H. Rome, M.D., Euphemie A. Brown, M.D.

ISSUE WORKSHOP 73 9:00 a.m.-10:30 a.m.
Tudor Room 7, Mezzanine, Royal York

ATOD-TV (ALCOHOL, TOBACCO AND OTHER DRUGS) AND COMMUNITY ATTITUDES REGARDING DRUG ABUSE
Collaborative Session with the National Institute on Drug Abuse

Chp.: Timothy P. Condon, Ph.D.

ISSUE WORKSHOP 74 9:00 a.m.-10:30 a.m.
Conference Room B, Mezzanine, Sheraton Centre

DISABLED DOCTORS: INSURERS SEEK A SECOND OPINION

Chp.: Kenneth L. Appelbaum, M.D.
Participant: Barry W. Wall, M.D.

ISSUE WORKSHOP 75 9:00 a.m.-10:30 a.m.
Conference Room C, Mezzanine, Sheraton Centre

WHITE HOUSE CASES: RISK ASSESSMENT AND MANAGEMENT

Chp.: Robert T.M. Phillips, M.D.
Participant: Margaret H. Coggins, Ph.D.

ISSUE WORKSHOP 76 9:00 a.m.-10:30 a.m.
Conference Room F, Mezzanine, Sheraton Centre

ADVOCACY: REACHING THE MEDIA ON MENTAL HEALTH

Chp.: Edward B. Gogek, M.D.
Participant: Jim Gogek, M.A.

ISSUE WORKSHOP 77 9:00 a.m.-10:30 a.m.
Windsor Room, Mezzanine, Sheraton Centre

PRIVACY OR REIMBURSEMENT? AN UNEXPECTED CHOICE

Co-Chps.: Kathleen C. Dougherty, M.D., Kenneth M. Certa, M.D.

ISSUE WORKSHOP 78 9:00 a.m.-10:30 a.m.
York Room, Mezzanine, Sheraton Centre

GAY PSYCHIATRISTS: AN AMSTERDAM PERSPECTIVE

Chp.: Nicolaas F.J. Hettinga, M.D.
Participants: Ruud A.M. Feijen, M.D., Bastiaan L. Oele, M.D., Wilco Tuinebreijer, Piet-Hein Van Harm, Wim Van Der Plaat, M.D.

ISSUE WORKSHOP 79 9:00 a.m.-10:30 a.m.
Dufferin Room, Second Floor, Sheraton Centre

COMMUNITY THERAPY: TREATMENT FOR SEVERE BPD

Co-Chps.: Glenn N. Siegel, M.D., Mary J. Pittman, M.S.
11:00 a.m. Sessions

DISCUSSION GROUPS 11-12

These are limited to 25 participants on a first-come, first-served basis.

DISCUSSION GROUP 11 11:00 a.m.-12:30 p.m.
Confederation Room 4, Mezzanine, Royal York

Jimmie C. Holland, M.D., on Psychiatric Issues in Chronic Illness: Cancer As Paradigm

DISCUSSION GROUP 12 11:00 a.m.-12:30 p.m.
Confederation Room 6, Mezzanine, Royal York

Edward F. Foulks, M.D., on How to Participate in Mental Health Advocacy Organizations

LECTURE 22
11:00 a.m.-12:30 p.m.
Room 107, Lower Level, Convention Centre

Joseph E. LeDoux, Ph.D.

Emotion, Memory and the Brain

Chp.: Jatk M. Gorman, M.D.
Co-Chp.: Richard M. Brockman, M.D.

Considerable progress has been made in elucidating the brain pathways involved in fear, including those that allow humans to learn about novel threats and to detect and respond to threatening stimuli. Joseph E. LeDoux, Ph.D., reviews recent findings on the neural mechanisms underlying fear, including emotional learning and memory, and the interface with motor systems that control behavioral, autonomic and endocrine responses. He also examines how these advances may lead to more refined definitions of emotional disorders and hopefully to new, more specific approaches to treatment. Dr. LeDoux is the Henry and Lucy Moses Professor of Science at the Center for Neural Science and the Department of Psychology at New York University in New York City. He is the author of numerous scientific papers and three books, including The Emotional Brain. He is a member of the Editorial Boards of several journals, including Neuron, Learning and Memory and Behavioral Neuroscience. A member of the Dana Alliance for Brain Research, he delivered the Soloweys Award Lecture in Neuroscience in 1997. He is the recipient of a MERIT Award research grant from the National Institute of Mental Health. Dr. LeDoux received his doctorate from the State University of New York at Stony Brook.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

MASTER EDUCATOR CLINICAL CONSULTATIONS 13-15

11:00 a.m.-12:30 p.m.

These are limited to 25 participants on a first-come, first-served basis.

13 Marvin I. Herz, M.D., on the Treatment of Schizophrenia
New Brunswick Room, Mezzanine, Royal York

14 Michael H. Sacks, M.D., on Inpatient Management of Comorbid Axis II Disorders
Nova Scotia Room, Mezzanine, Royal York

15 James E. Dillon, M.D., on Antisocial Behavior Through the Life Cycle: Clinical and Forensic Issues
Saskatchewan Room, Mezzanine, Royal York

THESE SESSIONS ARE OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 23-24

MEDIA SESSION 23 11:00 a.m.-12:30 p.m.
Ontario Room, Convention Floor, Royal York

INNOVATIVE COMMUNITY APPROACHES FOR THE HOMELESS

Chp.: Edward K. Rynearson, M.D.

43 Straight Dope
(36 minutes)

Distributor: First Run Icarus Films
153 Waverly Place
New York, NY 10014

Straight Dope documents homeless punk youth as they design projects that educate their community about HIV. Faced with IV drug use and the harsh reality of life on the street, these youths prove the effectiveness of

(Continued on next page)
empowering the individuals within a community to speak for themselves. By documenting this outreach from its inception, *Straight Dope* explores the many levels of working with a high-risk subculture. This video is designed to be used as an inspirational training tool for those interested in working with youth at risk today.

**National Educational Media Network Gold Apple Winner, 1997**

**44 The Dark Side of the Moon**  
(25 minutes)

**Distributor:** Fanlight Productions  
47 Halifax Street  
Boston, MA 02130

This moving documentary weaves together the stories of three mentally disabled men, formerly homeless, who have overcome despair, stigma and isolation to become valued members of their community. Joe, diagnosed with paranoid schizophrenia, now provides peer counseling and manages an apartment complex for homeless men. After years of hospitalization for schizophrenia, Ron now advocates for patients’ rights and is raising his six-year-old son as a single parent. John still struggles with paranoia, but now lives independently and works as an artist and poet. After years of feeling hopeless and helpless, through their relationships with understanding friends and community resources, they now help others.

**MEDIA SESSION 24**  
11:00 a.m.-2:00 p.m.  
Civic Ballroom, Second Floor, Sheraton Centre

**DSM-IV: NEW DIAGNOSTIC ISSUES**

Chp.: Ian E. Alger, M.D.

**45 Psychotic Disorders**  
(30 minutes)

**46 Anxiety Disorders**  
(30 minutes)

**47 Mood Disorders**  
(30 minutes)

Distributor: American Psychiatric Press, Inc.  
for 45, 46  
1400 K Street, N.W.  
and 47  
Washington, DC 20005

This series of three clinical programs reveals additions and changes from *DSM-III-R* to *DSM-IV* for mood, psychotic and anxiety disorders. Each videotape focuses on one particular area of psychiatric diagnosis and contains enactments of three outstanding clinicians’ actual patient interviews. Nancy C. Andreasen, M.D., Andrew H. Woods Professor of Psychiatry, University of Iowa College of Medicine, is the interviewer for *Psychotic Disorders*. Andrew E. Skodol II, M.D., Associate Professor of Clinical Psychiatry at the College of Physicians and Surgeons of Columbia University, is the interviewer for *Anxiety Disorders*. Ellen Frank, Ph.D., Professor of Psychiatry and Psychology at the University of Pittsburgh School of Medicine, is the interviewer for *Mood Disorders*. Each videotape begins with an introductory discussion between the clinician and the moderator. The clinician then conducts three, 10-minute psychiatric diagnostic interviews. Following each interview, the clinician and the moderator discuss the taped segments and comment on issues illustrated during the interviews. These issues include: how the *DSM-IV* diagnostic criteria were utilized in the interview, how diagnostic markers were elicited and how interpersonal issues, as well as diagnostic markers were identified. The interviews utilize reference data to examine conclusions reached during the interviews. Each tape also demonstrates good interviewing techniques and highlights the development of a good doctor/patient relationship.

**Discussant:** Andrew E. Skodol II, M.D.

**MEDICAL UPDATE 3**  
11:00 a.m.-12:30 p.m.  
Room 104C, Lower Level, Convention Centre

**THE HEPATIC CYTOCHROME P450 SYSTEM**

Chp.: Philip R. Muskin, M.D.  
Presenter: Norman Sussman, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

**RESEARCH CONSULTATION WITH**  
11:00 a.m.-12:30 p.m.  
York Room, Mezzanine, Royal York

2 Kenneth B. Wells, M.D., on Developing a Career/Program/Grant in Mental Health Services Research

This session is limited to 25 participants on a first-come, first-served basis.

**SCIENTIFIC AND CLINICAL REPORT**  
SESSIONS 20-29

**SCIENTIFIC AND CLINICAL REPORT SESSION 20**  
11:00 a.m.-12:30 p.m.  
Room 205B, Street Level, Convention Centre
CHALLENGING CLINICAL ISSUES IN SCHIZOPHRENIA

Chp.: Alan M. Gruenberg, M.D.
Co-Chp.: Nat H. Sandler, M.D.

59 Schizophrenia: A Language or Thought Disorder? 11:00 a.m.
Martin Harrow, Ph.D., Adrienne M. Altman, B.A.,
Eileen M. Martin, Ph.D., Jennifer D. Janopaul, B.A.,
James R. Sands, Ph.D., Thomas H. Jobe, M.D.

60 Suicide Attempts in Schizophrenia: Demoralization or Depression? 11:30 a.m.
Kathleen Restifo, Ph.D., Jill M. Harkavy-Friedman, Ph.D., Patrick E. Shrouf, Ph.D.

61 Predictors of Schizophrenia 12 noon
Matti K. Isohanni, M.D., Paula Rantakallio, M.D.,
Peter B. Jones, Ph.D., Marjor-Riitta Jarvelin, Ph.D.,
Irene T. Isohanni, M.A., Taru Makikyro, M.D., Pirko Rasanen, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 21
11:00 a.m.-12:30 p.m.
Room 205D, Street Level, Convention Centre

PSYCHOPHARMACOLOGY

Chp.: Richard Balon, M.D.
Co-Chp.: Gabriella Ba, M.D.

62 Olanzapine: Safe in Clozapine-Induced Agranulocytosis 11:00 a.m.
L. Kola Oyewumi, M.D., John Craven, M.D.

63 Sildenafil for Erectile Dysfunction: A One-Year Study 11:30 a.m.
Waguih R. Guirguis, M.D., Murray C.
Maytom, M.D., Malcolm Orr, Ian H. Osterloh, M.D.,
Mike D. Smith, Ph.D.

64 Adverse Event Profiles Associated with Long-Term Fluoxetine Treatment 12 noon
Roy Tamura, Ph.D., David Michelson, M.D., Karen Sundell, B.S., Charles M. Beasley, Jr., M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 22
11:00 a.m.-12:30 p.m.
Room 206C, Street Level, Convention Centre

MENTAL HEALTH STRESSES IN CHILDREN

Chp.: Roslyn Seligman, M.D.
Co-Chps.: Sukhmani K. Gill, M.D.

65 Psychological Functioning and Child Abuse in Adolescents 11:00 a.m.
Charles A. Sanislow, Ph.D., Carlos M. Grilo, Ph.D.,
Dwain C. Fehon, Psy.D., Steve Martino, Ph.D.,
Thomas H. McGlashan, Ph.D.

66 Clinical Judgment in Reports of Childhood Sexual Abuse 11:30 a.m.
Cheryl Gore-Felton, Ph.D., Cheryl Koopman, Ph.D.,
Carl Thoresen, Ph.D., Bruce Arnow, Ph.D., David Spiegel, M.D.

67 Homeless Children: Stresses and Mental Health Problems 12 noon
Bonnie T. Zima, M.D., Regina Bussing, M.D.,
Marina Bystritsky, M.A., Mel Widawski, M.A.,
Thomas R. Belin, Ph.D., Bemadette Benjamine, M.S.C.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 23
11:00 a.m.-12:30 p.m.
Room 104A, Lower Level, Convention Centre

BRAIN IMAGING

Chp.: Susan Mirow, M.D.
Co-Chp.: Ilise D. Lombardo, M.D.

68 Basal Ganglia Choline Levels in True Drug Response 11:00 a.m.
Maurizio Fava, M.D., Shamsah B. Sonawalla, M.D.,
Perry R. Renshaw, M.D., Constance M. Moore, Ph.D.,
Jonathan E. Alpert, M.D., Andrew A.
Nierenberg, M.D., Jerrold F. Rosenbaum, M.D.

69 Neuroimaging of Attention to Emotional Experience 11:30 a.m.
Richard D. Lane, M.D., Gereon Fink, M.D.,
Phyllis M. Chua, M.D., Raymond J. Dolan, M.D.

70 Atrophy and Metabolite Abnormality in Movement Disorder 12 noon
Jay W. Seastunk II, M.D., Subhendra Sarkar, Ph.D.,
Steven R. Kreibaum, Ph.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 24
11:00 a.m.-12:30 p.m.
Caledon Room, Lobby Level, Crowne Plaza

BIPOLAR GROUP: AT-RISK POPULATION

Chp.: Paul J. Goodnick, M.D.
Co-Chp.: Sheryl D. Jones, M.D.

(Continued on next page)
WEDNESDAY

71 Which Unipolar Depressives Are Really Bipolar? 11:00 a.m.
Joseph F. Goldberg, M.D., Martin Harrow, Ph.D.

72 Postpartum Course of Bipolar Illness 11:30 a.m.
Ruta M. Nonacs, M.D., Adele C. Vigueria, M.D.,
Lee S. Cohen, M.D.

73 Treatment of Bipolar Spectrum Symptoms 12 noon
Ronald A. Rabin, M.D., Clifford H. Siegel, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 25
11:00 a.m.-12:30 p.m.
Ontario Room, Lower Level, Crowne Plaza
TREATMENT ISSUES IN ANXIETY DISORDERS

Chp.: Arthur Rifkin, M.D.
Co-Chp.: Paul McCarthy, M.D.

74 Cognitive and/or Behavioral Therapy in Social Phobia 11:00 a.m.
Jean A. Cottraux, M.D., Ivan Note, M.D., Elane Albuisson, M.D., Sainan Yao, M.D., Nathalie Etikmedjian, M.D., Isabelle Jalencques, M.D.

75 The Association Between Symptom Changes and Clinical Outcome in Panic Disorder 11:30 a.m.
David Michelson, M.D., Roy Tamura, Ph.D., Sharon Hoog, M.D., Rosalinda Tepner, R.Ph., Mark A. Demittrack, M.D., Gary D. Tollefson, M.D.

76 Platelet and Plasmatic MAO in Anxiety Disorders 12 noon
Oscar R. Carton, M.D., Hans Spatz

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 26
11:00 a.m.-12:30 p.m.
Confederation Room 3, Mezzanine, Royal York
DIAGNOSIS AND METHODOLOGY IN PERSONALITY DISORDERS

Chp.: Winston W. Shen, M.D.
Co-Chp.: Rima Styra, M.D.

77 Divalproex for Aggression in Personality Disorders 11:00 a.m.
Richard J. Kavoussi, M.D.

78 Internal Consistency and Overlap of DSM-IV Personality Disorders 11:30 a.m.
Carlos M. Grilo, Ph.D., Thomas H. McGlashan, M.D.,
Mary C. Zanarini, Ed.D., Charles A. Sanislow, Ph.D.,
Elayne Daniels, Ph.D., Robert Stout, Ph.D.,
Leslie C. Morey, Ph.D.

79 Identifying Personality Disorders: Towards the Development of a Clinical Screening Instrument 12 noon
H. George Nurnberg, M.D., Glenn A. Martin, M.D.,
Eugene C. Somoza, M.D., Emil F. Coccaro, M.D.,
Andrew E. Skodol II, M.D., John M. Oldham, M.D.,
Gavin Andrews, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 27
11:00 a.m.-12:30 p.m.
Quebec Room, Mezzanine, Royal York
FORENSIC PSYCHIATRY

Chp.: Charles L. Scott, M.D.
Co-Chp.: Trevor I. Prior, M.D.

80 Psychiatric Disability Exam for Employment Discrimination and the Americans with Disabilities Act 11:00 a.m.
Lauren J. Wylonis, M.D., Robert L. Sadoff, M.D.

81 The Effect of Depression on Competency: A Survey 11:30 a.m.
Kevin C. Hails, M.D.

82 Malpractice Law and Managed Care: New Developments 12 noon
Eugene L. Lowenkopf, M.D., Abe M. Rychik, J.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 28
11:00 a.m.-12:30 p.m.
Tudor Room 7, Mezzanine, Royal York
PSYCHIATRIC EPIDEMIOLOGY

Chp.: Kathleen R. Merikangas, Ph.D.
Co-Chp.: Bradley N. Gaynes, M.D.

83 Prevalence of Dementia in Centenarians 11:00 a.m.
Ben A. Blansjaar, M.D., Rene Thomassen, M.D.,
Henri W. van Schaick, M.D.

84 Is Schizophrenia on the Decline? 11:30 a.m.
Carolyn M. Woogh, M.D.

85 A Prospective Analysis of Alcohol Use Disorders 12 noon
Rosa Maria Crum, M.D., Corey Smith, M.H.S.,
Laura Pratt, B.A., James C. Anthony, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.
SCIENTIFIC AND CLINICAL REPORT SESSION 29
11:00 a.m.-12:30 p.m.
Huron Room, Second Floor, Sheraton Centre
THE WIDE WORLD OF NEUROPSYCHIATRY
Chp.: Stephen I. Kramer, M.D.
Co-Chp.: Kathy M. Vincent, M.D.

86 Drug-Induced Delirium in Intensive Care Units 11:00 a.m.
Kwo-Hwa Tseng, M.D., Tong-Ting Wu, M.D., Chuen-Lin Su, M.D.

87 Role of Sympathoadrenal Dysfunction in Hyperthermia 11:30 a.m.
RONALD J. GURREA, M.D.

88 Epilepsy and Psychosis: A Neurodevelopmental Hypothesis 12 noon
Anthony Feinstein, M.D.

THIS SESSION WILL BE AUDIOTAPED.

WORKSHOPS
COMPONENTS 42-49

COMPONENT WORKSHOP 42 11:00 a.m.-12:30 p.m.
Room 205A, Street Level, Convention Centre
HOW TO LAUNCH A SUCCESSFUL PRIVATE PRACTICE
APA Assembly's Committee of Area Early Career Psychiatrists and APA Committee of Early Career Psychiatrists
Chp.: William E. Callahan, Jr., M.D.
Participants: Ann S. Maloney, M.D., Barry W. Wall, M.D.

COMPONENT WORKSHOP 43 11:00 a.m.-12:30 p.m.
Room 205C, Street Level, Convention Centre
PSYCHIATRIC TRAINING AT HOME AND ABROAD
APA Council on International Affairs
Chp.: Daniel A. Monti, M.D.
Participants: James B. Potash, M.D., John H. Lloyd, M.D., Husam Alathari, M.D., Jonathan W. Bolton, M.D.

COMPONENT WORKSHOP 44 11:00 a.m.-12:30 p.m.
Room 206A, Street Level, Convention Centre
CLINICAL ASSESSMENT MANAGEMENT OF SEXUAL HARASSMENT: 1998 UPDATE
APA New Jersey Psychiatric Association's Committee on Women
Co-Chps.: Rita R. Newman, M.D., Angela M. Hegarty, M.D.
Participants: Annette J. Hollander, M.D., Arlene G. Sherer, M.D., Sharyn A. Lenhart, M.D.

COMPONENT WORKSHOP 45 11:00 a.m.-12:30 p.m.
Grenadier Room, Lobby Level, Crowne Plaza
THE AMERICANS WITH DISABILITIES ACT AND THE RECOVERING PHYSICIAN
APA Committee on Training and Education in Addiction Psychiatry
Chp.: Jonathan I. Ritvo, M.D.
Participants: David A. Burlage, J.D., Michael H. Gendel, M.D., David R. McDuff, M.D., Shawn Wilson, M.D.

COMPONENT WORKSHOP 46 11:00 a.m.-12:30 p.m.
Humber Room, Lobby Level, Crowne Plaza
RISK MANAGEMENT ISSUES IN PSYCHIATRIC PRACTICE
APA Psychiatrists' Purchasing Group, Inc.
Chp.: Alan L. Levenson, M.D.
Participants: Ellen R. Fishbein, M.D., Martin G. Tracy, J.D., Frank G. Feeley, J.D.

COMPONENT WORKSHOP 47 11:00 a.m.-12:30 p.m.
Ballroom, Convention Floor, Royal York
SPIRITUAL AND RELIGIOUS ISSUES IN MENTAL HEALTH AND ILLNESS
APA Committee on Religion and Psychiatry and APA Council on National Affairs
Co-Chps.: George T. Harding IV, M.D., Reverend Clark S. Aist, Ph.D.
Participants: Allen E. Bergin, Ph.D., T. Byram Karasu, M.D., Roger C. Sider, M.D., Reverend Peter Van Katwyk, Ph.D.

COMPONENT WORKSHOP 48 11:00 a.m.-12:30 p.m.
Conference Room B, Mezzanine, Sheraton Centre
BEING AFRAID: WHEN TRAINEES FEAR FOR THEIR SAFETY
APA Committee of Residents and Fellows
Co-Chps.: Derek G. Puddester, M.D., Zachary Solomon, M.D.
Participants: Debra Safek, M.D., Robin R. Randall, M.D., Laura C. Toner, M.D.
COMPONENT WORKSHOP 49  11:00 a.m.-12:30 p.m.
York Room, Mezzanine, Sheraton Centre

CULTURAL OUTCOMES IN THE ELDERLY: AN INDUSTRY PERSPECTIVE
APA Committee on Ethnic Minority Elderly
Chp.: Jacobo E. Mintzer, M.D.
Participants: Michael Pontecorvo, Ph.D., Jamie S. Street, M.D., Marc Cantillon, M.D., Thomas McRae, M.D., Peter J. Whitehouse, M.D.

ISSUES 80-90

ISSUE WORKSHOP 80  11:00 a.m.-12:30 p.m.
Room 206B, Street Level, Convention Centre

ISSUE WORKSHOP 81  11:00 a.m.-12:30 p.m.
Room 206D, Street Level, Convention Centre

ISSUE WORKSHOP 82  11:00 a.m.-12:30 p.m.
Kingsway Room, Lobby Level, Crowne Plaza

ISSUE WORKSHOP 83  11:00 a.m.-12:30 p.m.
Oakville Room, Lobby Level, Crowne Plaza

ISSUE WORKSHOP 84  11:00 a.m.-12:30 p.m.
Toronto Room, Convention Floor, Royal York

ISSUE WORKSHOP 85  11:00 a.m.-12:30 p.m.
Alberta Room, Mezzanine, Royal York

ISSUE WORKSHOP 86  11:00 a.m.-12:30 p.m.
British Columbia Room, Mezzanine, Royal York

ISSUE WORKSHOP 87  11:00 a.m.-12:30 p.m.
Manitoba Room, Mezzanine, Royal York

ISSUE WORKSHOP 88  11:00 a.m.-12:30 p.m.
Conference Room F, Mezzanine, Sheraton Centre

ISSUE WORKSHOP 89  11:00 a.m.-12:30 p.m.
Conference Room G, Mezzanine, Sheraton Centre

ISSUE WORKSHOP 90  11:00 a.m.-12:30 p.m.
Kent Room, Second Floor, Sheraton Centre

GROUP THERAPY: MAKING UNTREATABLE PATIENTS TREATABLE
Joint Session with the American Group Psychotherapy Association, Inc.
Co-Chps.: C. Donald Williams, M.D., Miguel A. Leibovich, M.D.
WEDNESDAY

12 noon Sessions

FORUMS 7-9

FORUM 7  12 noon-1:30 p.m.
Room 104B, Lower Level, Convention Centre

TRUST IN HUMAN SUBJECT RESEARCH

Chp.: John M. Oldham, M.D.
Participants: Paul S. Appelbaum, M.D., Evan G. DeRenzio, Ph.D., Laurie M. Flynn, M.A., Robert J. Levine, M.D.

FORUM 8  12 noon-1:30 p.m.
Territories Room, Mezzanine, Royal York

THE IMPACT OF AMERICAN PSYCHIATRY ON THE DEVELOPMENT OF PSYCHIATRY IN ASIA
APA's Kun-Po Soo Award

Chp.: Robert O. Pasnau, M.D.
Co-Chps.: Roy W. Menninger, M.D., Ton-That Niem, M.D.
Participants: Ching-Piao Chien, M.D., Kyu-Hang Lee, M.D., Masahisa Nishizono, M.D., Zhang Mingyuan, M.D.

FORUM 9  12 noon-1:30 p.m.
Windsor Room, Mezzanine, Sheraton Centre

WHO WILL PAY FOR THE TREATMENT OF SUBSTANCE ABUSE?
Collaborative Session with the National Institute on Drug Abuse

Chp.: Roger E. Meyer, M.D.
Participants: Jerome H. Jaffe, M.D., William H. Goldman, M.D.

NEW RESEARCH

POSTER SESSION 11
12 noon-2:00 p.m.
Room 106, Lower Level, Convention Centre

VARIOUS PSYCHIATRIC ISSUES

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

12:30 p.m. Session

MEDIA SESSION 25
12:30 p.m.-2:00 p.m.
Ontario Room, Convention Floor, Royal York

NOON JAZZ FESTIVAL

Chp.: Edward K. Rynearson, M.D.

48 Can’t You Hear the Wind Howl?
(77 minutes)

Distributor: Sweet Home Pictures
9819 Champa Drive
Dallas, TX 75218

Can’t You Hear the Wind Howl? shows the life and music of Robert Johnson. Over 50 years of mystery have surrounded this gifted bluesman who lived in the rural South of the 1920s and 1930s. Few details of his life were known; in fact, only two photographs of him are known to exist. He was a loner, who supposedly shook hands with the devil for his extraordinary talent, and who was murdered when he was just 27 years old. He could charm young women into a night’s shelter and warmth as he drifted from town to town playing a circuit of juke joints, country picnics and street corners. He performed his original songs with unmatched intensity and style: songs about shady women, nights of terror, and walking with the devil—Hellhound On My Trail, Dust My Broom, Crossroad Blues, Walkin’ Blues, Sweet Home Chicago and Come On In My Kitchen. Johnson recorded only 29 songs, but they constitute the most astonishing, influential body of work any bluesman has ever committed to wax. Now award-winning actor Danny Glover takes us on an evocative and enthralling journey through Robert Johnson’s short life by revealing for the first time his true story, based upon new factual information along with exclusive interviews with people who knew him, and by vividly recreating Johnson’s life from boyhood to his death in 1938. Robert Johnson is portrayed by W.C. Handy Award-winning blues musician Kevin Moore (aka Keb’ Mo’), who mimes both Johnson’s guitar and voice to the original Vocation recordings.

1:00 p.m. Sessions

COURSES 89-92
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

(Continued on next page)
WEDNESDAY

COURSE 89 1:00 p.m.-5:00 p.m.
Room 702, 700 Level, Convention Centre

PSYCHIATRY AND FAMILY MEDICINE: SHARING CARE

Director: Nick S. Kates, M.B.
Faculty: Marilyn Craven, M.D., Jonathan S. Davine, M.D.

COURSE 90 1:00 p.m.-5:00 p.m.
Room 703, 700 Level, Convention Centre

SKILLS FOR MENTORS AND PROTÉGÉS IN THE NEW ERA

Co-Directors: Paul A. Rodenhauser, M.D., Ramona Dvorak, M.D.
Faculty: Albert F. Painter, Psy.D., John R. Rudisill, Ph.D.

COURSE 91 1:00 p.m.-5:00 p.m.
Room 711, 700 Level, Convention Centre

USE OF MELATONIN AND LIGHT IN SLEEP AND MOOD DISORDERS

Director: Alfred J. Lewy, M.D.

COURSE 92 1:00 p.m.-5:00 p.m.
Room 714B, 700 Level, Convention Centre

ADVANCES IN DIAGNOSIS AND MANAGEMENT OF ALZHEIMER'S DISEASE IN PRACTICE

Co-Directors: Vinod Kumar, M.D., J. Wess Ashford, Jr., M.D.
Faculty: Jack S. Krasuski, M.D.

MEDIA SESSION 26
1:00 p.m.-4:00 p.m.
Room 718B, 700 Level, Convention Centre

COMPUTERIZED MEDICAL RECORDS/PRACTICE MANAGEMENT SOFTWARE: PART III

Co-Chps.: Steven E. Hyler, M.D., Russell F. Lim, M.D.

49 Booting Up Your Practice
Theron C. Bowers, M.D.

Although the computer is a common tool in many or most psychiatric practices, its use remains confined to primarily administrative jobs such as billing and scheduling. As a cognitive-based specialty with a primary task of collecting and evaluating patient information, electronic database management has numerous potential benefits for psychiatrists in all areas of practice. This presentation will explore issues regarding computerized clinical database management in psychiatric practices and examine potential barriers and challenges in maintaining electronic records. The presentation will also illustrate the benefits and goals of an efficient computerized clinical system by demonstrating a patient-tracking computer program based on a relational database. Using this program the presenters will show the basic requirements of a patient-tracking system, such as records of progress notes, mental status examinations and medications. They will also demonstrate more advanced and specialized features in tracking a patient's progress and monitoring medication side effects. Finally, there will be instructions on implementing a computerized record keeping system in private practice.

50 A Computer Assessment Using Scores and Narratives
Elliott D. Luby, M.D.

The basic model for computerized assessment will first be described using a computerized slide show with a laptop PC and an LCD projector. Although the model is very simply based upon expectations and performances, it is a transformation of Erikson’s theory of the psychosocial development of children. Research has shown that to acquire confidence in self (autonomy) and confidence in others (trust), expectations of self and others have to be met through performances in 16 life vectors or basic biopsychosocial needs. This model identifies the cognitive distortions (erroneous expectations) and patterns of reaction (destructive performances) that prevent a person from functioning in the community, and even more to the point, how to correct them. The interview protocol is made up of checklists and open-ended questions and recorded in paper form. In the second part of this demonstration an example will be entered into the laptop, and the machine will then interactively construct a short summary of numerical scores, such as imbalances between expectations and performances; the number of serious problems noted; and narrative transcriptions when they occur. The resulting summary will be distributed.

51 Relational Database in Clinical Practice
James H. Grubbs, M.D.

Commercially available relational database programs, such as Microsoft Access, can be readily adapted to psychiatric practice for the collection and analysis of clinically relevant data. Those data can then be used to fulfill multiple purposes, including the rapid preparation of clinical documents and reports, the analysis of patient populations and practice patterns, and quality improvement. This presentation will demonstrate the basic functions of a relational database and the associated word-processing and analytical programs. Participants will be able to discuss the use of these programs in their own practices. Simple queries will be produced on demand and more elaborate functions, such as merging documents and analyzing parts of the database, will be demonstrated.
LECTURE 23
2:00 p.m.-3:30 p.m.
Ballroom, Convention Floor, Royal York

Nora D. Volkow, M.D.
Cocaine and the Addicted Brain
Collaborative Session with the National Institute on Drug Abuse

Chp.: Marc Galanter, M.D.
Co-Chp.: Saundra L. Stock, M.D.

New insights into the ways commonly abused drugs affect the human brain have been made possible by positron-emission tomography (PET) and other imaging methods. Nora D. Volkow, M.D., one of the first researchers to use PET to study the biochemical and functional changes in the brain from chronic exposure to drugs of abuse, discusses findings from imaging studies of cocaine’s effects on the brain. Reinforcing effects of cocaine appear to be a consequence of dopamine transporter blockade and cocaine’s fast pharmacokinetics. Studies in cocaine addicts have shown decreased function of the dopamine system and dysfunction in cortical areas known to be modulated by dopamine. These changes are likely to account for the anhedonia associated with chronic cocaine use and the compulsive drug administration characteristic of cocaine addiction. Dr. Volkow is Associate Professor of Psychiatry at the State University of New York at Stony Brook. Previously she was Chairman of the Medical Department and Director of the National Institute on Drug Abuse/Department of Energy Imaging Center at Brookhaven National Laboratory in Upton, New York. She has received a Laughlin Fellowship from the American College of Psychiatrists and the Scandiafrin Scholarship for Outstanding Young Nuclear Medicine Researchers. She is the author of more than 200 journal articles and book chapters and the editor of three books. Dr. Volkow received her medical degree from the National University of Mexico in Mexico City and completed postgraduate training in psychiatry at New York University.

Frontiers of Science Lecture Series
THIS SESSION WILL BE AUDIOTAPED.

LECTURE 24
2:00 p.m.-3:30 p.m.
Dominion Ballroom, Second Floor, Sheraton Centre

APA’S BENJAMIN RUSH AWARD LECTURE

Elizabeth Lunbeck, Ph.D.
The Empty Self: BPD in Historical Perspective

Chp.: Dilip Ramchandani, M.D.
Co-Chp.: Janet E. Ordway, M.D.

Since the 1940s, studies of the American personality have painted a portrait of cultural and characterological decline, telling of the demise of a disciplined, patriarchal Victorianism that produced autonomous, inner-directed individuals and the rise of a modernity that yielded a superficial, other-directed and fundamentally disturbed personality as its paradigmatic figure. Over the same period, psychiatrists noted the disappearance of classically neurotic patients and the proliferation of those suffering from vague conditions of maladjustment and discontent. Since the 1960s they have diagnosed these patients as borderlines. Elizabeth Lunbeck, Ph.D., discusses the clinical and cultural emergence of borderline personality disorder and examines the extent to which the new diagnosis is implicated in the production of new types of patients. Dr. Lunbeck is Associate Professor of History at Princeton University. She is the author of The Psychiatric Persuasion: Knowledge, Gender, and Power in Modern America, which received the John Hope Franklin Prize from the American Studies Association and the Morris D. Forkosch Prize for the best book in intellectual history published in 1994. She is co-editor of Proof and Persuasion: Essays on Authority, Objectivity, and Evidence and the coauthor of an upcoming critical edition of an early American psychoanalytic case, entitled The Psychoanalysis of Rachel K. Dr. Lunbeck has received numerous fellowships, including a National Endowment for the Humanities Fellowship and several awards from the National Institutes of Health. She received her doctorate from Harvard University and was a postdoctoral fellow at the Rutgers-Princeton Program in Mental Health Research. THIS SESSION WILL BE AUDIOTAPED.
MEDIA SESSIONS 27-28

MEDIA SESSION 27 2:00 p.m.-5:00 p.m.
Ontario Room, Convention Floor, Royal York

SUBSTANCE ABUSE: GLOBAL AND HISTORICAL PERSPECTIVES
Chp.: Cheryl A. Kennedy, M.D.

52 Dealing with the Demon: A Three-Part Series
(55 minutes)
Distributor: First Run Icarus Films
153 Waverly Place
New York, NY 10014

After 75 years of a concerted global fight to restrict the supply of addictive drugs, the world is currently facing unprecedented levels of illicit drug production, with 10 times more heroin produced now than during the last “plague” of the 1970s. Dealing with the Demon is the story of opiates, told in three parts, which gives a powerful insight into society’s epic struggle with all drugs of addiction.

Episode One: The Seeds of War
The Seeds of War traces the growth of the international drug trade and the failure of the United States-led process of international prohibition to contain it. The film opens with a bumper opium harvest in Afghanistan and links this to the recent rise in middle-class heroin use in the United States. This provides the launching point for an inquiry into the history of the drug trade, which takes us to former British opium factories on the banks of the Ganges and through the archives of Persia and China.

Episode Two: An Unholy Alliance
This episode examines the relationship between the drug trade and war, detailing the involvement of the CIA in Vietnam and Afghanistan during the Cold War. From the time of Chiang Kai Shek in China, through the front lines of the Cold War, in Southeast Asia, the Golden Triangle, and later in Vietnam, An Unholy Alliance examines how priorities designed to defeat communism led to the protection and spread of illicit drugs.

Episode Three: Containing the Fallout
The final film in the series investigates the spread of heroin use, its role in fueling the AIDS epidemic, and the most effective means for dealing with illicit drugs. In a remote village in Thailand, the film shows the devastating move by villagers away from traditional opium to the much more dangerous use of heroin, a widespread occurrence that is contributing to Asia’s massive AIDS epidemic. The film then examines (in the United States and overseas) the historical evolution of what is called a harm-reduction strategy for dealing with drug use. In the United States, harm reduction is strongly resisted, because some have labeled it a form of “legalization.” Containing the Fallout observes how the historical tussle between the criminal view and the medical view of illicit drug use is played out against a world-wide plague of opiate addiction. AIDS is finally forcing many nations, including our own, to confront the reality of failed drug policies.

MEDIA SESSION 28 2:00 p.m.-5:00 p.m.
Civic Ballroom, Second Floor, Sheraton Centre

CHILDHOOD ISSUES
Chp.: Richard E. D’Alli, M.D.

53 Healing Wounded Hearts
(28 minutes)
Distributor: Aquarius Productions, Inc.
5 Powderhouse Lane
Sherborn, MA 01770

This outstanding new video is an excellent teaching tool for parents going through divorce and for their children, mental health professionals and divorce mediators. Fears, confusion, loss and just plain sadness often interfere with our ability to communicate feelings with loved ones about this painful process. Healing Wounded Hearts invites healthy discussion of the typical feelings associated with divorce. Listening to the thoughts and feelings of other children and parents about divorce gives us a window through which to explore our own feelings and begin the healing process.

54 When the Bough Breaks
(90 minutes)
Distributor: Filmakers Library
124 East 40th Street
New York, NY 10016

Current theory holds that if a child does not properly attach itself to a caregiver in the first three years, the implications for later life are profound. This can show up as overly aggressive behavior, serious learning problems and delinquency. The film crew followed three mothers and their problem children, ages 10 months to three years. All represent middle-class, low-risk, intact families. The film traces them through three months of therapy at the C.M. Hincks Treatment Centre in Toronto. Two of the children have never slept through the entire night, and one child has a serious eating disorder. She holds food in her mouth for up to three hours, refusing to swallow. The families of these children are pushed to the edge of despair in trying to manage them. Cameras were placed in the homes of the families and tapes of therapy sessions were used to observe the behavior of the children and their interaction with their parents. It becomes clear that children, even before they can speak, give out signals of disturbance. If there is not proper intervention, the entire family can be thrown into turmoil.
This film looks at families struggling with preschoolers who have serious behavior problems: such as tantrums, rages, persistent disobedience, whining and hyperactivity. These are the traits that drive both parents and teachers to distraction. Many children with early antisocial behavior grow up to be persistent offenders in later life. Once they get into the criminal justice system, it is often too late to rehabilitate them. This video demonstrates how early interventions at a special needs preschool can help parents learn positive reinforcement tactics to break the cycle of oppositional behavior. Parents learn the techniques to control their children and teach them to control themselves. We watch the unflappable teachers interact with these difficult children, putting boundaries on their disruptive behavior. While the film is set in Great Britain, the emotions of the parents, behaviors of the children, support offered by professionals, and behavior-modification methods reveal universal themes.

PRESIDENTIAL SESSION: A TIME OF VIOLENCE, PART II
2:00 p.m.-5:00 p.m.
Room 104D, Lower Level, Convention Centre
INTERGROUP VIOLENCE
Chp.: Alan A. Stone, M.D.
Participants: Professor Richard Hackman, Professor Richard Wrangham, Professor Adam J. Kuper, Susan Woodward, M.D.

REVIEW OF PSYCHIATRY: PART V
2:00 p.m.-5:30 p.m.
Room 105, Lower Level, Convention Centre
PSYCHOLOGICAL TRAUMA: PREVALENCE, COURSE, PSYCHobiology AND TREATMENT
Chp.: Rachel Yehuda, Ph.D.
21 Epidemiology of Trauma and PTSD
Naomi Breslau, Ph.D.
22 Longitudinal Development of Post-Traumatic Disorders
Arieh Y. Shalev, M.D.
23 Evaluating the Effects of Psychological Trauma Using Neuroimaging Techniques
Scott L. Rauch, M.D.
24 Neuroendocrinology of Trauma and PTSD
Rachel Yehuda, Ph.D.
25 Psychosocial Treatments for PTSD
Edna B. Foa, Ph.D.
26 Pharmacotherapy of PTSD
Randall D. Marshall, M.D.

SYMPOSIUM 59-86
SYMPOSIUM 59
2:00 p.m.-5:00 p.m.
Room 205A, Street Level, Convention Centre
OUTCOME MEASUREMENT IN PSYCHIATRY: A CRITICAL REVIEW
Chp.: Tal Burt, M.D.
Co-Chp.: Waguih W. Ishak, M.D.
A Outcome Measurement: Definition, History and Review of Available Tools
Waguih W. Ishak, M.D., Tal Burt, M.D.
B The Ideal Outcome Measurement Tool
Susan Eisen, Ph.D.
C Critical Appraisal of Different Outcome Measurement Tools
Jean Endicott, Ph.D.
D Implementing Outcome Assessment in a Clinical Facility
Lloyd I. Sederer, M.D.
E Outcome Measures: Computers, Managed Care and Rehabilitation
Zebulon C. Taintor, M.D., Russell F. Lim, M.D.

THIS SESSION WILL BE AUDIOTAPEd.

SYMPOSIUM 60
2:00 p.m.-5:00 p.m.
Room 205B, Street Level, Convention Centre
CLINICAL SUBTYPING OF SCHIZOPHRENIA
Chp.: Paul C. Bermanzohn, M.D.
A Associated Syndromes in Chronic Schizophrenia
Paul C. Bermanzohn, M.D., Linda Porto, M.S.N., Samuel G. Sits, M.D.
B Is There Room for a Schizo-Obsessive Subtype?
Joseph Zohar, M.D., Yehuda Sasson, M.D.
C How Vulnerable Are Schizophrenia Patients to Depression?
Martin Harrow, Ph.D., James R. Sands, Ph.D., Joseph F. Goldberg, M.D., Rajiv P. Sharma, M.D., Robert Faull, B.A.
D Antidepressants and Benzodiazepines in Schizophrenia
Samuel G. Siris, M.D., Paul C. Bermanzohn, M.D.,
Dawn Oughourlian, B.A.

E Is Panic a Schizophrenia Subtype?
Paul C. Bermanzohn, M.D., Donald S. Rae, M.A.,
Linda Porta, M.S.N., Samuel G. Siris, M.D.

Discussant: Nina R. Schooler, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 61 2:00 p.m.-5:00 p.m.
Room 205C, Street Level, Convention Centre
ANXIETY SPECTRUM DISORDERS: A NEW MILLENNIUM
Chp.: Eric Hollander, M.D.

A The Anxiety Spectrum and the Obsessive-Compulsive Spectrum
Eric Hollander, M.D., Cheryl M. Wong, M.D.,
Charles Cartwright, M.D., Bonnie A.
Aronowitz, Ph.D., Concetta M. DeCaria, Ph.D.,
Gina Delgiudice-Asch, M.D., Tomer Begaz, B.A.

B New Findings in the Neurobiology and Treatment of Panic
Jack M. Gorman, M.D.

C Social Phobia: Part of a Shyness Spectrum?
Murray B. Stein, M.D., Denise Chavira, B.A.

D PTSD
Joseph Zohar, M.D.

E Diagnosing and Treating Coexisting Anxiety and Depression
Norman Sussman, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 62 2:00 p.m.-5:00 p.m.
Room 205D, Street Level, Convention Centre
JUVENILE OFFENDERS: MODERN ISSUES FOR CHILD PSYCHIATRY
Chp.: William M. Womack, M.D.

A A Systems Approach to Mental Health in Juvenile Facilities
William M. Womack, M.D.

B Teaching Clinical Skills to Correction Staff: A Necessity, Not an Option
Lisa M. Boesky, Ph.D., Jana Ewing, Ph.D.

C Suicidal and Self-Mutilating Behavior in Incarcerated Adolescents
Jana Ewing, Ph.D., Lisa M. Boesky, Ph.D.

D Treatment of Traumatic Bereavement with Incarcerated Youth
Edward K. Rynearson, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 63 2:00 p.m.-5:00 p.m.
Room 206A, Street Level, Convention Centre
DETECTION AND TREATMENT OF STIMULANT ABUSE
Collaborative Session with the National Institute on Drug Abuse
Chp.: David A. Gorelick, M.D.

A Detection of Stimulant Abuse
Jeffery N. Wilkins, M.D.

B Psychosocial Treatment for Stimulant Abusers
Douglas M. Ziedonis, M.D.

C Pharmacological Treatment of Stimulant Abuse
David A. Gorelick, M.D.

D Psychiatric Comorbidity in Stimulant Abusers
Richard N. Rosenthal, M.D.

E Methamphetamine Abuse: New Developments
Steven L. Batki, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 64 2:00 p.m.-5:00 p.m.
Room 206B, Street Level, Convention Centre
THE RELATIONSHIP BETWEEN SEASONALITY, EATING AND MOOD
Chp.: Allan S. Kaplan, M.D.

A Serotonin Dysfunction in Bulimia and SAD
Robert D. Levitan, M.D., Allan S. Kaplan, M.D.,
Gregory M. Brown, M.D., Franco J. Vaccarino, Ph.D.,
Sidney H. Kennedy, M.D., Anthony J. Levitt, M.D.,
Russell T. Joffe, M.D.

B Seasonality of Mood and Eating in Bulimia and SAD
Allan S. Kaplan, M.D., Robert D. Levitan, M.D.,
Anthony J. Levitt, M.D.

C Comorbidity of SAD and Bulimia in a Clinic and Community Sample
Anthony J. Levitt, M.D., Allan S. Kaplan, M.D.,
Robert D. Levitan, M.D., Michael Boyle, M.S.W.

D Bulimia Nervosa and SAD: Overlapping Treatment
Raymond W. Lam, M.D.
Discussant: David C. Jimerson, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 65  2:00 p.m.-5:00 p.m.
Room 206C, Street Level, Convention Centre

PERSONALITY DISORDERS RESEARCH IN CANADA
Chp.: Joel F. Paris, M.D.
A The Etiology of Personality Disorder Traits
John Livesley, M.D., Kerry L. Jang, Ph.D.
B Prospective Follow-Up of Borderline Personality:
Mechanisms of Change
Paul S. Links, M.D., Ronald Heslegrave, Ph.D.
C Implications of Research on Psychological Risk
Factors in BPD
Joel F. Paris, M.D.
D Risk Factors for Borderline Pathology in Children
Jaswant Guzder, M.D., Phyllis Zeikowitz, Ed.D.,
Joel F. Paris, M.D.
E Defenses in Personality and Depressive Disorders
J. Christopher Perry, M.D.
Discussant: Paul E. Garfinkel, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 66  2:00 p.m.-5:00 p.m.
Room 206D, Street Level, Convention Centre

DYNAMIC PERSPECTIVES ON TREATMENT RESISTANCE
Chp.: Barri A. Belnap, M.D.
Co-Chp.: Eric M. Plakun, M.D.
A Treatment Resistance and the Dynamics of the
Dual Treatment Relationship
James M. Ellison, M.D.
B Readiness for Change in Treatment Resistance
Barri A. Belnap, M.D.
C Enactment and Treatment-Refractory Depression
Eric M. Plakun, M.D.
D Treatment Resistance: A Cognitive-Behavioral
Perspective
Michael E. Thase, M.D.
Discussant: Edward R. Shapiro, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 67  2:00 p.m.-5:00 p.m.
Room 206E, Street Level, Convention Centre

PATHWAYS TO HOMELESSNESS
Chp.: Donald A. Wasylekni, M.D.
A An Integrative Approach to Research with
Homeless Persons
George S. Tolomiczenko, Ph.D., Paula N.
Goering, Ph.D., Donald A. Wasylekni, M.D.,
Katherine Boydell, Ph.D.
B Prevalence of Mental Illness Among Homeless
Persons
Donald A. Wasylekni, M.D., George S.
Tolomiczenko, Ph.D., Paula N. Goering, Ph.D.,
Tammy Morrell-Bellai, Ph.D., Michael Higgins, B.A.,
Nicole A. Tenn-Lyn, B.S., Carole Bentley, B.A.
C Pathways into First-Time Homelessness
Paula N. Goering, Ph.D., Tammy Morrell-Bellai, Ph.D.,
Michael Higgins, B.A., Katherine Boydell, Ph.D.,
George S. Tolomiczenko, Ph.D., Donald A.
Wasylekni, M.D.
D Neuropsychological and Personality Factors
George S. Tolomiczenko, Ph.D., Teresa
Sotla-Royes, M.A., Paula N. Goering, Ph.D.,
Donald A. Wasylekni, M.D.
E HIV Prevalence and Risk Factors in an Adult
Homeless Population
Mark N. Halman, M.D., George S. Tolomiczenko, Ph.D.,
Paula N. Goering, Ph.D., Donald A. Wasylekni, M.D.,
Carol Major, MLT
Discussant: Ezra S. Susser, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 68  2:00 p.m.-5:00 p.m.
Room 206F, Street Level, Convention Centre

PSYCHOSOCIAL ASPECTS OF HIV RISK AMONG
YOUNG IV DRUG USERS
Chp.: Howard J. Osofsky, M.D.
A Overview of the Collaborative Injection-Drug
Users Study (CIDUS II)
Edgar Monterrosa, M.D.
B Psychopathology and HIV Risk Behavior Among
Young Injection-Drug Users
Patricia Simon-Morse, Ph.D., Edward Morse, Ph.D.
C Injection-Drug Users and HIV Risk in Chicago
Demographics and Gang Behavior
Lorna Thorpe, M.P.H., Lawrence Ouellet, Ph.D.,
Antonio Jiminez, M.A., Wendell Johnson, Ph.D.,
Mike Hansen, M.P.H., Wayne Weibel, Ph.D.
D Violence, Trauma and HIV Among Young
Injection-Drug Users
Nance Sohler, Ph.D., Theresa Diaz, M.D., Ezra S.
Susser, M.D.
Discussant: Edgar Monterrosa, M.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 69 2:00 p.m.-5:00 p.m.
Room 103A, Lower Level, Convention Centre

THE MANY FACES OF THE DRUG PROBLEM
Joint Session with the InterAmerican Council of Psychiatric Organizations

Chp.: Carlos Leon-Andrade, M.D.
Co-Chp.: Roberto E. Chaskel, M.D.

A Substance Abuse: A Vision from the United States
Pedro Ruiz, M.D., Rodolfo D. Fahrer, M.D.

B Substance Abuse: A South American Perspective
Carlos Leon-Andrade, M.D.

C International Drug Trafficking
Roberto E. Chaskel, M.D., Ruben J.
Hernandez-Serrano, M.D., Luis G. Ruiz, M.D.

D Substance Abuse and HIV/AIDS: A Problem for the Americas
Rodolfo D. Fahrer, M.D.

E Substance Abuse: A Caribbean Perspective
Sharon C. Harvey, M.D.

Discussants: Renato D. Alarcon, M.D., Antonio
Pacheco, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 70 2:00 p.m.-5:00 p.m.
Room 104A, Lower Level, Convention Centre

DOCTORS AND DRUG COMPANIES: UNHOLY ALLIANCE OR MATCH MADE IN HEAVEN?

Chp.: Irwin N. Hassenfeld, M.D.

A Promotion in the Guise of Education
Irwin N. Hassenfeld, M.D.

B The Developmental History of a Pharmaceutical Lecture
Joseph Di Giacomo, M.D.

C Psychology and Ethics of Giving and Receiving
Carl Mindell, M.D.

D Organizational Perspective on Industry Support
Carolyn B. Robinowitz, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 71 2:00 p.m.-5:00 p.m.
Room 104B, Lower Level, Convention Centre

MEDICATION: CHANGING A PERSON OR TREATING A PATIENT?

Chp.: Susan C. Vaughan, M.D.
Co-Chp.: Steven P. Roose, M.D.

A Stability of Personality Disorders with Treatment for Chronic Depression
Robert M.A. Hirschfeld, M.D., James P.
McCullough, Jr., Ph.D., James M. Russell, M.D.,
Martin B. Keller, M.D.

B Does Medication Change Personality Organization?
Carlos Blanco-Jerez, M.D., Linda S. Mullen, M.D.,
Susan C. Vaughan, M.D., John F. Clarkin, Ph.D.,
Michael R. Liebowitz, M.D., Steven P. Roose, M.D.

C Defense Mechanisms and Axis I: Searching for Stability
Linda S. Mullen, M.D., Carlos Blanco-Jerez, M.D.,
Susan C. Vaughan, M.D., James H. Kocsis, M.D.,
Roger Vaughan, Ph.D., Steven P. Roose, M.D.

D Biological Studies in Personality Disorders
Emil F. Coccaro, M.D.

Discussant: Robert Michels, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 72 2:00 p.m.-5:00 p.m.
Room 104C, Lower Level, Convention Centre

HERBAL MEDICINE: ANCIENT ROOTS TO MODERN USE

Chp.: Michael W. Smith, M.D.
Co-Chp.: Charles S. Grob, M.D.

A Herbal Medicine and Psychiatry: Potential for Toxicity
Michael W. Smith, M.D., Oscar V. Rosas, M.D.,
Mariana Delgado, M.D.

B Kava: Ancient Beverage to Modern Psychotherapeutic Medicine
Dennis J. McKenna, Ph.D.

C Antidepressant Activity of Hypericum Perforatum: St. John's Wort
Jerry M. Cott, Ph.D.

D Plant Entheogens As Medicine
Charles S. Grob, M.D.

Discussant: Keh-Ming Lin, M.D.

THIS SESSION WILL BE AUDIOTAPED.
WEDNESDAY

SYMPOSIUM 73  2:00 p.m.-5:00 p.m.
Caledon Room, Lobby Level, Crowne Plaza
CLASSIC AND ATYPICAL NEUROLEPTICS IN DEMENTIA
Chp.: Jacobo E. Mintzer, M.D.
A A Neurochemical Rationale for the Use of Neuroleptics in Dementia
Dario F. Mirski, M.D.
B Classic Neuroleptics in Dementia
Davangere P. Devanand, M.D.
C Atypical Neuroleptics in Dementia
S. Craig Risch, M.D.
D Efficacy and Safety of Atypical Neuroleptics in Dementia
Jacobo E. Mintzer, M.D.
Discussant: George T. Grossberg, M.D.

SYMPOSIUM 74  2:00 p.m.-5:00 p.m.
Kingsway Room, Lobby Level, Crowne Plaza
CATATONIA AND OTHER MOTOR SYNDROMES: HOW CLOSELY RELATED?
Chp.: Andrew J. Francis, Jr., M.D.
Co-Chp.: Stephanie Kruger, M.D.
A Diagnostic and Therapeutic Relevance of Catatonia
Brendan T. Carroll, M.D.
B Catatonia and Non-Catatonic Motor Syndromes in Schizophrenia
Peter Braunig, M.D., Stephanie Kruger, M.D.,
Jurgen Hoffler, M.D., Ingrid Bornor, M.D., Gerald Shugar, M.D.
C Similarity of Catatonia and NMS
Andrew J. Francis, Jr., M.D., Georgios Petrides, M.D.
D Prevalence and Clinical Significance of Catatonic Symptoms in Mania
Stephanie Kruger, M.D., Peter Braunig, M.D.,
Gerald Shugar, M.D.
E Neurological Soft Signs in Schizophrenia Subtypes
Oliver Rommel, M.D., Peter Braunig, M.D., Jurgen Hoffler, M.D.,
Paul Kwitt, Ingrid Bornor, M.D.
Discussant: Patricia I. Rosebush, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 75  2:00 p.m.-5:00 p.m.
Ballroom A, Lower Level, Crowne Plaza
PRACTICE PROFILE OF UNITED STATES AND CANADIAN PSYCHIATRISTS
Joint Session with the Canadian Psychiatric Association
Chp.: Michael F. Myers, M.D.
A Practice Profile Survey by the Canadian Psychiatric Association: Study, Design and Results
D. Blake Woodside, M.D.
B Findings from the American Psychiatric Association's Practice Research Network Study of Psychiatric Patients and Treatments
Harold Alan Pincus, M.D., Deborah A. Zarin, M.D.,
Terri L. Tanielian, M.A., Ana P. Suarez, M.P.H.,
Julie L. Johnson, M.A., Joyce C. West, M.P.P.,
John S. McIntyre, M.D.
C The Practice Profile Study by the Canadian Psychiatric Association: Methodological Issues
Elizabeth Lin, Ph.D.
Deborah A. Zarin, M.D., Harold Alan Pincus, M.D.,
Joyce C. West, M.P.P., Ana P. Suarez, M.P.H.,
Terri L. Tanielian, M.A., Julie L. Johnson, M.A.,
John S. McIntyre, M.D.
E Canadian Human Resource Surveys: Policy Implications
Nady El-Guebaly, M.D.
F The American Psychiatric Association's Practice Research Network Study of Patients and Treatments: Policy Implications
John S. McIntyre, M.D., Harold Alan Pincus, M.D.,
Deborah A. Zarin, M.D., Joyce C. West, M.P.P.,
Terri L. Tanielian, M.A., Ana P. Suarez, M.P.H.,
Julie L. Johnson, M.A.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 76  2:00 p.m.-5:00 p.m.
Niagara Room, Lower Level, Crowne Plaza
PSYCHIATRIC ASPECTS OF EPILEPSY
Chp.: Moises Gaviria, M.D.
Co-Chp.: Andres Kanner, M.D.
A Diagnosis and Outcome of Psychogenic Nonepileptic Events
Andres Kanner, M.D.
(Continued on next page)
B Brain SPECT in Paroxysmal Psychiatric Episodes
Thomas H. Jobe, M.D., Ovidio A. De Leon, M.D.,
Jerry Sychra, Ph.D., Michael Blend, D.O., Daniel
Pavel, Quin Lin, Ph.D., Moises Gaviria, M.D.

C Treatment of Psychogenic Nonepileptic Events
Prema V. Sanne, M.D.

D Lamotrigine in the Treatment of Epileptic
Psychosis
Ovidio A. De Leon, M.D., Kevin Furmaga,
Pharm.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 77 2:00 p.m.-5:00 p.m.
Ontario Room, Lower Level, Crowne Plaza
NEW ANTICONVULSANTS IN MOOD DISORDERS: AN
UPDATE
Chp.: Mark A. Frye, M.D.
A Pharmacology and Pharmacokinetics of New
Anticonvulsants
Terence A. Ketter, M.D., Mark A. Frye, M.D.,
Timothy A. Kimbrell, M.D., Robert M. Post, M.D.
B Lamotrigine in Bipolar Disorder
Joseph R. Calabrese, M.D.
C An Open Trial of Gabapentin in Bipolar Disorder
L. Trevor Young, M.D.
D Gabapentin and Lamotrigine Monotherapy in
Mood Disorder: An Update
Mark A. Frye, M.D., Terence A. Ketter, M.D.,
Elizabeth A. Osuch, M.D., Timothy A. Kimbrell, M.D.,
Andrew M. Speer, M.D., Robert M. Dunn, M.D.,
Robert M. Post, M.D.
E Neuroimaging of Response to Lamotrigine and
Gabapentin
Timothy A. Kimbrell, M.D., Terence A. Ketter, M.D.,
Mark A. Frye, M.D., Robert M. Dunn, M.D.,
Andrew M. Speer, M.D., Elizabeth A. Osuch, M.D.,
Robert M. Post, M.D.

Discussant: Robert M. Post, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 78 2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine, Royal York
COLLABORATIVE STUDY OF PERSONALITY DISORDERS
Chp.: Thomas H. McGlashan, M.D.
A An Overview of the Study and the Sample
John G. Gunderson, M.D., Thomas H.
McGlashan, M.D., Leslie C. Morey, Ph.D.,
M. Tracie Shea, Ph.D., Andrew E. Skodol II, M.D.
B Diagnostic Interview for DSM-IV Personality
Disorders: Test-Retest and Interrater Reliability
Mary C. Zanarini, Ed.D., Donna Bender, Ph.D.,
Regina T. Dolan, Ph.D., Elizabeth Schaefer, Ed.M.,
Charles A. Sanislow, Ph.D.
C Functional Impairment in Four Personality
Disorder Types
Andrew E. Skodol II, M.D., M. Tracie Shea, Ph.D.,
Robert Stout, Ph.D., Thomas H. McGlashan, M.D.,
Martin B. Kellor, M.D., John M. Oldham, M.D.,
Regina T. Dolan, Ph.D.
D Axis II Comorbidity of DSM-IV Personality
Disorders
Carlos M. Grilo, Ph.D., Thomas H. McGlashan, M.D.,
Charles A. Sanislow, Ph.D., Blayne Daniels, Ph.D.,
Mary C. Zanarini, Ed.D., Carole T. Goldberg, Ph.D.,
Regina T. Dolan, Ph.D., Leslie C. Morey, Ph.D.,
M. Tracie Shea, Ph.D., John G. Gunderson, M.D.,
Andrew E. Skodol II, M.D.
E Stability of Personality Disorder: Diagnoses and
Criteria
M. Tracie Shea, Ph.D., Robert Stout, Ph.D.,
Regina T. Dolan, Ph.D., Andrew E. Skodol II, M.D.,
Leslie C. Morey, Ph.D., Mary C. Zanarini, Ed.D.
F Dimensions and Categories in Personality
Disorder
Leslie C. Morey, Ph.D., John G. Gunderson, M.D.,
Michael J. Lyons, Ph.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 79 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine, Royal York
CURRENT TRENDS IN RUSSIAN PSYCHIATRY
Chp.: Valery N. Krasnov, M.D.
A Development of Russian Psychiatry: Current
Condition and Trends
Valery N. Krasnov, M.D.
B Economic Research Program in Russian
Psychiatry
Vassilei Yastrebbov, M.D., Lioubov S.
Chevtchenko, Ph.D.
C Psychiatric Care in Russia: Situation and
Perspectives
Isaac Ya. Gurovich, Ph.D., Yanina A.
Storozhakova, Ph.D., Alexander B. Shmuiker, Ph.D.
D Russian Psychiatry and the Law: Facts and
Problems
Svetlana Polubinska
E Alcohol and Substance Abuse Disorders in Russia for the Last Two Decades (1976-1996)
Alexander V. Nemtsov, Ph.D.

F Biological Treatment of Mental Disorders in Russia
Sergey N. Mosolov, M.D.

G Criteria of Depression in General Somatic Practice
Olga P. Vertogradova, Ph.D., Igor L. Stepanov, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 80 2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine, Royal York

MEDICATIONS DEVELOPMENT FOR SUBSTANCE DEPENDENCE
Collaborative Session with the National Institute on Drug Abuse
Chp.: Thomas R. Kosten, M.D.

A Targeted Subgroups for Cocaine Pharmacotherapies
Thomas R. Kosten, M.D.

B Targets for Medication to Prevent Relapse
Charles P. O'Brien, M.D.

C Levomethadyl Acetate Hydrochloride and Buprenorphine Treatment
Eric C. Strain, M.D.

D Cocaine Pharmacotherapy: Human Laboratory Studies
Marian W. Fischman, Ph.D.

E Pharmacotherapy for Opiate and Stimulant Dependence
Frank J. Vocci, Ph.D.

Discussant: Herbert D. Kleber, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 81 2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine, Royal York

HORMONES AND DEPRESSION: TREATMENT IMPLICATIONS
Chp.: Stuart N. Seidman, M.D.

A Testosterone and Male Depression: A Clinical Review
Stuart N. Seidman, M.D.

B Exogenous DHEA and Antiglucocorticoids in Depression
Victor I. Reus, M.D., Owen M. Wolkowitz, M.D.

C Estrogen and Depressive Disorders in Women
Mary F. Morrison, M.D.

D Thyroid Hormones and Mood Disorders
Gregory M. Sullivan, M.D., Julie A. Hatterer, M.D.,
Jack M. Gorman, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 82 2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine, Royal York

PSYCHIATRIC ETHICS: FACING THE 21ST CENTURY
Chp.: Sydney Bloch, M.D.
Co-Chp.: Glen O. Gabbard, M.D.

A Misuse and Abuse of Psychiatry: A Fifty-Year Overview
Paul Chodoff, M.D.

B Professional Boundaries in Psychiatry
Glen O. Gabbard, M.D.

C The Ethics of Managed Mental Health Care
Stephen A. Green, M.D.

D The Ethics of For-Profit Managed Care Is an Oxymoron
Leon Eisenberg, M.D.

E Codes of Ethics and Psychiatry
Sydney Bloch, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 83 2:00 p.m.-5:00 p.m.
Tudor Room 7, Mezzanine, Royal York

ESTROGEN, PROGESTERONE, TESTOSTERONE AND DYSPHORIA
Co-Chps.: Barbara D. Bartlik, M.D., Susan Rako, M.D.

A Estrogen and Testosterone: Natural Antidepressants?
Susan Rako, M.D.

B Menopause, Mood, MAO and Hormone Replacement
Edward L. Klaiber, M.D.

C Sex Therapy in Women with Testosterone Deficiency
Barbara D. Bartlik, M.D.

Discussant: Leslie H. Gise, M.D.
WEDNESDAY

SYMPOSIUM 84  2:00 p.m.-5:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

CUTTING-EDGE POLYPHARMACY FOR MOOD DISORDERS
Chp.: Andrew A. Nierenberg, M.D.

A  Switching Strategies in Refractory Depression
  Maurizio Fava, M.D.

B  Lithium Augmentation of the Newer Antidepressants
  Andrew A. Nierenberg, M.D.

C  The Use of Pindolol to Potentiate Antidepressant Medication
  Pierre Blier, M.D., Richard Bergeron, M.D.

D  Rational Polypharmacy for Refractory Bipolar Disorder
  Andrew L. Stoll, M.D., Marlene P. Freeman, M.D.

E  Inositol: A Novel Augmentation for Mood Disorders
  Robert H. Belmaker, M.D., Joseph A. Levine, M.D.,
  Ora Kofman, Ph.D.

Discussant: Maurizio Fava, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 85  2:00 p.m.-5:00 p.m.
Windsor Room, Mezzanine, Sheraton Centre

OKLAHOMA CITY: TRAUMA AND RENEWAL AFTER TERRORISM
Chp.: Phebe M. Tucker, M.D.
Co-Chp.: Sara Jo Nixon, Ph.D.

A  Terrorism and Community Resilience
  Robert Vincent, Ph.D., Elaine Christiansen, M.S.,
  Sara Jo Nixon, Ph.D., Betty Pfefferbaum, M.D.

B  Terrorism Impacts Oklahoma City Students
  Sandra Allen, Ph.D., Eric Dlugokinski, Ph.D.,
  Sara Jo Nixon, Ph.D., Rick Tivis, M.P.H., Robin Gurwitch, Ph.D.,
  Betty Pfefferbaum, M.D.

C  Traumatic Bereavement in Mothers and Grandmothers
  Suzanne W. Whittlesey, R.N., Betty Pfefferbaum, M.D.,
  James R. Allen, M.D., Phebe M. Tucker, M.D.,
  Nicholas McDonald, Ph.D., Michelle Rosa, Ph.D.,
  Heather Huszti, Ph.D.

D  Trauma and Recovery in Highly Exposed Adults
  Phebe M. Tucker, M.D., Betty Pfefferbaum, M.D.,
  Warren Dixon, Ph.D., Nicholas McDonald, Ph.D.,
  Gwen Allen, M.S.W.

E  Resiliency in Oklahoma City Fire Fighters
  Sara Jo Nixon, Ph.D., John Schorr, Ph.D., Angela Bourdeaus, B.S., Robert Vincent, Ph.D.

Discussant: Bruce D. Perry, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 86  2:00 p.m.-5:00 p.m.
City Hall Room, Second Floor, Sheraton Centre

SOCIETAL AND CULTURAL ADAPTATIONS TO TRAUMA
Chp.: Bessel A. van der Kolk, M.D.
Co-Chp.: Judith L. Herman, M.D.

A  Does Vengeance Heal Psychic Trauma?
  James Gilligan, M.D.

B  Individual and Communal Recovery in Bosnia-Herzegovina
  Judith L. Herman, M.D., Aida Hasimbegovic, Ph.D.,
  Seila Kulenavic-Latal, M.D., Momir Smitran, M.D.,
  N. Becirvev

C  Violence Turns Me On: Nazi Skinhead Adolescents in Germany
  Annette Streeck-Fischer

D  Human Rights Abuses in Turkey: Examples and Challenges
  Sahika Yuksel, M.D.

E  After Apartheid: South Africa's Truth and Reconciliation
  Merle Friedman

3:00 p.m. Session

NEW RESEARCH

POSTER SESSION 12
3:00 p.m.-5:00 p.m.
Room 106, Lower Level, Convention Centre

HEALTH SERVICES AND ANXIETY DISORDERS

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
4:00 p.m. Session

MEDIA SESSION 29
4:00 p.m.-5:00 p.m.
Room 718B, 700 Level, Convention Centre

COMPUTER PRODUCTION WORKSHOP
Co-Chprs.: Russell F. Lim, M.D., Steven E. Hyler, M.D.

7:00 p.m. Sessions

INDUSTRY-SUPPORTED SYMPOSIA 43-47

INDUSTRY-SUPPORTED SYMPOSIUM 43
7:00 p.m.-10:00 p.m.
Auditorium, Lower Level, Convention Centre

NEUROCOGNITION IN SCHIZOPHRENIA
Supported by Janssen Pharmaceutica and Research Foundation
Chp.: Lili C. Kopala, M.D.
Co-Chp.: William C. Wirshing, M.D.
A Neurocognitive Deficits in Schizophrenia: Traits or States?
Keith Nuechterlein, Ph.D.
B Functional Outcome Correlates of Neurocognitive Deficits in Schizophrenia
Michael F. Green, Ph.D.
C Spatial Working Memory in Schizophrenia
Susan R. McGurk, Ph.D.
D Cognitive Deficits in First-Episode Schizophrenia
Kimberley P. Good, Ph.D., Lili C. Kopala, M.D.
E Cognitive Changes with Aging in Schizophrenia
Philip D. Harvey, Ph.D.
F Impact of Antipsychotic Pharmacotherapy on Neurocognition
William C. Wirshing, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 44
7:00 p.m.-10:00 p.m.
Canadian Room, Convention Floor, Royal York

MANAGEMENT OF MENTAL DISORDERS IN BABY BOOMERS AND BEYOND
Supported by Pfizer Inc.
Chp.: Martin B. Keller, M.D.
A Aging and Adaptation to Life and Illness: A Psychiatric Perspective
George E. Vaillant, M.D.
B Late-Life Depression
Donald P. Hay, M.D.
C Anxiety, Agitation and Insomnia
Carl Salzman, M.D.
D Interface of Depression and Medical Illness
Richard C. Veith, M.D.
E Behavioral Symptoms of Alzheimer’s and Other Dementias
Sanford I. Finkel, M.D.

INDUSTRY-SUPPORTED SYMPOSIUM 45
7:00 p.m.-10:00 p.m.
Concert Hall, Convention Floor, Royal York

PREDICTING OUTCOMES OF ANTIDEPRESSANT TREATMENT
Supported by Pharmacia & Upjohn Company, Inc.
Chp.: Andrew F. Leuchter, M.D.
Co-Chp.: Andrew A. Nierenberg, M.D.
A Clinical Predictors of Response to Antidepressants
Andrew A. Nierenberg, M.D., Jordan W. Smoller, M.D.
B Neurophysiologic Predictors of Treatment Response
Ian A. Cook, M.D., Andrew F. Leuchter, M.D.,
Sebastian H.J. Uijtdehaage, Ph.D., Michelle Abrams, R.N., Catherine Anderson-Hanley, Ph.D.,
Susan Rosenberg-Thompson, M.N., Jennifer Dunkin, Ph.D.
C Neurotransmitter Depletion and Outcome in Depression
Pedro L. Delgado, M.D., Francisco A. Moreno, M.D.,
Rebecca L. Potter, M.D., Alan J. Gelenberg, M.D.
D Neuroimaging Indicators of Treatment Effectiveness
Harold A. Sackeim, Ph.D.
E Differential Therapeutic Responses in Depression
Andrew F. Leuchter, M.D., Ian A. Cook, M.D.,
Michelle Abrams, R.N., Catherine Anderson-Hanley, Ph.D.,
Susan Rosenberg-Thompson, M.N.,
Sebastian H.J. Uijtdehaage, Ph.D., Jennifer Dunkin, Ph.D.
Discussant: Barry D. Lebowitz, Ph.D.
WEDNESDAY

INDUSTRY-SUPPORTED SYMPOSIUM 46
7:00 p.m.-10:00 p.m.
Frontenac Ballroom, Street Level, Westin Harbour Castle

THERAPEUTIC CHALLENGES IN GERIATRIC PSYCHIATRY
Supported by Forest Laboratories, Inc.

Chp.: Bruce G. Pollock, M.D.
Co-Chp.: Benoit H. Mulsant, M.D.

A Diagnosis and Biology of Late-Life Depression and Dementia
P. Murali Doraiswamy, M.D.

B The Management of Anxiety in Late Life
Alastair J. Flint, M.B.

C Treatment-Resistant Depression in Late Life
Benoit H. Mulsant, M.D.

D Comorbid Dementia and Depression in Late Life
Barnett S. Meyers, M.D.

E Behavioral Disturbances of Dementia
Bruce G. Pollock, M.D.

Discussant: Carl G. Gottfries, Ph.D.

MEDIA SESSIONS 30-31

MEDIA SESSION 30 7:00 p.m.-10:00 p.m.
Ontario Room, Convention Floor, Royal York

JAPANESE AND VIETNAMESE STORIES OF TRAUMA AND RECOVERY

Chp.: Francis G. Lu, M.D.

56 Momiji: Japanese Maple
(26 minutes)

Distributor: NAATA Distribution
346 Ninth Street, 2nd Floor
San Francisco, CA 94103

The filmmaker offers an intimate and moving documentary about three generations of her Japanese-Canadian family. We see the psychological issues raised from her grandparents’ immigration to Canada, internment during WWII (similar to the fate of the Japanese Americans), through the prosperous but intolerant 1950s and 1960s, and the present multicultural family.

57 Kim’s Story: The Road from Vietnam
(48 minutes)

Distributor: First Run Icarus Films
153 Waverly Place
New York, NY 10014

If there was one photograph that captured the horrific nature of the Vietnam War, it was that of a nine-year-old girl running naked down a road, screaming in agony from napalm burns that had eaten into her flesh. The photographer who took that picture of young Kim Phuc was awarded a Pulitzer Prize. Four years ago, she and her husband defected to Toronto, Canada, where they were given initial sanctuary by Quaker activist Nancy Pocock. In telling Kim’s story, award-winning filmmaker Shelley Saywell filmed doctors and journalists who ensured her survival 25 years ago. In order to confront her past, Kim comes to
America, where she meets many people who help fill in the holes of her story, the things she cannot remember or knew only from the perspective of an injured child. The climactic end shows her speaking at a Veterans' Day ceremony at Washington's Vietnam War Memorial and meeting a veteran who claimed responsibility for ordering the napalm strike that almost killed her.

58 The Shot Heard Round the World
(67 minutes)

Distributor: Filmmakers Library
124 East 40th Street
New York, NY 10016

When Yoshi Hattori, a Japanese high school exchange student, was shot to death in 1993 by a suburban homeowner, the whole world was shocked once again at America's gun culture. Christine Choy, director of the award-winning film Who Killed Vincent Chin? spent three years researching the event and the ensuing criminal and civil trials. The result is this searing study of the pathology of urban fear, gun violence, criminal justice and cultural miscommunication. Yoshi had approached the Baton Rouge home of Rodney and Bonnie Peairs seeking directions to a Halloween party. Bonnie feared the stranger walking up her driveway and summoned her husband. Gun in hand, Rodney shouted "freeze" to which Yoshi, unfamiliar with the idiom, did not comply. Rodney then pulled the trigger. Yoshi's parents, who had raised their son to admire America, suffered their loss with dignity. They recall their son as an honor student who enjoyed life with his host family and was well liked by his new classmates. Rodney Peairs had an extensive gun collection. The film does not take sides regarding his claim that he was defending his rights as a homeowner. Avoiding simple answers, it serves up a complex picture, letting the audience draw their own conclusions about one of the most controversial criminal cases in recent years.

SYMPOSIUM 87-94

SYMPOSIUM 87 7:00 p.m.-10:00 p.m.
Room 205D, Street Level, Convention Centre

THE ROLE OF COERCION IN PSYCHIATRY

Chp.: Roger Peele, M.D.
Co-Chp.: M. Jeanne Spurlock, M.D.

A Coercion of Motivation: General Issues
Naomi B. Heller, M.D.

B The History of Involuntary Treatment
John P. Shemo, M.D.

C The History of Involuntary Treatment of Those with Addiction
William W. Van Stone, M.D.

D The Role of Coercion in Hospital Management
Lynn DeLacy, M.S.

E The Role of Coercion in Treatment of the Homeless Mentally Ill
Lien A. Hung, M.D.

Discussants: Paul Chodoff, M.D., M. Jeanne Spurlock, M.D.

This session will be audiorecorded.

PSYCHIATRIC PERSPECTIVES ON RACE AND BOXING

Chp.: Ian R. Tofler, M.B.

59 When We Were Kings: The Untold Story of the Rumble in the Jungle
(180 minutes)

Distributor: Swank Motion Pictures, Inc.
350 Vanderbilt Motor Parkway
Hauppauge, NY 11787

This award-winning documentary is the untold story of the events and activities leading up to the boxing match between Mohammed Ali and George Foreman in Zaire in 1974. This program will address how the issues presented in this film affect the 1990s United States' racial relationships as seen in the world of sports. How sporting events transcend many societal boundaries will be discussed, and the importance of role models from professional sports will be evaluated. At the conclusion of this film, the panel will also discuss the role a violent sport, such as boxing, plays and what impact it has on the collective consciousness of the United States. This session, presented by members of the International Society for Sport Psychiatry, will explore the issues in the film with a focus on the response to the film by different demographic groups in the United States.

Discussants: Joshua W. Calhoun, M.D., Ronald L. Kamm, M.D.

SYMPOSIUM 87 7:00 p.m.-10:00 p.m.
Room 205D, Street Level, Convention Centre

THE ROLE OF COERCION IN PSYCHIATRY

Chp.: Roger Peele, M.D.
Co-Chp.: M. Jeanne Spurlock, M.D.

A Coercion of Motivation: General Issues
Naomi B. Heller, M.D.

B The History of Involuntary Treatment
John P. Shemo, M.D.

C The History of Involuntary Treatment of Those with Addiction
William W. Van Stone, M.D.

D The Role of Coercion in Hospital Management
Lynn DeLacy, M.S.

E The Role of Coercion in Treatment of the Homeless Mentally Ill
Lien A. Hung, M.D.

Discussants: Paul Chodoff, M.D., M. Jeanne Spurlock, M.D.

This session will be audiorecorded.
SYMPOSIUM 88  7:00 p.m.-10:00 p.m.
Room 206D, Street Level, Convention Centre

FINDING THE PERSON IN WRITING ABOUT PATIENTS
Chp.: John S. Strauss, M.D.
A Katherine Holden: A Patient
   Jeanne L. Steiner, D.O.
B The Reunion
   Jaak Rakfeldt, Ph.D.
C On Rounds in a Psychiatric Hospital
   Dolly D. Jacobson, M.S.W.
D Jorge’s Story
   Carole T. Goldberg, Ph.D.
E The Portrait
   Charles D. Atkins, M.D.
Discussant: Leston L. Havens, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 89  7:00 p.m.-10:00 p.m.
Room 206F, Street Level, Convention Centre

FRENCH AND AMERICAN: VIVE LA DIFFERENCE!
Chp.: Simon-Daniel Kipman, M.D.
Co-Chp.: John A. Talbott, M.D.
A Is There a Cultural Psychiatry in France?
   Jean-Charles Pascal, M.D., Alexandra MacLean, M.D.
B Is There a Cultural Psychiatry in America?
   Rodrigo A. Muñoz, M.D.
C The Treatment of Substance Abuse in France
   Simon-Daniel Kipman, M.D.
D The Treatment of Substance Abuse in America
   Robert B. Millman, M.D.
E A Day in the Life of a French Psychiatrist with a Liberal Practice
   Jean-Michel Thurin, M.D.
F A Day in the Life of a Psychiatrist in America
   Robert Micheils, M.D.
Discussants: Gerald J. Sarwer-Foner, M.D., Alexandra MacLean, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 90  7:00 p.m.-10:00 p.m.
Room 104A, Lower Level, Convention Centre

MUSIC THERAPY IN PSYCHIATRIC CARE
Chp.: John S. McIntyre, M.D.
Co-Chp.: Bryan C. Hunter, Ph.D.
A Music Therapy and Psychiatry: An Overview
   John S. McIntyre, M.D.
B Music Therapy for an Aging Population
   David S. Smith, Ph.D.
C Music Therapy for Short-Term Inpatient Psychiatric Treatment
   Carol L. Shultis, M.Ed.
D Music-Assisted Cognitive-Behavioral Interventions
   Thomas H. Kerr, M.A.
E Reimbursement for Music Therapy Services
   Bryan C. Hunter, Ph.D.
Discussant: Robert I. Slayton, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 91  7:00 p.m.-10:00 p.m.
Room 104B, Lower Level, Convention Centre

COMPUTER-ASSISTED PSYCHOTHERAPY
Chp.: Robert A. Bailey, M.D.
Co-Chp.: Edward M. Kovachy, Jr., M.D.
A Computer-Assisted Treatment of Dual-Diagnosis Patients
   Robert J. Bischoff, Ph.D.
B Therapy Partner: A Computer-Assisted Psychotherapy Program
   Robert A. Bailey, M.D., Edward M. Kovachy, Jr., M.D.,
   Jerrold L. Shapiro, Ph.D., Alan Cooper, B.A., Amy Goldfein, Ph.D.
C Computer-Assisted Psychotherapy for Brief Treatment Groups
   Jerrold L. Shapiro, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 92 7:00 p.m.-10:00 p.m.
Room 104C, Lower Level, Convention Centre
CURRENT PERSPECTIVES ON PSYCHIATRY AND RELIGION
Chp.: James K. Boehnlein, M.D.
A A Cross-Cultural Perspective of Psychiatry and Religion
Ronald M. Wintrob, M.D., Charles C. Hughes, Ph.D.
B Cults and New Religious Movements
Marc Galanter, M.D.
C Religion and Psychiatry: Bioethics As Arbiter of Mutual Respect
Laurence J. O'Connell, Ph.D.
D Psychiatry and Religion: Changes in Research and Training
David B. Larson, M.D., James L. Collins, M.D.
Discussant: Edward F. Foulks, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 93 7:00 p.m.-10:00 p.m.
Alberta Room, Mezzanine, Royal York
PSYCHOTHERAPIES IN COMMUNITY PSYCHIATRY
Joint Session with the American Association of Community Psychiatrists
Chp.: David A. Moltz, M.D.
A Psychotherapies in Community Psychiatry
Clifton R. Tennison, Jr., M.D.
B Psychotherapies and Psychosis
Joel S. Feiner, M.D.
C Psychotherapy for People of Color with Serious Mental Illness
Andres J. Pumariega, M.D.
D Family Psychoeducation: Outcome and Application
William R. McFarlane, M.D.
E Biopsychosocial Treatments for Depressed Patients
Gabor I. Keitner, M.D., Christine E. Ryan, Ph.D., Ivan W. Miller, Ph.D., David A. Solomon, M.D.
THIS SESSION WILL BE AUDIOTAPE.

GENETICS OF PERSONALITY AND BEHAVIOR
Chp.: John M. Oldham, M.D.
Co-Chp.: Andrew E. Skodol II, M.D.
A Genetics of Personality and Behavior
Kathleen R. Merikangas, Ph.D., Joel Swendsen, Ph.D., Martin Preisig, M.D.
B The Genetic Structure of Personality Disorder Traits
John Livesley, M.D., Kerry L. Jang, Ph.D.
C Gene Mapping of Human Personality Traits
C. Robert Cloninger, M.D.
D Genetics of Antisocial Personality Disorder
Remi J. Cadoret, M.D., Kristin Caspers, Ph.D., Douglas R. Langbehn, M.D.
E Genetics of Schizotypal and BPD
Larry J. Siever, M.D.
Discussant: Alan M. Gruneberg, M.D.
THIS SESSION WILL BE AUDIOTAPE.
American Psychiatric Association

Audiotapes
Recorded Live!

High Quality Continues for the 1998 Annual Meeting ...

Live recordings will be available for most of the following:

- Lectures
- Advances in Research
- Medical Updates
- Symposia
- Scientific and Clinical Reports
- Round Table Discussion
- Debate
- Practice Guidelines Update
- Research Advances in Medicine

Tapes may be purchased on site at Mobiltape's booth at the Convention Centre.

Mobiltape Company, Incorporated
24730 Avenue Tibbitts, Suite 170
Valencia, CA 91355
Phone: (805) 295-0504 (800) 369-5718
Website: www.mobiltape.com
THURSDAY, JUNE 4, 1998

151ST ANNUAL MEETING

8:00 a.m. Sessions

COURSES 93-97
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 93 8:00 a.m.-12 noon
Room 702, 700 Level, Convention Centre
MANAGING THE FEAR OF VIOLENCE
Director: Arthur Z. Berg, M.D.

COURSE 94 8:00 a.m.-12 noon
Room 705, 700 Level, Convention Centre
TIME-LIMITED DYNAMIC THERAPY FOR DIFFICULT PATIENTS
Director: Hanna Levenson, Ph.D.

COURSE 95 8:00 a.m.-12 noon
Room 707, 700 Level, Convention Centre
COGNITIVE-BEHAVIORAL TREATMENT OF SPECIFIC PHOBIAS
Co-Directors: Martin M. Antony, Ph.D., Richard P. Swinson, M.D.

COURSE 96 8:00 a.m.-12 noon
Room 708, 700 Level, Convention Centre
PARTIAL HOSPITALIZATION FOR PATIENTS WITH BPD
Director: Lawrence L. Kennedy, M.D.

COURSE 97 8:00 a.m.-12 noon
Room 709, 700 Level, Convention Centre
VIDEO REVIEW OF NEUROPSYCHIATRIC CONDITIONS
Co-Directors: Thomas E. Hansen, M.D., Edward C. Lauterbach, M.D.
Faculty: Dietrich P. Blumer, M.D., Brendan T. Carroll, M.D.

9:00 a.m. Sessions

COURSE 98-100
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSES 98-100
Course descriptions are available in the CME Course Brochure included in your registration packet. Admission by ticket only.

COURSE 98 9:00 a.m.-4:00 p.m.
Room 711, 700 Level, Convention Centre
MULTIMODAL THERAPY OF SEVERE EATING DISORDERS
Director: Kathryn J. Zerbe, M.D.

COURSE 99 9:00 a.m.-4:00 p.m.
Room 713A, 700 Level, Convention Centre
DIAGNOSTIC CHALLENGES IN NEUROPSYCHIATRY
Co-Directors: Patricia I. Rosebush, M.D., Michael F. Mazurek, M.D.
Faculty: Sarah Garside, M.D., Anthony J. Levinson, M.A.

COURSE 100 9:00 a.m.-4:00 p.m.
Room 716A, 700 Level, Convention Centre
DEMENTIA: ADVANCED DIAGNOSIS AND TREATMENT
Director: William E. Reichman, M.D.
Faculty: Jeffrey L. Cummings, M.D., David L. Sultzer, M.D., Jacobo E. Mintzer, M.D., Peter M. Aupperle, M.D.

9:00 a.m. Sessions

CLINICAL CASE CONFERENCE 4
9:00 a.m.-10:30 a.m.
Caledon Room, Lobby Level, Crowne Plaza
PSYCHOTHERAPY WITH PERSONS WITH HIV CONSIDERING PROTEASE INHIBITORS
Presenter: Warren M. Liang, M.D.
Discussant: Francine Cournos, M.D.

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.
THE Relevance of Justice to the Victims of Human Rights Abuses

Chp.: Deborah Spitz, M.D.
Co-Chp.: Karla A. Blackwood, M.D.

Countries emerging from periods of serious violations of human rights face a range of options, from impunity to criminal prosecution, for dealing with those thought to be responsible for the violations. Richard Goldstone, Justice of the Constitutional Court of South Africa, discusses whether truth commissions are an appropriate mechanism, examines how impunity has frequently resulted in further abuses and evaluates the effects of the South African Truth and Reconciliation Commission. Justice Goldstone was appointed to the Constitutional Court in 1994. He is head of the board of the Human Rights Institute of South Africa and president of the National Institute of Crime Prevention and the Rehabilitation of Offenders. In addition, he is Chancellor of the University of Witwatersrand in Johannesburg and a member of the Board of the university’s School of Law. From 1991 to 1994 he served as chairperson of the Commission of Inquiry Regarding Public Violence and Intimidation, which became known as the Goldstone Commission. From 1994 to 1996 he served as the chief prosecutor of the United Nations International Criminal Tribunals for the former Yugoslavia and Rwanda. He is a member of the International Panel established in 1997 by the Government of Argentina to monitor that country’s inquiry into Nazi activities in the Argentine Republic since 1938. The many awards he has received locally and internationally include the International Human Rights Award of the American Bar Association. Justice Goldstone trained in law at the University of Witwatersrand.

INTERNATIONAL LECTURE SERIES

THIS SESSION WILL BE AUDIOTAPED.
We are unaccustomed to thinking of end-stage renal disease (ESRD) as a terminal illness, yet its mortality rate is higher than that associated with HIV or many types of cancer. While dialysis or transplantation sustain life, the underlying disease responsible for causing renal failure often continues its inexorable progress. The adjusted mortality rate for hemodialysis patients is 21.3/100 dialysis years, and the risk of death for a 45-year-old maintained with dialysis is 20 times that of someone of the same age not on dialysis. Treatment can become a Sisyphean ordeal, and cessation of dialysis is increasingly an option. In New England, 24% of ESRD patient deaths are now preceded by dialysis discontinuation. Advance directives, such as living wills or health care proxies, are completed by only about 4% of our patients with ESRD. Perhaps not surprisingly, in a survey of the nephrologists and surgeons who care for these patients, only one out of 11 doctors had completed his/her own advance directive. We propose to establish a Renal Palliative Care Initiative to improve the terminal treatment of individuals with ESRD. As part of the program, this videotape will be used to promote discussion of end-of-life issues between patients, their families and staff.

Discussant: Lewis M. Cohen, M.D.

62 The Nicholas Effect
(12 minutes)

Distributor: Corporate Productions, Inc.
Attention: Dick Ridgeway
4516 Mariota Avenue
Toluca Lake, CA 91602

In 1994, seven-year-old Nicholas Green was murdered during a robbery while vacationing in Italy with his parents and sister. This moving video recaptures the decision of Californians Maggie and Reg Green to donate some of their son’s organs (and tissue) to enable others to live and to have a future that Nicholas was denied. Footage of the boy at school, his funeral services and the Greens revealing facts about some of the individuals who benefitted from their altruism are sure to encourage others to emulate this charitable deed. These parents have transformed their private pain into increased public awareness of the need for organ donation.

NEW RESEARCH

ORAL/SLIDE SESSIONS 13-14
9:00 a.m.-10:30 a.m.

13 PSYCHOPHARMACOLOGY
Room 205B, Street Level, Convention Centre

14 MOOD DISORDERS, PSYCHOIMMUNOLOGY,
VIOLENCE, BRAIN IMAGING, AND TRAUMA AND
VICTIMIZATION
Room 205D, Street Level, Convention Centre

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.
THURSDAY

REVIEW OF PSYCHIATRY: PART VI
9:00 a.m.-12:30 p.m.
Room 105, Lower Level, Convention Centre

ADDITIONS
Collaborative Session with the National Institute on Drug Abuse
Chp.: Elinore F. McCance-Katz, M.D.

27 Substance Abuse and HIV Disease: Entwined and Intimate Entities
Robert P. Cabaj, M.D.

28 Contemporary Issues in Dual Diagnosis
H. Westley Clark, M.D.

29 Alcohol Dependence: Sex, Gender and Medications
Myroslava K. Romach, M.D.

30 Opiate Dependence and Current Treatments
Susan M. Stine, M.D.

31 Current Issues in Nicotine Dependence and Treatment
Douglas M. Ziedonis, M.D.

WORKSHOPS

COMPONENTS 50-54

COMPONENT WORKSHOP 50 9:00 a.m.-10:30 a.m.
Room 205A, Street Level, Convention Centre

PSYCHIATRIC DIMENSIONS OF DISASTERS
APA Committee on Psychiatric Dimensions of Disasters
Chp.: Robert J. Ursano, M.D.
Participants: Michael Blumenfield, M.D., Ann E. Norwood, M.D.

COMPONENT WORKSHOP 51 9:00 a.m.-10:30 a.m.
Room 206A, Street Level, Convention Centre

PRINCIPLES OF ABUSE AND MISUSE OF PSYCHIATRY
APA Committee on Abuse and Misuse of Psychiatry in the United States
Co-Chps.: Margaret F. Jensvold, M.D., Eric A. Plaut, M.D.
Participants: Alban J. Coghill, M.D., Abraham L. Halpern, M.D., Andrew Siegel, M.D.

COMPONENT WORKSHOP 52 9:00 a.m.-10:30 a.m.
Room 206B, Street Level, Convention Centre

SEX AND POWER IN THE WORKPLACE: YOUR ROLE AND LIABILITY
APA Committee on Occupational Psychiatry
Chp.: Marcia Scott, M.D.
Participants: Nada L. Stotland, M.D., Peter Petesch, J.D., Leora Rosen, Ph.D., Robert C. Larsen, M.D.

COMPONENT WORKSHOP 53 9:00 a.m.-10:30 a.m.
Kingsway Room, Lobby Level, Crowne Plaza

PSYCHOTHERAPY WITH LESBIANS AND BISEXUAL WOMEN
APA Northern California Psychiatric Society's Committee on Gay, Lesbian and Bisexual Issues
Chp.: Ellen Haller, M.D.
Participants: Karin L. Hastik, M.D., Kathryn J. Lee, M.D.

COMPONENT WORKSHOP 54 9:00 a.m.-10:30 a.m.
Oakville Room, Lobby Level, Crowne Plaza

CHANGING MODELS OF RURAL MENTAL HEALTH CARE
APA Corresponding Task Force on Rural Psychiatry
Chp.: Stuart A. Copans, M.D.
Participants: James L. Day, M.D., Diane K. Fast, M.D., Richard T. Palmisano, M.S., Edward Gordon, M.D.

ISSUES 91-105

ISSUE WORKSHOP 91 9:00 a.m.-10:30 a.m.
Room 205C, Street Level, Convention Centre

INTERVENTION PROGRAMS FOR MEDICAL STUDENT STRESS
Co-Chps.: Paul K. Dagg, M.D., Mark H. Ujjainwalla, M.D.

ISSUE WORKSHOP 92 9:00 a.m.-10:30 a.m.
Room 206C, Street Level, Convention Centre

A COMPARISON OF EUROPEAN AND AMERICAN PSYCHIATRY
Co-Chps.: Michael A. Schwartz, M.D., Bill Fulford, M.D.
Participants: Jean Naudin, M.D., Donald M. Mender, M.D., Elena B. Bezubova, M.D.

ISSUE WORKSHOP 93 9:00 a.m.-10:30 a.m.
Room 206D, Street Level, Convention Centre

OUTPATIENT COMMITMENT: THE NEW YORK EXPERIENCE
Chp.: Howard W. Telson, M.D.
Participants: Manuel Trujillo, M.D., Luis R. Marcos, M.D., Michael S. Lesser, M.D., Henry J. Steadman, Ph.D.
<table>
<thead>
<tr>
<th>Workshop 94</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Room 104D, Lower Level, Convention Centre</td>
<td></td>
</tr>
<tr>
<td>MATCHING DRUG-ADDICTED PATIENTS TO SERVICES</td>
<td></td>
</tr>
<tr>
<td>Collaborative Session with the National Institute on Drug Abuse</td>
<td></td>
</tr>
<tr>
<td>Chp.: Peter Delany, D.S.W.</td>
<td></td>
</tr>
<tr>
<td>Participants: David R. Gastfriend, M.D., Andrea Barthwell, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 95</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humber Room, Lobby Level, Crowne Plaza</td>
<td></td>
</tr>
<tr>
<td>ETHICS IN MANAGING DEPRESSION DURING PREGNANCY</td>
<td></td>
</tr>
<tr>
<td>Chp.: John H. Coverdale, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participant: Laurence B. McCullough, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 96</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toronto Room, Convention Floor, Royal York</td>
<td></td>
</tr>
<tr>
<td>INSANITY LAWS AND PERSONALITY DISORDERS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Alan R. Felthous, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Ernest S. Barratt, M.D., John M.W. Bradford, M.B., Henning Sass, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 97</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alberta Room, Mezzanine, Royal York</td>
<td></td>
</tr>
<tr>
<td>MEDICOLEGAL IMPLICATIONS OF NOVEL ANTI-Psychotics</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Douglas Mossman, M.D., Douglas S. Lehrer, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 98</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>British Columbia Room, Mezzanine, Royal York</td>
<td></td>
</tr>
<tr>
<td>EMPLOYMENT DISABILITY AND ACCOMMODATION DILEMMAS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Harold J. Bursztajn, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Patricia Illingworth, J.D., Margaret Somerville, M.D., Michael L. Perlin, J.D., Rodney J.S. Deaton, M.D., J.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 99</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manitoba Room, Mezzanine, Royal York</td>
<td></td>
</tr>
<tr>
<td>CULTURAL COMPETENCE AND THE HAITIAN PATIENT</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Jacques Vital-Herne, M.D., Pierre A. Jean-Noel, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Jean B. Trophas, M.D., Georges J. Casimir, M.D., Joel Pierre-Louis, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 100</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tudor Room 7, Mezzanine, Royal York</td>
<td></td>
</tr>
<tr>
<td>TRAINING FOR PSYCHIATRIC ADMINISTRATION</td>
<td></td>
</tr>
<tr>
<td>Joint Session with the American Association of Psychiatric Administrators</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: L. Mark Russakoff, M.D., Paul A. Rodenhausser, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 101</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference Room B, Mezzanine, Sheraton Centre</td>
<td></td>
</tr>
<tr>
<td>UNWELCOME TREATMENT? TREATING THE MANDATED PATIENT</td>
<td></td>
</tr>
<tr>
<td>Chp.: Susan Stabinsky, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Harvey Stabinsky, M.D., Michael M. Scimeca, M.D., David W. Preven, M.D., Ali Khadivi, Ph.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 102</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference Room F, Mezzanine, Sheraton Centre</td>
<td></td>
</tr>
<tr>
<td>BEYOND MEDICAL SCHOOL: THE MBA ADVANTAGE</td>
<td></td>
</tr>
<tr>
<td>Chp.: Arthur L. Lazarus, M.D., M.B.A.</td>
<td></td>
</tr>
<tr>
<td>Participants: Adele C. Foley, John S. Lloyd, M.B.A.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 103</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>York Room, Mezzanine, Sheraton Centre</td>
<td></td>
</tr>
<tr>
<td>CONSCIENCE-CENTERED PSYCHIATRIC ETHICS</td>
<td></td>
</tr>
<tr>
<td>Co-Chps.: Matthew R. Galvin, M.D., Margaret Gaffney, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participant: Barbara Stilwell, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 104</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dufferin Room, Second Floor, Sheraton Centre</td>
<td></td>
</tr>
<tr>
<td>UNDERSTANDING THE DYNAMICS OF ABUSIVE RELATIONSHIPS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Gary J. Maier, M.D.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop 105</th>
<th>9:00 a.m.-10:30 a.m.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kenora Room, Second Floor, Sheraton Centre</td>
<td></td>
</tr>
<tr>
<td>EXECUTIVE DISTRESS: THREE TREATMENT MODELS</td>
<td></td>
</tr>
<tr>
<td>Chp.: Jeffrey P. Kahn, M.D.</td>
<td></td>
</tr>
<tr>
<td>Participants: Kenneth Eisdol, Ph.D., Miguel A. Leibovich, M.D.</td>
<td></td>
</tr>
</tbody>
</table>
THURSDAY

11:00 a.m. Sessions

DISCUSSION GROUP 13
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.
David A. Goldberg, M.D., on Psychotherapy Education (For Residents Only)
Confederation Room 4, Mezzanine, Royal York

MASTER EDUCATOR CLINICAL CONSULTATION 18
11:00 a.m.-12:30 p.m.
This session is limited to 25 participants on a first-come, first-served basis.
Anthony L. Rostain, M.D., on Treatment of Adolescents with Complex ADHD and Tourette's Syndrome
New Brunswick Room, Mezzanine, Royal York

THIS SESSION IS OPEN TO APA MEMBERS ONLY. BLUE REGISTRATION BADGE OR APA MEMBERSHIP CARD REQUIRED FOR ADMITTANCE.

MEDIA SESSIONS 34-35

MEDIA SESSION 34  11:00 a.m.-12:30 p.m.
Ontario Room, Convention Floor, Royal York
TRANSRACIAL ADOPTION
Chp.: Russell F. Lim, M.D.
64 Whose Child Is This? (50 minutes)
Distributor:! Filmakers Library
124 East 40th Street
New York, NY 10016

After the Indian tribes were vanquished in North America, the governments of the United States and Canada systematically destroyed their cultures as well. Young children were taken from the tribes and sent to missionary and government residential schools where they were not allowed to use their native language. By the time the schools closed in the 1960s, six generations had grown up without their parents, in alien environments. Having no parental models, they became poor parents themselves, prey to alcoholism and apt to be abusive. Often their babies would be whisked away for adoption by stable white families by social workers who deemed their Indian families unlikely to provide an appropriate environment. Thus, the tribes would lose many of their children. This film looks at several families in which adults have been repatriated. At 16 months Katrina was adopted by a loving Scottish family, which returned with her to Scotland. As she grew up, she felt increasingly alienated from the White society that surrounded her. Now a mother of a four-year-old, she returns to Alert Bay to find her roots. The film shows that it is a complicated emotional process to re-establish native ties on a reservation. In Idaho, a young Lakota boy is being claimed by his biological father. The White adoptive parents fear the trauma of separation could be devastating. There is an active tribal organization that scours the world for lost Native-American children and fosters repatriation. The film reveals both well-meaning and exploitive adoptive families and the wrenching process of trying to heal old wounds.

MEDIA SESSION 35  11:00 a.m.-12:30 p.m.
Civic Ballroom, Second Floor, Sheraton Centre
RESILIENCY ARISING FROM DESPAIR IN RURAL AMERICA
Chp.: Pierre A. Rioux, M.D.
65 Where Have All the Children Gone? The Crisis in Rural Communities (55 minutes)
Distributor: Filmakers Library
124 East 40th Street
New York, NY 10016

Focusing on North Dakota, this thoughtful documentary looks at the crisis facing many rural communities. What these communities are facing is the abandonment of farms, the departure of young people, closures of local schools and failures of small businesses. This is a poignant portrait of people who love their land but are being forced out by economic circumstances beyond their control. The attachment to the land is expressed by author Kathleen Norris, who evokes the unique beauty of the prairie. The filmmaker was one of the 12 children featured in this documentary who grew up in North Dakota. Only two remain in the state. She shows the hard economic reality with which the farmers struggle as family farms no longer support a new generation. The broader implication is that an entire region of our country could become a wasteland. How can this trend be reversed? Among the possible solutions shown are the more profitable business of processing the farm products locally rather than shipping such commodities to out-of-state food-processing plants. We see one co-op that is starting to do this. There is no single solution to this problem which demands national attention.
THURSDAY

MEDICAL UPDATE 4
11:00 a.m.-12:30 p.m.
Room 104C, Lower Level, Convention Centre

PREGNANCY OUTCOME FOLLOWING THE USE OF ANTIDEPRESSANTS
Chp: Jennifer I. Downey, M.D.
Presenter: Irena Nulman, M.D.
THIS SESSION WILL BE AUDIOTAPE.
THURSDAY

99 Accuracy of Memory Reporting by Patients with HIV Disease 11:30 a.m.
Sean B. Routke, Ph.D., Mark H. Halman, M.D.,
Chris Bassel, M.A.

100 For What DSM-IV Disorders Do Outpatients Want Treatment? 12 noon
Jill I. Mattia, Ph.D., Mark Zimmerman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 34
11:00 a.m.-12:30 p.m.
Caledon Room, Lobby Level, Crowne Plaza

DIAGNOSTIC ISSUES IN PTSD
Chp.: Nelli L. Mitchell, M.D.
Co-Chp.: Suk-Whan Oh, M.D.

101 Comorbidity of Complex PTSD and OCD
Susan Mirow, M.D. 11:00 a.m.

102 PTSD Following an Earthquake in Southern India: A Study of 1,582 Individuals
Shamsah B. Sonawalla, M.D., Rajesh M.
Parikh, M.D., Rakesh Jain, B.A., Neha Gada, B.A.,
Minnmayi Kulkarni, B.A., Shona Vas, B.A., Marissa
D'Mello, M.A.

103 Psychiatric Symptoms Following an Earthquake
Rajesh M. Parikh, M.D., Shamsah B.
Sonawalla, M.D., Diaple Sham, M.A., Marissa
D'Mello, M.A., Terence Quadros, M.A., Thomas
Puliyel, M.A.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 35
11:00 a.m.-12:30 p.m.
Ontario Room, Lower Level, Crowne Plaza

EATING DISORDERS
Chp.: David C. Jimerson, M.D.
Co-Chp.: Gerard Sanacora, M.D.

104 Feedback of Activity in the Treatment of Obesity
11:00 a.m.
Daniel J. Safer, M.D., Richard P. Allen, Ph.D.,
Thomas A. Wadden, Ph.D.

105 Self-Help for Binge Eating Disorder 11:30 a.m.
Jacqueline Carter, D.Phil., Christopher G.
Fairburn, D.M.

106 Attachment Dynamics of Eating Disorders
12 noon
Marc A. Lindberg, Ph.D., Stuart W. Thomas, Ph.D.,
Colleen Opell, M.A.
THIS SESSION WILL BE AUDIOTAPED.

107 Educating Medical Students About Physician-Patient Sex 11:00 a.m.
John H. Coverdale, M.D.

108 Increasing the Pool of AMG Psychiatry Applicants 11:30 a.m.
Walter Weintraub, M.D., S. Michael Plaut, Ph.D.,
Eric Weintraub, M.D.

109 Changing Medical Student Attitudes About Spanking 12 noon
Amy C. Brodkey, M.D., Edward Gracely, Ph.D.,
Beth Rabin, M.A., Irwin Hyman, Ph.D., Mindy
Rothbart, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SCIENTIFIC AND CLINICAL REPORT SESSION 37
11:00 a.m.-12:30 p.m.
Quebec Room, Mezzanine, Royal York

COMORBID DEPRESSION, PERSONALITY DISORDER
AND SUBSTANCE MISUSE
Chp.: Douglas Mossman, M.D.
Co-Chp.: Clifford A. McNaughton, M.D.

110 Alcohol Consumption in Mood and Anxiety Disorders 11:00 a.m.
Mark H. Pollack, M.D., John J. Worthington III, M.D.,
Maurizio Fava, M.D., Michael W. Otto, Ph.D.,
Bonnie Zucker, B.S., Jerrold F. Rosenbaum, M.D.,
Robert Gould, Ph.D.

111 Personality and Substance Misuse in Families 11:30 a.m.
Collaborative Presentation with the National Institute on Drug Abuse
Stewart Gabel, M.D., Michael C. Stallings, Ph.D.,
Stephanie Schmitz, Ph.D., Susan E. Young, Ph.D.,
Thomas J. Crowley, M.D., David W. Fulker, Ph.D.

112 A Prospective Analysis of Depression and Heavy Drinking in Women 12 noon
Anita R. Dixit, M.H.S., Rosa Maria Crum, M.D.
THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SCIENTIFIC AND CLINICAL REPORT SESSION 38
11:00 a.m.-12:30 p.m.
Tudor Room 7, Mezzanine, Royal York

EMERGING TRENDS IN THE MANAGEMENT OF
PSYCHIATRIC ILLNESS
Chp.: Donald A. Wasylenki, M.D.
Co-Chp.: Antonio Pacheco, M.D.

113 Current Prescribing Practices for Bipolar Patients
11:00 a.m.
Eric D. Peselow, M.D., Ronald R. Fieve, M.D.,
Lara Fieve

114 Medicare Review Enhancement of Psychiatric
Consultation 11:30 a.m.
Joseph L. Antonowicz, M.D., Michael W.
Kaufmann, M.D.

115 Use of the New Antiepileptic Drug Topiramate As
a Mood Stabilizer 12 noon
David B. Marcotte, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 39
11:00 a.m.-12:30 p.m.
City Hall Room, Second Floor, Sheraton Centre

PSYCHOSOCIAL FACTORS IN VIOLENCE AND RISK FOR
SELF-HARM
Chp.: John W. Thompson, Jr., M.D.
Co-Chp.: Jose M. Silveira, M.D.

116 Religious Delusions and Self-Harm: Suicide
11:00 a.m.
Gary J. Maier, M.D., Lynn Burgess, B.S.N., Edwin
Foster, B.S.

117 Violence in the Lives of Adult Borderline Patients
11:30 a.m.
Mary C. Zanarini, Ed.D., Frances R.
Frankenburg, M.D., D. Bradford Reich, M.D.,
Margaret F. Marino, Ph.D., Michelle C. Haynes, A.B.

118 Spousal Homicide and Extended Suicide in
Quebec 12 noon
Dominique Bourget, M.D., Pierre W. Lagne, M.D.,
Javad Moamai, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SCIENTIFIC AND CLINICAL REPORT SESSION 40
11:00 a.m.-12:30 p.m.
Huron Room, Second Floor, Sheraton Centre

SEEING CLEARLY IN PSYCHIATRIC RESEARCH
Chp.: Norman E. Rosenthal, M.D.
Co-Chp.: Driss Moussaoui, M.D.

119 Bright Light Therapy for Bulimia Nervosa
11:00 a.m.
Devra L. Braun, M.D., Suzanne R. Sunday, Ph.D.,
Victor M. Fornari, M.D., Katherine A. Halmi, M.D.

120 The Validity of Autobiographical Memory
11:30 a.m.
Daniel Offer, M.D., Marjorie Kaiz, B.S., Kenneth I.
Howard, Ph.D., Emily S. Bennett, M.S.

121 How Blind Is Double-Blind? 12 noon
Michael Sobel, M.D., Eric D. Peselow, M.D.,
Ronald R. Fieve, M.D.

THIS SESSION WILL BE AUDIOTAPE.

WORKSHOPS

COMPONENTS 55-60

COMPONENT WORKSHOP 55 11:00 a.m.-12:30 p.m.
Room 205A, Street Level, Convention Centre

PATHOLOGY TO PRIDE: EVOLVING VIEWS OF
HOMOSEXUALITY
APA New York County District Branch's Committee
on Gay and Lesbian Issues
Co-Chps.: Kenneth B. Ashley, M.D., Laura J.
Bernay, M.D.
Participant: Robert J. Mitchell, M.D.

COMPONENT WORKSHOP 56 11:00 a.m.-12:30 p.m.
Room 206B, Street Level, Convention Centre

FIGHTING MANAGED CARE COMPANIES: EMPLOY-
MENT RETIREMENT INCOME SECURITY ACT (ERISA)
LIMITATIONS
APA Council on Psychiatry and Law, APA Commission
on Judicial Action, APA Joint Commission on
Government Relations and APA Joint Commission on
Public Affairs
Chp.: Renee L. Binder, M.D.
Participants: Paul S. Appelbaum, M.D., J. Richard
Ciccone, M.D., Ronald A. Shellow, M.D., Nada L.
Stotland, M.D., Michelle Riba, M.D.

COMPONENT WORKSHOP 57 11:00 a.m.-12:30 p.m.
Grenadier Room, Lobby Level, Crowne Plaza

CONSENSUS WORKSHOP ON PSYCHODYNAMIC
INSTRUCTION
APA Consortium on Special Delivery Settings and
APA Commission on Psychotherapy by Psychiatrists
Chp.: Vivian B. Pender, M.D.
Participants: Norman A. Clemens, M.D., Ruth E.
Frydman, M.D., Lawrence C. Sack, M.D.
THURSDAY

COMPONENT WORKSHOP 58  11:00 a.m.-12:30 p.m.
Number Room, Lobby Level, Crowne Plaza

GLOBAL EDUCATION IN PSYCHIATRY: UNITY AND DIVERSITY
APA Committee on International Education

Chp.: Winston W. Shen, M.D.
Participants: Houshang G. Hamadani, M.D., J. Randolph Hillard, M.D., Michael J. Napoliello, M.D., Suzanne M. Renaud, M.D., Alan L. Gordon, M.D., Miguel A. Leibovich, M.D., John B. Sikorski, M.D., Cassandra E. Harewood, M.D.

COMPONENT WORKSHOP 59  11:00 a.m.-12:30 p.m.
Oakville Room, Lobby Level, Crowne Plaza

GETTING YOUR PATIENT HOUSING, ENTITLEMENTS AND FREE MEDICATIONS: A PRIMER
APA Committee on Poverty, Homelessness and Psychiatric Disorders

Chp.: Stephen M. Goldfinger, M.D.
Participants: Andrea White, M.S.W., Joel S. Feiner, M.D., Walter S. Jennings, Jr., M.D., Albert A. Hyman, M.D.

COMPONENT WORKSHOP 60  11:00 a.m.-12:30 p.m.
Kenora Room, Second Floor, Sheraton Centre

CROSS-CULTURAL MENTAL ILLNESS: THE TRUE CHAMELEON
APA CMHS and Zeneca Minority Fellowships

Chp.: Xenia H. Johnson, M.D.
Participants: Husam Alathari, M.D., Daniel B. Martinez, M.D., Jacquelyn B. Chang, M.D.

ISSUES 106-116

ISSUE WORKSHOP 106  11:00 a.m.-12:30 p.m.
Room 206A, Street Level, Convention Centre

INTEGRATED CLINICAL SYSTEMS FOR PSYCHIATRIC CARE

Chp.: Wesley E. Sowers, M.D.
Participant: Gordon H. Clark, Jr., M.D.

ISSUE WORKSHOP 107  11:00 a.m.-12:30 p.m.
Room 206D, Street Level, Convention Centre

PRESCRIBING FOR OTHER CLINICANS

Chp.: Lloyd I. Sederer, M.D.
Participants: James M. Ellison, M.D., Catherine Keyes, J.D.

ISSUE WORKSHOP 108  11:00 a.m.-12:30 p.m.
Room 104D, Lower Level, Convention Centre

SPIRITUAL/RELIGIOUS ASSESSMENT: WHY AND HOW?

Co-Chps.: Francis G. Lu, M.D., James L. Collins, M.D.
Participants: David B. Larson, M.D., Christina M. Puchalski, M.D.

ISSUE WORKSHOP 109  11:00 a.m.-12:30 p.m.
Niagara Room, Lower Level, Crowne Plaza

PRESEVERING QUALITY IN OUTPATIENT PSYCHIATRY

Co-Chps.: David G. Kretetz, D.O., Roberta R. Ball, D.O.
Participant: Geetha Kumar, M.D.

ISSUE WORKSHOP 110  11:00 a.m.-12:30 p.m.
Toronto Room, Convention Floor, Royal York

SOCIAL AMNESIA: RESOCIALIZING PSYCHIATRIC RESEARCH

Chp.: Carl I. Cohen, M.D.
Participants: Cecile Rousseau, M.D., Kenneth S. Thompson, M.D., Carlos Mutaner, M.D., David Williams, Ph.D.

ISSUE WORKSHOP 111  11:00 a.m.-12:30 p.m.
Alberta Room, Mezzanine, Royal York

THE MAKING OF A BEHAVIORAL PREVENTIVE MEDICINE FELLOWSHIP

Chp.: Michael A. Silver, M.D.
Participants: Steven J. Schleifer, M.D., Martin E. Glasser, M.D., Lisa J.F. Miller, Ph.D.

ISSUE WORKSHOP 112  11:00 a.m.-12:30 p.m.
British Columbia Room, Mezzanine, Royal York

MENTAL HEALTH PEER ADVOCACY IN A GENERAL HOSPITAL EMERGENCY ROOM

Chp.: Happy Scherer, M.A.
Participants: Lynne Davidson, M.S.W., Jeffrey D. DeLisle, M.D.

ISSUE WORKSHOP 113  11:00 a.m.-12:30 p.m.
Conference Room B, Mezzanine, Sheraton Centre

COMPLIANCE: DIRECTLY OBSERVED THERAPY AND OTHER STRATEGIES

Chp.: Michael M. Scimeca, M.D.
Participants: Susan Stabinsky, M.D., Mary Alice O'Dowd, M.D., Harvey Stabinsky, M.D., David W. Preven, M.D.
THURSDAY

ISSUE WORKSHOP 114  11:00 a.m.-12:30 p.m.  
Conference Room F, Mezzanine, Sheraton Centre

SEXUAL ABUSE CASE: PSYCHOTHERAPY AND NEUROBIOLOGY

Co-Chps.: Patricia L. Gerbarg, M.D., Jose A. Saporta, Jr., M.D.

ISSUE WORKSHOP 115  11:00 a.m.-12:30 p.m.  
York Room, Mezzanine, Sheraton Centre

SUICIDE PREVENTION: NEW PUBLIC HEALTH PERSPECTIVES

Chp.: Neal L. Cohen, M.D.
Participants: Peter M. Marzuk, M.D., Lloyd B. Potter, Ph.D.

ISSUE WORKSHOP 116  11:00 a.m.-12:30 p.m.  
Dufferin Room, Second Floor, Sheraton Centre

HIV AND HISPANICS: TREATMENT AND PREVENTION

Chp.: Pedro Ruiz, M.D.
Participants: Rodrigo A. Muñoz, M.D., Lourdes M. Dominguez, M.D., Humberto L. Martinez, M.D., John G. Langrod, Ph.D.

12 noon Sessions

FORUM 10
12 noon-1:30 p.m.
Room 104B, Lower Level, Convention Centre

PRESCRIPTION OF MEDICINE BY NONPHYSICIANS: CONCERN FOR THE PUBLIC WELFARE AND POLITICAL PRESSURES

Chp.: Ronald A. Shellow, M.D.
Participants: Jay B. Cutler, J.D., Rodrigo A. Muñoz, M.D., Jeremy A. Lazarus, M.D., Michelle Riba, M.D., Scott D. Hagaman, M.D., Dudley M. Stewart, Jr., M.D., Maurice Rappaport, M.D.

NEW RESEARCH

POSTER SESSION 15  
12 noon-2:00 p.m.
Room 106, Lower Level, Convention Centre

PSYCHOPHARMACOLOGY

For further information on New Research Sessions, please refer to the New Research Program and Abstracts Book included in your registration packet.

12:30 p.m. Sessions

MEDIA SESSIONS 36-37

MEDIA SESSION 36  12:30 p.m.-2:00 p.m.
Ontario Room, Convention Floor, Royal York

SINGLE MOTHERS OF CHOICE

Chp.: Gail E. Robinson, M.D.

66 Ms. Conceptions
(56 minutes)

Distributor: First Run Icarus Films  
153 Waverly Place  
New York, NY 10014

What makes a vibrant, college-educated, single, 30-something woman decide to pack up the search for Mr. Right and pick up a $250 vial of sperm instead? Over the past decade, the birth rate among this group of women has nearly tripled. They may have given up on relationships but are unwilling to sacrifice motherhood. In their models of family, men are superfluous. Lea is 32 and has chosen artificial insemination, though it makes her feel “dirty” and leaves her wondering “who will really be the father of this child.” Rebecca, 38, is tired of her “party girl” life and scours personal ads for a suitable “live donor.” Anne, 39, who was “accidentally” impregnated by her ex-boyfriend, must cope with a wanted, but solitary, pregnancy. The film also looks at the burgeoning sperm industry from artificial insemination trade shows to custom-ordered sperm (“the specimen is available in standard or pre-washed”), to the suppliers of raw materials, the anonymous donors who are helping to create children they will never know. As it examines both sides of the “single mother by choice” controversy, Ms. Conceptions charms as it lends invaluable insight into the “family values” debate raging in the political arena, the media, and the hearts of three women who decide to go it alone.

1996 Gemini Award Winner, Best Documentary, Academy of Canadian Cinema & Television
Silver Apple Winner, 1996 National Educational Media Network Competition
1995 International Women’s Film Festival (Madrid)
THURSDAY

MEDIA SESSION 37 12:30 p.m.-2:00 p.m.
Civic Ballroom, Second Floor, Sheraton Centre

TRANSGENDER PERSPECTIVES: WOMEN TO MEN
Chp.: Shosmanna M. Gillick, M.D.

67 You Don't Know Dick
(74 minutes)
Distributor: Films Transit
402 East Notre Dame
Montreal, PQ, Canada H2Y 1C8

This film portrays the journeys of six men who were once women. Its examination of gender transformation causes all of us to reexamine our own search for identity.

The National Educational Media Network's Gold Apple Award Winner, 1997

2:00 p.m. Sessions

SYMPOSIA 95-118

SYMPOSIUM 95 2:00 p.m.-5:00 p.m.
Room 205A, Street Level, Convention Centre

NEW TREATMENTS FOR HEROIN ADDICTION
Chp.: Laurence M. Westreich, M.D.

A Changes in Heroin Addiction
Laurence M. Westreich, M.D.

B Levomethdyl Acetate Hydrochloride (LAAM): Opioid-Substitution Therapy
Paul P. Casadonte, M.D.

C Buprenorphine for Opiate Dependence: Clinic and Office-Based Paradigms
Paul J. Fudala, Ph.D.

D Methadone Anonymous
Duncan McGonagle, R.N.

E Ultra-Rapid Opiate Detoxification
Lance L. Gooberman, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 96 2:00 p.m.-5:00 p.m.
Room 205B, Street Level, Convention Centre

BRAIN SIGNALING PATHWAYS IN PSYCHIATRIC SYNDROMES
Chp.: Gary B. Kaplan, M.D.

A Brain Circuitry and Signaling Mechanisms of Cocaine
Ronald P. Hammer, Ph.D.

B Brain Signaling Mechanisms in Opiate Dependence
Gary B. Kaplan, M.D.

C Abnormal Intracellular Signaling in Mood Disorders
Jerry J. Warsh, M.D., Peter P. Li, Ph.D., L. Trevor Young, M.D.

D Regulation of Transmembrane Signaling by Mood Stabilizers
Husseini K. Manji, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 97 2:00 p.m.-5:00 p.m.
Room 205C, Street Level, Convention Centre

PSYCHIATRY SERVICES RESEARCH IN PRACTICE AND POLICY
Chp.: Kenneth B. Wells, M.D.
Co-Chp.: Junius J. Gonzales, M.D.

A Depression Outcomes: What Do Patients Need and Want?
Junius J. Gonzales, M.D., Kevin Weinfurt, Ph.D., Kamila Bajwa, B.A., Kevin Schulman, M.D.

B Health Insurance and Treatment Seeking for Depression
Shelly F. Greenfield, M.D., Joelle M. Reizes, M.A., Larry Muenz, Ph.D., Barbara Kopans, B.A.,
Douglas G. Jacobs, M.D.

C Mental Health Care, Education Services and ADHD: Who Needs to Pay Attention?
Regina Bussing, M.D., Bonnie T. Zima, M.D.

D Implementing Practice Guidelines for Schizophrenia
Mark Olfson, M.D.

E Improving Treatment Resources for Primary Care Depressed Patients in Managed Care: The Partners in Care Approach
Kenneth B. Wells, M.D., Lisa V. Rubenstein, M.D.,
Jurgen Unutzer, M.D., Jeanne Miranda, Ph.D.,
Maga Jackson, M.D.

Discussant: Howard H. Goldman, M.D.

THIS SESSION WILL BE AUDIOTAPED.
THURSDAY

SYMPOSIUM 98 2:00 p.m.-5:00 p.m.
Room 205D, Street Level, Convention Centre

21ST CENTURY PSYCHIATRY: INTERNET APPLICATIONS
Chp.: Rima Styra, M.D.
A Resources for Psychiatrists on the Internet
Rima Styra, M.D.
B Psychiatry Embracing New Technology: Tele-Neuro-Psychiatry
Turan M. Itil, M.D., Kurt Z. Itil, Pierre Le Bars
C Emerging Trends in Networked Psychiatry
Stephen Pogorski, Ph.D.
D Patients' Contact with Psychiatrists via E-Mail in Clinical Practice
Kenneth R. Silk, M.D.
E Continuing Education in Psychiatry via the Internet
Ivan L. Silver, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 99 2:00 p.m.-5:00 p.m.
Room 206C, Street Level, Convention Centre

PRACTICING EVIDENCE-BASED PSYCHIATRY: BIPOLAR DISORDER
APA Steering Committee on Practice Guidelines
Chp.: John S. McIntyre, M.D.
A Use of Formal Measures in Clinical Care
Jacqueline Samson, Ph.D., Kimberly A. Yonkers, M.D., Laurie McQueen, M.S.W.
B Clinical Practice Guidelines for Treatment
Robert M.A. Hirschfeld, M.D., Harold Alan Pincus, M.D., Leslie Seigle
C What's Really Going on in the Treatment of Bipolar Disorder?
Ellen Leibenluft, M.D., Deborah A. Zarin, M.D., Ana P. Suarez, M.P.H., Harold Alan Pincus, M.D.

Discussant: Deborah A. Zarin, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 100 2:00 p.m.-5:00 p.m.
Room 206D, Street Level, Convention Centre

BIOLOGICAL RHYTHMS: DEPRESSION TREATMENT IMPLICATIONS
Joint Session with the Asher Depression Center/Feinberg Clinical Neuroscience Research Institute at Northwestern University
Chp.: William T. McKinney, Jr., M.D.
Co-Chp.: Nancy Witty, M.A.
A Modulatory Role of Melatonin on Circadian Responses
Margarita L. Dubocovich, Ph.D.
B Disruption of Circadian Rhythm: Effects on Mood, Performance and Sleep
Phyllis Zee, M.D.
C Biological Rhythms and Clinical Psychopharmacology
James J. Stockard, M.D.
D Animal Models: Linking Circadian Rhythms with Affective Disorder
Fred Turek, Ph.D.

Discussant: Michael H. Ebert, M.D.
THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 101 2:00 p.m.-5:00 p.m.
Room 206F, Street Level, Convention Centre

TREATING NICOTINE DEPENDENCE IN PSYCHIATRIC PATIENTS
Collaborative Session with the National Institute on Drug Abuse
Chp.: Michael G. Goldstein, M.D.
A Motivating Psychiatric Patients to Attempt Smoking Cessation
Michael G. Goldstein, M.D.
B Smoking Cessation in Patients with Depression
Alexander H. Glassman, M.D., Lirio S. Covey, Ph.D.
C Treating Nicotine Dependence in Substance-Abusing Patients
Raymond S. Niaura, Ph.D.
D Treating Nicotine Dependence in Schizophrenia Patients
Douglas M. Ziedonis, M.D.
E Treating First-Line Failures
John R. Hughes, M.D.

THIS SESSION WILL BE AUDIOTAPE.

SYMPOSIUM 102 2:00 p.m.-5:00 p.m.
Room 104A, Lower Level, Convention Centre

BIPOLARITY AND COMORBIDITY: CLINICAL MANAGEMENT
Chp.: Hagop S. Akiskal, M.D.
(Continued on next page)
A Bipolar Disorders: The Anxious Connection
Susan L. McElroy, M.D.

B Bipolar II, Rapid Cycling, Mixed States and Borderline Personality
Hagop S. Akiskal, M.D.

C Bipolar Disorder and Substance Abuse
Kathleen T. Brady, M.D.

D Juvenile Mania: Mixed States in ADHD
Joseph Biederman, M.D.

E Neurologic Comorbidity and Mania in Old Age
Kenneth I. Shulman, M.D.

Discussant: Rodrigo A. Muñoz, M.D.

THIRD SESSION WILL BE AUDIOTAPED.

SYMPOSUM 103 2:00 p.m.-5:00 p.m.
Room 104B, Lower Level, Convention Centre

EATING DISORDERS: PATHOGENESIS, COURSE AND TREATMENT

Chp.: Joel Yager, M.D.
Co-Chp.: David B. Herzog, M.D.

A The Function of Leptin in Anorexia Nervosa
Katherine A. Halmi, M.D., Margherita Mattel, Ph.D., Hong Wang, B.A., Jeffrey R. Friedman, M.D., Claire Wiseman, Ph.D.

B Vulnerabilities Contributing to Eating Disorders
Walter H. Kaye, M.D., Lisa R. Lillenfeld, Ph.D., Kathleen R. Merikangas, Ph.D., Michael Strober, Ph.D., Katherine Plotnikov, Ph.D.

C Mortality in Eating Disorders

D Long-Term Outcome of Bulimia Nervosa
James E. Mitchell, M.D., Pamela K. Keel, B.A., Scott Crow, M.D.

E The APA's Eating Disorder Practice Guideline: Revised
Joel Yager, M.D., Helen L. Egger, M.D., Deborah A. Zarin, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSUM 104 2:00 p.m.-5:00 p.m.
Room 104C, Lower Level, Convention Centre

DISASSOCIATION AND TRAUMA: PSYCHIATRIC COMORBIDITY

Chp.: David Spiegel, M.D.

A Features Associated with Dissociation in Aging Trauma Survivors
Rachel Yehuda, Ph.D., Stacey Namm, Celia Perugganan, M.D.

B Somatoform Dissociation Related to Reported Trauma
Richard Van Dyck, M.D., Eliert Nijenhuis, Ph.D., Lohan Vanderlinden, Ph.D., Philip Spinoven, Ph.D., Onno Van der Hart, Ph.D.

C Dissociation and Emotional Distress During Trauma
Charles R. Marmar, M.D., Daniel S. Weiss, Ph.D., Thomas J. Metzler, M.A., Kevin L. DeLucchi, Ph.D.

D Somatoform Dissociation As Related to Animal Defense
Eliert Nijenhuis, Ph.D., Philip Spinoven, Ph.D., Lohan Vanderlinden, Ph.D., Richard Van Dyck, M.D., Onno Van der Hart, Ph.D.

E Comorbidity of PTSD and Dissociative Disorders
J. Douglas Bremner, M.D.

F Dissociative, PTSD and Anxiety Symptoms After Incest
David Spiegel, M.D., Catherine Classen, Ph.D., Cheryl Koopman, Ph.D., Cheryl Gore-Felton, Ph.D., Bita Nouriani

Discussant: Robert L. Spitzer, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSUM 105 2:00 p.m.-5:00 p.m.
Room 104D, Lower Level, Convention Centre

RESULTS OF THE NIDA COLLABORATIVE COCAINE TREATMENT STUDY

Collaborative Session with the National Institute on Drug Abuse

Chp.: Michael E. Thase, M.D.
Co-Chp.: Paul Crits-Christoph, Ph.D.

A Rationale of the NIDA Collaborative Cocaine Treatment Study
Lynne Siqueland, Ph.D.

B Drug Outcome of the NIDA Collaborative Cocaine Treatment Study
Paul Crits-Christoph, Ph.D.
C Secondary Outcomes of the NIDA Collaborative Cocaine Treatment Study
Michael E. Thase, M.D.

D Drop-Out in the NIDA Collaborative Cocaine Treatment Study
Arlene F. Frank, Ph.D.

E Predictors of Outcome of the NIDA Collaborative Cocaine Treatment Study
Roger D. Weiss, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 106  2:00 p.m.-5:00 p.m.
Kingsway Room, Lobby Level, Crowne Plaza

PSYCHIATRISTS AS OWNERS AND MANAGERS OF DELIVERY SYSTEMS
APA Consultation Service Board

Chp.: Robert K. Schreter, M.D.
Co-Chp.: Bert Pepper, M.D.

A The Professional Affiliation Group Model
Benjamin Liptzin, M.D.

B First Year Operating Experience of a District Branch Originated IPA Practice
Barton J. Blinder, M.D.

C Managed Care: The New Colonialism
Anthony M. D'Agostino, M.D.

D Nuts and Bolts Issues in Provider-Owned Delivery Systems
Peter Benet, M.D.

E Problems in Psychiatrist-Owned and Managed Delivery Systems
Ronnie S. Stangler, M.D.

Discussant: Robert K. Schreter, M.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 107  2:00 p.m.-5:00 p.m.
Ballroom A, Lower Level, Crowne Plaza

SPIRITUALITY AND HEALTH: STATE-OF-THE-ART SCIENTIFIC AGENDA

Chp.: Harold G. Koenig, M.D.
Co-Chp.: David B. Larson, M.D.

A Religion, Spirituality and Physical Health
Harold G. Koenig, M.D.

B Religion, Spirituality and Mental Health
Michael E. McCullough, Ph.D.

C Religion, Spirituality and Addictions
David B. Larson, M.D.

D Religion, Spirituality and the Neurosciences
Frank H. Gawin, M.D.

Discussant: Linda K. George, Ph.D.
THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 108  2:00 p.m.-5:00 p.m.
Niagara Room, Lower Level, Crowne Plaza

AN INTEGRATIVE APPROACH TO PSYCHIATRY

Chp.: James S. Gordon, M.D.

A Transforming Psychiatric Practice
James S. Gordon, M.D.

B When Patients Present with Parapsychological Experiences
Elisabeth F. Targ, M.D.

C The Use of Acupuncture in Psychiatric Treatment
John M. Ackerman, M.D.

D Nutritional and Herbal Therapies in Psychiatric Treatment
Georgelle Carpenter, M.D.

THIS SESSION WILL BE AUDIOTAPED.

SYMPOSIUM 109  2:00 p.m.-5:00 p.m.
Ontario Room, Lower Level, Crowne Plaza

CLINICAL PRACTICE GUIDELINES FOR PSYCHOTHERAPIES

Chp.: K. Roy MacKenzie, M.D.

A The Practice and Role of Psychotherapies in Psychiatry
Paul M. Cameron, M.D.

B Clinical Practice Guidelines for the Psychotherapies from the Canadian Psychiatric Association
Molyn Leszcz, M.D., K. Roy MacKenzie, M.D.

C Use and Misuse of Clinical Practice Guidelines
Marcia K. Goin, M.D.

D Guidelines for Therapy of Personality Disorders
John M. Oldham, M.D.

THIS SESSION WILL BE AUDIOTAPED.
## THURSDAY

### SYMPOSIUM 110 2:00 p.m.-5:00 p.m.
Alberta Room, Mezzanine, Royal York

**NEW ADVOCACY CHALLENGES FOR SOCIAL PSYCHIATRY**  
Joint Session with the American Association for Social Psychiatry

Chp.: Leah J. Dickstein, M.D.  
Co-Chp.: Edward F. Foulks, M.D.

| A | Advocacy in Social Psychiatry | Edward F. Foulks, M.D. |
| B | True Community/Academic Partnerships | Carl C. Bell, M.D. |
| C | Advocacy in Child and Adolescent Psychiatry | Elizabeth B. Weller, M.D., Ronald A. Weller, M.D. |
| D | Advocacy for the Elderly | Kenneth M. Sakauye, M.D. |
| E | Advocacy and Substance Abuse | Joseph J. Westermeyer, M.D. |
| F | Advocating for Their Own: A Cultural Dilemma | Silvia W. Olarte, M.D. |
| G | Ongoing and New Gender Issues Requiring Advocacy | Leah J. Dickstein, M.D. |

**THIS SESSION WILL BE AUDIOTAPED.**

### SYMPOSIUM 111 2:00 p.m.-5:00 p.m.
British Columbia Room, Mezzanine, Royal York

**PSYCHODYNAMIC THERAPY RESEARCH IN THE NEW CENTURY**

Chp.: Susan C. Vaughan, M.D.  
Co-Chp.: Lisa A. Mellman, M.D.

| A | Psychodynamic Therapy for Panic: An Open Clinical Trial | Fredric N. Busch, M.D., Barbara L. Milrod, M.D. |
| B | Outcome in Long-Term Psychodynamic Psychotherapy | Lisa A. Mellman, M.D., Edith M. Cooper, Ph.D., Roger Mackinnon, M.D., Andrew E. Skodol II, M.D. |
| C | A Self-Report Measure of Psychological Capacities | Edith M. Cooper, Ph.D., Lisa A. Mellman, M.D., Roger Mackinnon, M.D., Andrew E. Skodol II, M.D. |
| D | Computerizing Records to Determine What Actually Works for Whom | Peter Graham, Ph.D., Paul Clifford, M.A. |

**Discussant:** Jerald Kay, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

### SYMPOSIUM 112 2:00 p.m.-5:00 p.m.
Manitoba Room, Mezzanine, Royal York

**NEW APPROACHES FOR OPIATE DETOXIFICATION**  
Collaborative Session with the National Institute on Drug Abuse

Chp.: Herbert D. Kleber, M.D.  
Co-Chp.: Thomas R. Kosten, M.D.

| A | Lofexidine for Opiate Detox: Recent U.K. Studies | John Strang, M.D. |
| B | Clonidine, Naltrexone and Buprenorphine in Rapid Detox | Thomas R. Kosten, M.D. |
| C | Ultra-Rapid Detoxification Under Anesthesia | Herbert D. Kleber, M.D. |
| D | The Use of Acupuncture in Opiate Detoxification | Janet Knoefal, Ph.D. |
| E | Enhancing Naltrexone Treatment After Detoxification | Bruce J. Rounsaville, M.D., Kathleen M. Carroll, Ph.D., Lisa R. Fenton, P.S.D. |

**Discussant:** Charles E. Riordan, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**

### SYMPOSIUM 113 2:00 p.m.-5:00 p.m.
Quebec Room, Mezzanine, Royal York

**DEFICIT SYNDROME: RESEARCH AND TREATMENT**

Chp.: Wayne S. Fenton, M.D.  
Co-Chp.: Brian Kirkpatrick, M.D.

| A | Deficit Syndrome: Marker of a Separate Disease? | Brian Kirkpatrick, M.D. |
| B | A National Research Program in the Deficit Syndrome in Schizophrenia | Sonia Dellus, M.D., Michel Pettit, M.D., Florence Tribaud, M.D., Dominique Campion, M.D., Jean Costentin, M.D., Jean Marc Constans, M.D., PHRC's Group |
| C | Course and Prognosis in Deficit Schizophrenia | Wayne S. Fenton, M.D. |
| D | Treatment of Primary Negative Symptoms | Robert R. Conley, M.D., Deanna L. Kelly, Pharm.D., Carol A. Tamminga, M.D. |

**Discussant:** Jerald Kay, M.D.  
**THIS SESSION WILL BE AUDIOTAPED.**
THURSDAY

E  Psychosocial Rehabilitation for Negative Symptoms
   Robert K. Heinssen, Ph.D.
   Discussant: Thomas H. McGlashan, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPHOSUM 114  2:00 p.m.-5:00 p.m.
Territories Room, Mezzanine, Royal York

TRAUMATIC BRAIN INJURY: PERSPECTIVES AND PEARLS

Chp.: Robin A. Hurley, M.D.
Co-Chp.: Ali M. Hashmi, M.D.

A  The Clinician's View of Traumatic Brain Injury
   Kimberly A. Arlinghaus, M.D.

B  The Psychiatrist's View of Traumatic Brain Injury
   Cindy B. Ivanhoe, M.D.

C  The Neuropsychologist's View of Traumatic Brain Injury
   Corwin Boake, Ph.D.

D  The Patient's View of Traumatic Brain Injury
   Phillip M. Colvard
   Discussant: Stuart C. Yudofsky, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPHOSUM 115  2:00 p.m.-5:00 p.m.
Tudor Room 7, Mezzanine, Royal York

IT'S NOT JUST AN EMERGENCY ROOM: URGENT CARE
AND TRAINING IN AN ERA OF COST CONTAINMENT
Joint Session with the APA Consortium on Special Delivery Settings and the American Association for Emergency Psychiatry

Chp.: Michael H. Allen, M.D.

A  Psychiatric Intensivism: A New Element in Emergency Services
   Michael H. Allen, M.D.

B  Crisis Alternatives to Hospitalization in the VA System
   Eile M. Francis, M.D.

C  A Fully Mobile Psychiatric Emergency System
   Joseph J. Zealberg, M.D.

D  Teaching Emergency Psychiatry: A Model Curriculum
   Rachel L. Glick, M.D., Jennifer S. Brasch, M.D.,
   Jodi L. Lotchy, M.D., Janet S. Richmond, M.S.W.,
   Victor G. Stiebel, M.D.

E  A Survey of Training Programs in Emergency Psychiatry
   Jennifer S. Brasch, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPHOSUM 116  2:00 p.m.-5:00 p.m.
Essex Room, Mezzanine, Sheraton Centre

INTRODUCTION TO PSYCHODERMATOLOGY

Chp.: Thomas M. Gragg, M.D.

A  Psychiatric Treatment of Stress-Related Dermatoses
   Iona H. Ginsburg, M.D.

B  Body Dysmorphic Disorder in Dermatology Practice
   Caroline S. Koblenzer, M.D.

C  Psychopharmacological Treatment of Psychodermatological Disorders
   John Y. Koo, M.D.

D  The Interface Between Dermatology and Psychiatry
   Thomas M. Gragg, M.D.

E  Pitfalls in Psychosomatic Diagnosis: A Cautionary Tale
   Peter J. Koblenzer, M.D.
   THIS SESSION WILL BE AUDIOTAPED.

SYMPHOSUM 117  2:00 p.m.-5:00 p.m.
Windsor Room, Mezzanine, Sheraton Centre

DRUGS AND PSYCHOTHERAPY IN ANXIETY DISORDERS

Chp.: Dr. Heinz Katschnig
Co-Chp.: Michael R. Liebowitz, M.D.

A  Behavioral Therapy Versus Clomipramine for OCD: Methodological Issues
   Michael J. Kozak, Ph.D., Edna B. Foa, Ph.D.,
   Michael R. Liebowitz, M.D.

B  Drugs and Psychotherapy in Panic Disorder: Methodological Issues
   Dr. Heinz Katschnig, Dr. Peter Berger,
   Dr. Gabriele Sacha, Michaela Amerling, M.D.,
   Dr. Anita Holzinger, Dagmar Maielhofer, M.D.,
   Bettina Bankier, M.D.

C  Drugs and Psychotherapy in Social Phobia: Methodological Issues
   Michael R. Liebowitz, M.D., Richard G.
   Heimberg, Ph.D., Franklin R. Schneier, M.D.
   Discussants: Murray B. Stein, M.D., Edna B. Foa, Ph.D.
   THIS SESSION WILL BE AUDIOTAPED.
SYMPOSIUM 118  2:00 p.m.-5:00 p.m.
City Hall Room, Second Floor, Sheraton Centre

CLINICAL UPDATE ON PREMENSTRUAL DYSPHORIC DISORDER

Chp.: Stephanie Klein-Stern, M.D.

A  Premenstrual Dysphoria: Diagnosis, Epidemiology and Comorbidity
   Jean Endicott, Ph.D.

B  Chronobiology of Premenstrual Dysphoric Disorder
   Barbara L. Parry, M.D., Richard L. Hauger, M.D.,
   J. Christian Gillin, M.D., Jeffrey Elliott, Ph.D.

C  Sertraline Versus Desipramine in PMS Treatment
   Ellen W. Freeman, Ph.D., Karl Rickels, M.D.,
   Steven J. Sondheimer, M.D.

D  An Algorithm for the Treatment of Premenstrual Dysphoric Disorder
   Stephanie Klein-Stern, M.D., James J. Strain, M.D.

Discussant: Leslie H. Gise, M.D.

THIS SESSION WILL BE AUDIOTAPED.
1998 ANNUAL MEETING
TOPIC AREAS FOR THE SCIENTIFIC PROGRAM

DISORDERS
1. AIDS and HIV-Related Disorders
2. Alcohol and Drug-Related Disorders
3. Anxiety Disorders
4. Cognitive Disorders (Dementia, Depression, Amnestic, etc.)
5. Dissociative Disorders
6. Eating Disorders
7. Infant and Childhood Disorders
8. Premenstrual Dysphoric Disorder
9. Mood Disorders
10. Personality Disorders
11. Schizophrenia and Other Psychotic Disorders
12. Sexual and Gender Identity Disorders
13. Sleep Disorders
14. Somatoform Disorders
15. Unlisted Disorders

PRACTICE AREAS
16. Administration
17. Private Practice
18. Public Sector
19. University
20. Other

SUBSPECIALTY AREAS OR SPECIAL INTERESTS
21. Academic Psychiatry
22. Addiction Psychiatry
23. Adolescent Psychiatry
24. Biological Psychiatry
25. Brain Imaging
26. Child and Adolescent Psychiatry
27. Community Psychiatry and Prevention
28. Consultation-Liaison and Emergency Psychiatry
29. Cross-Cultural and Minority Psychiatry
30. Diagnostic Issues
31. Ethics
32. Forensic Psychiatry
33. Genetics
34. Geriatric Psychiatry
35. Neurobiology
36. Neuropsychiatry
37. Psychiatric Education
38. Psychiatric Rehabilitation
39. Psychoanalysis
40. Research Issues
41. Social Psychiatry
42. Stress
43. Suicide
44. Violence, Trauma and Victimization

TREATMENTS
45. Behavior and Cognitive Therapies
46. Combined Pharmacotherapy and Psychotherapy
47. Couple and Family Therapies
48. Group Therapy
49. Individual Psychotherapies
50. Psychopharmacology
51. Somatic Therapies
52. Treatment Techniques and Outcome Studies

OTHER ISSUES
53. Computers
54. Creativity and the Arts
55. Gay and Lesbian Issues
56. Gender
57. Historical Questions
58. Human Rights
59. Managed Care and Health Care Funding
60. Mental Retardation (Child/Adolescent/Adult)
61. Political Questions
62. Professional and Personal
63. Religion, Spirituality and Psychiatry
64. Resident and Medical Student Concerns
65. Presidential Theme: New Challenges for Proven Values—Defending Access, Fairness, Ethics, Decency
66. Stigma/Advocacy
67. Women's Issues
68. Drug Addiction—A Treatable Disease: A Special Research-Based Program Track

GUIDE TO USING THE TOPIC INDEX
Use this index to find sessions of interest to you. There are five overall topics: Disorders, Practice Areas, Subspecialty Areas or Special Interests, Treatments, and Other Issues. Under each overall topic, you will find subtopics listed in alphabetical order with the formats (type of session) listed alphabetically underneath. Within each format you will find the title of the individual session listed by number. The listing will also show the page number the session appears on. You should refer to the page number in this Program Book to obtain further details about the session.
<table>
<thead>
<tr>
<th>Topic Index</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TOPIC 1: AIDS AND HIV-RELATED DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>AIDS EDUCATION PROGRAMS</td>
<td></td>
</tr>
<tr>
<td>1 Clinical and Neuropsychiatric Dimensions of HIV Disease</td>
<td>41</td>
</tr>
<tr>
<td>2 AIDS Among Special Patient Populations</td>
<td>73</td>
</tr>
<tr>
<td>CLINICAL CASE CONFERENCE</td>
<td></td>
</tr>
<tr>
<td>4 Psychotherapy with Persons with HIV Considering Protease Inhibitors</td>
<td>105</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>98 The Relationship Between Diagnosis and HIV Risk</td>
<td>111</td>
</tr>
<tr>
<td>99 Accuracy of Memory Reporting by Patients with HIV Disease</td>
<td>112</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>68 Psychosocial Aspects of HIV Risk Among Young IV Drug Users</td>
<td>93</td>
</tr>
<tr>
<td>WORKSHOPS - COMPONENTS</td>
<td></td>
</tr>
<tr>
<td>5 New and Alternative Treatments in HIV Care</td>
<td>21</td>
</tr>
<tr>
<td>29 Promises and Problems with New Treatments for HIV</td>
<td>54</td>
</tr>
<tr>
<td>WORKSHOPS - ISSUES</td>
<td></td>
</tr>
<tr>
<td>24 Protease Inhibitors in the Mentally Ill with HIV</td>
<td>29</td>
</tr>
<tr>
<td>116 HIV and Hispanics: Treatment and Prevention</td>
<td>115</td>
</tr>
<tr>
<td><strong>TOPIC 2: ALCOHOL AND DRUG-RELATED DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>CME COURSES</td>
<td></td>
</tr>
<tr>
<td>32 Addiction Treatment in Psychiatric Populations</td>
<td>9</td>
</tr>
<tr>
<td>37 Assessment and Treatment of Nicotine Dependence</td>
<td>15</td>
</tr>
<tr>
<td>42 Dual Diagnosis: Basic Principles of Successful Intervention</td>
<td>16</td>
</tr>
<tr>
<td>47 Dual Diagnosis: Advanced Clinical Application, Programmatic Innovation and Treatment Strategies</td>
<td>30</td>
</tr>
<tr>
<td>59 Dealing with Resistance in Addiction Patients</td>
<td>41</td>
</tr>
<tr>
<td>62 Update on the Treatment of Substance Use Disorders</td>
<td>73</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>20 Nicotine: An Enemy or an Ally?</td>
<td>9</td>
</tr>
<tr>
<td>MEDIA PRESENTATION</td>
<td></td>
</tr>
<tr>
<td>52 Dealing with the Demon: A Three-Part Series</td>
<td>90</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>85 A Prospective Analysis of Alcohol Use Disorders</td>
<td>84</td>
</tr>
<tr>
<td>110 Alcohol Consumption in Mood and Anxiety Disorders</td>
<td>112</td>
</tr>
<tr>
<td>112 A Prospective Analysis of Depression and Heavy Drinking in Women</td>
<td>112</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>40 Medical Marijuana: Options and Problems</td>
<td>65</td>
</tr>
<tr>
<td>69 The Many Faces of the Drug Problem</td>
<td>94</td>
</tr>
<tr>
<td>95 New Treatments for Heroin Addiction</td>
<td>116</td>
</tr>
<tr>
<td><strong>TOPIC 3: ANXIETY DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>CME COURSE</td>
<td></td>
</tr>
<tr>
<td>66 Therapeutic Puzzle: OCD</td>
<td>42</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>11 New Treatments for Anxiety Disorders: Clinical Approaches for Successful Outcomes</td>
<td>6</td>
</tr>
<tr>
<td><strong>TOPIC 4: COGNITIVE DISORDERS (DELIRIUM, DEMENTIA, AMNESIC, ETC.)</strong></td>
<td></td>
</tr>
<tr>
<td>CME COURSES</td>
<td></td>
</tr>
<tr>
<td>55 Autism and Asperger's Syndrome Across the Life Span</td>
<td>30</td>
</tr>
<tr>
<td>78 Delirium in the General Hospital</td>
<td>73</td>
</tr>
<tr>
<td>INDUSTRY-SUPPORTED SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>14 Alzheimer's Disease: Practical Treatment Approaches</td>
<td>7</td>
</tr>
<tr>
<td>31 Age-Related Memory Loss: Detection and Treatment</td>
<td>13</td>
</tr>
<tr>
<td>36 Hot Topics in Alzheimer's Disease</td>
<td>68</td>
</tr>
<tr>
<td>PRACTICE GUIDELINES UPDATE</td>
<td></td>
</tr>
<tr>
<td>Practice Guidelines: Delirium and HIV/AIDS</td>
<td>78</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORTS</td>
<td></td>
</tr>
<tr>
<td>83 Prevalence of Dementia in Centenarians</td>
<td>84</td>
</tr>
<tr>
<td>92 The Ten-Point Clock Test in the General Hospital</td>
<td>111</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>27 Emerging Trends in the Treatment of Dementia</td>
<td>61</td>
</tr>
<tr>
<td>73 Classic and Atypical Neuroleptics in Dementia</td>
<td>95</td>
</tr>
<tr>
<td><strong>TOPIC 5: DISSOCIATIVE DISORDERS</strong></td>
<td></td>
</tr>
<tr>
<td>CME COURSES</td>
<td></td>
</tr>
<tr>
<td>7 Dissociative Disorder Not Otherwise Specified: Diagnosis and Treatment with Ego State Therapy</td>
<td>1</td>
</tr>
<tr>
<td>46 Trauma, Dissociation and Memory</td>
<td>16</td>
</tr>
<tr>
<td>SCIENTIFIC AND CLINICAL REPORT</td>
<td></td>
</tr>
<tr>
<td>93 Incidence of Dissociative Identity Disorder in Psychiatric Inpatients</td>
<td>111</td>
</tr>
<tr>
<td>SYMPOSIUM</td>
<td></td>
</tr>
<tr>
<td>104 Dissociation and Trauma: Psychiatric Comorbidity</td>
<td>118</td>
</tr>
<tr>
<td>WORKSHOP - ISSUE</td>
<td></td>
</tr>
<tr>
<td>66 The Occurrence of Dissociative Identity Disorder in Psychiatric Inpatients</td>
<td>79</td>
</tr>
</tbody>
</table>
## TOPIC INDEX

### TOPIC 6: EATING DISORDERS (Page 11)

<table>
<thead>
<tr>
<th>CME COURSES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>44 Therapeutic Interventions in Eating Disorders</td>
<td>16</td>
</tr>
<tr>
<td>98 Multimodal Therapy of Severe Eating Disorders</td>
<td>105</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LECTURE</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Integrating New Knowledge in Treating the Eating Disorders</td>
<td>24</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATIONS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Anorexia and Bulimia Nervosa</td>
<td>50</td>
</tr>
<tr>
<td>17 Eating Disorders</td>
<td>106</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS (Page 104)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feedback of Activity in the Treatment of Obesity</td>
<td>112</td>
</tr>
<tr>
<td>Self-help for Binge Eating Disorder</td>
<td>112</td>
</tr>
<tr>
<td>Attachment Dynamics of Eating Disorders</td>
<td>112</td>
</tr>
<tr>
<td>Bright Light Therapy for Bulimia Nervosa</td>
<td>113</td>
</tr>
</tbody>
</table>

### SYMPOSIUM (Page 16)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are Eating and Substance Abuse Disorders Related?</td>
<td>37</td>
</tr>
<tr>
<td>Etiology of Eating Disorders: High-Risk Groups</td>
<td>65</td>
</tr>
<tr>
<td>The Relationship Between Seasonality, Eating and Mood</td>
<td>92</td>
</tr>
<tr>
<td>Eating Disorders: Pathogenesis, Course and Treatment</td>
<td>118</td>
</tr>
</tbody>
</table>

### TOPIC 7: INFANT AND CHILDHOOD DISORDERS (Page 4)

<table>
<thead>
<tr>
<th>CME COURSE</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 ADD in Children and Adolescents</td>
<td>1</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORT (Page 29)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Birth Outcomes Following Prenatal Exposure to Fluoxetine</td>
<td>27</td>
</tr>
</tbody>
</table>

### SYMPOSIUM (Page 44)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Devastating Effects of Childhood Abuse on Mind and Brain</td>
<td>66</td>
</tr>
</tbody>
</table>

### TOPIC 8: PREMENSTRUAL DYSPHORIC DISORDER (Page 48)

<table>
<thead>
<tr>
<th>SCIENTIFIC AND CLINICAL REPORT</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal Diurnal S-HIAA with Premenstrual Syndrome and Premenstrual Dysphoric Disorder</td>
<td>53</td>
</tr>
</tbody>
</table>

### SYMPOSIUM (Page 118)

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Update on Premenstrual Dysphoric Disorder</td>
<td>122</td>
</tr>
</tbody>
</table>

### TOPIC 9: MOOD DISORDERS (Page 12)

<table>
<thead>
<tr>
<th>CME COURSES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 Psychiatric Disorders in Pregnancy and Postpartum</td>
<td>2</td>
</tr>
<tr>
<td>84 Depression: Individual/Group Interpersonal Therapy</td>
<td>74</td>
</tr>
<tr>
<td>91 Use of Melatonin and Light in Sleep and Mood Disorders</td>
<td>88</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>INDUSTRY-SUPPORTED SYMPOSIUM</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maintenance Treatment of Depression: The Final Episode</td>
<td>2</td>
</tr>
<tr>
<td>Depression As a Risk Factor for Cardiovascular and Cerebrovascular Disease: Emerging Data and Clinical Perspectives</td>
<td>2</td>
</tr>
<tr>
<td>Intervention for Refractory Bipolar Disorder</td>
<td>6</td>
</tr>
<tr>
<td>Chronic Depression: Optimizing Long-Term Treatment</td>
<td>7</td>
</tr>
<tr>
<td>Issues in the Long-Term Management of Depression</td>
<td>7</td>
</tr>
<tr>
<td>Depressive Disorders: Advances in Clinical Management</td>
<td>10</td>
</tr>
<tr>
<td>Treatment of Depression in Difficult Situations</td>
<td>10</td>
</tr>
<tr>
<td>Sexual Dysfunction, Depression and Antidepressants</td>
<td>12</td>
</tr>
<tr>
<td>Clinical Challenges in the Treatment of Depression Subtypes</td>
<td>69</td>
</tr>
<tr>
<td>Treating the Difficult-to-Treat Depressed Patient</td>
<td>70</td>
</tr>
</tbody>
</table>

### TOPIC 10: PERSONALITY DISORDERS (Page 25)

<table>
<thead>
<tr>
<th>CME COURSES</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 The Practical Management of Personality Disorder</td>
<td>5</td>
</tr>
<tr>
<td>35 Special Problems in Treating Borderline Patients</td>
<td>15</td>
</tr>
<tr>
<td>45 Disorders of the Self: Differential Diagnosis and Treatment</td>
<td>16</td>
</tr>
<tr>
<td>56 Sound and Fury: Treating BPD Patients Who Act Out</td>
<td>74</td>
</tr>
<tr>
<td>96 Partial Hospitalization for Patients with BPD</td>
<td>105</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LECTURE</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 The Empty Self: BPD in Historical Perspective</td>
<td>89</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MASTER EDUCATOR CLINICAL CONSULTATIONS</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>7 OCD and the Obsessive-Compulsive Spectrum</td>
<td>50</td>
</tr>
<tr>
<td>16 Treating Borderline Patients Effectively Within Managed Care</td>
<td>106</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVIEW OF PSYCHIATRY</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Psychobiology of Personality Disorders</td>
<td>60</td>
</tr>
</tbody>
</table>

---

**Total Pages:** 125
<table>
<thead>
<tr>
<th>TOPIC INDEX</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>2 Personality in Different Anxiety Disorders</td>
</tr>
<tr>
<td>3 Personality Traits and Response to Antidepressants</td>
</tr>
<tr>
<td>4 Schizotypy and Cognition in Borderline Personality</td>
</tr>
<tr>
<td>77 Divalproex for Aggression in Personality Disorders</td>
</tr>
<tr>
<td>78 Internal Consistency and Overlap of DSM-IV Personality Disorders</td>
</tr>
<tr>
<td>79 Identifying Personality Disorders: Towards the Development of a Clinical Screening Instrument</td>
</tr>
<tr>
<td>117 Violence in the Lives of Adult Borderline Patients</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td>22 Stress and Personality Disorders</td>
</tr>
<tr>
<td>23 Personality: Neurobiology and Life Experience</td>
</tr>
<tr>
<td>65 Personality Disorders Research in Canada</td>
</tr>
<tr>
<td>78 Collaborative Study of Personality Disorders</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>79 Community Therapy: Treatment for Severe BPD</td>
</tr>
<tr>
<td><strong>TOPIC 11: SCHIZOPHRENIA AND OTHER PSYCHOTIC DISORDERS</strong></td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td>4 Cognition in Schizophrenia: The New Therapeutic Goal</td>
</tr>
<tr>
<td>7 Mood Disorders in Schizophrenia: United States and European Perspectives</td>
</tr>
<tr>
<td>10 Women and Psychosis: From Lab Bench to Clinical Practice</td>
</tr>
<tr>
<td>13 Individuating the Treatment of Psychoses</td>
</tr>
<tr>
<td>21 New Atypical Drugs Versus Clinical Experience</td>
</tr>
<tr>
<td>22 Optimizing Patient Outcomes with Novel Antipsychotics: Changing Expectations</td>
</tr>
<tr>
<td>26 Expanding the Spectrum of Psychoses: The Interface of Affect</td>
</tr>
<tr>
<td>30 Practical Approaches to the Treatment of Psychoses in the Elderly</td>
</tr>
<tr>
<td>38 Exploring the Course of Schizophrenia</td>
</tr>
<tr>
<td>43 Neurocognition in Schizophrenia</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
</tr>
<tr>
<td>18 Schizophrenia, Dopamine Receptors and Antipsychotic Drugs</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
</tr>
<tr>
<td>13 The Treatment of Schizophrenia</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATIONS</strong></td>
</tr>
<tr>
<td>16 Schizophrenia: The Community's Response</td>
</tr>
<tr>
<td>25 I'm Still Here, the Truth About Schizophrenia: A Non-Fiction Film</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>49 Expanding Versus Static Ventricle Schizophrenia</td>
</tr>
<tr>
<td>53 Olanzapine Versus Placebo in the Treatment of Acute Mania</td>
</tr>
<tr>
<td>54 Olanzapine Versus Risperidone and Haloperidol in the Treatment of Schizophrenia</td>
</tr>
<tr>
<td>55 The Differential Risk of Tardive Dyskinesia with Olanzapine</td>
</tr>
<tr>
<td>59 Schizophrenia: A Language or Thought Disorder?</td>
</tr>
<tr>
<td>60 Suicide Attempts in Schizophrenia: Demoralization or Depression?</td>
</tr>
<tr>
<td>61 Predictors of Schizophrenia</td>
</tr>
<tr>
<td>84 Is Schizophrenia on the Decline?</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td>2 Is There an Obsessive-Compulsive Subtype of Schizophrenia?</td>
</tr>
<tr>
<td>19 Late-Onset Schizophrenia: New Insights</td>
</tr>
<tr>
<td>34 Affective Dysfunctions in Schizophrenia</td>
</tr>
<tr>
<td>47 Schizophrenia: A Neurodevelopmental Perspective</td>
</tr>
<tr>
<td>48 Management of Schizophrenia with Comorbid Disorders</td>
</tr>
<tr>
<td>50 Pharmacological Treatments in Schizophrenia and Their Effect on Cognitive Function</td>
</tr>
<tr>
<td>51 Early Detection and the Treatment of First Psychosis</td>
</tr>
<tr>
<td>60 Clinical Subtyping of Schizophrenia</td>
</tr>
<tr>
<td>113 Deficit Syndrome: Research and Treatment</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>42 Issues in Tobacco Use and Schizophrenia</td>
</tr>
<tr>
<td><strong>TOPIC 12: SEXUAL AND GENDER IDENTITY DISORDERS</strong></td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
</tr>
<tr>
<td>85 The Assessment and Treatment of Child Molestors</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td>3 Management of Iatrogenic Sexual Dysfunction</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORT</strong></td>
</tr>
<tr>
<td>24 Sexual Addiction: An Integrated Understanding</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
</tr>
<tr>
<td>60 Transgender Awareness</td>
</tr>
<tr>
<td><strong>TOPIC 13: SLEEP DISORDERS</strong></td>
</tr>
<tr>
<td><strong>CME COURSES</strong></td>
</tr>
<tr>
<td>40 Overview and Update of Sleep Disorders Medicine</td>
</tr>
<tr>
<td>52 Advanced Topics in Sleep Medicine for Psychiatrists</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>22 The Evaluation Process in Obstructive Sleep Apnea</td>
</tr>
<tr>
<td>31 Changes in Insomnia During the Treatment of Depression</td>
</tr>
<tr>
<td><strong>TOPIC 14: SOMATOFORM DISORDERS</strong></td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
</tr>
<tr>
<td>58 The Evaluation and Management of Pain</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td>37 Update on Diagnosis: Pathophysiology and Treatment of Primary Headache Disorders for the Practicing Psychiatrist</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATIONS</strong></td>
</tr>
<tr>
<td>5 Patients with Symptoms of Somatization</td>
</tr>
<tr>
<td>10 Evaluation and Management of Chronic Pain Patients With and Without Medication Dependence</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
</tr>
<tr>
<td>39 Chronic Pain Disorder Following Injury</td>
</tr>
<tr>
<td>40 A Family Study of Fibromyalgia</td>
</tr>
<tr>
<td><strong>SYMPOSIA</strong></td>
</tr>
<tr>
<td>116 Introduction to Psychodermatology</td>
</tr>
<tr>
<td><strong>TOPIC 15: UNLISTED DISORDERS</strong></td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
</tr>
<tr>
<td>18 ADD in Adults</td>
</tr>
<tr>
<td><strong>INDUSTRY-SUPPORTED SYMPOSIA</strong></td>
</tr>
<tr>
<td>44 Management of Mental Disorders in Baby Boomers and Beyond</td>
</tr>
</tbody>
</table>
# TOPIC INDEX

## MASTER EDUCATOR CLINICAL CONSULTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>The Father in Psychopathology and Psychotherapy: Case Discussions Where Fathering and Being Fathered Affect Recovery from Mental Illness: Dynamic and Developmental Considerations</td>
</tr>
<tr>
<td>76</td>
<td>Assessing the Need for Mental Health Services Among High-Risk Children</td>
</tr>
</tbody>
</table>

## MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>90</td>
<td>Healing Wounded Hearts</td>
</tr>
<tr>
<td>90</td>
<td>When the Bough Breaks</td>
</tr>
<tr>
<td>91</td>
<td>Breaking the Cycle</td>
</tr>
</tbody>
</table>

## REVIEW OF PSYCHIATRY

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>Child Psychopharmacology</td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>52</td>
<td>Attachment Security of Mothers and Adolescents</td>
</tr>
<tr>
<td>83</td>
<td>Psychological Functioning and Child Abuse in Adolescents</td>
</tr>
<tr>
<td>83</td>
<td>Clinical Judgment in Reports of Childhood Sexual Abuse</td>
</tr>
</tbody>
</table>

## SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>92</td>
<td>Juvenile Offenders: Modern Issues for Child Psychiatry</td>
</tr>
</tbody>
</table>

## WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Use of Culture in Interventions for Young Children</td>
</tr>
<tr>
<td>46</td>
<td>The New Social Security Income Rule for Children: Practical Issues</td>
</tr>
<tr>
<td>54</td>
<td>Effective Psychiatric Work in the Juvenile Justice System</td>
</tr>
</tbody>
</table>

## WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>Challenges to Confidentiality in Child Psychiatry</td>
</tr>
<tr>
<td>79</td>
<td>Psychiatric Assessment of Juvenile Dangerousness</td>
</tr>
</tbody>
</table>

## TOPIC 27: COMMUNITY PSYCHIATRY AND PREVENTION

### MEDIA PRESENTATION

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>45</td>
<td>In Their Shoes: Community Mental Health in Texas</td>
</tr>
</tbody>
</table>

### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>52</td>
<td>Some Long-term Consequences of Orphanage Care</td>
</tr>
<tr>
<td>53</td>
<td>Telepsychiatry in Georgia: A Multichannelled Approach</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>103</td>
<td>Psychotherapies in Community Psychiatry</td>
</tr>
</tbody>
</table>

## WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>22</td>
<td>New Roles for Psychiatrists Resolving Community Conflicts</td>
</tr>
<tr>
<td>86</td>
<td>Developing Alternatives to Outpatient Commitment</td>
</tr>
<tr>
<td>86</td>
<td>Involuntary Case Management for the Mentally Ill</td>
</tr>
<tr>
<td>108</td>
<td>Outpatient Commitment: The New York Experience</td>
</tr>
</tbody>
</table>

## TOPIC 28: CONSULTATION-LIAISON AND EMERGENCY PSYCHIATRY

### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Blacks &amp; Jews</td>
</tr>
<tr>
<td>32</td>
<td>I Shall Not Be Removed: The Life of Marion Riggs</td>
</tr>
<tr>
<td>32</td>
<td>Ali God's Children</td>
</tr>
<tr>
<td>44</td>
<td>Shattering the Stences</td>
</tr>
<tr>
<td>82</td>
<td>The Dark Side of the Moon</td>
</tr>
<tr>
<td>100</td>
<td>Momiji: Japanese Maple</td>
</tr>
<tr>
<td>100</td>
<td>Kim's Story: The Road from Vietnam</td>
</tr>
<tr>
<td>101</td>
<td>The Shot Heard Round the World</td>
</tr>
<tr>
<td>110</td>
<td>Whose Child Is This?</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>The Burden of World Mental Health: The World Health Organization and the World Federation for Mental Health Responses</td>
</tr>
<tr>
<td>71</td>
<td>Culture and Ethnicity: An Arab Perspective</td>
</tr>
<tr>
<td>102</td>
<td>French and American: Vive La Difference!</td>
</tr>
</tbody>
</table>

### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>OCD: Spanish Perspective</td>
</tr>
<tr>
<td>78</td>
<td>Navajo Psychology</td>
</tr>
<tr>
<td>85</td>
<td>Psychiatric Training at Home and Abroad</td>
</tr>
<tr>
<td>86</td>
<td>Cultural Outcomes in the Elderly: An Industry Perspective</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Collaboration in Eastern and Southern Africa</td>
</tr>
<tr>
<td>28</td>
<td>Culturally Relevant Services for African Americans</td>
</tr>
<tr>
<td>29</td>
<td>Mental Health of Elderly Asian Indians: Issues and Solutions</td>
</tr>
</tbody>
</table>

## MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>77</td>
<td>A Mother's Grief</td>
</tr>
<tr>
<td>77</td>
<td>Grown-Up Tears</td>
</tr>
<tr>
<td>107</td>
<td>The Nicholas Effect</td>
</tr>
</tbody>
</table>

## MEDICAL UPDATES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>25</td>
<td>Congestive Heart Failure</td>
</tr>
<tr>
<td>82</td>
<td>The Hepatic Cytochrome P450 System</td>
</tr>
</tbody>
</table>

## SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>53</td>
<td>Care Model's Guide Primary Care Psychiatry Teaching</td>
</tr>
<tr>
<td>85</td>
<td>Drug-Induced Delirium in Intensive Care Units</td>
</tr>
</tbody>
</table>

## SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>61</td>
<td>Gender Issues in Cancer Treatment</td>
</tr>
<tr>
<td>121</td>
<td>It's Not Just an Emergency Room: Urgent Care and Training in an Era of Cost Containment</td>
</tr>
</tbody>
</table>

## WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Cardiac Psychiatry</td>
</tr>
<tr>
<td>22</td>
<td>The Hamilton-Wenworth HSO Mental Health Program</td>
</tr>
<tr>
<td>29</td>
<td>Consultation-Liaison Psychiatry: Problem Solving and Lifelong Learning</td>
</tr>
<tr>
<td>48</td>
<td>Cultural Issues in Consultation-Liaison Psychiatry</td>
</tr>
<tr>
<td>55</td>
<td>Severe Mental Illness in Family Medicine Settings</td>
</tr>
<tr>
<td>86</td>
<td>Avoiding Admission: Psychiatric Home Care</td>
</tr>
</tbody>
</table>

## TOPIC 29: CROSS-CULTURAL AND MINORITY PSYCHIATRY

### DISCUSSION GROUP

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>Cultural Psychiatry</td>
</tr>
</tbody>
</table>

### FORUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>67</td>
<td>The Impact of American Psychiatry on the Development of Psychiatry in Asia</td>
</tr>
</tbody>
</table>

### LECTURE

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>75</td>
<td>Immigration and Psychopathology: Is There a Connection?</td>
</tr>
</tbody>
</table>

### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>Blacks &amp; Jews</td>
</tr>
<tr>
<td>32</td>
<td>I Shall Not Be Removed: The Life of Marion Riggs</td>
</tr>
<tr>
<td>32</td>
<td>Ali God's Children</td>
</tr>
<tr>
<td>44</td>
<td>Shattering the Stences</td>
</tr>
<tr>
<td>82</td>
<td>The Dark Side of the Moon</td>
</tr>
<tr>
<td>100</td>
<td>Momiji: Japanese Maple</td>
</tr>
<tr>
<td>100</td>
<td>Kim's Story: The Road from Vietnam</td>
</tr>
<tr>
<td>101</td>
<td>The Shot Heard Round the World</td>
</tr>
<tr>
<td>110</td>
<td>Whose Child Is This?</td>
</tr>
</tbody>
</table>

### SYMPOSIUM

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>38</td>
<td>The Burden of World Mental Health: The World Health Organization and the World Federation for Mental Health Responses</td>
</tr>
<tr>
<td>71</td>
<td>Culture and Ethnicity: An Arab Perspective</td>
</tr>
<tr>
<td>102</td>
<td>French and American: Vive La Difference!</td>
</tr>
</tbody>
</table>

### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>OCD: Spanish Perspective</td>
</tr>
<tr>
<td>78</td>
<td>Navajo Psychology</td>
</tr>
<tr>
<td>85</td>
<td>Psychiatric Training at Home and Abroad</td>
</tr>
<tr>
<td>86</td>
<td>Cultural Outcomes in the Elderly: An Industry Perspective</td>
</tr>
</tbody>
</table>

### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Page #</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Collaboration in Eastern and Southern Africa</td>
</tr>
<tr>
<td>28</td>
<td>Culturally Relevant Services for African Americans</td>
</tr>
<tr>
<td>29</td>
<td>Mental Health of Elderly Asian Indians: Issues and Solutions</td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>56 Clinical Response to Valproate in Seizure Patients</td>
<td>53</td>
</tr>
<tr>
<td>57 Nortriptyline for Grief-Related Depression in Elders</td>
<td>53</td>
</tr>
<tr>
<td>58 Two-Year Outcome of Psychotic Depression in Late-Life</td>
<td>53</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>38</td>
</tr>
<tr>
<td>20 Agitation in the Elderly</td>
<td>38</td>
</tr>
<tr>
<td><strong>WORKSHOPS - COMPONENTS</strong></td>
<td>20</td>
</tr>
<tr>
<td>2 Nursing Home Psychiatry: Problems and Solutions</td>
<td>20</td>
</tr>
<tr>
<td>24 Successful Practice in Long-Term Care</td>
<td>47</td>
</tr>
<tr>
<td><strong>TOPIC 35: NEUROBIOLOGY</strong></td>
<td>56</td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
<td>56</td>
</tr>
<tr>
<td>4 Toward a Neurobiology of Psychotherapy</td>
<td>56</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td>74</td>
</tr>
<tr>
<td>19 The Convergence of Neurobiology and Psychodynamics</td>
<td>74</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>116</td>
</tr>
<tr>
<td>96 Brain Signaling Pathways in Psychiatric Syndromes</td>
<td>116</td>
</tr>
<tr>
<td><strong>TOPIC 36: NEUROPSYCHIATRY</strong></td>
<td>23</td>
</tr>
<tr>
<td><strong>ADVANCES IN RESEARCH</strong></td>
<td>23</td>
</tr>
<tr>
<td>Advances in Neuropsychiatry</td>
<td>23</td>
</tr>
<tr>
<td><strong>CME COURSES</strong></td>
<td>8</td>
</tr>
<tr>
<td>29 Psychiatric Disorders Related to Epilepsy</td>
<td>8</td>
</tr>
<tr>
<td>49 Advances in Neuropsychiatry</td>
<td>17</td>
</tr>
<tr>
<td>88 Traumatic Brain Injury: Neuropsychiatric Assessment</td>
<td>74</td>
</tr>
<tr>
<td>97 Video Review of Neuropsychiatric Conditions</td>
<td>105</td>
</tr>
<tr>
<td>99 Diagnostic Challenges in Neuropsychiatry</td>
<td>105</td>
</tr>
<tr>
<td>100 Dementia: Advanced Diagnosis and Treatment</td>
<td>105</td>
</tr>
<tr>
<td><strong>MASTER EDUCATOR CLINICAL CONSULTATION</strong></td>
<td>44</td>
</tr>
<tr>
<td>6 The Treatment of Agitation and Aggression in Neuropsychiatric Patients</td>
<td>44</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td>85</td>
</tr>
<tr>
<td>67 Role of Sympathoadrenal Dysfunction in Hyperthermia</td>
<td>85</td>
</tr>
<tr>
<td>88 Epilepsy and Psychosis: A Neurodevelopmental Hypothesis</td>
<td>85</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>121</td>
</tr>
<tr>
<td>74 Catatonia and Other Motor Syndromes: How Closely Related?</td>
<td>95</td>
</tr>
<tr>
<td>76 Psychiatric Aspects of Epilepsy</td>
<td>95</td>
</tr>
<tr>
<td>114 Traumatic Brain Injury: Perspectives and Pearls</td>
<td>121</td>
</tr>
<tr>
<td><strong>TOPIC 37: PSYCHIATRIC EDUCATION</strong></td>
<td>5</td>
</tr>
<tr>
<td><strong>CME COURSES</strong></td>
<td>5</td>
</tr>
<tr>
<td>15 Teaching Psychiatry? Let Hollywood Help!</td>
<td>5</td>
</tr>
<tr>
<td>22 Advanced Interviewing Techniques</td>
<td>5</td>
</tr>
<tr>
<td>31 How to Pass the Boards! The Part II Oral Exam</td>
<td>8</td>
</tr>
<tr>
<td>38 Psychiatric Training for Disaster</td>
<td>15</td>
</tr>
<tr>
<td>77 Conceptual Tools for Psychotherapy Supervision</td>
<td>73</td>
</tr>
<tr>
<td>90 Skills for Mentors and Protégés in the New Era</td>
<td>88</td>
</tr>
<tr>
<td><strong>DISCUSSION GROUP</strong></td>
<td>23</td>
</tr>
<tr>
<td>3 The Future of Psychiatric Education in the 21st Century</td>
<td>23</td>
</tr>
<tr>
<td><strong>FORUM</strong></td>
<td>56</td>
</tr>
<tr>
<td>6 Challenges in Teaching Psychiatry in the Next Century</td>
<td>56</td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td>50</td>
</tr>
<tr>
<td>14 Educational Imperative: A Unified Psychotherapy Curriculum</td>
<td>50</td>
</tr>
<tr>
<td><strong>MEDIA PRESENTATIONS</strong></td>
<td>59</td>
</tr>
<tr>
<td>29 Paranoia</td>
<td>59</td>
</tr>
<tr>
<td>30 Step on a Crack</td>
<td>59</td>
</tr>
<tr>
<td>31 Deception: Munchausen's Disorder</td>
<td>60</td>
</tr>
<tr>
<td>32 Turning the Tables</td>
<td>60</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td>112</td>
</tr>
<tr>
<td>107 Educating Medical Students About Physician-Patient Sex</td>
<td>112</td>
</tr>
<tr>
<td>108 Increasing the Pool of AMG Psychiatry Applicants</td>
<td>112</td>
</tr>
<tr>
<td>109 Changing Medical Student Attitudes About Spanking</td>
<td>112</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>71</td>
</tr>
<tr>
<td>52 A Worldwide Challenge: World Psychiatric Association's Responses</td>
<td>71</td>
</tr>
<tr>
<td><strong>WORKSHOPS - COMPONENTS</strong></td>
<td>113</td>
</tr>
<tr>
<td>57 Consensus Workshop on Psychodynamic Instruction</td>
<td>113</td>
</tr>
<tr>
<td>58 Global Education in Psychiatry: Unity and Diversity</td>
<td>114</td>
</tr>
<tr>
<td><strong>WORKSHOPS - ISSUES</strong></td>
<td>21</td>
</tr>
<tr>
<td>5 How to Teach the Biopsychosocial Model Effectively</td>
<td>21</td>
</tr>
<tr>
<td>10 The Psychodynamic Formulation: Why Bother?</td>
<td>22</td>
</tr>
<tr>
<td>16 Using Standardized Patients to Evaluate Psychiatric Clinical Clerks</td>
<td>22</td>
</tr>
<tr>
<td>38 ABPN Examinations and Canadians</td>
<td>48</td>
</tr>
<tr>
<td>40 The Standardized Patient in Psychiatric Education</td>
<td>48</td>
</tr>
<tr>
<td>52 How to Write and Publish in Psychiatry</td>
<td>55</td>
</tr>
<tr>
<td>62 IMGs in the United States: Problem or Solution?</td>
<td>79</td>
</tr>
<tr>
<td>65 ABPN Update: Requirements for the ABPN Examination</td>
<td>79</td>
</tr>
<tr>
<td>85 Workforce and Recruitment: We Can Make a Difference</td>
<td>85</td>
</tr>
<tr>
<td><strong>TOPIC 38: PSYCHIATRIC REHABILITATION</strong></td>
<td>86</td>
</tr>
<tr>
<td><strong>SCIENTIFIC AND CLINICAL REPORTS</strong></td>
<td>53</td>
</tr>
<tr>
<td>46 Integrating Physical Rehabilitation Services into an Inpatient Psychiatric Unit</td>
<td>53</td>
</tr>
<tr>
<td>80 Psychiatric Disability Exam for Employment Discrimination and the Americans with Disabilities Act</td>
<td>84</td>
</tr>
<tr>
<td><strong>SOCIAL SECURITY WORKSHOP</strong></td>
<td>78</td>
</tr>
<tr>
<td>Disability Evaluation Under Social Security: A Presentation for Treating Psychiatrists</td>
<td>78</td>
</tr>
<tr>
<td><strong>WORKSHOP - COMPONENT</strong></td>
<td>20</td>
</tr>
<tr>
<td>3 How Your Patients' Disablement Will Be Evaluated</td>
<td>20</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
<td>109</td>
</tr>
<tr>
<td>98 Employment Disability and Accommodation Dilemmas</td>
<td>109</td>
</tr>
<tr>
<td><strong>TOPIC 39: PSYCHOANALYSIS</strong></td>
<td>36</td>
</tr>
<tr>
<td><strong>SYMPOSIUM</strong></td>
<td>36</td>
</tr>
<tr>
<td>13 The Medical Psychoanalyst: Multiple Roles</td>
<td>36</td>
</tr>
<tr>
<td><strong>WORKSHOP - ISSUE</strong></td>
<td>54</td>
</tr>
<tr>
<td>49 The Role of Enactment in Psychiatric Treatment</td>
<td>54</td>
</tr>
<tr>
<td><strong>TOPIC 40: RESEARCH ISSUES</strong></td>
<td>87</td>
</tr>
<tr>
<td><strong>CME COURSE</strong></td>
<td>15</td>
</tr>
<tr>
<td>36 Doing Research on a Shoestring Budget</td>
<td>15</td>
</tr>
<tr>
<td><strong>FORUMS</strong></td>
<td>29</td>
</tr>
<tr>
<td>1 What's Really Going on in Psychiatry? The APA Practice Research Network</td>
<td>29</td>
</tr>
<tr>
<td>7 Trust in Human Subject Research</td>
<td>87</td>
</tr>
<tr>
<td>TOPIC INDEX</td>
<td></td>
</tr>
<tr>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td><strong>LECTURE</strong></td>
<td>Page #</td>
</tr>
<tr>
<td>3 Services Effectiveness Research: Relevance, Challenges and Future Directions</td>
<td>17</td>
</tr>
</tbody>
</table>

**NEW RESEARCH SESSIONS**

1 Young Investigators' Poster Session  20
2 Young Investigators' Oral/Slide Session  30
3 Young Investigators' Oral/Slide Session  30
4 Young Investigators' Poster Session  59
5 Oral/Slide Session  45
6 Oral/Slide Session  45
7 Poster Session  55
8 Poster Session  68
9 Oral/Slide Session  75
10 Oral/Slide Session  75
11 Poster Session  87
12 Poster Session  98
13 Oral/Slide Session  107
14 Oral/Slide Session  107
15 Poster Session  115

**SCIENTIFIC AND CLINICAL REPORTS**

63 Slendesta: Erectile Dysfunction: A One-Year Study  83
120 The Validity of Autobiographical Memory  113
121 How Blind Is Double-Blind?  113

**WORKSHOP - COMPONENT**

20 Advances in Veterans Affairs Schizophrenia Research  46

**TOPIC 41: SOCIAL PSYCHIATRY**

**MEDIA PRESENTATIONS**

2 Daughters of the Troubles: Belfast Stories  14
65 Where Have All the Children Gone? The Crisis in Rural Communities  110

**SCIENTIFIC AND CLINICAL REPORT**

44 Maximizing Community Resources in a Rural Setting  53

**SYMPOSIA**

58 When Sports Goes Over the Line  72
67 Pathways to Homelessness  93
97 Psychiatry Services Research in Practice and Policy  116
110 New Advocacy Challenges for Social Psychiatry  120

**WORKSHOP - COMPONENT**

59 Getting Your Patient Housing, Entitlements and Free Medications: A Primer  114

**WORKSHOPS - ISSUES**

17 Hello Dolly: Psychiatry and Assisted Reproduction  22
70 Challenges in Resocializing Psychiatric Education  80
101 Unwelcome Treatment? Treating the Mandated Patient  109

**TOPIC 42: STRESS**

**CME COURSE**

17 Managing the Stress of Malpractice Litigation  5

**WORKSHOP - COMPONENT**

39 Physicians Under Fire: Understanding and Help  79

**TOPIC 43: SUICIDE**

**SCIENTIFIC AND CLINICAL REPORTS**

8 Kevorkian's List: Psychosocial or Medical Factors?  26
9 Psychological Impact of a Patient's Suicide on Psychiatrists  26
10 Covariates of Suicidality in Dysphoric Mania  26

**WORKSHOP - ISSUE**

115 Suicide Prevention: New Public Health Perspectives  115

**TOPIC 44: VIOLENCE, TRAUMA AND VICTIMIZATION**

**CLINICAL CASE CONFERENCE**

2 Psychotherapy with Women Who Have Experienced Domestic Violence  42

**CME COURSES**

8 Assessing Threats and Violence at Home and Work  1
19 Risk Assessment for Violence  5
23 Management and Treatment of the Violent Patient  5
27 The Psychiatrist's Role in Sexual Harassment  8
93 Managing the Fear of Violence  105

**INDUSTRY-SUPPORTED SYMPOSIUM**

29 Clinical Aspects of Violence  12

**MEDIA PRESENTATIONS**

10 Licensed to Kill  32
21 Rape: A Crime of War  50
22 Glimmer of Hope  51
34 Responses in Music to Violence Against Women  70
59 When We Were Kings: The Untold Story of the Rumble in the Jungle  101

**SYMPOSIA**

3 Violence and Abuse: Full Circle  34
17 Multigenerational Aspects of Trauma  37
30 Family Violence and Psychiatry: Canada and the United States  62
85 Oklahoma City: Trauma and Renewal After Terrorism  98
86 Societal and Cultural Adaptations to Trauma  98

**WORKSHOPS - COMPONENTS**

4 Political Violence in the Post-Cold War Era  21
7 Dealing with Violence in Schools  21
50 Psychiatric Dimensions of Disasters  108

**WORKSHOPS - ISSUES**

36 Facing Television Violence in Clinical Practice  47
41 Predatory Abuse: Exploitation of the Elderly  48
50 Conceptualization and Boundaries of Trauma  54
104 Understanding the Dynamics of Abusive Relationships  109
114 Sexual Abuse Case: Psychotherapy and Neurobiology  115

**TREATMENTS**

**TOPIC 45: BEHAVIOR AND COGNITIVE THERAPIES**

**CME COURSES**

3 Cognitive Therapy for Severe Mental Disorders  1
10 Hypnosis in Psychiatry  1
14 Cognitive Therapy: The Basics  2
26 Dialectical Behavior Therapy for Patients with BPD  6
48 Introduction to Behavior Therapy  16
95 Cognitive-Behavioral Treatment of Specific Phobias  105
### TOPIC INDEX

**WORKSHOPS - ISSUES**
- 39 Cognitive Therapy for Personality Disorders 48
- 55 Toning and Chanting: Accessing and Expressing the Nonverbal 55

**TOPIC 46: COMBINED PHARMACOTHERAPY AND PSYCHOTHERAPY**
- CME COURSE 50 Medication Backup: A Practical Guide 30
- SYMPOSIUM 66 Dynamic Perspectives on Treatment Resistance 93

**TOPIC 47: COUPLE AND FAMILY THERAPIES**
- CME COURSES 24 Integrative Couple Therapy: Skills and Techniques 5 39 Families and Medical Illness: An Integrative Treatment Approach 15 72 Enhancing Marital Intimacy Therapy 56
- WORKSHOP - ISSUE 32 Video Case Studies of Couples in Treatment 47

**TOPIC 48: GROUP THERAPY**
- CME COURSES 9 Introduction to Psychodynamic Group Psychotherapy 1 34 Outpatient Group Therapy for the Seriously Mentally Ill 15
- SYMPOSIUM 1 Evaluating Group Interventions for Cancer Patients 33
- WORKSHOPS - ISSUES 12 Group Treatment for Traumatized Drug-Using Women 22 84 Group Therapy: Making Untreatable Patients Treatable 86

**TOPIC 49: INDIVIDUAL PSYCHOTHERAPIES**
- CONTINUOUS CLINICAL CASE CONFERENCES 17 Psychotropics in Residency Training: Part I 16 42 Psychotropics in Residency Training: Part II
- CME COURSES 2 Interpersonal Psychotherapy 1 21 The Advanced Practice of Psychotherapy 5 61 Brief Psychodynamic Psychotherapy: The Core Conflictual Relationship Theme Method 41 69 Interpersonal Psychotherapy 42 73 Clinical Management of Regressive Dependency 56 94 Time-Limited Dynamic Therapy for Difficult Patients 105
- DISCUSSION GROUP 7 Development and Psychopathology: Clinical Perspectives 48

**TOPIC 50: PSYCHOPHARMACOLOGY**
- CME COURSES 41 Anticonvulsants in Child, Adolescent and Adult Psychiatry 16 64 Drug Treatment of Schizophrenia 41 75 Rational Use of Hormone-Replacement Therapy and Antidepressants in Postmenopausal Women 56

**MEDIA PRESENTATION**
- 38 Cytochrome Interactions via the Web 76

**SCIENTIFIC AND CLINICAL REPORTS**
- SYMPOSIAS 17 Haloperidol Versus Clozapine in Autistic Disorder 27 18 Cost of Olanzapine Treatment Compared with Haloperidol for Schizophrenia: Results from a Randomized Clinical Trial 27 62 Olanzapine: Safe in Clozapine-Induced Agranulocytosis 83 64 Adverse Event Profiles Associated with Long-Term Fluoxetine Treatment 83 89 Effects of Discontinuing Long-Term Antidepressants 111 113 Current Prescribing Practices for Bipolar Patients 113 115 Use of the New Antiepileptic Drug Topiramate As a Mood Stabilizer 113

**SYMPOSIAS**
### TOPIC INDEX

#### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 NMS: Diagnosis, Treatment and Aftercare</td>
<td>28</td>
</tr>
<tr>
<td>48 Pharmacotherapy of Addictive Disorders</td>
<td>48</td>
</tr>
<tr>
<td>107 Prescribing for Other Clinicians</td>
<td>114</td>
</tr>
</tbody>
</table>

#### TOPIC 51: SOMATIC THERAPIES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Homeopathic Medicine and Psychiatry</td>
<td>29</td>
</tr>
<tr>
<td>58 Acupuncture, Oriental Medicine and Psychiatry</td>
<td>55</td>
</tr>
</tbody>
</table>

#### TOPIC 52: TREATMENT TECHNIQUES AND OUTCOME STUDIES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 Homeopathic Medicine and Psychiatry</td>
<td>29</td>
</tr>
<tr>
<td>58 Acupuncture, Oriental Medicine and Psychiatry</td>
<td>55</td>
</tr>
</tbody>
</table>

#### CME COURSES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>60 ECT Practice Update</td>
<td>41</td>
</tr>
<tr>
<td>80 ECT: New Directions in Practice and Research</td>
<td>73</td>
</tr>
</tbody>
</table>

#### MEDICAL UPDATE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Herbal Medicine</td>
<td>51</td>
</tr>
</tbody>
</table>

#### SCIENTIFIC AND CLINICAL REPORTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>95 Clinical Predictors of Recurrent Depression</td>
<td>111</td>
</tr>
<tr>
<td>96 Correlates of Dropping Out of Substance Abuse Treatment</td>
<td>111</td>
</tr>
<tr>
<td>97 Measuring the Quality of Care for Schizophrenia</td>
<td>111</td>
</tr>
</tbody>
</table>

#### SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>41 Practicing Evidence-Based Psychiatry: MDD</td>
<td>65</td>
</tr>
<tr>
<td>59 Outcome Measurement in Psychiatry: A Critical Review</td>
<td>91</td>
</tr>
<tr>
<td>90 Music Therapy in Psychiatric Care</td>
<td>102</td>
</tr>
<tr>
<td>99 Practicing Evidence-Based Psychiatry: Bipolar Disorder</td>
<td>117</td>
</tr>
<tr>
<td>108 An Integrative Approach to Psychiatry</td>
<td>119</td>
</tr>
<tr>
<td>111 Psychodynamic Therapy Research in the New Century</td>
<td>120</td>
</tr>
</tbody>
</table>

#### WORKSHOP - COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 Guidelines for Collaborative Treatment in Psychiatry</td>
<td>21</td>
</tr>
</tbody>
</table>

#### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Insight into Illness: A Deterrent or an Enhancement?</td>
<td>21</td>
</tr>
<tr>
<td>83 When Clozapine Alone Is Not Enough</td>
<td>86</td>
</tr>
<tr>
<td>113 Compliance: Directly Observed Therapy and Other Strategies</td>
<td>114</td>
</tr>
</tbody>
</table>

#### TOPIC 53: COMPUTERS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>33 How to Apply the Internet: Advanced Topics</td>
<td>9</td>
</tr>
</tbody>
</table>

#### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Computerized Patient Records</td>
<td>19</td>
</tr>
<tr>
<td>14 Practice-Management Software on the Cheap!</td>
<td>44</td>
</tr>
<tr>
<td>15 Computer Psychiatric Record Creation and Use for Solo Psychiatrists</td>
<td>44</td>
</tr>
<tr>
<td>16 Psych Script Software to Create Typed Psych Notes</td>
<td>44</td>
</tr>
<tr>
<td>26 Comprehensive Clinician's Desktop</td>
<td>56</td>
</tr>
<tr>
<td>27 An Electronic Medical Record for Psychiatry</td>
<td>57</td>
</tr>
<tr>
<td>28 Computer-Assisted Service Planning (CASP)</td>
<td>57</td>
</tr>
<tr>
<td>37 Psychotherapy on the Internet</td>
<td>75</td>
</tr>
<tr>
<td>39 Computer-Assisted Psychotherapy</td>
<td>77</td>
</tr>
<tr>
<td>49 Booting Up Your Practice</td>
<td>88</td>
</tr>
<tr>
<td>50 A Computer Assessment Using Scores and Narratives</td>
<td>88</td>
</tr>
<tr>
<td>51 Relational Database in Clinical Practice</td>
<td>88</td>
</tr>
<tr>
<td>99 Computer Production Workshop</td>
<td>99</td>
</tr>
</tbody>
</table>

#### SYMPOSIA

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>91 Computer-Assisted Psychotherapy</td>
<td>102</td>
</tr>
<tr>
<td>98 21st Century Psychiatry: Internet Applications</td>
<td>117</td>
</tr>
</tbody>
</table>

#### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Hands-On Web Work: Part I</td>
<td>21</td>
</tr>
<tr>
<td>15 Hands-On Web Work: Part II</td>
<td>28</td>
</tr>
<tr>
<td>17 Producing a Web Page: Introduction</td>
<td>39</td>
</tr>
</tbody>
</table>

#### TOPIC 54: CREATIVITY AND THE ARTS

**DAYS OF CREATION SESSION**

- A Musical Presentation from The Guarneri String Quartet

#### LECTURES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 Making Things Up</td>
<td>17</td>
</tr>
<tr>
<td>5 Artists' Inspiration: Sentiment, Sentimentality or Neither of the Above</td>
<td>23</td>
</tr>
<tr>
<td>15 Ward Stories: Writing About Medicine</td>
<td>57</td>
</tr>
</tbody>
</table>

#### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 Nobody's Business</td>
<td>25</td>
</tr>
<tr>
<td>9 Pennies from Heaven</td>
<td>25</td>
</tr>
<tr>
<td>13 Shine</td>
<td>33</td>
</tr>
<tr>
<td>33 Contact</td>
<td>60</td>
</tr>
<tr>
<td>48 Can't You Hear the Wind Howl?</td>
<td>87</td>
</tr>
</tbody>
</table>

#### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>57 Artists at Mid Life: Confrontations with Death</td>
<td>72</td>
</tr>
</tbody>
</table>

#### WORKSHOP - COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>11 Love Letters: Short Drama with Analytical Interpretation and Discussion</td>
<td>28</td>
</tr>
</tbody>
</table>

#### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>53 George Gershwin at 100: A Creative Genius Re-Examined</td>
<td>55</td>
</tr>
<tr>
<td>54 Art and Audience: The Creative Interaction</td>
<td>55</td>
</tr>
</tbody>
</table>

#### TOPIC 55: GAY AND LESBIAN ISSUES

**FORUM**

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 Psychiatry: 25 Years Since Depathologizing Homosexuality</td>
<td>55</td>
</tr>
</tbody>
</table>

#### SYMPOSIUM

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 Gay Men, Lesbians and Bisexuals: Controversial Issues</td>
<td>36</td>
</tr>
</tbody>
</table>

#### WORKSHOPS - COMPONENTS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 Beyond Coming Out</td>
<td>28</td>
</tr>
<tr>
<td>40 The Experience of Coming Out in Psychiatry</td>
<td>79</td>
</tr>
<tr>
<td>53 Psychotherapy with Lesbians and Bisexual Women</td>
<td>108</td>
</tr>
<tr>
<td>55 Pathology to Pride: Evolving Views of Homosexuality</td>
<td>113</td>
</tr>
</tbody>
</table>

#### WORKSHOPS - ISSUES

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>46 International Perspectives on Gay Psychiatry</td>
<td>48</td>
</tr>
<tr>
<td>78 Gay Psychiatrists: An Amsterdam Perspective</td>
<td>80</td>
</tr>
<tr>
<td>110 Social Amnesia: Resocializing Psychiatric Research</td>
<td>114</td>
</tr>
</tbody>
</table>

#### TOPIC 56: GENDER

#### MEDIA PRESENTATIONS

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>35 Packing Heat</td>
<td>70</td>
</tr>
<tr>
<td>66 Ms. Conceptions</td>
<td>115</td>
</tr>
<tr>
<td>67 You Don't Know Dick</td>
<td>116</td>
</tr>
</tbody>
</table>

#### WORKSHOP - ISSUE

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>57 Transgender Issues</td>
<td>55</td>
</tr>
</tbody>
</table>

#### TOPIC 57: HISTORICAL QUESTIONS

#### MEDIA PRESENTATION

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>63 Beautiful Dreamers</td>
<td>107</td>
</tr>
</tbody>
</table>

#### WORKSHOP - COMPONENT

<table>
<thead>
<tr>
<th>Topic</th>
<th>Page #</th>
</tr>
</thead>
<tbody>
<tr>
<td>25 The History of Managed Care in Psychiatry</td>
<td>47</td>
</tr>
</tbody>
</table>

---

**TOTAL:** 133
## TOPIC INDEX

### TOPIC 58: HUMAN RIGHTS

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>40</td>
</tr>
<tr>
<td>25</td>
<td>106</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Media Presentation</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>20</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop - Component</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>32</td>
<td>54</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>8</td>
<td>22</td>
</tr>
<tr>
<td>27</td>
<td>29</td>
</tr>
<tr>
<td>51</td>
<td>55</td>
</tr>
<tr>
<td>69</td>
<td>80</td>
</tr>
</tbody>
</table>

### TOPIC 59: MANAGED CARE AND HEALTH CARE FUNDING

<table>
<thead>
<tr>
<th>CME Courses</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>2</td>
</tr>
<tr>
<td>54</td>
<td>30</td>
</tr>
<tr>
<td>70</td>
<td>42</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Discussion Group</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Research Consultation With</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>82</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scientific and Clinical Reports</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>14</td>
<td>26</td>
</tr>
<tr>
<td>15</td>
<td>26</td>
</tr>
<tr>
<td>45</td>
<td>53</td>
</tr>
<tr>
<td>114</td>
<td>113</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>31</td>
<td>62</td>
</tr>
<tr>
<td>79</td>
<td>96</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Components</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>27</td>
<td>47</td>
</tr>
<tr>
<td>56</td>
<td>113</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>23</td>
<td>29</td>
</tr>
<tr>
<td>35</td>
<td>47</td>
</tr>
<tr>
<td>45</td>
<td>48</td>
</tr>
<tr>
<td>61</td>
<td>55</td>
</tr>
<tr>
<td>111</td>
<td>114</td>
</tr>
</tbody>
</table>

### TOPIC 60: MENTAL RETARDATION (CHILD/adolescent/adult)

<table>
<thead>
<tr>
<th>CME Course</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>68</td>
<td>42</td>
</tr>
</tbody>
</table>

### TOPIC 61: POLITICAL QUESTIONS

<table>
<thead>
<tr>
<th>CME Course</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>49</td>
<td>67</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop - Issue</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>75</td>
<td>80</td>
</tr>
</tbody>
</table>

### TOPIC 62: PROFESSIONAL AND PERSONAL

<table>
<thead>
<tr>
<th>CME Courses</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>30</td>
<td>8</td>
</tr>
<tr>
<td>51</td>
<td>30</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Discussion Groups</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Forums</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>29</td>
</tr>
<tr>
<td>5</td>
<td>56</td>
</tr>
<tr>
<td>10</td>
<td>115</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scientific and Clinical Report</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>113</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>75</td>
<td>95</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Components</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19</td>
<td>46</td>
</tr>
<tr>
<td>52</td>
<td>108</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>21</td>
</tr>
<tr>
<td>19</td>
<td>28</td>
</tr>
</tbody>
</table>

### TOPIC 63: RELIGION, SPIRITUALITY AND PSYCHIATRY

<table>
<thead>
<tr>
<th>CME Course</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Lectures</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>49</td>
</tr>
<tr>
<td>21</td>
<td>75</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Scientific and Clinical Report</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>116</td>
<td>113</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Symposium</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>92</td>
<td>103</td>
</tr>
<tr>
<td>107</td>
<td>119</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshop - Component</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>47</td>
<td>85</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Workshops - Issues</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>22</td>
</tr>
<tr>
<td>63</td>
<td>79</td>
</tr>
<tr>
<td>89</td>
<td>86</td>
</tr>
<tr>
<td>108</td>
<td>114</td>
</tr>
</tbody>
</table>
TOPIC 64: RESIDENT AND MEDICAL STUDENT
CONCERNS

DISCUSSION GROUPS
9 The Treatment of Lesbians and Gay Men: Are the Psychiatric Issues Really Different? 74
13 Psychotherapy Education 110

RESEARCH CONSULTATION WITH
3 Residency to Research: Transitioning As Junior Faculty 111

RESIDENTS' SESSION
Meet the Experts: Sunny Side-Up 15

WORKSHOPS - COMPONENTS
1 Malpractice and Litigation in Psychiatric Residency 20
14 Life After Residency: Making a Career Choice 28
22 Access to Patients: Are Residents Being Carved Out? 46
23 Current Issues in Medical Student Education 46
30 Psychiatry Fellowships: Resident to Resident 54
31 Film Clubs: How to Have Fun While Learning Psychiatry 54
42 How to Launch a Successful Private Practice 85
48 Being Afraid: When Trainees Fear for Their Safety 85

WORKSHOPS - ISSUES
67 When a Medical Student Commits Suicide 79
86 Leadership: The Challenge for the 21st Century 86
88 Becoming a Psychiatrist in the New Millennium 86
91 Intervention Programs for Medical Student Stress 108
102 Beyond Medical School: The MBA Advantage 109

TOPIC 65: PRESIDENTIAL THEME: NEW CHALLENGES FOR PROVEN VALUES—DEFENDING ACCESS, FAIRNESS, ETHICS, DEENCY

CME COURSE
53 Writing About Clinical Experiences 30

SYMPOSIA
8 Developing Mental Health Care in a Post-Totalitarian Society 35
11 International Health Care and Telepsychiatry 36
28 The Changing Role of Psychiatrists in the Hospital 62
82 Psychiatric Ethics: Facing the 21st Century 97
87 The Role of Coercion in Psychiatry 101
88 Finding the Person in Writing About Patients 102
106 Psychiatrists As Owners and Managers of Delivery Systems 119

WORKSHOPS - ISSUES
9 Values in the Physician/Patient Managed Health Care Relationship 22
103 Conscience-Centered Psychiatric Ethics 109
109 Preserving Quality in Outpatient Psychiatry 114

TOPIC 66: STIGMA/ADVOCACY

LECTURE
10 APA's Patient Advocacy Award Lecture 43

MEDIA PRESENTATIONS
4 Breathing Lessons: The Life and Work of Mark O'Brien 19
5 Untold Desires 19
23 Conversations at the Carter Center: Coping with the Stigma of Mental Illness 51
24 Mental Illness: The Family's Story 51

WORKSHOP - COMPONENT
33 Psychiatry and the Pharmaceutical Industry 54

WORKSHOPS - ISSUES
76 Advocacy: Reaching the Media on Mental Health 80
112 Mental Health Peer Advocacy in a General Hospital Emergency Room 114

TOPIC 67: WOMEN'S ISSUES

INDUSTRY-SUPPORTED SYMPOSIUM
9 Estrogen Enhancement of Mood and Memory in Postmenopausal Women 4

LECTURE
16 Dr. Alexandra Symonds' Legacy of Advancing Women Psychiatrists and Promoting Women's Mental Health: Sailing Toward the Next Millennium 58

SCIENTIFIC AND CLINICAL REPORTS
5 Prevention of Postpartum Episodes in Bipolar Women 26
6 Alcohol Dependency and Affective Illness Among Women 26
7 Dysphoric Moods in Women: Menopause or Myth? 26

SYMPOSIA
12 Women's Reproductive Health and Psychological Issues 36
54 The Connections Between Gender and Victimization 71

WORKSHOPS - COMPONENTS
26 Women Psychiatrists: Their Triumphs and Tragedies 47
41 The Search Committee and Issues for Women 79
44 Clinical Assessment Management of Sexual Harassment: 1998 Update 85

WORKSHOP - ISSUE
37 Swimming with the Sharks 47

TOPIC 68: DRUG ADDICTION—A TREATABLE DISEASE:
A SPECIAL RESEARCH-BASED PROGRAM TRACK

ADVANCES IN RESEARCH
Substance Abuse 23

DISCUSSION GROUPS
9 Behavioral Approaches to the Treatment of Drug Dependence 17
10 Substance Use Disorders and HIV Infection in 1998: Where Are We with Prevention and Treatment? 74

FORUM
9 Who Will Pay for the Treatment of Substance Abuse? 87

LECTURES
4 Substance Abuse and Reward Systems in the Brain 18
17 The Surprising Efficacy of Treatments for Addictive Disorders 58
23 Cocaine and the Addicted Brain 89

MASTER EDUCATOR CLINICAL CONSULTATIONS
9 Dual Diagnosis: Cases and Discussion 50
11 Effective Engagement of the Substance Abuser in Office Practice 76

MEDIA PRESENTATIONS
36 Trainspotting 70
40 Prevention of Substance Abuse Risk for Families at Risk 77

NIDA/NIH GRANTSMANSHIP WORKSHOP
Dos and Don'ts in Writing Your First NIH Grant 33

135
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abbey, Susan E</td>
<td>21, 35, 48</td>
</tr>
<tr>
<td>Abel, Gene G</td>
<td>61, 74</td>
</tr>
<tr>
<td>Abrams, Michelle</td>
<td>99</td>
</tr>
<tr>
<td>Abu-Salha, Mohammad</td>
<td>52</td>
</tr>
<tr>
<td>Ackerman, John M</td>
<td>119</td>
</tr>
<tr>
<td>Adams, Frank</td>
<td>73</td>
</tr>
<tr>
<td>Adams, Laura N</td>
<td>53</td>
</tr>
<tr>
<td>Adams, Martha</td>
<td>36</td>
</tr>
<tr>
<td>Adams, Susan</td>
<td>111</td>
</tr>
<tr>
<td>Addington, Donald E</td>
<td>9</td>
</tr>
<tr>
<td>Addonizio, Gerard C</td>
<td>28</td>
</tr>
<tr>
<td>Adler, Lawrence E</td>
<td>9</td>
</tr>
<tr>
<td>Aferiot, Dan</td>
<td>37</td>
</tr>
<tr>
<td>Agras, W. Stewart</td>
<td>16</td>
</tr>
<tr>
<td>Ahmed, Rownak</td>
<td>26</td>
</tr>
<tr>
<td>Akerlele, Evaristo O</td>
<td>54</td>
</tr>
<tr>
<td>Akiskal, Hagop S</td>
<td>4, 72, 117, 118</td>
</tr>
<tr>
<td>Akiskal, Karenen</td>
<td>72</td>
</tr>
<tr>
<td>Ak, Adele F</td>
<td>52</td>
</tr>
<tr>
<td>Akman, Jeffrey S</td>
<td>8</td>
</tr>
<tr>
<td>Al-Radi, Osama M</td>
<td>71</td>
</tr>
<tr>
<td>Alarcon, Renato D</td>
<td>79, 94</td>
</tr>
<tr>
<td>Alotham, Hutter</td>
<td>85, 114</td>
</tr>
<tr>
<td>Albusson, Eliane</td>
<td>84</td>
</tr>
<tr>
<td>Alen, Atalay</td>
<td>54</td>
</tr>
<tr>
<td>Alex, Norman E</td>
<td>28, 61</td>
</tr>
<tr>
<td>Alexopoulos, George S</td>
<td>38</td>
</tr>
<tr>
<td>Alger, Ian E</td>
<td>22, 24, 36, 47, 51, 77, 82</td>
</tr>
<tr>
<td>Allen, Gwen</td>
<td>98</td>
</tr>
<tr>
<td>Allen, James R</td>
<td>98</td>
</tr>
<tr>
<td>Allen, Michael H</td>
<td>121</td>
</tr>
<tr>
<td>Allen, Richard P</td>
<td>112</td>
</tr>
<tr>
<td>Allen, Sandra</td>
<td>98</td>
</tr>
<tr>
<td>Allwood, Clifford W</td>
<td>21</td>
</tr>
<tr>
<td>Alpert, Jonathan E</td>
<td>27, 83</td>
</tr>
<tr>
<td>Alpha, Patiel</td>
<td>47</td>
</tr>
<tr>
<td>Almadi, Osama M</td>
<td>86</td>
</tr>
<tr>
<td>Altermann, Arthur I</td>
<td>61</td>
</tr>
<tr>
<td>Altman, Adrienne M</td>
<td>83</td>
</tr>
<tr>
<td>Amador, Xavier F</td>
<td>63</td>
</tr>
<tr>
<td>Ambreereen, Uzma</td>
<td>71</td>
</tr>
<tr>
<td>Amering, Michaela</td>
<td>121</td>
</tr>
<tr>
<td>Amsterdam, Jay D</td>
<td>13</td>
</tr>
<tr>
<td>Anand, Amrit</td>
<td>62</td>
</tr>
<tr>
<td>Ananth, Jambur V</td>
<td>47</td>
</tr>
<tr>
<td>Anders, Thomas F</td>
<td>26</td>
</tr>
<tr>
<td>Andersen, Arnold E</td>
<td>66</td>
</tr>
<tr>
<td>Andersen, Scott W</td>
<td>6</td>
</tr>
<tr>
<td>Anderson, Cheryl D</td>
<td>79</td>
</tr>
<tr>
<td>Anderson-Hanley, Catherine</td>
<td>99</td>
</tr>
<tr>
<td>Andreassen, Nancy C</td>
<td>55</td>
</tr>
<tr>
<td>Andrenesch, Dr. Carmen</td>
<td>35</td>
</tr>
<tr>
<td>Andrews, Gavin</td>
<td>84</td>
</tr>
<tr>
<td>Angell, Richard H</td>
<td>47</td>
</tr>
<tr>
<td>Anisam, Hyme</td>
<td>37</td>
</tr>
<tr>
<td>Anthraenelli, Robert M</td>
<td>9</td>
</tr>
<tr>
<td>Anthony, James C</td>
<td>84</td>
</tr>
<tr>
<td>Antonowicz, Joseph L</td>
<td>113</td>
</tr>
<tr>
<td>Antony, Martin M</td>
<td>105</td>
</tr>
<tr>
<td>Arfin, Fuad F</td>
<td>52</td>
</tr>
<tr>
<td>Appelbaum, Kenneth L</td>
<td>80</td>
</tr>
<tr>
<td>Appelbaum, Paul S</td>
<td>8, 20, 46, 54, 87, 113</td>
</tr>
<tr>
<td>Aquila, Ralph</td>
<td>7</td>
</tr>
<tr>
<td>Araki, Shelly</td>
<td>100</td>
</tr>
<tr>
<td>Arato, Mihaly</td>
<td>69</td>
</tr>
<tr>
<td>Arlinghaus, Kimberly A</td>
<td>121</td>
</tr>
<tr>
<td>Arnow, Bruce</td>
<td>83</td>
</tr>
<tr>
<td>Aronowitz, Bonnie A</td>
<td>3, 9, 92</td>
</tr>
<tr>
<td>Artheme, Javad</td>
<td>111</td>
</tr>
<tr>
<td>Arroyo, William</td>
<td>28, 79</td>
</tr>
<tr>
<td>Ash, Peter</td>
<td>61, 80</td>
</tr>
<tr>
<td>Ashford, Jr. J. Weiss</td>
<td>88</td>
</tr>
<tr>
<td>Ashley, Kenneth B.</td>
<td>113</td>
</tr>
<tr>
<td>Ashton, Adam K</td>
<td>3</td>
</tr>
<tr>
<td>Aspery, Sven</td>
<td>68</td>
</tr>
<tr>
<td>Atkins, Charles D</td>
<td>102</td>
</tr>
<tr>
<td>Atkinson, Jr., J. Hampton</td>
<td>73</td>
</tr>
<tr>
<td>Aupperle, Peter M</td>
<td>105</td>
</tr>
<tr>
<td>Axtel, Auby H</td>
<td>44</td>
</tr>
<tr>
<td>Ayar, Hana E</td>
<td>52</td>
</tr>
<tr>
<td>Bagg, Gabriele</td>
<td>83</td>
</tr>
<tr>
<td>Babb, Suzanne</td>
<td>83</td>
</tr>
<tr>
<td>Badger, Lee W</td>
<td>53</td>
</tr>
<tr>
<td>Bagby, Michael</td>
<td>38</td>
</tr>
<tr>
<td>Bailey, Jennie W</td>
<td>27</td>
</tr>
<tr>
<td>Bailey, Robert A</td>
<td>102</td>
</tr>
<tr>
<td>Baijo, Kamilo</td>
<td>116</td>
</tr>
<tr>
<td>Baker, Brian</td>
<td>21, 25</td>
</tr>
<tr>
<td>Bakshe, David</td>
<td>13</td>
</tr>
<tr>
<td>Baldessarini, Ross J</td>
<td>52, 111</td>
</tr>
<tr>
<td>Ball, John D</td>
<td>66</td>
</tr>
<tr>
<td>Ball, Roberta R</td>
<td>114</td>
</tr>
<tr>
<td>Balon, Richard</td>
<td>3, 30, 47, 56, 74, 83</td>
</tr>
<tr>
<td>Bankier, Bettina</td>
<td>121</td>
</tr>
<tr>
<td>Banks, Amy E</td>
<td>36</td>
</tr>
<tr>
<td>Barber, James B</td>
<td>10</td>
</tr>
<tr>
<td>Barbour, Jack M</td>
<td>28</td>
</tr>
<tr>
<td>Bard, Terry</td>
<td>22</td>
</tr>
<tr>
<td>Barlow, David H</td>
<td>39</td>
</tr>
<tr>
<td>Barratt, Ernest S</td>
<td>109</td>
</tr>
<tr>
<td>Barry II, John J</td>
<td>8</td>
</tr>
<tr>
<td>Baranick, Andrea</td>
<td>33</td>
</tr>
<tr>
<td>Barthwell, Andrea</td>
<td>109</td>
</tr>
<tr>
<td>Bartlik, Barbara D</td>
<td>26, 97</td>
</tr>
<tr>
<td>Baruchin, Andrea</td>
<td>33</td>
</tr>
<tr>
<td>Basco, Monica A</td>
<td>1, 77</td>
</tr>
<tr>
<td>Basen, Steven M</td>
<td>69</td>
</tr>
<tr>
<td>Basel, Chris</td>
<td>112</td>
</tr>
<tr>
<td>Basso, Ana Maria</td>
<td>9</td>
</tr>
<tr>
<td>Basen, Bruce</td>
<td>27</td>
</tr>
<tr>
<td>Batley, Scott</td>
<td>83</td>
</tr>
<tr>
<td>Barke, Steven L</td>
<td>92</td>
</tr>
<tr>
<td>Baum, Antonia L</td>
<td>72</td>
</tr>
<tr>
<td>Baydog, Rogelio D</td>
<td>65</td>
</tr>
<tr>
<td>Beal, Claudette H</td>
<td>56</td>
</tr>
<tr>
<td>Beal, John O</td>
<td>56</td>
</tr>
<tr>
<td>Beasley, Jr., Charles M</td>
<td>53, 83</td>
</tr>
<tr>
<td>Beautejeur, Pierre A</td>
<td>36</td>
</tr>
<tr>
<td>Becbuck, William</td>
<td>48</td>
</tr>
<tr>
<td>Beclivec, N.</td>
<td>98</td>
</tr>
<tr>
<td>Beck, James C</td>
<td>46</td>
</tr>
<tr>
<td>Beck, Judith S</td>
<td>48</td>
</tr>
<tr>
<td>Beck, Daniel F</td>
<td>26</td>
</tr>
<tr>
<td>Beckett, Heilmut</td>
<td>4</td>
</tr>
<tr>
<td>Beeler, Ann</td>
<td>43</td>
</tr>
<tr>
<td>Begaz, Tommy</td>
<td>3, 9, 92</td>
</tr>
<tr>
<td>Bogen, Daniel M</td>
<td>72</td>
</tr>
<tr>
<td>Belman, Bernard D</td>
<td>36</td>
</tr>
<tr>
<td>Bellin, Thomas R</td>
<td>83</td>
</tr>
<tr>
<td>Bell, Barbara</td>
<td>37</td>
</tr>
<tr>
<td>Bell, Carl C</td>
<td>21, 34, 120</td>
</tr>
<tr>
<td>Bell, Karen</td>
<td>13</td>
</tr>
<tr>
<td>Bellack, Alan S</td>
<td>63</td>
</tr>
<tr>
<td>Belanche, Francois</td>
<td>36</td>
</tr>
<tr>
<td>Beilman, Robert H</td>
<td>98</td>
</tr>
<tr>
<td>Beisop, Barri A</td>
<td>93</td>
</tr>
<tr>
<td>Benchet, Badreddane</td>
<td>52</td>
</tr>
<tr>
<td>Bender, Donna S</td>
<td>96</td>
</tr>
<tr>
<td>Benedek, Elisa P</td>
<td>47, 54, 57</td>
</tr>
<tr>
<td>Benet, Peter</td>
<td>119</td>
</tr>
<tr>
<td>Benjam, Bernadette</td>
<td>83</td>
</tr>
<tr>
<td>Bennett, Dwayne L</td>
<td>52</td>
</tr>
<tr>
<td>Bennett, Emily S</td>
<td>113</td>
</tr>
<tr>
<td>Benoyle, Babte</td>
<td>93</td>
</tr>
<tr>
<td>Beresin, Eugene V</td>
<td>50</td>
</tr>
<tr>
<td>Berg, Arthur Z</td>
<td>105</td>
</tr>
<tr>
<td>Berg, Paul S.D.</td>
<td>1</td>
</tr>
<tr>
<td>Berger, Dr. Peter</td>
<td>121</td>
</tr>
<tr>
<td>Berger, Joseph</td>
<td>67, 111</td>
</tr>
<tr>
<td>Berger, Steven</td>
<td>56</td>
</tr>
<tr>
<td>Bergeron, Richard</td>
<td>98</td>
</tr>
<tr>
<td>Bergin, Allen E</td>
<td>75, 85</td>
</tr>
<tr>
<td>Bergma, Alan S</td>
<td>21</td>
</tr>
<tr>
<td>Belfango, Carlos</td>
<td>111</td>
</tr>
<tr>
<td>Berman, Benca</td>
<td>34, 67</td>
</tr>
<tr>
<td>Berman, Robert M</td>
<td>62</td>
</tr>
<tr>
<td>Bermanzohn, Paul C</td>
<td>34, 91, 92</td>
</tr>
<tr>
<td>Bernay, Laura J</td>
<td>113</td>
</tr>
<tr>
<td>Bernstein, Carol A</td>
<td>5, 23, 48</td>
</tr>
<tr>
<td>Bernstein, David P</td>
<td>39</td>
</tr>
<tr>
<td>Bezazubova, Elena B</td>
<td>108</td>
</tr>
<tr>
<td>Biancorno, Jacqueline</td>
<td>52</td>
</tr>
<tr>
<td>Bickford, Paula</td>
<td>9</td>
</tr>
<tr>
<td>Biederman, Joseph</td>
<td>7, 118</td>
</tr>
<tr>
<td>Bienielfeld, David G</td>
<td>53</td>
</tr>
<tr>
<td>Binder, Renee L</td>
<td>8, 12, 113</td>
</tr>
<tr>
<td>Binder-Bynes, Karen</td>
<td>37</td>
</tr>
<tr>
<td>Binley, Mark</td>
<td>16</td>
</tr>
<tr>
<td>Birley, Dr. James L.T</td>
<td>35</td>
</tr>
<tr>
<td>Bischof, Robert J</td>
<td>102</td>
</tr>
</tbody>
</table>
PARTICIPANT INDEX

Cohen, Lee S .......................... 6, 9, 27, 36, 52, 84
Cohen, Lewis M .......................... 107
Cohen, Neal L .......................... 115
Cohen, Toby A .......................... 9
Cohn-Haft, Herra J ......................... 21
Coid, Jeremy W .......................... 46
Cole, Steven A .......................... 30
Collins, James L .......................... 79, 103, 114
Collins, Jerome A .......................... 27
Collins, Mary H .......................... 27
Collins, Pamela Y .......................... 80
Colton, Patricia .......................... 66
Colvard, Philip M .......................... 121
Condon, Timothy P .......................... 70, 80
Conley, Robert R .......................... 120
Conn, David K .......................... 47
Connery, Linda L .......................... 28
Connor, Daniel F .......................... 42
Constans, Jean Marc .......................... 120
Cook, Ian A .......................... 99
Cook, Peter E .......................... 48
Cooper, Alan .......................... 102
Cooper, Edith M .......................... 120
Copans, Stuart A .......................... 108
Coplan, Jeremy D ......................... 12
Cosentino-Long, Sera .......................... 26
Coshal, Balbir S .......................... 27
Costa e Silva, Jorge A .......................... 63
Cott, Jerry M .......................... 94
Costa, Jean .......................... 84
Cournos, Francine .......................... 21, 105
Coverdale, John H .......................... 109, 112
Covey, Lino S .......................... 117
Cox, Dale N .......................... 20, 78
Craven, John .......................... 83
Craven, Marilyn .......................... 22, 88
Crenshaw, Theresa L .......................... 12
Crosby, John F .......................... 21
Crisp-Christoph, Paul .......................... 118
Cross, C Deborah .......................... 29, 47, 111
Crow, Scott .......................... 118
Crowley, Brian .......................... 11
Crowley, Thomas J .......................... 112
Croze, Colette .......................... 63
Crum, Roso Maria .......................... 84, 112
Cruz, des Anges .......................... 42
Cuasole, Anne Marie .......................... 22
Cummings, Jeffrey L .......................... 13, 17, 100, 105
Cutler, Andrew J .......................... 59
Cutler, Joy B .......................... 79, 115
Cutler, Neil L .......................... 62
Cyz, Bobby .......................... 72

Dannals, Robert .......................... 52
Dannecker, Segmiller M .......................... 48
Danko, Michael .......................... 111
Dansky, Bonnie S .......................... 37
Dash, Robert .......................... 21
Davidson, Jonathan R.T .......................... 6, 10
Davidson, Lynne .......................... 114
Dave, Caroline A .......................... 27
Davis, Dave M .......................... 46
Davis, Glenn C .......................... 79
Davis, John M .......................... 41
Dawson, Howard E .......................... 62
Day, James L .......................... 28, 108
Deakin, John F.W .......................... 63
DeAkins, Susan M .......................... 43
DeAntyja, Ann .......................... 36
Deaton, Rodney J.S .......................... 109
DeCicca, Conchetta M .......................... 3, 9, 92
deGroot, Janet M .......................... 22, 65
DeLucchi, Kevin L .......................... 118
Demitrack, Mark A .......................... 114
Denicoff, Kirk D .......................... 6
Denny, Lisa .......................... 66
DePaoli, Jr., J. Raymond .......................... 63
DePrato, Debra K .......................... 54
DeRenzo, Evan G .......................... 87
DeS Groseilliers, J.P .......................... 48
Deutschman, Daniel A .......................... 39
DeWavenand, Davangere P .......................... 13, 62, 95
de Villiers, Priscilla .......................... 62
Devlin, Michael J .......................... 24
Devlin, Marten W .......................... 38
Dewan, Mantosh J .......................... 15
Diaz, Thomas .......................... 93
Dickson, Thad .......................... 61
Diller, Arthur C .......................... 6
Dickstein, Daniel P .......................... 28, 86
Dickstein, Leah J .......................... 28, 30, 55, 58, 86, 120
Dietz, Park E .......................... 12
Di Giacomo, Joseph .......................... 94
Dillon, James E .......................... 21, 26, 48, 61, 80, 81
Ditts, Stephen L .......................... 65, 79
DiMarino, Elizabeth .......................... 21
Dimatou, Sonia .......................... 111
Dix, Aninka R .......................... 112
Dixon, Lisa B .......................... 10
Dixon, Warren .......................... 98
Dlugonski, Eric .......................... 98
Dluhy, John M .......................... 19, 77
D'Mello, Marissa .......................... 112
Dogheran, Joseph .......................... 11
Dogheran, Karl .......................... 16
Dolans, Raymond J. .......................... 66, 83
Dolans, Regina T .......................... 19
Doll, Richard .......................... 33
Dollans, Sonia .......................... 120
Dominguez, Lourdes M .......................... 115
Dominguez, Roberto A .......................... 54
Dongier, Maurice H.l .......................... 74
Doozy, Rachelle .......................... 100
Dorszwan, P. Murall .......................... 100
Dorier, David J .......................... 118
Dorian, Paul .......................... 21
Dorson, James W .......................... 55
Dott, Sharon G .......................... 17
Dougherty, Kathleen C .......................... 80
Downey, Jennifer L .......................... 74, 111
Dozois, Ronald I. .......................... 47
Drapeau, Alain .......................... 37
Drevets, Wayne C .......................... 66
Dreier, Karen G .......................... 62
Druss, Elizabeth C .......................... 57
Dubin, William R. .......................... 5
Dubocovich, Margaretta L .......................... 117
Duff, Steven .......................... 100
Duffy, Janelle D .......................... 17
Dunkin, Jennifer .......................... 99
Dunn, Edward .......................... 37
Dunn, Robert M .......................... 96
Dunn, Robert T .......................... 6
Dunne, David L .......................... 7, 69
Duvdevani, Tamir .......................... 37
Duy, Jeff .......................... 3
Dvorak, Ramond .......................... 88
Dvoskin, Joel A .......................... 54
Dworkin, Robert H .......................... 63
Dyck, George .......................... 47

Ebert, Michael H .......................... 79, 117
Eckman, Thad .......................... 61
Eddy, Sara .......................... 41
Egger, Helen L .......................... 118
Eisen, Eileen L. .......................... 10, 34
Eisen, Susan .......................... 91
Eichenberg, Leon .......................... 97
Eisenhardt, Shatt J. .......................... 1
Eisold, Kenneth .......................... 109
Eist, Harold I .......................... 11, 34
Beberg, Olivia .......................... 39
Elam, Suzannah M .......................... 28
El-Gebaly, Nady .......................... 95
Elbashir, Byron A .......................... 52
Elfersen, Emily .......................... 67
Ellis, Jeffrey .......................... 62, 122
Elliot, Richard L .......................... 2
Eills, David M .......................... 22
Elson, James M .......................... 93, 114
Emmanuel, Naresh P .......................... 52
Emmele, Graham-J .......................... 42
Endicott, Jean .......................... 91, 122
Engel, Anna G .......................... 21
Epping-Jordan, Mark .......................... 9
Erich, Sheila .......................... 37
Escobar, Javier J .......................... 75
Efekmdjian, Nathalie .......................... 84
Evans, Dwight L .......................... 10, 11
Evans, Javelt D .......................... 38, 67
Evans, Kenneth R .......................... 38, 53
Evans, Suzeeth .......................... 61
Evans, W. .......................... 84, 96
Ewing, Jane .......................... 92
**PARTICIPANT INDEX**

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fievé, Ronald R</td>
<td>26, 113</td>
</tr>
<tr>
<td>Fievé, Lara</td>
<td>113</td>
</tr>
<tr>
<td>Fischbein, Ellen R</td>
<td>85</td>
</tr>
<tr>
<td>First, Michael B</td>
<td>5, 74</td>
</tr>
<tr>
<td>Fink, Gereon</td>
<td>83</td>
</tr>
<tr>
<td>Fink, Paul Jay</td>
<td>21</td>
</tr>
<tr>
<td>Finkel, Stanford I</td>
<td>99</td>
</tr>
<tr>
<td>Finnegan, Loretta P</td>
<td>5, 45</td>
</tr>
<tr>
<td>Firat, Michael B</td>
<td>5, 74</td>
</tr>
<tr>
<td>Fischbein, Eileen R</td>
<td>85</td>
</tr>
<tr>
<td>Fischman, Marian W</td>
<td>97</td>
</tr>
<tr>
<td>Fishman, Baruch</td>
<td>35</td>
</tr>
<tr>
<td>Roberthy, Joseph A</td>
<td>121</td>
</tr>
<tr>
<td>Roberthy, Lois T</td>
<td>21</td>
</tr>
<tr>
<td>Rahrn, Gerald H</td>
<td>40</td>
</tr>
<tr>
<td>Rieschhacker, W. Wolfgang</td>
<td>4</td>
</tr>
<tr>
<td>Rimming, Candace M</td>
<td>8</td>
</tr>
<tr>
<td>Rint, Alastair J</td>
<td>53, 100</td>
</tr>
<tr>
<td>Flores, Andrea T</td>
<td>118</td>
</tr>
<tr>
<td>Floyd, Reta D</td>
<td>28</td>
</tr>
<tr>
<td>Flynn, Laurie M</td>
<td>46, 54, 87</td>
</tr>
<tr>
<td>Foa, Edna B</td>
<td>91, 121</td>
</tr>
<tr>
<td>Foley, Adele C</td>
<td>109</td>
</tr>
<tr>
<td>Foley, Carmel A</td>
<td>46, 54</td>
</tr>
<tr>
<td>Foote, William W</td>
<td>1</td>
</tr>
<tr>
<td>Ford, Charles V</td>
<td>1</td>
</tr>
<tr>
<td>ForE-Arcand, Lisa G</td>
<td>52</td>
</tr>
<tr>
<td>Fornax, Victor M</td>
<td>113</td>
</tr>
<tr>
<td>Forstein, Marshall</td>
<td>41, 73</td>
</tr>
<tr>
<td>Foster, Edwin</td>
<td>113</td>
</tr>
<tr>
<td>Fouks, Edward F</td>
<td>81, 103, 120</td>
</tr>
<tr>
<td>Fouras, George A</td>
<td>28</td>
</tr>
<tr>
<td>Frances, Allen J</td>
<td>47</td>
</tr>
<tr>
<td>Frances, Richard J</td>
<td>47, 76, 65</td>
</tr>
<tr>
<td>Francis, Elle M</td>
<td>121</td>
</tr>
<tr>
<td>Francis, Jr., Andrew J</td>
<td>95</td>
</tr>
<tr>
<td>Frank, Arlene F</td>
<td>119</td>
</tr>
<tr>
<td>Frank, Deborah</td>
<td>45</td>
</tr>
<tr>
<td>Frank, Ellen A</td>
<td>2, 9</td>
</tr>
<tr>
<td>Frank, Justin A</td>
<td>25</td>
</tr>
<tr>
<td>Frankenburg, Frances R</td>
<td>113</td>
</tr>
<tr>
<td>Frausto, Teresa</td>
<td>58</td>
</tr>
<tr>
<td>Fredrickson, Paul A</td>
<td>30</td>
</tr>
<tr>
<td>Freebury, D. Richard</td>
<td>11, 17, 40</td>
</tr>
<tr>
<td>Friedlander, Robert</td>
<td>17, 46</td>
</tr>
<tr>
<td>Freeman, Daniel M.A</td>
<td>22</td>
</tr>
<tr>
<td>Freeman, Ellen W</td>
<td>122</td>
</tr>
<tr>
<td>Freeman, Marlene H</td>
<td>58</td>
</tr>
<tr>
<td>Friedman, Michael A</td>
<td>30, 72</td>
</tr>
<tr>
<td>Friedman, Jeffrey R</td>
<td>118</td>
</tr>
<tr>
<td>Friedman, Merle</td>
<td>98</td>
</tr>
<tr>
<td>Friedman, William N</td>
<td>62</td>
</tr>
<tr>
<td>Fries, Sven</td>
<td>67</td>
</tr>
<tr>
<td>Fro sagt, Diane</td>
<td>54</td>
</tr>
<tr>
<td>Frost, William A</td>
<td>55</td>
</tr>
<tr>
<td>Frost, J. James</td>
<td>52</td>
</tr>
<tr>
<td>Fydeyman, Ruth E</td>
<td>113</td>
</tr>
<tr>
<td>Fye, Mark A</td>
<td>6, 16, 96</td>
</tr>
<tr>
<td>Fyday, Paul J</td>
<td>116</td>
</tr>
<tr>
<td>Fylud, Bill</td>
<td>108</td>
</tr>
<tr>
<td>Fulker, David W</td>
<td>112</td>
</tr>
<tr>
<td>Kursha, Kevin</td>
<td>96</td>
</tr>
<tr>
<td>Fyer, Abby J</td>
<td>64</td>
</tr>
<tr>
<td>Gabbard, Glen O</td>
<td>47, 64, 70</td>
</tr>
<tr>
<td>Gabrielson, Knut</td>
<td>68</td>
</tr>
<tr>
<td>Gada, Neha</td>
<td>73</td>
</tr>
<tr>
<td>Gagebel, Prof. Dr. Wolfgang</td>
<td>63</td>
</tr>
<tr>
<td>Gaffney, Margaret</td>
<td>109</td>
</tr>
<tr>
<td>Gafni, Annaram</td>
<td>37</td>
</tr>
<tr>
<td>Gaghe, Pierre W</td>
<td>113</td>
</tr>
<tr>
<td>Gast, Paul</td>
<td>27</td>
</tr>
<tr>
<td>Galdamer, Marc</td>
<td>65, 76, 99</td>
</tr>
<tr>
<td>Galvin, Matthew R</td>
<td>109</td>
</tr>
<tr>
<td>Garmne, Peter D</td>
<td>22</td>
</tr>
<tr>
<td>Gardiner, Roberta</td>
<td>16</td>
</tr>
<tr>
<td>Garsfeld, Paul E</td>
<td>24, 37, 66</td>
</tr>
<tr>
<td>Garmo, Jessica L</td>
<td>26</td>
</tr>
<tr>
<td>Garside, Sarah</td>
<td>105</td>
</tr>
<tr>
<td>Gavler, David L</td>
<td>53</td>
</tr>
<tr>
<td>Garetfriend, David K</td>
<td>138</td>
</tr>
<tr>
<td>Gavin, Stewart</td>
<td>72</td>
</tr>
<tr>
<td>Gavirat, Moises</td>
<td>95, 96</td>
</tr>
<tr>
<td>Gavin, Frank H</td>
<td>119</td>
</tr>
<tr>
<td>Gaynes, Bradley B</td>
<td>64</td>
</tr>
<tr>
<td>Gehm, Noele K</td>
<td>4</td>
</tr>
<tr>
<td>Gellenberg, Alvin J</td>
<td>7, 24, 99</td>
</tr>
<tr>
<td>Gehrter, Joel</td>
<td>39</td>
</tr>
<tr>
<td>Geller, Jeffrey L</td>
<td>64</td>
</tr>
<tr>
<td>Gemar, Michael</td>
<td>38</td>
</tr>
<tr>
<td>Gendel, Michael H</td>
<td>85</td>
</tr>
<tr>
<td>Gendorio, Laura A</td>
<td>27</td>
</tr>
<tr>
<td>George, Linda K</td>
<td>22, 19</td>
</tr>
<tr>
<td>George, Mark S</td>
<td>17, 66</td>
</tr>
</tbody>
</table>

**G**

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gabor, Richard</td>
<td>119</td>
</tr>
<tr>
<td>Gable, Stewart</td>
<td>112</td>
</tr>
<tr>
<td>Gabrielson, Knut</td>
<td>68</td>
</tr>
<tr>
<td>Gada, Neha</td>
<td>73</td>
</tr>
<tr>
<td>Gaub, Dr. Wolfgang</td>
<td>63</td>
</tr>
<tr>
<td>Gaffney, Margaret</td>
<td>109</td>
</tr>
<tr>
<td>Gafni, Annaram</td>
<td>37</td>
</tr>
<tr>
<td>Gaghe, Pierre W</td>
<td>113</td>
</tr>
<tr>
<td>Gast, Paul</td>
<td>27</td>
</tr>
<tr>
<td>Galdamer, Marc</td>
<td>65, 76, 99</td>
</tr>
<tr>
<td>Galvin, Matthew R</td>
<td>109</td>
</tr>
<tr>
<td>Garmne, Peter D</td>
<td>22</td>
</tr>
<tr>
<td>Gardiner, Roberta</td>
<td>16</td>
</tr>
<tr>
<td>Garsfeld, Paul E</td>
<td>24, 37, 66</td>
</tr>
<tr>
<td>Garmo, Jessica L</td>
<td>26</td>
</tr>
<tr>
<td>Garside, Sarah</td>
<td>105</td>
</tr>
<tr>
<td>Gavler, David L</td>
<td>53</td>
</tr>
<tr>
<td>Garetfriend, David K</td>
<td>138</td>
</tr>
<tr>
<td>Gavin, Stewart</td>
<td>72</td>
</tr>
<tr>
<td>Gavirat, Moises</td>
<td>95, 96</td>
</tr>
<tr>
<td>Gavin, Frank H</td>
<td>119</td>
</tr>
<tr>
<td>Gaynes, Bradley B</td>
<td>64</td>
</tr>
<tr>
<td>Gehm, Noele K</td>
<td>4</td>
</tr>
<tr>
<td>Gellenberg, Alvin J</td>
<td>7, 24, 99</td>
</tr>
<tr>
<td>Gehrter, Joel</td>
<td>39</td>
</tr>
<tr>
<td>Geller, Jeffrey L</td>
<td>64</td>
</tr>
<tr>
<td>Gemar, Michael</td>
<td>38</td>
</tr>
<tr>
<td>Gendel, Michael H</td>
<td>85</td>
</tr>
<tr>
<td>Gendorio, Laura A</td>
<td>27</td>
</tr>
<tr>
<td>George, Linda K</td>
<td>22, 19</td>
</tr>
<tr>
<td>George, Mark S</td>
<td>17, 66</td>
</tr>
<tr>
<td>Gabe, Robert A</td>
<td>47</td>
</tr>
<tr>
<td>Gersberg, Patricia L</td>
<td>115</td>
</tr>
<tr>
<td>Gershon, Elliott S</td>
<td>63</td>
</tr>
<tr>
<td>Gerfert, Elizabeth V</td>
<td>54</td>
</tr>
<tr>
<td>Girod, Esidro A</td>
<td>111</td>
</tr>
<tr>
<td>Gil, Shalit S</td>
<td>52</td>
</tr>
<tr>
<td>Gill, Kathryn J</td>
<td>73</td>
</tr>
<tr>
<td>Gill, Sukhman K</td>
<td>46, 83</td>
</tr>
<tr>
<td>Gill, Shoshannah M</td>
<td>53, 116</td>
</tr>
<tr>
<td>Gilles, Laure</td>
<td>35</td>
</tr>
<tr>
<td>Gilligan, James</td>
<td>98</td>
</tr>
<tr>
<td>Gillin, J. Christian</td>
<td>62, 122</td>
</tr>
<tr>
<td>Ginsburg, Iowa H</td>
<td>121</td>
</tr>
<tr>
<td>Glasser, Martin E</td>
<td>114</td>
</tr>
<tr>
<td>Glassman, Alexander H</td>
<td>9, 70, 117</td>
</tr>
<tr>
<td>Glazier, William M</td>
<td>12, 53</td>
</tr>
<tr>
<td>Glenn, Trevor D</td>
<td>21</td>
</tr>
<tr>
<td>Glick, Ira D</td>
<td>10</td>
</tr>
<tr>
<td>Glick, Rachel L</td>
<td>121</td>
</tr>
<tr>
<td>Glog, Ruedi</td>
<td>48</td>
</tr>
<tr>
<td>Gluckman, Myron L</td>
<td>36</td>
</tr>
<tr>
<td>Gachfeld, Linda G</td>
<td>80</td>
</tr>
<tr>
<td>Grodolb, And G</td>
<td>22</td>
</tr>
<tr>
<td>Goering, Howard H</td>
<td>116</td>
</tr>
<tr>
<td>Goldman, Stephen A</td>
<td>66</td>
</tr>
<tr>
<td>Goft, Donald C</td>
<td>67</td>
</tr>
<tr>
<td>Gogek, Edward B</td>
<td>29, 80</td>
</tr>
<tr>
<td>Gogek, Jim</td>
<td>80</td>
</tr>
<tr>
<td>Goin, Malv E</td>
<td>113</td>
</tr>
<tr>
<td>Goin, Ronald M</td>
<td>26, 113</td>
</tr>
<tr>
<td>Ginkel, Arnold I</td>
<td>35</td>
</tr>
<tr>
<td>Goldberg, Caroline I</td>
<td>96, 122</td>
</tr>
<tr>
<td>Goldberg, David A</td>
<td>110</td>
</tr>
<tr>
<td>Goldberg, Ivan K</td>
<td>9, 21</td>
</tr>
<tr>
<td>Goldberg, Joel O</td>
<td>48</td>
</tr>
<tr>
<td>Goldberg, Joseph F</td>
<td>26, 84, 91</td>
</tr>
<tr>
<td>Goldberg, Sir David Paul</td>
<td>43, 56</td>
</tr>
<tr>
<td>Goldstein, Arnold J</td>
<td>102</td>
</tr>
<tr>
<td>Goldfinger, Stephen M</td>
<td>54, 80, 114</td>
</tr>
<tr>
<td>Goldman, Howard H</td>
<td>116</td>
</tr>
<tr>
<td>Goldman, Stephen A</td>
<td>66</td>
</tr>
<tr>
<td>Goldman, William H</td>
<td>87</td>
</tr>
<tr>
<td>Goldstein, Jill M</td>
<td>6, 66</td>
</tr>
<tr>
<td>Goldstein, Michael G</td>
<td>15, 117</td>
</tr>
<tr>
<td>Goldstone, Justice Richard</td>
<td>40, 106</td>
</tr>
<tr>
<td>Gonzales, Junius J</td>
<td>116</td>
</tr>
<tr>
<td>Gonzalo, Franciso J</td>
<td>36</td>
</tr>
<tr>
<td>Gooberman, Lance L</td>
<td>116</td>
</tr>
<tr>
<td>Good, Kimberley P</td>
<td>99</td>
</tr>
<tr>
<td>Goodkin, Karl</td>
<td>21</td>
</tr>
<tr>
<td>Goodman, April R</td>
<td>27</td>
</tr>
<tr>
<td>Goodman, Julie M</td>
<td>6</td>
</tr>
<tr>
<td>Goodman, Wayne K</td>
<td>6</td>
</tr>
<tr>
<td>Goodman, Paul J</td>
<td>83</td>
</tr>
<tr>
<td>Goodwin, Frederick K</td>
<td>67</td>
</tr>
<tr>
<td>Goodwin, Pamelia J</td>
<td>33</td>
</tr>
<tr>
<td>Gopalan, K. Surendran</td>
<td>29</td>
</tr>
<tr>
<td>Gordon, Alan L</td>
<td>27, 54, 114</td>
</tr>
<tr>
<td>Gordon, Edward</td>
<td>79, 108</td>
</tr>
<tr>
<td>Gordon, James S</td>
<td>119</td>
</tr>
<tr>
<td>Name</td>
<td>Pages</td>
</tr>
<tr>
<td>------------------</td>
<td>-------</td>
</tr>
<tr>
<td>Lachenmeier, Rint</td>
<td>26</td>
</tr>
<tr>
<td>Lacy, Timothy W.</td>
<td>71</td>
</tr>
<tr>
<td>Lahn, Deborah K</td>
<td>68</td>
</tr>
<tr>
<td>Lokavics, Magnus</td>
<td>47</td>
</tr>
<tr>
<td>Lam, Raymond W.</td>
<td>62, 92</td>
</tr>
<tr>
<td>Lane, Richard D.</td>
<td>66, 83</td>
</tr>
<tr>
<td>Lang, Hermann</td>
<td>35</td>
</tr>
<tr>
<td>Lang, Peter J.</td>
<td>66</td>
</tr>
<tr>
<td>Langbehn, Douglas</td>
<td>103</td>
</tr>
<tr>
<td>Langrod, John G.</td>
<td>115</td>
</tr>
<tr>
<td>Larsky, Melvin R.</td>
<td>64</td>
</tr>
<tr>
<td>Larsen, Robert C.</td>
<td>108</td>
</tr>
<tr>
<td>Larsen, Tor K.</td>
<td>67, 68</td>
</tr>
<tr>
<td>Larson, David B.</td>
<td>79, 103,114,119</td>
</tr>
<tr>
<td>Latts, Tracy T.</td>
<td>174</td>
</tr>
<tr>
<td>Laughrin, Thomas P.</td>
<td>66</td>
</tr>
<tr>
<td>Lauterbach, Edward C.</td>
<td>105</td>
</tr>
<tr>
<td>Lawson, William B.</td>
<td>63</td>
</tr>
<tr>
<td>Lazzer, Susan G.</td>
<td>8, 63</td>
</tr>
<tr>
<td>Lazarus, Arthur L.</td>
<td>48, 73, 109</td>
</tr>
<tr>
<td>Lazarus, Jeremy A.</td>
<td>8, 30, 115</td>
</tr>
<tr>
<td>Le Bars, Pierre</td>
<td>117</td>
</tr>
<tr>
<td>LeDoux, Joseph E.</td>
<td>81</td>
</tr>
<tr>
<td>Lebowitz, Barry D.</td>
<td>99</td>
</tr>
<tr>
<td>Lee, Hang</td>
<td>6, 34, 66</td>
</tr>
<tr>
<td>Lee, Kathryn J.</td>
<td>108</td>
</tr>
<tr>
<td>Lee, Kyu-Hang</td>
<td>87</td>
</tr>
<tr>
<td>Lee, SuHyung</td>
<td>64</td>
</tr>
<tr>
<td>Lee, Steven J.</td>
<td>28</td>
</tr>
<tr>
<td>Lee, Stephen H.</td>
<td>23</td>
</tr>
<tr>
<td>Lefebvre, Artele M.L.</td>
<td>73</td>
</tr>
<tr>
<td>Leffton, André</td>
<td>29</td>
</tr>
<tr>
<td>Lehmann, Laurent S.</td>
<td>197</td>
</tr>
<tr>
<td>Lehner, Douglas S.</td>
<td>109</td>
</tr>
<tr>
<td>Leibovitch, Ellen</td>
<td>19, 31, 117</td>
</tr>
<tr>
<td>Leibovitch, Miguel A.</td>
<td>5, 29, 86, 109, 114</td>
</tr>
<tr>
<td>Leigh, Moyle</td>
<td>21, 48</td>
</tr>
<tr>
<td>Lemoin, Patrick</td>
<td>80</td>
</tr>
<tr>
<td>Lennart, Shayan A.</td>
<td>6, 85</td>
</tr>
<tr>
<td>Leon, Joel</td>
<td>100</td>
</tr>
<tr>
<td>Leon-Andrade, Carlos</td>
<td>94</td>
</tr>
<tr>
<td>Leonard, Heintzla L.</td>
<td>71</td>
</tr>
<tr>
<td>Leonard, Sherry</td>
<td>9</td>
</tr>
<tr>
<td>Lesage, Alan D.</td>
<td>38</td>
</tr>
<tr>
<td>Leshner, Alan</td>
<td>23</td>
</tr>
<tr>
<td>Leslie, Catherine A.</td>
<td>53</td>
</tr>
<tr>
<td>Lesperance, France A.</td>
<td>21</td>
</tr>
<tr>
<td>Lesser, Arthur L.</td>
<td>40, 67</td>
</tr>
<tr>
<td>Lesser, Michael S.</td>
<td>108</td>
</tr>
<tr>
<td>Leszcz, Milyn</td>
<td>33, 119</td>
</tr>
<tr>
<td>Leuchter, Andrew F.</td>
<td>99</td>
</tr>
<tr>
<td>Levav, Itzhak</td>
<td>27</td>
</tr>
<tr>
<td>Levendusky, Philip G.</td>
<td>16</td>
</tr>
<tr>
<td>Levinson, Alan I.</td>
<td>85</td>
</tr>
<tr>
<td>Levinson, Hannia</td>
<td>105</td>
</tr>
<tr>
<td>Leverette, John S.</td>
<td>56</td>
</tr>
<tr>
<td>Levein, Gabrielle S.</td>
<td>6</td>
</tr>
<tr>
<td>Levin, Frances R.</td>
<td>16, 45, 61</td>
</tr>
<tr>
<td>Levin, Gilbert</td>
<td>9</td>
</tr>
<tr>
<td>Levin, Howard</td>
<td>25</td>
</tr>
<tr>
<td>Levin, Saul M.</td>
<td>27</td>
</tr>
<tr>
<td>Levine, Joseph A.</td>
<td>98</td>
</tr>
<tr>
<td>Levine, Robert J.</td>
<td>87</td>
</tr>
<tr>
<td>Levine, Sharon S.</td>
<td>53</td>
</tr>
<tr>
<td>Levinson, Anthony J.</td>
<td>105</td>
</tr>
<tr>
<td>Levitan, Robert D.</td>
<td>38, 92</td>
</tr>
<tr>
<td>Levitin, Teresa</td>
<td>33</td>
</tr>
<tr>
<td>Levitt, Anthony J.</td>
<td>62, 92</td>
</tr>
<tr>
<td>Levy, Norman B.</td>
<td>48</td>
</tr>
<tr>
<td>Lewin, Rebecca S.</td>
<td>55</td>
</tr>
<tr>
<td>Lewis, Bradley E.</td>
<td>60, 68</td>
</tr>
<tr>
<td>Lewis, Catherine F.</td>
<td>59</td>
</tr>
<tr>
<td>Lewis, David A.</td>
<td>31</td>
</tr>
<tr>
<td>Lewis, Dorothy O.</td>
<td>66</td>
</tr>
<tr>
<td>Lewis, Marshall E.</td>
<td>53</td>
</tr>
<tr>
<td>Lewis-Fernandez, Robert</td>
<td>8</td>
</tr>
<tr>
<td>Lewishall, Freda C.</td>
<td>54</td>
</tr>
<tr>
<td>Lewy, Alfred J.</td>
<td>62, 88</td>
</tr>
<tr>
<td>Li, Peter P.</td>
<td>116</td>
</tr>
<tr>
<td>Liang, Warren J.</td>
<td>105</td>
</tr>
<tr>
<td>Liddie, Peter F.</td>
<td>63</td>
</tr>
<tr>
<td>Lieberman, Jeffrey A.</td>
<td>7, 10, 67, 68</td>
</tr>
<tr>
<td>Liebowitz, Michael R.</td>
<td>6, 64, 68, 94, 121</td>
</tr>
<tr>
<td>Lifsonfield, Lisa R.</td>
<td>37, 118</td>
</tr>
<tr>
<td>Lim, Russell F.</td>
<td>8, 19, 44, 56, 76, 88, 91, 99, 110</td>
</tr>
<tr>
<td>Limoges, Richard F.</td>
<td>79</td>
</tr>
<tr>
<td>Lin, Elizabeth</td>
<td>26, 95</td>
</tr>
<tr>
<td>Lin, Keh-Ming</td>
<td>80, 94</td>
</tr>
<tr>
<td>Lin, Quin</td>
<td>96</td>
</tr>
<tr>
<td>Lindamer, Laurie A.</td>
<td>38</td>
</tr>
<tr>
<td>Lindberg, Marc A.</td>
<td>112</td>
</tr>
<tr>
<td>Lindenmayer, Jean Pierre</td>
<td>10, 86</td>
</tr>
<tr>
<td>Lindy, David C.</td>
<td>86</td>
</tr>
<tr>
<td>Linehan, Marsha M.</td>
<td>6, 64</td>
</tr>
<tr>
<td>Ling, Xiange</td>
<td>35</td>
</tr>
<tr>
<td>Links, Paul S.</td>
<td>61, 93</td>
</tr>
<tr>
<td>Lion, John R.</td>
<td>12</td>
</tr>
<tr>
<td>Lisatti, Don R.</td>
<td>21</td>
</tr>
<tr>
<td>Lisboa, Barbara K.</td>
<td>11</td>
</tr>
<tr>
<td>Lipton, Richard B.</td>
<td>69</td>
</tr>
<tr>
<td>Liston, Benjamin</td>
<td>62, 119</td>
</tr>
<tr>
<td>Litten, Raye</td>
<td>48</td>
</tr>
<tr>
<td>Livesley, John</td>
<td>5, 34, 93, 103</td>
</tr>
<tr>
<td>Lutwelyns, Alexis M.</td>
<td>36</td>
</tr>
<tr>
<td>Lloyd, John H.</td>
<td>46, 85</td>
</tr>
<tr>
<td>Lloyd, John S.</td>
<td>109</td>
</tr>
<tr>
<td>Lone, J. Pierre</td>
<td>47</td>
</tr>
<tr>
<td>Lotfi, Jordi S.</td>
<td>48, 121</td>
</tr>
<tr>
<td>Lombardo, Ilitte D.</td>
<td>83</td>
</tr>
<tr>
<td>Lombardo, Donna L.</td>
<td>79</td>
</tr>
<tr>
<td>Lopez, Jorge, R.</td>
<td>71</td>
</tr>
<tr>
<td>Loschen, Earl L.</td>
<td>71</td>
</tr>
<tr>
<td>Losonczy, Miklos F.</td>
<td>67</td>
</tr>
<tr>
<td>Louie, Kevin J.</td>
<td>111</td>
</tr>
<tr>
<td>Lowenkopf, Eugene R.</td>
<td>56, 84</td>
</tr>
<tr>
<td>Lu, Francis G.</td>
<td>1, 8, 22, 25, 44, 54, 60, 79, 86, 100, 114</td>
</tr>
<tr>
<td>Luby, Elliot D.</td>
<td>26, 96</td>
</tr>
<tr>
<td>Lunbeke, Elizabeth</td>
<td>89</td>
</tr>
<tr>
<td>Lydard, R. Bruce</td>
<td>10, 52</td>
</tr>
<tr>
<td>Lyons, Michelle J.</td>
<td>98</td>
</tr>
<tr>
<td>M</td>
<td>92</td>
</tr>
<tr>
<td>MacKean, Karen</td>
<td>95</td>
</tr>
<tr>
<td>MacKinnon, Roger</td>
<td>120</td>
</tr>
<tr>
<td>Magee, Maggi</td>
<td>36</td>
</tr>
<tr>
<td>Maharaq, Shari I.</td>
<td>66</td>
</tr>
<tr>
<td>Maierhofer, Dagmar</td>
<td>121</td>
</tr>
<tr>
<td>Major, Mario</td>
<td>4</td>
</tr>
<tr>
<td>Major, Carol</td>
<td>93</td>
</tr>
<tr>
<td>Maker, J. Pearley</td>
<td>21</td>
</tr>
<tr>
<td>Makley, Taru</td>
<td>83</td>
</tr>
<tr>
<td>Makris, Nikos</td>
<td>6</td>
</tr>
<tr>
<td>Malcom, Jr., Robert J.</td>
<td>37</td>
</tr>
<tr>
<td>Maldonado, 1</td>
<td>1</td>
</tr>
<tr>
<td>Malmquist, Carl P.</td>
<td>54, 78</td>
</tr>
<tr>
<td>Maloney, Ann S.</td>
<td>85</td>
</tr>
<tr>
<td>Manani, Catherine L.</td>
<td>52</td>
</tr>
<tr>
<td>Manji, Hussein K.</td>
<td>116</td>
</tr>
<tr>
<td>Manley, Miri S.</td>
<td>17</td>
</tr>
<tr>
<td>Manos, Peter J.</td>
<td>73, 111</td>
</tr>
<tr>
<td>Marangell, Lauren B.</td>
<td>73</td>
</tr>
<tr>
<td>Marcos, Luis R.</td>
<td>108</td>
</tr>
<tr>
<td>Marquette, David B.</td>
<td>113</td>
</tr>
<tr>
<td>Margul, Sigurd</td>
<td>67</td>
</tr>
<tr>
<td>Marler, Karen</td>
<td>27</td>
</tr>
<tr>
<td>Marler, Stephen R.</td>
<td>10, 41</td>
</tr>
<tr>
<td>Marghita, Katrina J.</td>
<td>7</td>
</tr>
<tr>
<td>Margolin, Lid</td>
<td>23</td>
</tr>
<tr>
<td>Marro, C. A.</td>
<td>113</td>
</tr>
<tr>
<td>Markou, Athina</td>
<td>9</td>
</tr>
<tr>
<td>Markowiz, John C.</td>
<td>1, 16, 35, 42, 78</td>
</tr>
<tr>
<td>Marmar, Charles R.</td>
<td>39, 118</td>
</tr>
<tr>
<td>Marmor, Theodore</td>
<td>36</td>
</tr>
<tr>
<td>Marshall, Randall D.</td>
<td>91</td>
</tr>
<tr>
<td>Martin, Eileen M.</td>
<td>83</td>
</tr>
<tr>
<td>Martin, Glenn A.</td>
<td>84</td>
</tr>
<tr>
<td>Martin, Marilyn L.</td>
<td>67</td>
</tr>
<tr>
<td>Martin, Ronald L.</td>
<td>46</td>
</tr>
<tr>
<td>Martinez, Daniel B.</td>
<td>114</td>
</tr>
<tr>
<td>Martinez, Humberto</td>
<td>22, 29, 115</td>
</tr>
<tr>
<td>Martino, Steve</td>
<td>26, 83</td>
</tr>
<tr>
<td>Marzouk, Peter M.</td>
<td>115</td>
</tr>
<tr>
<td>Massoud, Prakash S.</td>
<td>4</td>
</tr>
<tr>
<td>Masterson, James F.</td>
<td>16</td>
</tr>
<tr>
<td>Masterson, Julia A.</td>
<td>33</td>
</tr>
<tr>
<td>Matthew, Ninn T.</td>
<td>69</td>
</tr>
</tbody>
</table>

**PARTICIPANT INDEX**
N

Nadeem, Ethan A. .......................... 65
Nadeison, Carol C. .......................... 55, 58, 79
Nagamatsu, Herbert T. .......................... 9
Nahas, Ziad H. .......................... 64
Nair, Thomas R. .......................... 53
Nakajima, Gene A. .......................... 48
Namm, Stacey .......................... 37, 118
Napolitano, Michael J. .......................... 114
Naranjo, Claudia A. .......................... 65
Nasr, Claude .......................... 52
Nastalan, Henry A. .......................... 4, 53
Naudo, Margaret .......................... 33
Navarro, Mar .......................... 87
Noyak, Devdutt V. .......................... 68
Ndok, N. Charles .......................... 8, 20
Negrete, Juan C. .......................... 73
Nichold, Edward J. .......................... 78
Nelson, J. Craig .......................... 10, 69
Nelson, Richard A. .......................... 52
Nelson, Sonja .......................... 111
Nelson, William H. .......................... 71
Nemeroff, Charles B. .......................... 2, 36
Nemtsov, Alexander V. .......................... 97
Neumann, Margaret .......................... 33
Niederhoffer, Peter .......................... 100
New, Antonio S. .......................... 39
Newble, Cassie A. .......................... 54
Newman, Rita R. .......................... 37, 85
Nestorou, Eugen .......................... 42
Nestorou, Raymond S. .......................... 15, 117
Niedermeier, Julie A. .......................... 53
Nicotera, Ton-Thad .......................... 87
Nienhuis, Eric A. .......................... 13, 27, 83, 98, 99
Nikolov, Artemi .......................... 22
Nishimura, Masahiro .......................... 88
Nix, Sara Jo .......................... 98
Nol, Jenny .......................... 66
Nonacs, Rita M. .......................... 52, 84
Nom, Donna M. .......................... 8, 28, 37
Norns, Mariam .......................... 28
Norwood, Ann E. .......................... 15, 108
Nore, Ivan .......................... 84
Nottmman, Mark T. .......................... 54, 79, 86
Nowani, Bill .......................... 118
Novac, Andrei .......................... 37
Noyes, William .......................... 16
PARTICIPANT INDEX

Noyes, Jr., Russell .......................... 52
Nuechterlein, Keith H .......................... 99
Nutland, Sherwin B .......................... 57
Nunan, Irene .......................... 111
Nunes, Edward V .......................... 61, 69
Nurnberg, H. George .......................... 84
Nurnberger, Jr., John l .......................... 63
Nussbaum, Karin M .......................... 118

O

Oakman, Jonathan .......................... 52
O'Brien, Charles P .......................... 58, 97
O'Connell, Lonnie J .......................... 42
O'Dell, Jyll .......................... 26
O'Donnell, John H .......................... 21
O'Dowd, Mary Alice .......................... 114
Oel, Bastian L .......................... 80
O'Farrell, Timothy J .......................... 64
Olincy, Ann .......................... 9
Oliver, Karen A .......................... 63
Oliver, Karen A .......................... 63
Oliva, Noiva M .......................... 66
Olson, Lis .......................... 68
Okasha, Ahmed M.F .......................... 71
Okasha, Tarek A .......................... 71
Okin, Robert L .......................... 29
Oldham, John M .......................... 63, 64, 87, 96, 103, 119
Olsen, Mark .......................... 65, 116
Olney, Ann .......................... 61
Ols, Karen A .......................... 63
Ols, Karen A .......................... 63
Olovstein, Marion P .......................... 66
Okasha, Ahmed M.F .......................... 71
Olascoa, Patricia I .......................... 58
Ordway, Janet E .......................... 53, 89
Oren, Dan A .......................... 62
Ormond, Marian A .......................... 29
Osmooff, C. Richard .......................... 63
Ossein, Paul H .......................... 61
Or, Malcolm .......................... 83
Ort, Robert D .......................... 79
Oser, Osama T .......................... 71
O'Sky, Howard J .......................... 93
Osler, David N .......................... 65
Osterloh, Ian H .......................... 83
Ott, Robert B .......................... 55
Osch, Elizabeth A .......................... 96
Otto, Michael W .......................... 9, 112
Oster, Lawrence .......................... 93
Ouellet, Dawn .......................... 50
Oya, Loka .......................... 83

P

Pacheco, Antonio .......................... 94, 113
Painter, Albert F .......................... 73, 88
Palacios-Boix, Jorge A .......................... 73
Palanch, Dr. Vaidipuri .......................... 53
Palensako, Pete C .......................... 28
Palacios, Vera B .......................... 28
Palmer, Barton W .......................... 36, 67
Palmer, Christopher M .......................... 46
Palmisano, Richard T .......................... 108
Paloumbi, Joseph J .......................... 21
Pantano, Jr., Peter J .......................... 62
Papier, Paula G .......................... 22
Papp, L. A. .......................... 12
Pappas, Demetra .......................... 34, 67
Pardes, Herbert .......................... 23
Parikh, Rajesh M .......................... 412
Parikh, Sagar V .......................... 38
Paris, Jo F .......................... 39, 61, 93
Park, Katheryn .......................... 27
Parks, Joseph J .......................... 16
Parmentier, Patricia .......................... 62
Pary, Barbara L .......................... 62, 122
Pasla, Mahmood A .......................... 6
Pascal, Jean-Cherd .......................... 102
Pansau, Robert O .......................... 87
Patel, Shalini .......................... 26
Patel, Chandra .......................... 67
Patton, Michael T .......................... 3, 15
Patton, Robert S .......................... 65, 76
Patton, Kurt A .......................... 63
Pau, Paul .......................... 21
Pavei, Daniel .......................... 96
Pedrazza, Angelo .......................... 54, 75
Peele, Roger .......................... 26, 37, 101
Pendl, Kathleen S .......................... 26
Penner, Vivian B .......................... 113
Pendleton, James L .......................... 67
Pepper, Bert .......................... 119
Perez, Edgardo L .......................... 86
Perkins, Diana O .......................... 67
Perlin, Michael L .......................... 109
Penn, Laura P .......................... 110
Perry, Bruce D .......................... 66, 98
Perry, J. Christopher .......................... 52, 93
Perry, Samuel W .......................... 35
Perel, Emmanuel .......................... 48
Perugaman, Celia .......................... 118
Pesekow, Eric D .......................... 26, 113
Perez, Neal .......................... 86
Peters, Donald W .......................... 111
Petersen, Thomas .......................... 78
Pethsch, Peter .......................... 108
Petit, Michel .......................... 120
Petrides, Georgios .......................... 95
Perry, Fredrick .......................... 3
Pfeffer, Cynthia R .......................... 70
Pfeffer, Cynthia R .......................... 70
Phillips, Edward M .......................... 53
Phillips, Kathleen A .......................... 11
Phillips, Robert M .......................... 72, 47, 90
Pickard, John T .......................... 8
Pickard, David .......................... 10
Pierre-Louis, Joel .......................... 109
Pigott, Teresita A .......................... 6
Pin, Teresita A .......................... 6
Pincus, Harold Alan .......................... 29, 46, 65, 95, 117
Pine, Daniel S .......................... 33
Pitts, Steven E .......................... 36
Pittman, Mary J .......................... 80
Pittman, Mary J .......................... 80
Plaut, Eric A .......................... 108
Plaut, S. Michael .......................... 112
Plohm, Katherine .......................... 37, 118
Podewitz, Alan L .......................... 42
Poerjan, Joseph A .......................... 86
Pollack, Stephen .......................... 117
Pollack, David A .......................... 47, 80
Pollack, Mark H .......................... 9, 112
Pollack, Bruce G .......................... 100
Polubinsky, Svetlana .......................... 96
Pond, Ronald A .......................... 34
PonteCorra, Michael .......................... 86
Popper, Charles W .......................... 42
Porter, Laura .......................... 26
Porto, Linda .......................... 34, 91, 92
Posner, Joel A .......................... 12
Posever, Thomas .......................... 67
Post, Jerold M .......................... 1, 21
Post, Robert M .......................... 6, 66, 96
Potash, James B .......................... 64
Potter, Lloyd B .......................... 115
Potter, Rebecca L .......................... 99
Powell, Lynda H .......................... 26
Poznyak, Vladimir .......................... 35
Pratt, Laura .......................... 84
Presig, Martin .......................... 103
Preven, David W .......................... 29, 109, 114
Pritchard, Jennifer .......................... 72
Pren, Robert F .......................... 37
Prior, Trevor .......................... 84
Puccio, Yvonne .......................... 71
Putnam, W. .......................... 49
Putnam, W. .......................... 49
Quadros, Terence .......................... 112
Quinlan, Charles .......................... 26
Quilka, Frederic M .......................... 69
Quieshi, Jaffer H .......................... 86

R

Rabin, Beth .......................... 112
Rabin, Ronald A .......................... 84
Rabin, Peter V .......................... 7, 38
Raboch, Jfr. .......................... 71
Racaglia, Giovanni .......................... 4
Rae, Donald S .......................... 92
Rafferty, John T .......................... 79
Raj, Ashok .......................... 6
Raklett, Jacob .......................... 102
Rakoza, Susan .......................... 97
Ramchandani, Dilip .......................... 47, 89
Ramiree, Luis F .......................... 74
Ramirez, Paul M .......................... 5
Ramos, Oscar L .......................... 112
Rand, Elizabeth H .......................... 34, 53
Rantabl, Robin S .......................... 85
Rantakallio, Paula .......................... 145
<table>
<thead>
<tr>
<th>Participant Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wells, Kenneth B.</td>
<td>82, 116</td>
</tr>
<tr>
<td>Wells, Victoria E.</td>
<td>27</td>
</tr>
<tr>
<td>Wein, Michael M.</td>
<td>29</td>
</tr>
<tr>
<td>Wein, Richard</td>
<td>41</td>
</tr>
<tr>
<td>Weis-Behnken, Kathleen A.</td>
<td>68</td>
</tr>
<tr>
<td>West, Joyce C.</td>
<td>95</td>
</tr>
<tr>
<td>West, Scott A.</td>
<td>42</td>
</tr>
<tr>
<td>Westermeyer, Joseph J.</td>
<td>21, 37, 120</td>
</tr>
<tr>
<td>Westphal, James R.</td>
<td>2, 26</td>
</tr>
<tr>
<td>Westreich, Laurence M.</td>
<td>116</td>
</tr>
<tr>
<td>Whaten, Paul J.</td>
<td>66</td>
</tr>
<tr>
<td>Whatley, Joyce</td>
<td>62</td>
</tr>
<tr>
<td>White, Andrea</td>
<td>114</td>
</tr>
<tr>
<td>Whiteford, Harvey A.</td>
<td>36</td>
</tr>
<tr>
<td>Whitehouse, David J.M.</td>
<td>30, 73</td>
</tr>
<tr>
<td>Whitehouse, Peter J.</td>
<td>86</td>
</tr>
<tr>
<td>Whiteley, Diane K.</td>
<td>86</td>
</tr>
<tr>
<td>Whittington, Horace G.</td>
<td>46</td>
</tr>
<tr>
<td>Whitley, Suzanne W.</td>
<td>98</td>
</tr>
<tr>
<td>Widawski, Mel</td>
<td>83</td>
</tr>
<tr>
<td>Widiger, Thomas A.</td>
<td>34</td>
</tr>
<tr>
<td>Wiener, Jerry M.</td>
<td>37</td>
</tr>
<tr>
<td>Wiens, Timothy E.</td>
<td>8</td>
</tr>
<tr>
<td>Willey, Denise E.</td>
<td>78</td>
</tr>
<tr>
<td>Wilkinson, N.</td>
<td>92</td>
</tr>
<tr>
<td>Williams, C. Donald</td>
<td>41, 86</td>
</tr>
<tr>
<td>Williams, David</td>
<td>114</td>
</tr>
<tr>
<td>Williams, Glen D.</td>
<td>57</td>
</tr>
<tr>
<td>Williams, Susan</td>
<td>38</td>
</tr>
<tr>
<td>Williams, Wendol A.</td>
<td>66</td>
</tr>
<tr>
<td>Willson, Shawn</td>
<td>85</td>
</tr>
<tr>
<td>Wilson, Janice M.</td>
<td>36</td>
</tr>
<tr>
<td>Winchel, Ron M.</td>
<td>31</td>
</tr>
<tr>
<td>Winkelmann, John W.</td>
<td>16</td>
</tr>
<tr>
<td>Winstead, Daniel K.</td>
<td>11, 23</td>
</tr>
<tr>
<td>Winters, Allison</td>
<td>53</td>
</tr>
<tr>
<td>Wintrob, Ronald M.</td>
<td>103</td>
</tr>
<tr>
<td>Wishng, Donna A.</td>
<td>4</td>
</tr>
<tr>
<td>Wisnig, William C.</td>
<td>41, 69, 99</td>
</tr>
<tr>
<td>Wiseman, Claire</td>
<td>118</td>
</tr>
<tr>
<td>Wisner, Katherine L.</td>
<td>26</td>
</tr>
<tr>
<td>Willy, Nancy</td>
<td>117</td>
</tr>
<tr>
<td>Wolkowit, Wolfgang</td>
<td>63</td>
</tr>
<tr>
<td>Wolfe, David A.</td>
<td>62</td>
</tr>
<tr>
<td>Woodman, Catherine L.</td>
<td>52</td>
</tr>
<tr>
<td>Woods, Scott W.</td>
<td>39</td>
</tr>
<tr>
<td>Woodside, D. Blake</td>
<td>26, 95</td>
</tr>
<tr>
<td>Woodward, Susan</td>
<td>91</td>
</tr>
<tr>
<td>Woog, Carolyn M.</td>
<td>84</td>
</tr>
<tr>
<td>Wolley, Jill Ross</td>
<td>72</td>
</tr>
<tr>
<td>Worthington III, John J.</td>
<td>27, 112</td>
</tr>
<tr>
<td>Wozniak, Janet</td>
<td>8</td>
</tr>
<tr>
<td>Wingham, Professor Richard</td>
<td>91</td>
</tr>
<tr>
<td>Wright, David C.</td>
<td>34</td>
</tr>
<tr>
<td>Wright, Harry H.</td>
<td>28</td>
</tr>
<tr>
<td>Wright, Jesse H.</td>
<td>37, 48, 57, 77</td>
</tr>
<tr>
<td>Wu, Tong-Ting</td>
<td>85</td>
</tr>
<tr>
<td>Wulfs, Donald H.</td>
<td>21, 27</td>
</tr>
<tr>
<td>Wyron, Lauren J.</td>
<td>84</td>
</tr>
<tr>
<td>Yager, Joel</td>
<td>16, 106, 118</td>
</tr>
<tr>
<td>Yao, Sainan</td>
<td>84</td>
</tr>
<tr>
<td>Yarita-Tobias, Jose A.</td>
<td>42</td>
</tr>
<tr>
<td>Yastebov, Vassley</td>
<td>96</td>
</tr>
<tr>
<td>Yehuda, Rachel</td>
<td>37, 91, 118</td>
</tr>
<tr>
<td>Young, Alexander S.</td>
<td>111</td>
</tr>
<tr>
<td>Young, Beverly</td>
<td>86</td>
</tr>
<tr>
<td>Young, L. Trevor</td>
<td>96, 116</td>
</tr>
<tr>
<td>Young, Susan E.</td>
<td>112</td>
</tr>
<tr>
<td>Yudofsky, Stuart C.</td>
<td>15, 23, 41, 73, 121</td>
</tr>
<tr>
<td>Yule, Sahid</td>
<td>98</td>
</tr>
<tr>
<td>Yugeun-Todd, Deborah A.</td>
<td>65</td>
</tr>
<tr>
<td>Zajacko, John M.</td>
<td>3, 7</td>
</tr>
<tr>
<td>Zanarini, Mary C.</td>
<td>26, 84, 96, 113</td>
</tr>
<tr>
<td>Zarate, Jr., Carlos A.</td>
<td>65</td>
</tr>
<tr>
<td>Zarin, Deborah A.</td>
<td>29, 46, 65, 78, 95, 117, 118</td>
</tr>
<tr>
<td>Zayas, Elia M.</td>
<td>7</td>
</tr>
<tr>
<td>Zeitilberg, Joseph J.</td>
<td>121</td>
</tr>
<tr>
<td>Zeke, Phyllis</td>
<td>117</td>
</tr>
<tr>
<td>Zeikowitz, Phyllis</td>
<td>93</td>
</tr>
<tr>
<td>Zerbe, Kathryn J.</td>
<td>105</td>
</tr>
<tr>
<td>Ziedonis, Douglas M.</td>
<td>48, 92, 108, 117</td>
</tr>
<tr>
<td>Zil, John S.</td>
<td>54</td>
</tr>
<tr>
<td>Zima, Bonnie T.</td>
<td>78, 83, 116</td>
</tr>
<tr>
<td>Zimmerman, Mark</td>
<td>27, 112</td>
</tr>
<tr>
<td>Zohor, Joseph</td>
<td>3, 34, 91, 92</td>
</tr>
<tr>
<td>Zanberg, Gwen L.</td>
<td>66</td>
</tr>
<tr>
<td>Zucker, Bonnie</td>
<td>112</td>
</tr>
<tr>
<td>Zucker, Jay L.</td>
<td>29</td>
</tr>
<tr>
<td>Zulick, Barbara B.</td>
<td>22</td>
</tr>
<tr>
<td>Zubiak, Barbara B.</td>
<td>22</td>
</tr>
</tbody>
</table>
Unlike in previous years, the Review of Psychiatry Series will now serve as the inspiration for individual paperback books on specific topics. This new format is designed to continue an ongoing commitment to making this series a vital reference for the practicing clinician, in a more accessible, low cost format. Contributors share their expertise in the areas of Child Psychopharmacology, Psychotherapy and Violent Crime, Psychobiology of Personality Disorders, Interpersonal Psychotherapy, Psychological Trauma, and Addictions.

Each volume includes a foreword and afterword by the editor(s) that summarize key points, and each chapter features an extensive bibliography. These volumes are expected to be available for purchase at the 1998 annual meeting.*

Child Psychopharmacology
Edited by B. Timothy Walsh, M.D.
- Tics and obsessive-compulsive disorder
- Attention-deficit/hyperactivity disorder
- Psychosis
- Affective disorders
- Anxiety disorders
- Eating disorders
price TBA/Order #ADVR8833

Psychopathology and Violent Crime
Edited by Andrew E. Skodol, M.D.
- Violent crime and Axis I psychopathology
- Personalities of murderers
- Violent crime and Axis II psychopathology
- Biology of aggression
- Psychopathology, crime, and law
price TBA/Order #ADVR8834

*Volumes that are not available at the 1998 annual meeting will be published as available throughout 1998.
Psychobiology of Personality Disorders
Edited by Kenneth R. Silk, M.D.
- Psychopharmacological management
- Biological research for a biopsychosocial model
- Neurotransmitter function
- New strategies for psychobiologic investigation
(price TBA/Order #ADVR8835

Interpersonal Psychotherapy
Edited by John C. Markowitz, M.D.
- Maintenance IPT as a preventive treatment for depression
- IPT for depressed HIV-positive men and women
- IPT with depressed adolescents
- IPT for patients with bulimia
(price TBA/Order #ADVR8836

Psychological Trauma
Edited by Rachel Yehuda, Ph.D.
- Epidemiology of trauma and PTSD
- Longitudinal development of posttraumatic disorders
- Evaluating effects of psychological trauma using neuroimaging techniques
- Neuroendocrinology of trauma and PTSD
- Recovering from trauma
- Pharmacotherapy of PTSD
(price TBA/Order #ADVR8837

Addictions
Edited by Elinore F. McCance-Katz, M.D., Ph.D., and
Thomas Kosten, M.D.
- Nicotine dependence and treatment
- Alcohol dependence: sex, gender, and medications
- Opiate dependence and current treatments
- Substance abuse and HIV diseases
- Contemporary issues in dual diagnosis
(price TBA/Order #ADVR8838

Come see us at the APPI Bookstore
Or call toll free to charge your order
1-800-368-5777
Monday Through Friday 9am to 5pm EST
Or fax your order (202) 789-2648

American Psychiatric Press, Inc. 1400 K Street, N.W.
Washington, DC 20005

VISIT OUR WORLD WIDE WEB SITE AT
http://www.appi.org
CALL FOR PAPERS

PRESIDENT'S THEME:
The Clinician

Rodrigo A. Muñoz, M.D.
President

Pedro Ruiz, M.D., Chairperson
Scientific Program Committee

THE SUBMISSION SCHEDULE

<table>
<thead>
<tr>
<th>Format</th>
<th>Deadline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Course</td>
<td>September 8, 1998</td>
</tr>
<tr>
<td>Media</td>
<td>September 8, 1998*</td>
</tr>
<tr>
<td>Reports</td>
<td>September 8, 1998</td>
</tr>
<tr>
<td>Symposium</td>
<td>September 8, 1998</td>
</tr>
<tr>
<td>Workshops</td>
<td>Issue and Innovative: September 8, 1998</td>
</tr>
<tr>
<td></td>
<td>Component: September 21, 1998</td>
</tr>
<tr>
<td>Volunteer</td>
<td>September 8, 1998</td>
</tr>
<tr>
<td>New Research</td>
<td>January 6, 1999</td>
</tr>
</tbody>
</table>

Incomplete and/or Incorrect Forms Will Not Be Considered.

*A single copy of the media item must be included with submission material.

For complete submission forms, contact:
Scientific Program Committee, APA
1400 K Street, NW • Washington, DC 20005
(202) 682-6237
American Psychiatric Association

50th Institute on Psychiatric Services
Joint Meeting with the California Psychiatric Association

October 2-6, 1998 • Los Angeles, CA

"KALEIDOSCOPE OF CARE
Clinical Advances and Research and Educational Excellence"

Did you know that...

★ The 1997 Institute received the highest attendee rated evaluations and attracted over 2,000 registrants?

★ APA members receive a 40% discount on their cost for registration?

★ All scientific sessions will be held in the Westin Bonaventure Hotel?

★ Industry-Supported Breakfast, Lunch and Evening Symposia are presented each day?

★ You can earn 42 hours of CME/CEU credits for attending the Institute?

★ There are prize drawings, beverages and receptions held daily in the exhibit hall?

For further information, please write to:

Office to Coordinate Annual Meetings
American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20005
Telephone: (202) 682-6000
Fax: (202) 682-6345
INDUSTRY-SUPPORTED SYMPOSIUM 1
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Auditorium, Lower Level, Convention Centre

Maintenance Treatment of Depression: The Final Episode
Saturday, May 30, 1998 • Auditorium, Lower Level, Convention Centre • Toronto, Ontario, Canada
6:15 PM Dinner Buffet • 7:00 - 10:00 PM Educational Symposium • 10:00 PM Dessert Buffet

Jerrold E. Rosenbaum, MD
Chairperson

Welcome and Introduction: Jerrold E. Rosenbaum, MD
Depression Is a Recurrent & Chronic Illness: David J. Kupfer, MD
Morbidity of Depression: Major Causes, Targeted Responses: John F. Greden, MD
Antidepressant Maintenance Therapies: Improving Outcomes: A. John Rush, MD
The Reality of Current Antidepressant Maintenance Treatment: Ellen Frank, PhD
The SSRI Discontinuation Syndrome: Jerrold E. Rosenbaum, MD

Supported by an unrestricted educational grant from SmithKline Beecham Pharmaceuticals.

INDUSTRY-SUPPORTED SYMPOSIUM 2
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Room 106, Lower Level, Convention Centre

DEPRESSION AS A RISK FACTOR FOR CARDIOVASCULAR AND CEREBROVASCULAR DISEASE:
EMERGING DATA AND CLINICAL PERSPECTIVES
Saturday, May 30, 1998 • 7:00 PM - 10:00 PM • Toronto Convention Centre • Room 106
Charles B. Nemeroff, MD, PhD, Symposium Chairman

Sponsored by the American Psychiatric Association.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours of Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

The Clinical Course and Medical Management of Depressed Patients With Ischemic Heart Disease
Christopher M. O'Connor, MD
Associate Professor of Medicine
Department of Medicine
Division of Cardiology
Duke University Medical Center
Durham, North Carolina

Are Platelets the Link Between Depression and Ischemic Heart Disease?
Reunette W. Harris, Professor and Chairman
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Depression as a Contributing Factor in Cerebrovascular Disease
K. Ranga Rama Krishnan, MD
Professor of Psychiatry
Head, Division of Biological Psychiatry
Director, Affective Disorders Program
Department of Psychiatry and Behavioral Sciences
Duke University Medical Center
Durham, North Carolina

Heart Rate Variability in Depressive and Anxiety Disorders
Jack M. Gorman, MD
Professor of Psychiatry
Columbia University College of Physicians and Surgeons
Deputy Director
New York State Psychiatric Institute
New York, New York

Considerations for the Use of Antidepressants in Patients With Ischemic Heart Disease
Steven F. Roose, MD
Professor of Clinical Psychiatry
Columbia University College of Physicians and Surgeons
Co-Director, Late-Life Depression Clinic
New York State Psychiatric Institute
New York, New York

Interactive Panel Discussion
Moderated by Charles B. Nemeroff, MD, PhD

Supported by an unrestricted educational grant from SmithKline Beecham Pharmaceuticals.
INDUSTRY-SUPPORTED SYMPOSIUM 3
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Hall G, 800 Level, Convention Centre

Management of Iatrogenic Sexual Dysfunction

Saturday, May 30, 1998
Dinner Buffet: 6:00 PM - Symposium: 7:00-10:00 PM
Hall G • Toronto Convention Centre, Toronto, Canada

Chaired by:
Adam Keller Ashton, MD
Clinical Assistant Professor
Department of Psychiatry
SUNY at Buffalo School of Medicine

Program Objectives:
- To recognize antidepressant-induced sexual dysfunction either by clinical review or questionnaire
- To manage the patient with SRI-induced sexual dysfunction or to use SSRIs to treat selected primary sexual dysfunction

Sponsored by the American Psychiatric Association

Continuing Medical Education Credits:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Glaxo Wellcome Inc.

Agenda:
Welcome and Overview
Adam Keller Ashton, MD
Clinical Assistant Professor
Department of Psychiatry
SUNY at Buffalo School of Medicine

Etiology and Incidence
R. Taylor Segraves, MD, PhD
Professor, Department of Psychiatry
Case Western Reserve University

Assessment of Sexual Functioning
Anita L.H. Clayton, MD
Associate Professor of Psychiatric Medicine
University of Virginia

Management of SRI-Induced Sexual Dysfunction
Adam Keller Ashton, MD

SSRIs in Premature Ejaculation and Paraphilias
Richard Balon, MD
Professor of Psychiatry
Wayne State University School of Medicine

INDUSTRY-SUPPORTED SYMPOSIUM 4
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Canadian Room, Convention Floor, Royal York

Cognition in Schizophrenia

The New Therapeutic Goal
Saturday, May 30, 1998
6:30 PM - Reception / 7:00-10:00 PM - Symposium
Canadian Room, The Royal York Hotel
Toronto, Ontario, Canada

Agenda
6:30 PM RECEPTION
7:00 Welcome/Introduction Herbert Y. Meltzer, MD - Chairperson
Professor of Psychiatry and Pharmacology
Director, Division of Psychopharmacology
Department of Psychiatry
Vanderbilt University School of Medicine
Nashville, Tennessee

7:10 Dimensions of Cognitive Dysfunction in Schizophrenia:
The Kraepelinian Legacy Philip D. Harvey, PhD
Professor of Psychiatry
Mt. Sinai School of Medicine
New York, New York

7:30 Cortical Circuity and Cognition in Schizophrenia
David A. Lewis, MD
Professor, Departments of Psychiatry and Neuroscience
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

7:50 Functional MRI Studies of Cognitive Function
in Schizophrenia Daniel R. Weinberger, MD
Chief, Clinical Brain Disorders Branch
National Institute of Mental Health
Bethesda, Maryland

8:10 Effect of Antipsychotic Drugs on Cognition
in Schizophrenia Herbert Y. Meltzer, MD

8:30 Cognitive Impairment and Psychopharmacology as
Determinants of Ability to Work in Schizophrenia
Susan R. McGurk, PhD
Assistant Professor of Psychiatry
Department of Psychiatry
Vanderbilt University School of Medicine
Nashville, Tennessee

8:50 Discussant
David L. Braff, MD
Professor of Psychiatry
Department of Psychiatry
University of California, San Diego
La Jolla, California

9:10 Questions and Answers
Faculty

10:00 ADJOURN

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the CME activity.

155
INDUSTRY-SUPPORTED SYMPOSIUM 5
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Concert Hall, Convention Floor, Royal York

Program Chairperson
Michele T. Pato, MD
School of Medicine and Biomedical Sciences
State University of New York at Buffalo
Buffalo, New York

Program Co-Chairperson
Eric Hollander, MD
Mount Sinai School of Medicine
New York, New York

Phenotypic Components of OCD
David Paula, PhD
Yale University School of Medicine
New Haven, Connecticut

Are OCD Spectrum Disorders Different Phenotypes of OCD?
Eric Hollander, MD
Mount Sinai School of Medicine
New York, New York

OCD and Schizophrenia: Diagnostic and Treatment Considerations
Joseph Zohar, MD
Tel Aviv University
Tel Aviv, Israel

Molecular Genetics of OCD and Response to SSRIs
James L. Kennedy, MD, FRCPC
University of Toronto
Toronto, Ontario, Canada

Autoimmunity and OCD
Mark H. Rapaport, MD
University of California–San Diego School of Medicine
La Jolla, California

Sponsored by the American Psychiatric Association

The symposium is supported by an unrestricted educational grant from Solvay Pharmaceuticals, Inc., and Pharmacia & Upjohn, Inc.

OCD Subtypes: From Clinical to Molecular Genetics
Saturday, May 30, 1998
7:00 PM - 10:00 PM
Royal York Concert Hall

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 6
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

Pharmacotherapy of Bipolar Disorder:
Newest Advances
Sponsored by the American Psychiatric Association.
Saturday, May 30 - 7:00-10:00 p.m.
Sheraton Centre Toronto • Grand Ballroom • Lower Concourse
Complimentary hors d'oeuvres will be served prior to this session.
Paul E. Keck Jr., M.D., Program Chairperson

Rapid Loading Strategies in the Treatment of Acute Mania
Paul E. Keck Jr., M.D.
Associate Professor of Psychiatry and Pharmacology
Co-Director, Mood Disorders Clinic, University of Cincinnati

Bipolar Depression
John M. Zajecka, M.D.
Bipolar Psychosis, St. Luke's Medical Center

Maintenance Treatment in Bipolar Disorder
Charles L. Bowden, M.D.
Nancy E. Barnes, Professor of Psychiatry and Pharmacology
University of Iowa at Iowa City

Substance Abuse Complicating Manic Depression
Kathleen T. Brady, M.D., Ph.D.
Associate Professor of Psychiatry, Medical University of South Carolina

This program is supported by an unrestricted educational grant from Abbott Laboratories.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to sponsor continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. ©1998 ACME, Inc.
INDUSTRY-SUPPORTED SYMPOSIUM 7
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Frontenac Ballroom, Street Level, Westin Harbour Castle

Mood Disorders in Schizophrenia: U.S. and European Perspective

Professor Lewis Judd, Chair
University of CA, San Diego, USA

Professor Giorgio Racagni, Co-Chair
University of Milan, Italy

Depressive Symptomatology in Schizophrenia: Comorbid Disorders or Negative Symptoms
Professor Lewis L. Judd

The Interface Between Bipolar and Schizophrenic Disorders: The U.S. Approach
Professor Hagop Akiskal
University of CA, San Diego, USA

The Interface Between Bipolar and Schizophrenic Disorders: The European Approach
Professor Helmut Beckmann
University of Wurzburg, Germany

New Therapeutic Approaches in the Management of Mood Disorders in Schizophrenia: European Perspectives
Professor Wolfgang Fleischhacker
Innsbruck University Clinic, Austria

New Therapeutic Approaches in the Management of Mood Disorder in Schizophrenia: U.S. Perspectives
Professor William Carpenter
University of Maryland, USA

The Use of New Antipsychotics in the Treatment of Schizoaffective Disorders
Professor Mario Maj
Primo Policlinica Universitario, Italy

Discussants:
Professor Rodrigo Munoz
President, APA

Professor Julienn Mendlewicz
Erasmus Hospital, Brussels, Belgium

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association and supported by an unrestricted educational grant from the International Academy for Biomedical and Drug Research.

INDUSTRY-SUPPORTED SYMPOSIUM 8
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle

NOVEL ANTIPSYCHOTICS:
Use in Nonpsychotic Disorders Across the Life Cycle

To be held during the 1998 Annual Meeting of the American Psychiatric Association

Henry Nasrallah, MD—Chair

This program is sponsored by the American Psychiatric Association.
The program is supported by an unrestricted educational grant from Janssen Pharmaceutica and Research Foundation.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
INDUSTRY-SUPPORTED SYMPOSIUM 9
Saturday, May 30, 7:00 p.m. - 10:00 p.m.
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

Estrogen Enhancement of Mood and Memory in Postmenopausal Women
AN EDUCATIONAL SYMPOSIUM

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for a maximum of 7.5 hours in Category 1 credit towards the American Medical Association's Physician's Recognition Award and for the CME requirement of the APA. Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

Presentations and Faculty

Marjorie L. Shuer, MD, Chair
Uriel Halbreich, MD, Co-chair

Estrogens and Synapses:
Basic Neurobiology of Ovarian Steroids
Bruce S. McEwen, PhD Rockefeller University, New York, NY
Sexual Dimorphism, Memory, and Menopause
Marjorie L. Shuer, MD
Sun Health Research Institute, Scottsdale, AZ
Estrogen and Cognition in Postmenopausal Women
Barbara B. Sherwin, PhD
McGill University, Montreal, Quebec, Canada
Hormone Replacement Therapy:
Cognition and Alzheimer's Dementia
Uriel Halbreich, MD
State University of New York, Buffalo, NY
Practical Implications of Hormone Replacement Therapy: Using Natural Hormones
Joel T. Hargrove, MD Vanderbilt University, Nashville, TN

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Wyeth-Ayerst Laboratories

INDUSTRY-SUPPORTED SYMPOSIUM 10
Sunday, May 31, 9:00 a.m. - 12 noon
Auditorium, Lower Level, Convention Centre

Women & Psychosis: From Lab Bench to Clinical Practice
Sunday, May 31, 1998 • Auditorium, Lower Level, Convention Centre • Toronto, Ontario, Canada
8:15 am Breakfast Buffet • 9:00 - 12:00 Noon Educational Symposium

Lee S. Cohen, MD
Ruth A. Dickson, MD, FRCP
Chairperson
Co-Chairperson

Welcome and Introduction Lee S. Cohen, MD
Effects of Gonadal Steroids on Brain & Behavior David R. Rubinow, MD
Sex & Brain Abnormalities in Schizophrenia Jill M. Goldstein, PhD
Sex & Neuroendocrine Differences Following Treatment with Typical & Atypical Antipsychotics Lee S. Cohen, MD
Women, Prolactin & the New Neuroleptics Ruth A. Dickson, MD, FRCP
Atypical Antipsychotics in Women with Bipolar & Other Psychiatric Disorders Susan L. McElroy, MD

Lee S. Cohen, MD Harvard Medical School
Susan L. McElroy, MD University of Cincinnati
Massachusetts General Hospital College of Medicine
David R. Rubinow, MD National Institute of Mental Health
Ruth A. Dickson, MD, FRCP University of Calgary
Jill M. Goldstein, PhD Peter Lougheed Center of the Calgary General Hospital

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 5 hours in Category 1 credit towards the American Medical Association's Physician's Recognition Award and for the CME requirement of the APA. Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Lilly
NEW TREATMENTS FOR ANXIETY DISORDERS: CLINICAL APPROACHES FOR SUCCESSFUL OUTCOMES

Sunday, May 31, 1998 • 9:00 AM - 12:00 PM • Toronto Convention Centre • Room 106
David V. Sheehan, MD, MBA, Symposium Chairman

Sponsored by the American Psychiatric Association.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACME) to sponsor continuing medical education for physicians.

Gender Differences in the Epidemiology and Treatment of Anxiety Disorders
Teressa A. Pigott, MD
Associate Professor, Department of Psychiatry and Behavioral Sciences and Pharmacology and Toxicology
Director, Psychopharmacology Clinics and Clinical Therapeutics Research Program
Director, Clinical Trials
University of Texas Medical Branch
Galveston, Texas

Current Concepts in the Treatment of Panic Disorder
David V. Sheehan, MD, MBA, Symposium Chairman
Professor of Psychiatry
Director, Office of Research, Department of Psychiatry
Institute for Research in Psychiatry
University of South Florida
Tampa, Florida

Update on the Diagnosis and Treatment of Social Phobia
Michael R. Liebowitz, MD
Professor of Clinical Psychiatry
Columbia University College of Physicians and Surgeons
Director of Anxiety Disorders Clinic

The APA designates this educational activity for up to 3 hours of Category 1 credit toward the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician must claim only those hours that he/she actually spent in the educational activity.

New York State Psychiatric Institute
New York, New York

Obsessive-Compulsive Disorder: Diagnosis and Treatment
Wayne Goodman, MD
Interim Chairman and Professor
Department of Psychiatry
University of Florida College of Medicine
Gainesville, Florida

Management of Posttraumatic Stress Disorder: Diagnostic and Therapeutic Issues
Jonathan R.T. Davidson, MD
Professor of Psychiatry
Director of Anxiety and Traumatic Stress Program
Duke University Medical Center
Durham, North Carolina

Interactive Panel Discussion
Moderated by David V. Sheehan, MD, MBA

Light refreshments follow the symposium.

Supported by an unrestricted educational grant from SmithKline Beecham Pharmaceuticals.

BREAKFAST SYMPOSIUM

Challenges & Choices: New Frontiers in Managing Treatment-Refractory and Rapid Cycling Bipolar Disorder

Examine new and emerging pharmacotherapy and psychotherapy strategies at the symposium:

Intervention for Refractory Bipolar Disorder

Bipolar Disorder: Expert Consensus Survey Results
David A. Katin, MD

Management of Treatment-Refractory Bipolar Depression
Gary S. Sachs, MD, Chair

Options for Treatment-Refractory Rapid Cycling
Joseph R. Calabrese, MD

Alternative Treatment for Refractory Mania/Cycling
Robert M. Post, MD

Cognitive Behavioral Strategies for Bipolar Patients
Noreen A. Reilly-Harrington, PhD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from GlaxoWellcome
INDUSTRY-SUPPORTED SYMPOSIUM 13
Sunday, May 31, 9:00 a.m. - 12 noon
Canadian Room, Convention Floor, Royal York

Individualizing the Treatment of Psychosis
Chairperson
S. Charles Schulz, MD

Impact of Phases and Severity of Illness on Treatment Decisions Across the Age Spectrum
Robert L. Findling, MD
Management of Psychotic Aspects of Schizoaffective Disorder
Stephen M. Strakowski, MD
Treating Symptoms Comorbid with Psychosis in Schizophrenia
Jeffery A. Lieberman, MD
Treatment Issues with the Use of Antipsychotic Medications
Sharon G. Dott, MD
After Responding: What Happens Next?
Peter J. Waden, MD

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from ZENECO

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 14
Sunday, May 31, 9:00 a.m. - 12 noon
Concert Hall, Convention Floor, Royal York

Alzheimer's Disease Practical Treatment Approaches
You are cordially invited
to attend a breakfast symposium at the 1998 American Psychiatric Association

Sunday, May 31, 1998
Breakfast 8:00 AM - 9:00 AM
Symposium 9:00 AM - 12:00 PM
The Royal York Hotel
Concert Hall, Convention Floor
Toronto, Canada

Faculty
George I. Grossberg, MD (Chair)
Samuel W. Bell, Professor and Chair
Saint Louis University School of Medicine

Stevyn Ferris, PhD
Professor of Psychiatry
Executive Director, Aging and Disease Research Center
New York University Medical Center

Peter V. Rabins, MD, MPH
Director, Geriatric and Neuropsychiatry Section
John Hopkins University School of Medicine

Elia M. Zayy, MD
Director, Geriatric Consultation-Liaison
Saint Louis University Health Science Center

Educational Objectives
To enhance the importance of communication with the Alzheimer's disease patient and family and the use of therapeutic interventions.
AN EDUCATIONAL SYMPOSIUM PRESENTED
AT THE APA’S 151ST ANNUAL MEETING

CHRONIC DEPRESSION:
OPTIMIZING LONG-TERM TREATMENT

Sunday, May 31, 1998
Grand Ballroom, Sheraton Centre Toronto
123 Queen Street West, Toronto, Canada
Registration & Breakfast: 8:15 a.m. - 9:00 a.m.
Scientific Program: 9:00 a.m. - 12:00 noon

Chair:
Alan E. Schatzberg, M.D.

Distinguished Faculty
Martin B. Keller, M.D.
Susan G. Kornstein, M.D.
John M. Zajecka, M.D.
David Dunner, M.D.
Gabor I. Keitner, M.D.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Bristol-Myers Squibb

ISSUES IN THE LONG-TERM MANAGEMENT OF DEPRESSION

Long-Term Nature of Depression
Michael E. Thase, MD

New Developments in Acute Treatment of Depression
Stuart A. Montgomery, MD

Antidepressant Drug Mechanism of Action: Relationship to Efficacy
Dennis S. Charney, MD

Management Issues in Maintenance Treatment
A. John Rush, MD

Management of Sexual Side Effects of Antidepressant Therapy
Robert M.A. Hirschfeld, MD

Sunday, May 31, 1998
9:00 a.m. - 12:00 noon
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for a maximum of 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Organon
INDUSTRY-SUPPORTED SYMPOSIUM 17
Sunday, May 31, 9:00 a.m. - 12 noon
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

Juvenile Mood Disorders: from research to clinical practice
SUNDAY, MAY 31, 1998
9:00 a.m. - 12 Noon
Registration/Breakfast 8 a.m.
Metropolitan Ballroom West
Westin Harbour Castle
Toronto, Canada

Chair: Joseph Biederman, MD
Chief, Joint Program in Pediatric Psychopharmacology
Professor of Psychiatry
Harvard Medical School

Co-chair: Thomas J. Spencer, MD
Assistant Professor of Psychiatry
Harvard Medical School

ADHD and Juvenile Mania: An Overlooked Comorbidity?
Joseph Biederman, MD

Mania-Like Symptoms Suggestive of Childhood-Onset Bipolar Disorder in Clinically Referred Children
Janet Wozniak, MD
Clinical Assistant in Psychiatry
Massachusetts General Hospital
Instructor in Psychiatry
Harvard Medical School

ADHD with Bipolar Disorder: A Familial Subtype?
Stephen V. Farone, PhD
Associate Professor of Psychology
Harvard Medical School

Juvenile Bipolar Disorder and the Risk for Substance Abuse
Timothy E. Wilens, MD
Associate Professor of Psychiatry
Harvard Medical School

The Naturalistic Course of Pharmacologic Treatment of Children with Manic-Like Symptoms: A Systematic Chart Review
Thomas J. Spencer, MD

INDUSTRY-SUPPORTED SYMPOSIUM 18
Sunday, May 31, 1:30 p.m. - 4:30 p.m.
Auditorium, Lower Level, Convention Centre

The Depressed Woman: Contemporary Treatments
Sunday, May 31, 1998 • Auditorium, Lower Level, Convention Centre • Toronto, Ontario, Canada
12:45 pm Luncheon Buffet • 1:30 – 4:30 pm Educational Symposium
Myrna M. Weissman, PhD
Chairperson

Welcome and Introduction
Myrna M. Weissman, PhD

Treatment of Psychiatric Illness During Pregnancy & the Postpartum Period
Lee S. Cohen, MD

Interpersonal Psychotherapy for Antepartum Depression
Margaret G. Spinelli, MD

The Treatment of Depressed Women & Their Children
Myrna M. Weissman, PhD

Preventing Recurrence of Depression in Women
Ellen Frank, PhD

New Treatments for Premenstrual Dysphoric Disorder
Kimberly A. Yonkers, MD

Myrna M. Weissman, PhD
College of Physicians & Surgeons of Columbia University

Lee S. Cohen, MD
Harvard Medical School
Massachusetts General Hospital

Margaret G. Spinelli, MD
College of Physicians & Surgeons of Columbia University
NYS Psychiatric Institute

Kimberly A. Yonkers, MD
University of Texas Southwestern Medical Center at Dallas

Ellen Frank, PhD
University of Pittsburgh School of Medicine
Western Psychiatric Institute & Clinic

The American Psychiatric Association (APA) designates this educational activity for up to 3 hours in Category 1 credit toward the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
NEW FRONTIERS IN THE MANAGEMENT OF SOCIAL PHOBIA: DIAGNOSIS, TREATMENT, AND CLINICAL COURSE

Sponsored by the American Psychiatric Association. The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours of Category 1 credit toward the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours that he/she actually spent in the educational activity.

The Differential Diagnosis of Social Phobia
Murray B. Stein, MD, FRCP(C)
Associate Professor of Psychiatry
University of California San Diego
Director, Anxiety and Traumatic Stress Disorders Clinics
San Diego Veterans Affairs Healthcare System
San Diego, California

Gender Differences in the Presentation and Management of Social Phobia
Lisa S. Weinstock, MD
Anxiety and Depression Clinic
New York Hospital - Cornell Medical Center
White Plains, New York

Cognitive Behavior Therapy for Social Phobia: Theory, Outcome, and Future Directions
Michael W. Otto, PhD
Associate Professor of Psychology
Harvard Medical School
Director, Cognitive-Behavior Therapy Program
Massachusetts General Hospital
Boston, Massachusetts

Social Phobia: Designing a Pharmacologic Treatment Strategy
Mark H. Pollack, MD, Symposium Chairman
Associate Professor of Psychiatry
Harvard Medical School
Director, Anxiety Disorders Program
Massachusetts General Hospital
Boston, Massachusetts

Comorbid Social Anxiety and Body Dysmorphic Disorder:
Managing the Complicated Patient
Eric V. Hollander, MD
Professor of Psychiatry
Director, Clinical Psychopharmacology
Directors: Compulsive, Impulsive, and Anxiety Disorders Program
Mount Sinai School of Medicine
New York, New York

Interactive Panel Discussion
Moderated by Mark H. Pollack, MD
Light refreshments follow the symposium.

Supported by an unrestricted educational grant from SmithKline Beecham Pharmaceuticals

INDUSTRY-SUPPORTED SYMPOSIUM 19
Sunday, May 31, 1:30 p.m. - 4:30 p.m.
Room 106, Lower Level, Convention Centre

NICOTINE: An Enemy? or an Ally?

SUNDAY, MAY 31, 1998 • 1:30-4:30 PM • CONVENTION CENTRE • HALL G • TORONTO, CANADA

Refreshments will be served prior to the program

DEPRESSIVE RELAPSE PROVOKED BY SMOKING CESSATION
Alexander H. Glassman, MD, Symposium Chair
Chief, Clinical Psychopharmacology, New York State Psychiatric Institute,
Professor of Clinical Psychiatry, College Of Physicians & Surgeons, Columbia University,
New York, New York

A NICOTINE RECEPTOR DEFICIT IN SCHIZOPHRENIA
Robert Freedman, MD, Symposium Co-Chair
Professor of Psychiatry, University of Colorado Health Sciences Center,
Denver, Colorado

THE NEUROBIOLOGY OF NICOTINE DEPENDENCE
George F. Koob, PhD
Professor, Director, Division of Psychopharmacology, Department of Neuropharmacology,
The Scripps Research Institute, La Jolla, California

TREATING HEAVILY DEPENDENT AND COMORBID SMOKERS
John R. Hughes, MD
Professor, Department of Psychiatry, University of Vermont,
Burlington, Vermont

NICOTINE DEPENDENCE IN ALCOHOLICS
Richard D. Hurt, MD
Director, Mayo Nicotine Dependence Center, Professor of Medicine,
Mayo Medical School, Rochester, Minnesota

ACKNOWLEDGEMENTS
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours of Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours that he/she actually spent in the educational activity.

This symposium is supported by an unrestricted educational grant from Glaxo Wellcome Inc.
New Atypicals: Data Versus Clinical Experience

Sunday, May 31, 1998 • 1:30 pm - 4:30 pm
Canadian Room, Royal York Hotel

Chairperson: Ira D. Glick, MD
Co-chairperson: Stephen R. Marder, MD

- Historical Overview of the Treatment of Schizophrenia
  Ira D. Glick, MD
- Therapeutic Implications of Etiological Research
  Robin M. Murray, MD
- Atypical Antipsychotics: How Well Do They Really Work?
  Rajiv Tandon, MD

Newer Antipsychotics: Side Effect Profiles
Stephen R. Marder, MD

Services Research and the Use of Atypical Antipsychotics
Lisa B. Dixon, MD

Combining Atypicals With Psychosocial Interventions
Ira D. Glick, MD

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from ZENECA

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Optimizing Patient Outcomes With Novel Antipsychotics: Changing Expectations

Sunday, May 31, 1998
1:30 PM - 4:30 PM
Concert Hall, Royal York

Chairman's Introduction
Alan I. Green, MD

Antipsychotic Drugs: Translating Pharmacology Into Clinical Effects
David Pickar, MD

Early Intervention: Can We Change the Course of Illness?
Jeffrey A. Lieberman, MD

Aggression, Violence, and Suicide in Schizophrenia
Peter F. Buckley, MD

Comorbid Substance Abuse: Do Antipsychotic Drugs Have a Role?
Alan I. Green, MD

Beyond Symptoms: Optimizing Real-World Outcomes
Jean-Pierre Lindenmayer, MD

Discussant
Herbert Y. Meltzer, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by the American Psychiatric Association
Supported by an unrestricted educational grant from Novartis Pharmaceuticals Corporation
INDUSTRY-SUPPORTED SYMPOSIUM 23
Sunday, May 31, 1:30 p.m. - 4:30 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

The Anxiety Labyrinth: Finding a Pathway to the Solutions
Sunday, May 31, 1998
GRAND BALLROOM, SHERATON CENTRE TORONTO
123 QUEEN STREET WEST, TORONTO, CANADA
REGISTRATION & LUNCH: 1:00 p.m. - 1:30 p.m.
SCIENTIFIC PROGRAM: 1:30 p.m. - 4:30 p.m.

CHAIR:
Jonathan R. T. Davidson, M.D.

DISTINGUISHED FACULTY
James G. Barbee, M.D.
Jane Eisen, M.D.
R. Bruce Lydiard, M.D., Ph.D.
Jonathan R. T. Davidson, M.D.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Bristol-Myers Squibb

INDUSTRY-SUPPORTED SYMPOSIUM 24
Sunday, May 31, 1:30 p.m. - 4:30 p.m.
Metropolitan Ballroom East, Convention Level, Westin Harbour Castle

Depressive Disorders: Advances in Clinical Management
Sunday, May 31, 1998
1:30 P.M. - 4:30 P.M.
Metropolitan Ballroom East
Convention Level
Westin Harbour Castle

Depression Subtyping: Treatment Implications
Paula J. Clayton, MD

Strategies for Overcoming Treatment Resistance
J. Craig Nelson, MD

Assessment and Treatment of Depression by Computer
John H. Greist, MD

Dealing With Dangerous and Disturbing Side Effects
Edmund C. Settle, Jr., MD

Drug and Diet Interactions: Avoiding Therapeutic Paralysis
James W. Jefferson, MD

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association
Supported by an unrestricted educational grant from Organon
INDUSTRY-SUPPORTED SYMPOSIUM 25
Sunday, May 31, 1:30 p.m. - 4:30 p.m.
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

TREATMENT OF DEPRESSION IN DIFFICULT SITUATIONS

SUNDAY, MAY 31, 1998  1:30 p.m. - 4:30 p.m.
Registration/Lunch 12:30 p.m.
Metropolitan Ballroom West
Westin Harbour Castle
Toronto, Canada

Chair: DWIGHT L. EVANS, MD
Chairman, Department of Psychiatry
University of Pennsylvania
Health System

- Depression Adversely Affects Mental and Physical Health  DWIGHT L. EVANS, MD
- Treatment of Depression and Comorbid Anxiety  DENNIS S. CHARNEY, MD
  Deputy Chair for Academic and Scientific Affairs
  Yale University School of Medicine
- The Study of Affects with Neuroimaging  RAQUEL GUR, MD
  Professor of Psychiatry
  Director of Neuropsychiatry
  University of Pennsylvania School of Medicine
- Treatment of Severe Unipolar and Bipolar Depression  NED H. KALIN, MD
  Hedberg Professor and Chair of Psychiatry
  University of Wisconsin-Madison Medical School
- Recognizing and Treating Body Dysmorphic Disorder in Depressed Patients  KATHARINE A. PHILLIPS, MD
  Associate Professor of Psychiatry
  Brown University School of Medicine

This symposium is sponsored by the American Psychiatric Association.
It is supported by an unrestricted educational grant from Wyeth-Ayerst Laboratories.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to
sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3.0 hours
in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician
should claim only those hours of credit that he/she actually
spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 26
Sunday, May 31, 7:00 p.m. - 10:00 p.m.
Auditorium, Lower Level, Convention Centre

Expanding the Spectrum of Psychoses: The Interface of Affect

Sunday, May 31, 1998 • Auditorium, Lower Level, Convention Centre • Toronto, Ontario, Canada
6:15 PM Dinner Buffet • 7:00 - 10:00 PM Educational Symposium • 10:00 PM Dessert Buffet

William M. Glazer, MD
Chairperson

Paul E. Keck, Jr, MD
Co-Chairperson

Welcome and Introduction .................................................. William M. Glazer, MD
A Biological Basis for Overlap of Mood in Psychotic Disorders .................................................. Paul E. Keck, Jr, MD
The Psychopharmacologic Treatment of Schizoaffective Disorder .................................................. Susan L. McElroy, MD
Psychotic Major Depression .................................................. Alan E. Schatzberg, MD
Experience Using Olanzapine in the Treatment of Acute Bipolar Mania ........................................ Mauricio Tohen, MD, DrPH
Affective Disorders, Tardive Dyskinesia & Atypical Antipsychotics ............................................... William M. Glazer, MD

William M. Glazer, MD
Harvard Medical School
Massachusetts General Hospital

Paul E. Keck, Jr, MD
University of Cincinnati
College of Medicine

The American Psychiatric Association (APA) is accredited by the Accreditation Council for
Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit
Toward the AMA Physician’s Recognition Award and for the CME requirement of the APA.
Each physician should claim only those hours of credit that he/she actually spent in the
educational activity.

Supported by an unrestricted educational grant from Lilly
INDUSTRY-SUPPORTED SYMPOSIUM 27
Sunday, May 31, 7:00 p.m. - 10:00 p.m.
Hall G, 800 Level, Convention Centre

Sexual Dysfunction, Depression and Antidepressants

Chairled by:
Troy L. Thompson II, MD
Daniel Lieberman, Professor
Department of Psychiatry and Human Behavior
Jefferson Medical College and Hospital
Philadelphia, Pennsylvania

Program Objectives
To better understand...
- sexual dysfunction associated with depression and due to antidepressant medications
- the role that various antidepressants may play in causing, avoiding and correcting antidepressant-related sexual dysfunction
- an antidepressant with positive sexual side effects, antidepressants with fewer sexual side effects, and “atypical” and adjunctive approaches to correct sexual dysfunction due to antidepressants
- recent therapeutic advances to treat erectile dysfunction

Continuing Medical Education Credits:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Glaxo Wellcome Inc.

Agenda:
- Welcome and Overview
  Troy L. Thompson II, MD
- Avoiding and Managing Sexual Side Effects of Antidepressants
  Troy L. Thompson II, MD
- Sexual Side Effects of Commonly Prescribed Drugs
  Theresa L. Crenshaw, MD
  President
  Crenshaw Writing Company
  San Diego, California
  Author, Sexual Pharmacology
  (Norton, 1996)
- A Comprehensive Approach to Sexuality and Depression
  Donna C. Rennert, MD
  Professor of Psychiatry
  Loyola University
  Chicago, Illinois
- Questions, answers and discussion following each presentation and at end of symposium

INDUSTRY-SUPPORTED SYMPOSIUM 28
Sunday, May 31, 7:00 p.m. - 10:00 p.m.
Canadian Room, Convention Floor, Royal York

Treatment Strategies for Successful Outcomes in Patients With Panic Disorder

SUNDAY, MAY 31, 1998
Canadian Room, Royal York Hotel, Toronto, Ontario, Canada
6:00 PM - 7:00 PM Registration and Dinner
7:00 PM - 10:00 PM Scientific Program

Introduction and Overview
Jack M. Gorman, MD, Program Chair
Deputy Director, The New York State Psychiatric Institute
Professor of Psychiatry
Columbia University

Reduction in Panic Attacks, as a Single Measure, Is Insufficient for Assessing Treatment Efficacy in Panic Disorder
David A. Spiegel, MD
Research Professor and Associate Director
Center for Anxiety and Related Disorders
Boston University School of Medicine

Clinical Treatment Strategies for Successful Outcomes in Panic Disorder
Donald F. Klein, MD
Director of Therapeutics
The New York State Psychiatric Institute

Pharmacotherapy of Panic Disorder
Jack M. Gorman, MD

Cognitive-Behavioral Therapy of Panic Disorder
M. Katherine Shaw, MD
Director, Anxiety Disorders Prevention Program
Western Psychiatric Institute and Clinic/PSPCM
Professor of Psychiatry
University of Pittsburgh

Discussions: Robert A.M. Hirschfeld, MD
Tita Harris Distinguished Professor
Chair, Department of Psychiatry and Behavioral Sciences
University of Texas Medical Branch, Galveston

Summary and Conclusions
Jack M. Gorman, MD

Supported by an unrestricted educational grant from Pfizer
INDUSTRY-SUPPORTED SYMPOSIUM 29
Sunday, May 31, 7:00 p.m. - 10:00 p.m.
Concert Hall, Convention Floor, Royal York

SUNDAY, MAY 31, 1998, 7:00PM - 10:00PM
CONCERT HALL, ROYAL YORK HOTEL

CLINICAL ASPECTS OF VIOLENCE

AMERICAN PSYCHIATRIC ASSOCIATION

Risk Assessment for Violence
Phillip J. Resnick, MD (Moderator)
Professor of Psychiatry
Case Western Reserve University
School of Medicine
Cleveland, Ohio

Child and Adolescent Violence
Robert T.M. Phillips, MD
Adjunct Associate Professor of Psychiatry and Law
University of Maryland
School of Medicine and Law
Baltimore, Maryland

Assessment of Violent Threats
Park E. Dietz, MD
Clinical Professor of Psychiatry
UCLA School of Medicine
Los Angeles, California

Violence Against Psychiatrists
John R. Lion, MD
Clinical Professor of Psychiatry
University of Maryland School of Medicine
Private Practice
Baltimore, Maryland

Pharmacologic Approaches to Violence
Renee L. Bines, MD
Professor of Psychiatry
University of California San Francisco
San Francisco, California

John Monahan, PhD (Discussant)
Henry and Grace Dornes Professor of Law
Professor of Psychology and Legal Medicine
University of Virginia School of Law
Charlottesville, Virginia

This symposium is sponsored by the American Psychiatric Association. It is supported by an unrestricted educational grant from Hoepts Pharmaceuticals Corporation.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 30
Sunday, May 31, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

Practical Approaches to the Treatment of PSYCHOSES in the Elderly

Sponsored by the American Psychiatric Association.
Sunday, May 31 • 7:00-10:00 p.m.
Sheraton Centre • Grand Ballroom, Lower Concourse
Complimentary hors d’oeuvres will be served prior to the session.

Chronic and Late-Onset Psychotic Disorders
Ira R. Katz, M.D.,
(Professor of Psychiatry, University of Pennsylvania)

Organic Disorders with Psychotic Features in the Elderly
Jeffrey L. Cumings, M.D.,
(The August S. Rose Professor of Neurology, UCLA)

Treatment Options and Practical Issues for Elderly Patients with Psychoses
Pierre N. Tarot, M.D.,
(Associate Professor of Psychiatry and Medicine, University of Rochester)

Psychotic Disorders Among Patients in Long-Term Care Facilities
Barry W. Rosner, M.D.,
(Professor of Psychiatry, Thomas Jefferson University)

Nonpharmacologic Approaches in Managing Elderly Patients with Psychoses
Soo Bostock, M.D.,
(Associate Professor of Psychiatry and Behavioral Sciences; Director, Geopsychiatry Services, University of Washington)

This program is supported by an unrestricted educational grant from Abbott Laboratories.
Age-Related Memory Loss: Detection and Treatment

Sponsored by the American Psychiatric Association

Chair: Gary W. Small, MD
Professor of Psychiatry and Behavioral Sciences
Director, UCLA Center on Aging
UCLA School of Medicine
Los Angeles, California

Co-Chair: Lon S. Schneider, MD
Professor of Psychiatry, Neurology, and Gerontology
Department of Psychiatry and Behavioral Sciences
University of Southern California
Los Angeles, California

- From Age-Related Cognitive Decline to Dementia
  Steven H. Ferris, PhD
  Professor, Department of Psychiatry
  New York University School of Medicine
  Executive Director, Seilzer Aging and Dementia Research Center
  New York, New York

- Does Depression Predict Cognitive Decline in the Elderly?
  Davinder P. Devanand, MD
  Associate Professor of Clinical Psychiatry
  College of Physicians and Surgeons of Columbia University
  New York State Psychiatric Institute
  New York, New York

- Methods for Early Detection of Memory Loss
  Gary W. Small, MD

- From Neurobiology to Novel Treatments
  Murray A. Raskind, MD
  Professor and Vice-Chairman for Research
  Department of Psychiatry and Behavioral Sciences
  University of Washington School of Medicine
  Chief, Psychiatry Service
  Seattle VA Medical Center
  Seattle, Washington

- Current Memory Treatments: Challenges and Prospects
  Lon S. Schneider, MD

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by an unrestricted educational grant from Janssen Pharmaceuticals and Research Foundation

INDUSTRY-SUPPORTED SYMPOSIUM 32
Sunday, May 31, 7:00 p.m. - 10:00 p.m.
Metropolitan Ballroom West, Convention Level, Westin Harbour Castle

CONTEMPORARY ISSUES IN TREATMENT-RESISTANT DEPRESSION

Sunday, May 31, 1998
7:00 p.m. - 10:00 p.m.
Registration/Dinner 6 p.m.
Metropolitan Ballroom West
Westin Harbour Castle, Toronto, Canada

Chair: JAY D. AMSTERDAM, MD
Professor of Psychiatry
University of Pennsylvania School of Medicine

This symposium is sponsored by the American Psychiatric Association.
It is supported by an unrestricted educational grant from Wyeth-Ayerst Laboratories.
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

- Overview of Treatment-Resistant Depression
  ANDREW A. NIERENBERG, MD
  Associate Psychiatrist
  Associate Director, Depression Clinical and Research Program
  Massachusetts General Hospital

- Algorithms in Treatment-R refractory Depression
  JAN A. FAVCETT, MD
  Professor, Chairman and Director
  Department of Psychiatry
  Ruth Presbyterian-St. Luke's Medical Center

- Estrogen: What is the Magnitude of the Effect?
  BARBARA B. SHERWIN, PhD
  Professor, Department of Obstetrics and Gynecology
  Professor, Department of Psychology
  McGill University

- Combination Treatment in Resistant Depression
  DAVID BAKISH, MD
  Head, Psychopharmacology Unit
  Royal Ottawa Hospital

- Treatment-Resistant Depression: Pushing Out the Edges of the Envelope
  JAY D. AMSTERDAM, MD
Practical Clinical Strategies for Managing Refractory Depression, Agitation, and Antidepressant Side Effects

Monday, Tuesday, and Wednesday, June 1–3, 1998
Grand Ballroom, Sheraton Centre Toronto
123 Queen Street West, Toronto, Canada
Registration & Breakfast: 6:30 A.M.–7:30 A.M.
Scientific Program: 7:00 A.M.–8:30 A.M.

Accreditation
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for a maximum of 4.5 hours in Category 1 credit towards the American Medical Association’s Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

AN EDUCATIONAL SYMPOSIUM PRESENTED AT THE APA'S 151ST ANNUAL MEETING

CHAIR:
Robert E. Hales, M.D., M.B.A.

CO-CHAIR:
Stuart C. Yudofsky, M.D.

DISTINGUISHED FACULTY
Stephen M. Stahl, M.D., Ph.D.
Norman Sussman, M.D.
Michael E. Thase, M.D.
Anthony J. Rothschild, M.D.
Lauren B. Marangell, M.D.
George T. Grossberg, M.D.

Sponsored by the American Psychiatric Association

Supported by an unrestricted educational grant from Bristol-Myers Squibb

INDUSTRY-SUPPORTED SYMPOSIUM 35
Tuesday, June 2, 7:00 p.m.–10:00 p.m.
Auditorium, Lower Level, Convention Centre

PHARMACOTHERAPY COMBINATION STRATEGIES IN CLINICAL PRACTICE
To be held during the 1998 Annual Meeting of the American Psychiatric Association

Philip G Janicak, MD—Chair
Jan A Fawcett, MD—Cochair

This program is sponsored by the American Psychiatric Association.
The program is supported by an unrestricted educational grant from Janssen Pharmaceutica and Research Foundation.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.
The APA designates this educational activity for up to 3 hours in Category 1 credit towards the American Medical Association’s Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
**Hot Topics in Alzheimer's Disease**

Dinner will be served prior to the symposium.

**INTRODUCTION**
Lori S. Schneider, M.D., Program Chairman

**APOPROTIPID PROTEIN E-4 AND ALZHEIMER'S DISEASE: SEARCH FOR THE TRUTH**
Kathleen A. Welsh-Bohmer, Ph.D., Associate Professor
Department of Psychiatry, Duke University, Durham, North Carolina

**DIAGNOSTIC TESTING: BENEFITS OR JUST COSTS?**
Gary W. Small, M.D., Program Co-Chairman
Professor of Psychiatry and Biobehavioral Sciences
Direc, UCLA Center on Aging
University of California at Los Angeles, Los Angeles, California

**PREVENTION OF ALZHEIMER'S DISEASE: NON-STEROIDAL ANTI-INFLAMMATORY AGENTS, ESTROGENS AND H2 BLOCKERS**
John C. S. Beiser, M.D., MPH, Professor and Chair
Department of Mental Hygiene, Johns Hopkins University, Baltimore, Maryland

**ANTIOXIDANTS AND SELENIUM: ARE THEY READY FOR THE CLINIC?**
Pierre N. Tariot, M.D., Associate Professor of Psychiatry, Medicine, and Neurology
Department of Psychiatry, University of Rochester Medical Center, Rochester, New York

**CHOLINESTERASE INHIBITORS: GREATER THERAPEUTIC POSSIBILITIES?**
Martin R. Farlow, M.D., Professor and Vice-Chairman of Research
Department of Neurology, Indiana University, Indianapolis, Indiana

**DISCUSSION**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Supported by the American Psychiatric Association

**Update on Diagnosis: Pathophysiology and Treatment of Primary Headache Disorders for the Practicing Psychiatrist**

**Tuesday, June 2, 1998**
7:00 - 10:00 pm
Convention Centre, Hall G
Toronto, Canada

Dessert Reception Immediately Prior To Program

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association

**Supported by an unrestricted educational grant from Merck U.S. Human Health**
**INDUSTRY-SUPPORTED SYMPOSIUM 38**
Tuesday, June 2, 7:00 p.m. - 10:00 p.m.
Canadian Room, Convention Floor, Royal York

**Exploring the Course of Schizophrenia**

**Toronto, Ontario, Canada**
Royal York Hotel,
Canadian Room

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the CME activity.

**55th APA Annual Meeting**

Tuesday, June 2, 1998

6:30 p.m. Reception
7:00 p.m. Welcome and Introduction
Daniel E. Casey, MD
Chief, Psychiatry
Research/Psychopharmacology
Veterans Affairs Medical Center
Portland, Oregon

7:05 p.m. Rapidly Controlling Acute Psychotic Symptoms with Antipsychotic Drugs
William C. Wintring, MD
Professor of Psychiatry
UCLA School of Medicine
Chief, Schizophrenia Treatment Unit
West Los Angeles VA Medical Center
Los Angeles, California

Panel Discussion:
Question and Answer Session
Adjourn

**Relapse Prevention**
John Kane, MD
Chairman, Department of Psychiatry
Chief of Staff
Hillside Hospital
Glen Oaks, New York

**Long-Term Studies in Schizophrenia**
Improving Functional Outcomes
Mihaly Anto, MD, PhD
Professor of Psychiatry
President
Pharmaproject Ltd.
Budapest, Hungary

**Assessment and Treatment of Depression in Schizophrenia**
Donald E. Addison, MD
Head, Regional Clinical
Department of Psychiatry
Foothills Hospital
Calgary, Alberta, Canada

**Adverse Effects Profile of New Antipsychotic Agents**
Daniel E. Casey, MD

**Program Chairperson**
Maurizio Fava, MD
Harvard Medical School
Boston, Massachusetts

---

**INDUSTRY-SUPPORTED SYMPOSIUM 39**
Tuesday, June 2, 7:00 p.m. - 10:00 p.m.
Concert Hall, Convention Floor, Royal York

**Program**

- **Minor and Subsyndromal Depression and Their Treatment**
  - Mark B. Rapoport, MD
    - University of California-San Diego School of Medicine
    - La Jolla, California

- **Dysthmic Disorder**
  - David L. Dunner, MD
    - University of Washington School of Medicine
    - Seattle, Washington

- **Anxious Depression: Treatment Approaches**
  - Maurizio Fava, MD
    - Harvard Medical School
    - Boston, Massachusetts

- **Depression With Alcohol and/or Drug Abuse**
  - Patrick J. McGrath, MD
    - Columbia University College of Physicians and Surgeons
    - New York, New York

- **Psychotic Depression**
  - Barbara Hochstrasser, MD
    - Privatklinik
    - Meiringen, Switzerland

**Clinical Challenges in the Treatment of Depression Subtypes**

**Tuesday, June 2, 1998**
7:00 PM - 10:00 PM

**Royal York**

**Concert Hall**

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

This APA designates this educational activity for up to 3 hours in Category 1 credit with the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
INDUSTRY-SUPPORTED SYMPOSIUM 40
Tuesday, June 2, 7:00 p.m. - 10:00 p.m.
Grand Ballroom, Lower Concourse, Sheraton Centre

INDUSTRY-SUPPORTED SYMPOSIUM 41
Tuesday, June 2, 7:00 p.m. - 10:00 p.m.
Frontenac Ballroom, Street Level, Westin Harbour Castle

New Treatments for Schizophrenia
Carol A. Tamminga, M.D.
(Professor of Psychiatry, University of Maryland)

Anticonvulsants in Bipolar Disorder
Joseph R. Calabrese, M.D.
(Professor of Psychiatry, Case Western Reserve)

Treatment of Chronic Depression
James H. Kocsis, M.D.
(Professor of Psychiatry, New York Hospital-Cornell Medical Center)

Current Treatments for Eating Disorders
B. Timothy Walsh, M.D.
(William & Joy Ruane Professor of Psychiatry, College of Physicians and Surgeons, Columbia)

Advances in Geriatric Psychiatry
J. Craig Nelson, M.D.
(Professor of Psychiatry, Yale)

Complimentary hors d’oeuvres will be served prior to this session.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians.

The APA designates this educational activity for a maximum of 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Sponsored by the American Psychiatric Association (APA).
Supported by an unrestricted educational grant from Abbott Laboratories.

TREATING THE DIFFICULT TO TREAT DEPRESSED PATIENT

Tuesday, June 2, 1998
7PM to 10PM • Dinner from 6PM to 7PM
Frontenac Ballroom, Westin Harbour Castle
Toronto, Canada

STEVEN P. ROOSE, MD
CHAIRMAN

“When the Depressed Patient is Not Responding”

ALEXANDER H. GLASSMAN, MD
“Antidepressant Use in Patients with Heart Disease”

GLEN O. GABBARD, MD
“Treatment of Depression with Comorbid Personality Disorders”

KIMBERLY A. YONKERS, MD
“Estrogens and Progestins: Do They Cause or Treat Mood Disorders?”

CARL G. GOTTFRIES, PHD
“Treatment of Depressed Patients with Cognitive Impairment”

Sponsored by the American Psychiatric Association (APA).
Supported by an unrestricted educational grant from Forest Laboratories, Inc.

The APA is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirements of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

173
INDUSTRY-SUPPORTED SYMPOSIUM 43
Wednesday, June 3, 7:00 p.m. - 10:00 p.m.
Auditorium, Lower Level, Convention Centre

NEUROCOGNITION IN SCHIZOPHRENIA
To be held during the 1998 Annual Meeting of the American Psychiatric Association

Lili C Kopala, MD—Cochair
William C Wirshing, MD—Cochair

This program is sponsored by the American Psychiatric Association.

The program is supported by an unrestricted educational grant from Janssen Pharmaceuticals and Research Foundation.

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 44
Wednesday, June 3, 7:00 p.m. - 10:00 p.m.
Canadian Room, Convention Floor, Royal York

Management of Mental Disorders in Baby Boomers and Beyond

WELCOME AND INTRODUCTION
Martin B. Keller, MD, Program Chair
Professor and Chairman
Department of Psychiatry
and Human Behavior
Brown University
Executive Psychiatrist-in-Chief
Brown Affiliated Hospitals
Butler Hospital

AGING AND ADAPTATION TO LIFE AND ILLNESS: A PSYCHIATRIC PERSPECTIVE
George Vaillant, MD
Professor of Psychiatry
Harvard Medical School
Department of Psychiatry
Brigham and Women’s Hospital

LATE LIFE DEPRESSION
Donald B. Helg, MD
Associate Professor of Psychiatry
Vice Chair for Clinical Programs
Department of Psychiatry
St. Louis University

ANXIETY, AGITATION, AND INSOMNIA
Carl Salzman, MD
Professor of Psychiatry
Harvard Medical School

INTERFACE OF DEPRESSION AND MEDICAL ILLNESS
Richard C. Freed, MD
Director, GRECC
VA Puget Sound Health Care System
Professor and Acting Chairman
Psychiatry and Behavioral Sciences
University of Washington

BEHAVIORAL SYMPTOMS OF ALZHEIMER’S AND OTHER DEMENTIAS
Sanford L. Finlay, MD
Professor and Director
Division of Geriatric Psychiatry
Northwestern University Medical School

PANEL DISCUSSION: QUESTIONS AND ANSWERS
Martin B. Keller, MD
Moderator

The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician’s Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
PREDICTING OUTCOMES OF ANTIDEPRESSANT TREATMENT

Wednesday, June 3, 1998
6:15 PM - 10:00 PM Dinner/Symposium
Concert Hall, Royal York Hotel

Chairman: Andrew F. Leuchter, MD
Co-Chairman: Andrew A. Nierenberg, MD

"Clinical Predictors of Response to Antidepressants"
Andrew A. Nierenberg, MD

"Neuroimaging Indicators of Treatment Effectiveness"
Harold A. Sackheim, PhD

"Neuropsychological Predictors of Treatment Response"
Ian A. Cook, MD

"Differential Therapeutic Responses in Depression"
Andrew F. Leuchter, MD

"Neurotransmitter Depletion and Outcome in Depression"
Pedro L. Delgado, MD

Discussant: Barry D. Lebowitz, PhD

Sponsored by the American Psychiatric Association

Support by an unrestricted educational grant from Pharmaco & Upjohn Company.

Accreditation:
The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the AMA Physician's Recognition Award and for the CME requirement of the APA. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

INDUSTRY-SUPPORTED SYMPOSIUM 46
Wednesday, June 3, 7:00 p.m. - 10:00 p.m.
Frontenac Ballroom, Street Level, Westin Harbour Castle

Therapeutic Challenges in Geriatric Psychiatry

Wednesday, June 3, 1998
7:00 p.m. - 10:00 p.m. Registration and Reception 6:00 p.m. - 7:00 p.m.
Frontenac Ballroom Westin Harbour Castle Toronto, Ontario, Canada
# Practical Alzheimer's Disease Management:

* A Comparative Review of New Compounds, Diagnosis, Treatment & Outcomes Assessment

**Wednesday, June 3, 1998**  6:30 pm – 10:00 pm  – Symposium

Metropolitan Ballroom West / Westin Harbour Castle / Toronto, Ontario, Canada

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30</td>
<td>Reception</td>
<td></td>
</tr>
<tr>
<td>7:00</td>
<td>Welcome/Introduction</td>
<td>Jeffrey L. Cummings, MD, Chaimpusan</td>
</tr>
<tr>
<td></td>
<td>Augustus Rose Professor of Neurology; Professor of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, School of Medicine, Los Angeles, California</td>
<td></td>
</tr>
<tr>
<td>7:10</td>
<td>Recognition of Alzheimer's Disease: The Importance of Early Diagnosis to Desirable Patient Outcome</td>
<td>Rachelle DuBois, MD, PhD, Associate Professor of Neurology, Baylor College of Medicine, Houston, Texas</td>
</tr>
<tr>
<td>7:30</td>
<td>Pathogenesis of Alzheimer's Disease</td>
<td>Jeffrey L. Cummings, MD</td>
</tr>
<tr>
<td>8:00</td>
<td>Cognitive Enhancing and Disease Modifying Therapies in Alzheimer's Disease</td>
<td>Troy Sunderland, MD, Chief, Branch on Geriatric Psychiatry, National Institute of Mental Health, Bethesda, Maryland</td>
</tr>
<tr>
<td>8:25</td>
<td>Treating Behavioral Manifestations in Patients with Alzheimer's Disease: Differential Diagnosis and Therapies</td>
<td>David Sutton, MD, Associate Professor of Psychiatry, UCLA School of Medicine, Director, Geriatric Neuropsychiatric Division, West Los Angeles VA Medical Center, Los Angeles, California</td>
</tr>
<tr>
<td>8:55</td>
<td>Assessing Alzheimer's Disease Treatment Response: Outcomes Strategies for the Office Practice</td>
<td>Ina R. Katz, MD, PhD, Professor of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania</td>
</tr>
<tr>
<td>9:15</td>
<td>The Economic Implications of Early Diagnosis and Treatment of Alzheimer's Disease</td>
<td>Peter J. Neumann, ScD, Assistant Professor of Policy and Decision Sciences, Deputy Director, Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, Massachusetts</td>
</tr>
<tr>
<td>9:40</td>
<td>Questions and Answers Faculty</td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Adjourn</td>
<td></td>
</tr>
</tbody>
</table>

*The American Psychiatric Association (APA) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The APA designates this educational activity for up to 3 hours in Category 1 credit towards the APA Physician's Recognition Award and for the CME requirement of the APA. Each physician should determine only those hours of credit that he/she actually spent in the CME activity.*
Explore what's NEW for you

Visit the APA Resource Center
During the 1998 APA Annual Meeting

- Pick up Annual Meeting abstracts on disk
- Create your personalized CME certificate of attendance
- Explore APA's Web Site and subscribe to the Member-to-Member and PsychIMAGE Listservs
- Take home the latest on CPT coding, capitation, deselection, and managed care legal issues
- Explore the Job Bank; learn tips for conducting an effective job search
- Get advance copies of
  - American Journal of Psychiatry
  - Psychiatric News
  - Psychiatric Services
  - Psychiatric Practice & Managed Care newsletter
- Explore the AIDS interactive database for resources, conferences, funding opportunities, and allied organizations
- Save money and time with APA Sponsored Programs, e.g. car rentals, magazine subscriptions and the APA credit card
- Search the Ideas & Information Exchange database for public awareness activities
- Learn about the latest
  - practice guidelines
  - outcome studies, and
  - psychiatric research
- Pick up the Spring issue of Psychiatric Research Report
- See the exciting new “Let's Talk Facts” brochures
- Send a letter to Congress
- Pick up the new Congressional Directory

Win fantastic prizes
Refer to the Daily Bulletin for details!

APA Answer Center at 202-682-6000
APAfax Fax 888-267-5400
(Outside the U.S. & Canada dial 503-402-1365)
Web Site: www.psych.org
E-mail: apa@psych.org

APA Resource Center
Metro Toronto Convention Centre
Exhibit Halls A/B/C Upper Level

Saturday  May 30  11am - 5pm
Sunday   May 31  8am - 5pm
Monday   June 1  10am - 6pm
Tuesday  June 2  10am - 6pm
Wednesday June 3  10am - 3pm

American Psychiatric Association
1400 K Street, N.W.
Washington, DC 20005

Printed in USA